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Breast cancer is an important well-known estrogen receptor (ER) mediated disease. 
Interactions with ERs rely on salient features of estrogen molecules. If these features 
occur on other molecules they are likely to mimic estrogens (i.e. xenoestrogens). Until 
recently, ERs were thought to comprise only a single binding cleft (the ligand binding 
cleft (LBC)) which determined activity. In 1988, a second binding cleft (known as 
activation function (AF)-2) was discovered. AF-2 is intimately related to LBC both in 
its location and function. This thesis explores this relationship in greater detail. 
 
Xenoestrogens were selected for study based on their environmental prevalence. They 
were subjected to CALUXâ assays (a gene reporter assay based on expression of 
ERs) and MCF-7 (cultured ER+ve breast cancer cells) proliferation studies. Studies 
were carried out with individual estrogens and xenoestrogens and mixtures 
representing potential human exposure cocktails. Most combinations showed 
estrogenic additivity while some xenoestrogens in combinations had anti-estrogenic 
(ameliorative) effects. This has significant implications for the biological effects of 
complex cocktails humans are exposed to on a daily basis.  
 
In silico molecular modelling studies (Schrödinger platform) show an intimate 
connection between LBC and AF-2. This might explain the complex interactions 
(additive or ameliorative) between xenoestrogens in cocktails at the ER binding clefts. 
In silico studies showed that some xenoestrogens can interact at both the LBC and 
AF-2 (two-site binding model) and that this has implications for their biological 
effects. In an ER+ve breast cancer context interactions at ERs could influence cancer 
cell proliferation depending on the combination of xenoestrogens the person is 
exposed to.  
 
A descriptive cross-sectional study (n=227) that explored Canterbury (New Zealand) 
women’s and their daughters’ exposures to xenoestrogens showed that dietary and 
environmental xenoestrogens made a significant contribution (mean= 51.3%) to the 
total estrogenic load in women and was greater (58.1%) in their daughters. In a 
separate study blood samples were taken from women (n=47), and analysis (high 
performance liquid chromatography-mass spectrometry (LC-MS)) showed the 
presence of parabens (100.0% of women studied), phytoestrogens (93.6%) and EE2 
(2.1%). These results show that women were both exposed to and displayed blood 
levels of xenoestrogens. This could have implications in a breast cancer risk context.   
 
This thesis concludes that women and pre-pubertal girls are exposed to complex 
combinations of xenoestrogens. The combined estrogenic effects signal unscheduled 
(i.e. occurring before the scheduled time) cellular ER-mediated events; e.g., the earlier 
onset of puberty, and proliferation of ER+ve breast cancer cells. This is made more 
complex by the two-site binding model which can lead to amelioration of estrogenic 
effects. Thus, predicting xenoestrogen cocktail effects in a breast cancer risk setting is 
at best almost impossible. Further research will increase our understanding of the two-
site binding model and will provide opportunities for reducing exposure to breast 
cancer risk factors and perhaps developing new treatments for breast cancer.  
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Estrogens: the female sex hormones; refers to a group of three compounds (estrone, 
estradiol and estriol). Estrone is found in women and men in small amounts. It is 
produced in the adrenal gland and produced and stored in fatty tissue. Estradiol (E2) 
is the most active of the three compounds. It is produced by the ovaries in women and 
by the testes and adrenal glands in men. Estriol is the major estrogen produced during 
pregnancy. E3 is produced in large amounts in the placenta and levels in the mother 
and fetus rise continuously until just before birth.  
 
Androgens: the male sex hormones; refers to a group of five compounds, of which 
testosterone and dihydrotestosterone are the primary active hormones. 
Dihydrotestosterone is the metabolite of testosterone and is a more potent androgen 
than testosterone because it has a higher binding affinity for the androgen receptor. 
The other three androgens are intermediates in steroid hormone biosynthesis.  
 
Agonist: a compound that is able to bind to a receptor in a cell and produce the 
biological response that is controlled or triggered by the receptor. The ability to bind 
is known as affinity. The ability to produce the biological response is known the 
efficacy. An agonist can be endogenous such as the sex hormones or exogenous 
substances such as drugs or other chemicals. For the sex hormone receptors, the 
biological response that is of interest is gene transcription. For the sex hormone 
receptors, agonists activate (initiate, upregulate) receptor mediated transcription.  
 
Antagonist: a compound that is able to bind to a receptor in a cell and blocks or 
inhibits the biological response that is controlled or triggered by the receptor. An 
antagonist has affinity for the receptor but no efficacy. For the sex hormone receptors, 
antagonists block (inhibit, downregulate) receptor mediated transcription 
 
Agonist and antagonist are also used to describe the 3D conformation of the ER 
protein ligand binding domain (LBD) on ligand binding, specifically the difference in 
position of a-helix 12 (H12) of the LBD that occurs when an agonist or antagonist 
 xxiii 
ligand is bound; Thus, a ligand can be described as an agonist or antagonist and the 
ER can be described as taking an agonist or antagonist conformation.  
 
Selected estrogen receptor modulators (SERMs): a class of compounds that 
interact with the ER but unlike pure agonists or antagonists their mode of action 
depends on the cell type (tissue) they are acting on, resulting in selective inhibition or 
stimulation of estrogen-like action in the tissue.  
 
Xenoestrogen: a compound that an organism is exposed to via interactions that 
promote or interfere with ER-mediated gene transcription via binding with the ER. 
These include natural and synthetic estrogen mimicking compounds and exogenous 
naturally occurring estrogens. 
 
Coregulatory protein: a cellular protein that interacts with the ligand bound receptor 
at the ERE that enhances or suppresses gene transcription. Coregulator proteins that 
enhance or increase the rate of gene transcription are called coactivators and those 
that supress or decrease the rate of gene transcription are called corepressors. 
Coregulator protein activity is regulated by their absolute and relative expression 
levels in different cell types. Coregulator proteins allow for cell type and promoter 
specificity for transcription factors. 
 
Genomic signalling: The genomic signalling pathway is characterised by a change in 
gene expression which is mediated by direct interactions with the DNA. 
 
Non-genomic signalling: The non-genomic signalling pathway is characterised by 
rapid cellular responses mediated by secondary messenger proteins.  
 
Model: refers to the protein structure used for ligand docking obtained after the 
required processing and preparation of the published crystal structure is completed. 
The model also still contains the co-crystallised ligand.  
 
Additivity: In this thesis additivity describes the case in which xenoestrogens act 







The notation for ring designation and numbering substituent positions is illustrated in 
Figure A. The ring designation is often used in reference to other ligands that do not 
have this structure to describe the type of interactions with the receptor. Note that the 
ring designation given in Figure A for genistein does not follow the common 
convention for flavone ring designation, but is used in the ER literature.  
The binding cavity of the ERs is also described as having an A-ring end and a D-ring 
end, in reference to the usual orientation of E2 in the binding cavity. The A-ring end 



















































Chapter 1 Introduction 
 
 
1.1 General Introduction to Hormones 
A plethora of hormones regulates the body’s functions including growth and 
development, metabolism, electrolyte balance and reproduction (Hiller-Sturmhofel, et 
al., 1998). The endocrine system is a primary regulatory mechanism in the body. It 
synthesises and secretes hormones into the circulatory system and extracellular fluids 
in order to control and coordinate the function of distant organs, tissues and cells 
through receptor mediated responses. In general, there are 3 classes of hormone in 
mammals; steroid hormones (e.g. 17b-estradiol (E2)), protein and peptide hormones 
(e.g. insulin) and hormones derived from single amino acids (e.g. serotonin) 
(Leblebicioglu, et al., 2013). Endogenous steroid hormones are derived from a 
common precursor, cholesterol. They include estrogens, androgens, corticosteroids 
and progestogens (Fig. 1.1). Steroid hormones act via their cognate nuclear receptor; 
for example, estrogens act via the estrogen receptors and testosterone via the 
androgen receptor. Nuclear receptors are located in the cytoplasm and/or the nucleus 
of the target cells and are ligand inducible transcription factors, meaning that when 
the endogenous hormone diffuses into the cell, it binds a specific receptor protein and 
initiates transcription of target genes (Enmark, et al., 1999, Evans, 1988, Jensen, et 
al., 1972, Nilsson, et al., 2002, Nilsson, et al., 2001). Testosterone and E2 are two key 
steroid hormones important in the development of the fetus, particularly in 
determining whether the fetus develops male or female reproductive organs 
(Blaschko, et al., 2012, Jost, 1965, Mello, et al., 2005, Nef, et al., 2000). E2 is 
essential for developing primary and secondary sex characteristics in females, 
maintaining the female reproductive cycle, and in pregnancy (Zhu, et al., 1998). 
Progesterone is another endogenous steroid hormone that is involved in the complex 
regulation of normal female reproductive function. Progesterone has major 
physiological roles in the uterus, ovary, mammary gland and brain, and functions via 
its cognate nuclear receptor, the progesterone receptor (PR) (Graham, et al., 1997). 
The ratio of steroid hormones is crucial. If there are more estrogens present in a male 
fetus the formation of the sex organs is affected. This can cause birth defects such as 
Introduction 
 2 
hypospadias where the urethra forms abnormally, and cryptorchidism where one or 
both of the testes fail to descend (Aksglaede, et al., 2006).  
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Estrogens   
Figure 1.1: The key progestogens, corticosteroids, androgens and estrogens. 
 
There are two estrogen receptor (ER) isoforms, ERa and ERb, found in different 
amounts in different tissues, which respond differently to the estrogens. Therefore, the 
distribution of ER is important when assessing its role in each target tissue. The 
classical ERa targets include the uterus, mammary gland, placenta, liver, central 
nervous system, cardiovascular system and bones (Couse, et al., 1999, Couse, et al., 
1997, Zhang, et al., 2003). ERa responds to E2 with an increase in transcription of 
estrogen responsive genes, aiding in glucose metabolism and mating behaviour 
(Cross, et al., 1999, Laredo, et al., 2014, Mauvais-Jarvis, et al., 2013). The ERb target 
tissues include the prostate, testes, ovaries, pineal gland, thyroid, parathyroid, 
adrenals, pancreas, gallbladder, skin, urinary tract, lymphoid and erythroid tissues, 
lung, thymus, spleen, and localised areas of the brain (Couse, et al., 1997, Gustafsson, 
1999). ERb is essential for normal ovulation efficiency and immune responses but not 
for female or male sexual differentiation, fertility or lactation. ERa is often 
undetectable in ERb dominant tissues (Weiser, et al., 2008, Ying, et al., 2000); 
however, ERb is present in ERa dominant tissues and acts to control the expression 
of ERa, reducing the potency of estrogens acting via ERa (Hall, et al., 1999, Henley, 
et al., 2006, Lindberg, et al., 2003). There are 1069 estrogen responsive human genes 
corresponding to 1051 unique target promoters, according to the Knowledge Base for 
Estrogen Responsive Genes (KBERG) (Tang, et al., 2007). Many of these genes share 
ER isoform commonality, meaning both ER isoforms can induce gene transcription 
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1.2 Estrogens  
There are three endogenous estrogens, E2, estrone and estriol. They were discovered 
in the 1920’s and 1930’s by Adolf Butenandt and Edward Adelbert Doisy. Butenandt 
extracted them from horse urine and in 1939 won The Nobel Prize in Chemistry for 
his work on sex hormones (Tata, 2005). E2 cannot be stored in tissues, so is 
synthesised when required (Hanukoglu, 1992). The role and presence of estrone, E2 
and estriol in the body differ greatly depending on age, gender, stage of development 
and whether a woman is pregnant (Green, et al., 1987). The use of estrogens has had a 
huge impact, especially in human health and reproduction, for example the use of 
synthetic estrogens in contraception (Dhont, 2010).  
 
Total serum (free and protein bound) E2 levels vary substantially over the 
development and lifetime of a human and are different between males and females. 
Graham, (2012) reviewed the literature and demonstrated these differences (Fig. 1.2).  
These data highlight the dramatic increase in E2 levels at birth and the rapid decline 
in the first few days of life. Subsequently, the levels decline in post-menopausal 














There are many extensive reviews on the physiological effects of estrogens in the 
body in both males and females (Kuiper, et al., 1998, Nilsson, et al., 2002). To 
summarise, in females they are responsible for stimulating pubescent growth 
characteristics such as breasts, wider pelvis, fatty tissue around the buttocks and hips. 
In adults, they regulate the menstrual cycle, vaginal secretions and prepare the body 
for pregnancy by thickening the uterine lining. In males, E2 is mainly produced in the 
testes but also in the adrenal and pituitary glands. They promote the growth of the 
penis and development of the testicles, stimulate growth of facial and body hair, 
deepening of the voice and growth and maturation of sperm. High E2 levels are also 
linked to high libidos in men. In both males and females, they are important in 
cardiovascular function and the nervous system e.g. learning, memory, awareness, 
fine motor skills, temperature regulation, mood and reproductive functions.  
 
Estrogens are synthesised, when required, from the initial conversion of cholesterol to 
androstenedione. This can be directly converted into estrone or E2 via testosterone, 
catalysed by the enzyme aromatase. Estrone and E2 circulate around the body bound 
Figure 1.2: Human total (free + protein bound) serum E2 concentrations (Fowler, et 
al., 2011, Graham, 2012, Shutt, et al., 1974, Styne, 2004). Blue bars indicate male 
levels, pink bars indicate female levels. The overlap of male and female levels 
appears grey (graph from Graham, 2012 with permission).  
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to plasma-steroid binding hormones (known as steroid hormone binding globulin; 
SHBG) and albumin (Nagel, et al., 2004). Alternatively, E2 is also present as water 
soluble sulfate and glucuronide conjugates. E2 is metabolised via either hydroxylation 
by cytochrome P450 enzymes or via conjugation by estrogen sulfotrasnferases 
(sulfation) and UDP-glucuronyltransferases (glucuronidation). E2 is also 
dehydrogenated into the much less potent estrone. This is then stored in the body as 
estrone sulfate and is converted back into E2 when required (Liu, 2009). The unbound 
estrogens passively diffuse in and out of cells and only a small fraction 
(approximately 2%) of these unbound estrogens is responsible for their biological 
activity (Nagel, et al., 2004).  
 
1.2.1. 17b-Estradiol 
Estradiol is the primary and most potent of the endogenous female estrogen 
hormones. It exists as 2 isomers, 17a-estradiol and  17b-estradiol or E2, with the 
only distinguishing feature being the stereochemistry of carbon atom 17 (Dykens, et 
al., 2005, Littlefield, et al., 1990).  17a-Estradiol is not found in high concentrations 
and, compared with E2 has little to no estrogenic activity in ERa and ERb; 58% and 
11% compared with E2, respectively (Moos, et al., 2008). E2 is the dominant form of 
estradiol and is known to be responsible for the majority of estrogen action. It is 
synthesised from testosterone in many tissues and is responsible for gender 
determination in a fetus, the onset of puberty and maintaining female secondary sex 
characteristics including the reproductive cycle(Kleine, et al., 2016). E2 is also 
present in males but at much lower concentrations than in females of reproductive 
age; akin to concentrations found in prepubescent girls and post-menopausal women 
(Bergman, et al., 2012).  Women of child bearing age have much higher 
concentrations of E2, which fluctuate during the menstrual cycle. During the first part 
of the menstrual cycle, levels of E2 rise slowly then peak sharply, initiating ovulation 





Estrone is present at the lowest plasma concentration of the endogenous estrogens. 
Estrone and its sulfonated conjugated form, estrone sulfate, are most commonly found 
in menopausal women as their main form of estrogen. Most of the naturally occurring 
estrogen in post-menopausal women is synthesised in the adrenal cortex and other 
peripheral tissues from androstenedione (Kleine, et al., 2016). Estrone is a metabolite 
of E2 (Fig. 1.4), which is converted to E2, the more active estrogen, when needed 
(Hanukoglu, 1992). It is secreted by the ovaries along with E2 in women with normal 









Figure 1.3: Blood levels of estradiol in women showing the large changes during the 







Figure 1.4: E2 is metabolised to estrone via 17β-hydroxysteroid dehydrogenase. This 




Estriol is made in significant amounts by the placenta during pregnancy. When 
isolated from human placenta in 1931, the concentration of estriol found was much 
higher than the concentrations of estrone or E2. Studies show that although estriol 
levels present in pregnant women are high compared with non-pregnant and post-
menopausal women, estriol is not as potent as E2 (Heller, 1940). Interestingly, estriol 
was originally used to treat undesirable symptoms of menopause because it had been 
observed that estriol is present in the blood of women of reproductive age but is rarely 
found in the blood of perimenopausal women (Merrill, 1958). It has also been shown 
that estriol alone, acts as an ER agonist, but in the presence of E2 it acts as an 
antagonist (Melamed, et al., 1997). Estriol is a metabolite of E2; however, its 
biochemical function is not as well understood as other estrogens. E2 is converted to 







1.3 Estrogen Receptors 
The ERs are ligand inducible transcription factors that mediate most of the biological 
effects of estrogens in the body (Evans, 1988). There are 2 classes of ERs, (i) nuclear 
ERs (e.g. ERa and ERb) which belong to the nuclear receptor family and (ii) 
membrane ERs (e.g. GPER) (Hammes, et al., 2007) which are mainly G protein-
coupled receptors (Filardo, et al., 2000, Revankar, et al., 2005). The membrane ERs 
are cell surface receptors that are activated by endogenous estrogens (Soltysik, et al., 
2013). Current information is limited on the actions of these receptors; therefore, ER 
will refer to nuclear ERs from here on unless otherwise stated. There are two 
genetically distinct forms of ER; ERa and ERb. The ERa gene ESR1 is located on 
chromosome 6q25.1 and the ERb gene ESR2 is located on chromosome 14q23.2 
(Ariazi, et al., 2006, Ascenzi, et al., 2006). ERa consists of 595 amino acids and has a 
molecular weight of 66 kDa. Comparatively, ERb consists of 530 amino acids and has 








a molecular weight of 55 kDa. ERa was first identified in 1958, and cloned in 1986 
(Green, et al., 1986). ERb was not identified until 1996 (Mosselman, et al., 1996).  
 
Both ERa and ERb have 6 functional domains (A-F) which have varying amino acid 
commonality between domains (Couse, et al., 1997, Hall, et al., 2005, Kumar, et al., 
2011). These are the N-terminal or A/B domain, the DNA binding domain (DBD), the 
ligand binding domain (LBD), the hinge region (D) and the F or c-terminal region 
(Fig. 1.6) (Kumar, et al., 2011). Although the primary structure of these domains is 
well defined, there is limited understanding of the structural dynamics of ERs, 
including intra- and intermolecular communication under the influence of various 
associated coregulatory proteins and post translational modifications. A major 
obstacle to understanding the structural dynamics of ERs has been the complete 
structural characterisation of the ERs. Some regions (i.e. the DNA and ligand binding 
domains) have been crystallised and reside in a well ordered state (Brzozowski, et al., 
1997, Huang, et al., 2013, Johnson, et al., 2012, Nettles, et al., 2007, Simons, et al., 
2013, Wu, et al., 2005); however, other regions reside in an intrinsically disordered 
(ID) state, making any x-ray crystallography techniques almost impossible 
(Dahlmanwright, et al., 1995, Kumar, et al., 2003, McEwan, et al., 1996, Shen, et al., 
1996, Simons, et al., 2013, Warnmark, et al., 2001).  
 
 
Figure 1.6: Schematic representation of estrogen receptor protein structural domains. 
Within each segment, the number of amino acid residues is given. The % homology is 







1.3.1. ER Structure  
1.3.1.1. The N-terminal Domain 
The N-terminal domain or the A/B region of ERs do not have well-defined tertiary 
structure and exist in an ID state (Ascenzi, et al., 2006). One of the reasons for this is 
the ID region appears to help promote molecular recognition by providing surfaces 
capable of binding specific target molecules. This has been confirmed by circular 
dichroism, which showed 67% of the ERa N-terminal domain contains a random coil 
conformation. Comparatively, ERb has over 80% random coil conformation in its N-
terminal domain (Combet, et al., 2000, Warnmark, et al., 2001). It is thought that the 
high percentage of random coils allows for random sampling of the environment and 
facilitates appropriate concentration and affinity of the binding partners and proteins 
(Kumar, et al., 2003). Although the N-terminal region is not well defined structurally, 
it is thought to be involved in transcriptional regulation and has the activation 
function (AF)-1 functional region. AF-1 activates target genes by interacting with 
components of the transcriptional machinery that regulate gene transcription (Enmark, 
et al., 1999). It is constitutively active e.g. ligand independent. Among the ER 
transcription machinery, it is also regulated by insulin like growth factors and 
epidermal growth factors (Cozzini, et al., 2004, Hall, et al., 2005). This region 
exhibits on of the most distinctive differences between ERa and ERb; with the ERb 
region being significantly shorter (Kumar, et al., 2011). Interestingly, it is thought that 
the AF-1 region on the ERb isoform is a repressor region rather than an activation 
region as the name suggests (Delaunay, et al., 2000, Hall, et al., 1999).  
 
1.3.1.2. The DBD 
The DBD is the most similar region of the two ER isoforms, with 95% amino acid 
commonality (Cowley, et al., 1997). This region binds with a high affinity to specific 
DNA sequences in target gene promoter regions known as estrogen responsive 
elements (ERE). The ERE is composed of a palindromic hexanucleotide 5’ 
AGGTCAnnnTGACCT3’ (where n=any base) (Kleinhitpass, et al., 1989, Roche, et 
al., 1992, Wood, et al., 2001). Unsurprisingly, due to their high amino acid 
commonality, both ER isoforms share a high proportion of EREs (Kumar, et al., 
2011). The DNA binding region plays an important role in receptor dimerization, 
providing the surfaces for the head to head dimerization of two receptor molecules. It 
also dictates the binding affinity of the ER and modulates the recruitment of 
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coregulator proteins (Ascenzi, et al., 2006, Enmark, et al., 1999). The binding of the 
dimerised ER at EREs allows recruitment of transcriptional machinery and specific 
coregulatory proteins to transcribe the specific ER target genes. It comprises P box, D 
box, and zinc finger subdomains. The zinc finger subdomains are comprised of 8 
cysteine residues that coordinate with two Zn 2+ ions. The P box actively interacts 
with the ERE nucleotides and the D box is present at the dimerization interface (Figs. 
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Figure 1.7: Schematic diagram of type II zinc finger DNA binding domain of the 
ERs. Each circle represents one amino acid. The CI zinc finger interacts specifically 
with 5 base pairs of DNA and determines the DNA sequences recognized by the ER. 
The blue amino acids in the knuckle of the CI zine finger are in the P box and allow 
recognition of the ERE. The orange amino acids within the knuckle of the CII zinc 
finger constitute the D box, which is important for dimerization and contacts with the 





1.3.1.3. The D Domain 
The D domain, or the hinge region, has not been well characterised but is thought to 
contribute to the flexibility of the receptor structure, as it is located between two 
highly conservative domains of the receptor molecule, the DBD and ligand binding 
domain. There is only 36% amino acid commonality between the two ER isoforms, 
and this is thought to influence the DNA binding properties of individual receptors, 
while serving as an anchor for certain corepressor proteins (Ascenzi, et al., 2006, 





Figure 1.8: Tertiary structure of the ERa DBD dimer complexed with DNA and zinc 
(shown is space filling mode). Atom co-ordinates from PDB entry 1HCQ. Image 
produced in Schrödinger Suite 2017 Maestro. 






1.3.1.4. The LBD 
The LBD is the most studied region of the ERs. The LBD is composed of two binding 
sites, the ligand binding cleft (LBC), where E2 generally binds, and activation 
function (AF)-2 where coregulator proteins interact (Fig. 1.9) (Zhang, et al., 2003). 
The LBD has been well characterised individually, but not in the context of the whole 
receptor. It has been the source of many structural studies which have led to a 
significant proportion of current knowledge about the ERs (Blizzard, et al., 2005, 
Brzozowski, et al., 1997, Manas, et al., 2004, Mocklinghoff, et al., 2010, Shiau, et al., 




The structure of the ERs was first shown by Brzozowski (1997) and has been 
extensively reviewed since then; however, there has been no substantial new 
information on ERs since then but rather new interpretations of the structural 
dynamics and importance of the binding sites of the ERs(Ye, et al., 2018). The LBD 
has a globular structure that houses 11 a helices (Brzozowski, et al., 1997, Wu, et al., 











Figure 1.9: Tertiary structure of the ERα LBD with E2 (left) and ERb LBD with E2 
(right). Ribbons illustrate the α-helix protein structure. Thin lines illustrate flexible 
loops which are disordered regions connecting two ordered regions. Ribbons with 
arrows illustrate b sheet structure. The LBC (red) and AF-2 (green) are highlighted by 
dashed circles. Atom co-ordinates from PDB entry 1ERE (ERa) and 3OLS (ERb). 
Image produced in Schrödinger Suite 2017 Maestro.  
Introduction 
 14 
lining up on one side of helices 1 and 3 with helices 7, 10 and 11 on the other side. 
Additionally, Helix 12 resides in a perpendicular orientation depending on the ligand 
bound to the LBC (Fig.1.12) (Jordan, et al., 1985, Moore, et al., 2010, Robertson, 
2004). For example, helix 12 will cap the LBC when an agonist is bound to the LBC; 
however, it will reside in a slightly different orientation, often blocking the AF-2 site, 
when an antagonist is bound (Fratev, 2015). The agonist orientation of helix 12 allows 
for E2 to be buried in a highly hydrophobic environment (Brzozowski, et al., 1997). 
E2 interacts via its hydroxyl groups at positions 3 and 17, which plays a crucial role in 
orienting the hormone in the hydrophobic pocket (Moore, et al., 2010). The A and D 
rings are hydrogen bonded to Glu353 (305 ERb), Arg394 (346 ERb), water and 







Figure 1.10: Hydrogen bonding network of E2 in ERα (i) and ERb (ii). Atom co-




The AF-2 site 
The AF-2 site binds both the heat shock protein (e.g. when the ER is in its inactive 
state) and coregulatory proteins (e.g. coactivators and corepressor) (Huang, et al., 
2013). Like the LBC, the AF-2 site is a highly hydrophobic groove and is formed by 
helices 3, 4, 5 and 12 and the turn between 3 and 4 (Shiau, et al., 1998). Coregulatory 
proteins interact via a highly conserved LxxLL motif (where L=leucine and x=any 
other amino acid). The AF-2 site also functions cooperatively with the AF-1 region in 
the ERa isoform, synergistically activating the ER and thus transcription (Metivier, et 
al., 2001). The AF-2 site is strictly ligand dependent (Cozzini, et al., 2004), requiring 
ligand binding at the LBC, which causes a conformational change exposing the AF-2 
site.  
 
Partial and full antagonists induce conformations at the AF-2 region that are distinct 
from that observed in the presence of a pure agonist (Pike, et al., 2001). Classic 
examples are the breast cancer drugs raloxifene and tamoxifen, and the tamoxifen 
metabolite 4-hydroxytamoxifen (4-OHT) which both have structural similarities to E2 
(Fig. 1.11).  
 
 
Figure 1.11: Structures of (a) tamoxifen, (b) 4-hydroxytamoxifen (4-OHT) and (d) 




The binding of these drugs is accompanied by large structural changes in the tertiary 
structure of both ER isoforms (Brzozowski, et al., 1997, Pike, et al., 2001, Shiau, et 
al., 1998). The large piperidine extensions of the ligand provoke steric clashes that 
prevent H12 from adopting its characteristic conformation and thus formation of the 
AF-2 site. Instead, H12 lies in the would-be AF-2 site via a LxxML motif (where 
L=leucine, M=methionine and x=any other amino acid) (Fig. 1.12) (Pike, et al., 
2001).  
 
Interestingly, ERs associate with corepressors far more frequently than coactivators. 
The ERs associate with corepressor proteins that silence their activity in the absence 
of ligands, and activation therefore, involves displacement of the associated 
corepressors by the coactivators, an event that permits the functional interaction of the 
receptor with the cellular transcriptional machinery. More recently coregulator 
proteins have been studied, mainly through the use of peptides which highlight their 
key interactions with the ERs at AF-2. These are Lys362 and Glu542 (ERa) (Sun, et 
al., 2011) and Lys314 and Glu493 (ERb) (Wang, et al., 2006). These amino acids are 
known as capping molecules and are what initially attracts the coregulatory proteins 
to interact with the AF-2. The coregulatory proteins have multiple (up to three) 
H12
AF-2
Figure 1.12: Tertiary structure of ERa complexed with raloxifene (left) and 4-
hydroxytamoxifen. The AF-2 site is occupied with H12. Atom co-ordinates from 
PDB entry 1ERR (raloxifene) and 3ERT (4-hydroxytamoxifen). Image produced in 
Schrödinger Suite 2017 Maestro. 
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LxxLL (L=leucine and x= any other amino acid residue) motifs, where the carbonyl 
group on the amino acid backbone hydrogen bonds to the lysine and glutamic acid in 
the AF-2 domain, along with other key amino acid residues (Nolte, et al., 1998, Shiau, 
et al., 1998). These include van der Waals interactions with Leu310, Phe319, Leu324, 
Gln327, Val328, Leu331, Lue332, Leu490 and Met494 (Fig. 1.13) (Nolte, et al., 
1998). Current structural information on these interactions is limited due to the use of 
peptides rather than whole protein. Coregulatory proteins are distinctly larger than 
ERs, with their size ranging upwards of 160 kDa. Therefore, any complete structural 













Figure 1.13:Tertiary structure of the ERbAF-2 site complexed with steroid receptor 
coactivator (SRC) 1 peptide (red). Key amino acid interactions are highlighted.  Atom 




However, over the last decade it has become clear the AF-2 binds more widely than 
first anticipated. Interestingly, Wang and colleagues, surprisingly, found 4-OHT can 
displace H12 in the initial antagonist conformation induced by 4-OHT binding at the 
LBC and bind itself to the AF-2 site, suggesting a dual mechanism of action for the 
highly used breast cancer therapeutic (Fig. 1.14) (Wang, et al., 2006). Although this is 
still heavily debated, this possibility of small molecule binding may provide new 
insights into AF-2 interactions; this interaction could even suggest a new possible 


















Figure 1.14: Tertiary structure of ERb complexed with 4-hydroxytamoxifen (4-OHT) 
at both the LBC and AF-2. Atom co-ordinates from PDB entry 2FSZ. Image 
produced in Schrödinger Suite 2017 Maestro. 
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1.3.1.5. The F Region 
The F region or C-terminus region contains 42 amino acid residues and is known to 
impact homo-and hetero-dimerisation (Montano, et al., 1995). It also aids in the 
binding of the heat shock protein when the ERs are in an inactive state, thus 
modulates ligand mediated transcription. In addition, in an unliganded state, 
chaperone proteins interact with the F region, opening the binding cavity and making 
it accessible to the ligand (Ascenzi, et al., 2006, Yang, et al., 2010).  
 
Therefore, ERs behave dynamically such that their kinetic behaviour allows them to 
readily interact with DNA, ligands, coregulatory proteins and chromatin. Two ER 
isoforms exist and share distinct regions of sequence homology. They have both 
overlapping and unique functions which leads to complex mechanisms of action via a 
dynamic network of cell mediated responses (Ascenzi, et al., 2006, Yang, et al., 
2010).  
 
1.3.2. ER Function 
The ER has been defined as a cell receptor with exclusive nuclear localisation and its 
activity was considered solely derived from its direct interaction between EREs and 
the E2-ER complex, leading to initiation of gene transcription. Over the last 10-15 
years, knowledge of this classical genomic mechanism of action has been enriched by 
the discovery of other alternative modes of action by the E2-ER complex. The 
complexity of cell biology results in interactions at the DNA and crosstalk of different 
pathways, both initiated by E2-ER complex binding. These different modes of action 
can be divided into three sub-classes of ER action: classical genomic, non-classical 
genomic and non-genomic.  
 
1.3.2.1. The Classical Genomic Pathway 
The best understood classical genomic pathway is where the ER is bound to a heat 
shock protein (HSP), usually HSP90 (90 = 90 kDa), via the AF-2 site.  When a ligand 
(e.g. E2) binds in the LBC, it causes a conformational change that releases the ER 
from the HSP and closing of helix 12 into the AF-2 site (Zilli, et al., 2009). The 
receptor undergoes dimerisation and phosphorylation and translocates to the nucleus 
where it binds to the EREs on the DNA via the DNA binding domain (Ascenzi, et al., 
2006). The AF-1 and AF-2 mediate positive regulation of gene expression of ER. The 
two AF domains often act synergistically, although some gene promoters are activated 
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independently by either AF-1 or AF-2 (Benecke, et al., 2000). The transcriptional 
activity of ER is enhanced by binding of coactivators such as SRC1, TIF2, AIB1, etc. 
(Kim, et al., 2016). These proteins form large complexes that enhance ER driven 
transcription, including recruitment of histone acetyltransferases at the promoter site. 
Some coactivators also have enzymatic activities that post translationally modify the 
chromatin, initiating unwinding, thus exposing the transcription site to the 
transcription machinery (e.g. RNA polymerase) (Bulynko, et al., 2011). Part of the 
complex formed at the EREs includes proteins which aid in ER degradation. E1, E2 
and E3 ligases mark the ER for proteasomal degradation via the ubiquitin proteasome 
pathway, allowing for further access to the EREs via new E2-ER complexes (Zhou, et 
al., 2014). The ER is then recruited to the proteasome where it is degraded (Fig. 1.15) 






























1.3.2.2. The Non-classical Genomic Pathway 
Alternative ER binding sites to the EREs have been identified. This involves direct 
interaction of the ERs with ER transcription factors where the ER does not bind 
promoter DNA (i.e. protein-protein interactions). This pathway is still induced via 
ligand activation of ER; however, complexes are formed with ligand induced 
activation of ER/specificity protein (Sp) and ER/activation protein 1 (AP-1). AP-1 is a 
complex of two oncogenic transcription factors that form a heterodimer, jun and Fos 
(Fig. 1.16) (Bjornstrom, et al., 2005, Cheung, et al., 2005). This indirect ERE 
interaction by the ER is the only difference between the classical and non-classical 
genomic signalling pathways.  
Figure 1.15: Illustration of the classical genomic signalling pathway. The ER 
monomer is activated upon E2 ( ) binding, facilitating dissociation from the heat 
shock protein (HSP), dimerisation and translocation to the nucleus. The ER dimer 
binds to the estrogen response element (ERE) on the DNA and the coactivator (CoA) 
complex is formed. The ER is degraded at the proteasome (Prot) leading to altered 











Figure 1.16: Illustration of the non-classical genomic signalling pathway. The ER 
monomer is activated upon E2 ( ) binding, facilitating dissociation from the heat 
shock protein (HSP), dimerisation and translocation to the nucleus. The ER dimer 
binds to the estrogen response element (ERE) on the DNA via an intermediate protein 
(AP-1) and the coactivator (CoA) complex is formed. The ER is degraded at the 
proteasome (Prot) leading to altered gene transcription. P=phosphate and 




1.3.2.3. The Non-genomic Pathway 
Several reports have shown the ability of ERs to interact with cytoplasmic kinases via 
crosstalk between cytoplasmic kinase pathways and genomic ER action. Various 
signalling pathways are activated upon E2 binding to ERs. These rapid events may be 
classified into four main signalling cascades: (i) phospholipase C (PLC)/protein 
kinase C (PKCs) (Ferret, et al., 2001, Incerpi, et al., 2003, Marino, et al., 2001, 
Marino, et al., 1998, Morley, et al., 1992, Picotto, et al., 1999), (ii) Ras/Raf/mitogen-
activated protein kinase (MAPK) (Dos Santos, et al., 2002, Klinge, et al., 2005, 
Marino, et al., 2002, Migliaccio, et al., 2002, Russell, et al., 2000, Tanaka, et al., 
2003, Watters, et al., 1997, Woo, et al., 2005), (iii) phosphatidyl inositol 3 kinase 
(PI3K)/AKT (Acconcia, et al., 2005, Alexaki, et al., 2006, Bjornstrom, et al., 2005, 
Castoria, et al., 1999, Castoria, et al., 2001, Chambliss, et al., 2005, Levin, 2005, 
Marino, et al., 2005, Marino, et al., 2003, Simoncini, et al., 2000) and (iv) 
cAMP/protein kinase A (PKA) (Chen, et al., 1998, Farhat, et al., 1996, Gu, et al., 
1996, Malyala, et al., 2005, Picotto, et al., 1996, Picotto, et al., 1999). These 
pathways present numerous interactions with several other pathways. For example, 
the ERa-E2 complex interactions with the IGF-1 receptor (IGF-1R), leading to IGF-
1R activation and hence to MAPK signalling pathway activation (Kahlert, et al., 
2000). In addition, the ERa-E2 complex activates the epidermal growth factor 
receptor (EGFR) leading to an increase in the extracellular regulated kinases (ERK) 
and PI3K/AKT activities (Dos Santos, et al., 2002, Driggers, et al., 2002, Improta-
Brears, et al., 1999, Kupzig, et al., 2005, Razandi, et al., 2003, Zhang, et al., 2004). 
These pathways also have a crucial role in the E2 action as a survival agent. They 
enhance the expression of bcl-2, an anti-apoptotic agent, block the activation of 
p38/MAPK, reducing pro-apoptotic caspase-3 activation and promote G1 to S phase 
transition via the enhancement of cyclin D1 expression (Fig. 1.17) (Acconcia, et al., 
2005, Marino, et al., 2002, Marino, et al., 2003). 
 
ERb has the opposite effect on these signalling pathways. It regulates E2 signalling 
when co-expressed with ERa, causing a concentration dependent reduction in ERa 
mediated transcription (Matthews, et al., 2003). It also represses cyclin D1 expression 
and block ERa mediated induction when both ERs isoforms are present (Kilker, et 
al., 2004, Liu, et al., 2002). Recently ERb has also been reported to induce persistent 
membrane-initiated activation of p38/MAPK without any interference on survival 
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proliferative pathways, thus restoring the balance with apoptosis (Acconcia, et al., 
2005). Human epidermal growth factor receptor 2 (HER2) can also be down regulated 
by ERb and PTEN is upregulated, both of which lead to the down regulation of the 
PI3K/AKT pathway (Fig. 1.17) (Lindberg, et al., 2011). ERb has been considerably 
understudied in ER cell signalling and information is scarce. However, the 
significance of ERa signalling regulation is likely to have a major impact on these 
pathways.   
 
Figure 1.17: Illustration of the non-genomic signalling pathway. The ER monomer is 
activated upon E2 ( ) binding, facilitating dissociation from the heat shock protein 
(HSP) and dimerisation. The ER interacts with cell signalling pathways up/down-
regulating processes such as apoptosis and cell proliferation (from Spencer, 2016 and 






Clearly, ER actions are complex and importantly allow for tight regulation of 
estrogens in the body. However, the genomic and non-genomic pathways, although 
often studied independently, appear to be inherently linked. Therefore, when 
considering the actions of ERs in the non-genomic pathway (e.g. cell signalling 
pathways), not only does the cell signalling pathway become activated but in turn the 
ER is post-translationally modified (e.g. phosphorylated) which promotes the 
genomic pathway. For example, ligand bound ERa binds to SRC and Pi3K 
complexes leading to AKT and MAPK activation. In turn, ERa is post translationally 
modified at sites such as Try537 which allows recruitment of the E3 ligase, E6 





Figure 1.18: Illustration of the interplay between genomic and non-genomic 
signalling pathways. The ER dimer is phosphorylated by kinase proteins, which is 
required for genomic signalling, whilst activating non-genomic signalling pathways. 
E2 = ,  CoA= coactivator complex, Prot= proteasome, P=phosphate and 
Ub=ubiquitin. (Elements of this diagram were derived from Zhou et al., 2014. The 




This is just one example of the many post translational modifications of the ER which 
influence the stability, subcellular localisation, transcriptional activity and hormone 
sensitivity of the ligand activated ER-transcriptional apparatus. There are 
approximately 29 sites on the ER that undergo either phosphorylation, methylation, 
acetylation, sumoylation, palmitoylation or ubiquitylation (Le Romancer, et al., 
2011). Activation of these sites drives rapid signalling kinase cascades which lead to 
non-genomic mitogenic effects. These post translational events modulate ER function 
by altering its binding to ligands, to target gene promoters or to ER coactivators 
(Campbell, et al., 2001, Legoff, et al., 1994, Likhite, et al., 2006, Rayala, et al., 
2006).  
 
Altering these key ER functions can influence gene expression and the genomic 
pathway. There are many other interactions between hormonal and growth factor 
signalling pathways. These multiple signalling pathways downstream of receptor 
tyrosine kinases (e.g. EGRF) and insulin-like growth factor 1 receptor (IGF1R)) co-
ordinately regulate the dynamics of the ER mediated transcriptional regulation. 
MAPK mediates ER phosphorylation at S294, and cyclin E-cyclin dependent kinase 2 
(CDK2) phosphorylates ER at S342 to prime the ER-S-phase kinase associated 
protein 2 (SKP2) interaction.  
 
One of the key roles for post translational modifications of the ER is aiding in the 
formation of the coactivator complex and recruitment of proteins to the complex. 
There is a series of post translational modifications that lead to the recruitment of the 
transcriptional machinery and the degradation of the ER to the proteasome. The 
coactivators often have enzymatic activities which enable them to acetylate, methylate 
or demethylate (Lonard, et al., 2007), helping overcome the physical constraints of 
the highly coordinated chromatin encased template (Zhou, et al., 2014). Coactivation 
allows recruitment of the transcriptional machinery and thus gene transcription. The 
coactivators then recruit the appropriate ubiquitination proteins (E1, E2 and E3 
ligases) which makes a polyubiquitin chain and thus signals to the proteasome that the 
ER is ready for degradation.  
 
These actions are not isolated to endogenous estrogens and antagonists. They can be 





Xenoestrogens (from the Greek ξένος ‘xenos’ meaning foreign) are compounds that 
structurally mimic E2. To date, over 160 xenoestrogens have been identified (Brody, 
et al., 2006, Brody, et al., 2003, Brody, et al., 2007), being either natural or synthetic, 
many found in the environment (e.g. food). The chemical attributes for E2 mimicry 
are an aliphatic hydroxyl group (corresponding to the 17b-hydroxyl of E2) and an 
aromatic hydroxyl group (corresponding to the A ring 3-hydroxyl group of E2) 
separated by approximately 10 Å of hydrophobicity in the correct three-dimensional 
spatial arrangement (Ye, et al., 2018). In general, xenoestrogens are considered ER 
agonists but each has a different binding affinity; so, the cellular response they trigger 
depends on their individual binding affinity – this is termed estrogenicity. There have 
been numerous studies on the adverse effects of xenoestrogens in both animal and 
human populations. In animals they have been associated with reduced penis length 
and low levels of testosterone in American Alligators (Alligator mississippiensis) 
(Guillette, et al., 1996), imposex in molluscs (e.g. dog whelks (Nucella lapillus)) 
(Davies, et al., 1997) and vitellogenin biosynthesis in male fish (Kidd, et al., 2007, 
Sumpter, et al., 1995). 
 
In humans, xenoestrogens are thought to be one of the leading causes of adverse 
effects in human health and development due to their frequency in occurrence in the 
environment (UNEP/WHO, 2013). Studies have shown the profound effects of 
xenoestrogen exposure on the development and function of the male reproductive 
tract, namely abnormalities including hypospadias and cryptorchidism (Aksglaede, et 
al., 2006). The most notable finding was the increased incidence of hypospadias in 
sons of women consuming a vegetarian diet during pregnancy (North, et al., 2000). 
Indeed, vegetarians do not eat meat which makes soy and beans their main source of 
protein. Soy and beans are a major source of isoflavones (Kaufman, et al., 1997); 
therefore, it is possible that vegetarians are exposed to more xenoestrogens. A number 
of studies have also linked the decline in the male sperm count to xenoestrogen 
exposure, suggesting a decline between 1.5% and 3% per year (Carlsen, et al., 1992, 
Levine, et al., 2017, Swan, et al., 2000). The age of puberty has decreased over the 
last century, with the average age being 12 years old in the USA, down from 16-17 
years old at the turn of the 20th century (Pierce, et al., 2012). The onset of puberty is 
regulated by gonadotrophins which in turn stimulate an increase in estrogen levels 
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(MacGillivray, 2004). Unsurprisingly, xenoestrogens have been suggested as one of 
the main reasons for this change but of course, there have been changes in diet and 
nutrition during that time which could at least in part explain this (Willett, 2013).   
 
Sex-linked cancers are one of the most studied adverse human health effects 
associated with xenoestrogen exposure. Breast, testicular and prostate tissues all 
express ERs and therefore, respond to xenoestrogens in the same way it would to 
estrogens – proliferation. It is not unexpected that xenoestrogens can cause 
proliferation and thus the initiation and progression of cancer cells (Fernandez, et al., 
2010, Forouzanfar, et al., 2011).  
 
Some xenoestrogens (Fig. 1.19) are components of cosmetics, personal care products 
and pharmaceuticals, and are found naturally in food, as well as contaminants being in 
food and water, so exposure occurs by several routes including ingestion (Allmyr, et 
al., 2006, Allmyr, et al., 2008, Dayan, 2007, Muller, et al., 1998, Waring, et al., 
2008), absorption through the skin (Chedgzoy, et al., 2002, Darbre, et al., 2008, 
Dayan, 2007, Hayden, et al., 1997, Jungbauer, et al., 2014) and inhalation (Rudel, et 
al., 2009). Once xenoestrogens reach the bloodstream, they are subject to a variety of 
metabolic reactions designed to facilitate elimination from the body. It is also possible 
for metabolites to be estrogenic (Zalko, et al., 2003). Currently, most chemicals that 
are regulated, are regulated individually and safe levels determined (e.g. NOAEL); 
however, exposures to environmental chemicals is usually part of complex cocktail 
involving potentially combined effects – these cocktails are not regulated. In the 
context of xenoestrogens, since the individual components of a cocktail work through 
the same receptor interaction, it is very likely they will at least be additive. Therefore, 
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Phytoestrogens (from the Greek φυτόν ‘phytos’ meaning plant) are plant derived 
xenoestrogens, naturally occurring in foods such as beans and other legumes, grains, 
green vegetables (e.g. Brussel sprouts and spinach) and coffee (Grace, et al., 2003). 
They mainly belong to a large group of substituted natural phenolic compounds: the 
coumestans, prenylflavoniods and isoflavones. The most extensively researched are 
the isoflavones, commonly found in soy beans. Other phytoestrogens include the 
lignans and curcuminoids. Phytoestrogens were first observed in 1926 but have been 
extensively used in traditional medicines. Women have long used the hop plant 
(Humulus lupulus), which contains the prenylflavoniod 8-prenylnaringenin, to initiate 
their menstrual cycle (Verzele, 1986).  
 
Phytoestrogens exert their primary effects through ER binding and have a high 
structural analogy to E2. Interestingly, many phytoestrogens preferentially bind to 
ERb over ERa (Kuiper, et al., 1997, Lehmann, et al., 2008). It is thought that this 
preference is a result of the spatial arrangement of the hydroxyl groups.  
 
In addition, phytoestrogens have been associated with protective actions against a 
variety of cancers, cardiovascular disease and osteoporosis (Adlercreutz, 2002, 
Bhathena, et al., 2002, Cederroth, et al., 2009, Hughes, 1988, Jungbauer, et al., 2014, 
Karahalil, 2005, Patisaul, et al., 2010, Zhao, et al., 2011). The health benefits and 
potential adverse effects attributed to phytoestrogens are varied and controversial 
(Andres, et al., 2011, Bennetau-Pelissero, 2016, Rietjens, et al., 2017, Rietjens, et al., 
2013, Wuttke, et al., 2006). This has contributed to the lack of regulations around 
xenoestrogens in general, especially in mixtures.  
 
Genistein 
Genistein is a major isoflavone found in beans, including soy beans, and some green 
vegetables (e.g. spinach) (Coward, et al., 1993). Soy flour is commonly used in food 
manufacturing and is widely used in breads and cereals (Farzana, et al., 2015). 
Genistein preferentially binds to ERb over ERa (Kuiper, et al., 1997). Genistein has 
been extensively studied and is known for its possible protective effects against breast 
and prostate cancer (Spagnuolo, et al., 2015). However, there is a concentration 
dependence to the protective effects, where genistein is only protective at high 
exposure concentrations and at low exposure concentrations it promotes cancer cell 
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growth. Studies in MCF-7 cells show that exposure concentrations in the nanomolar 
range promoted cell proliferation, while concentrations in the micromolar range had 
an anti-proliferative effect. Interestingly, when E2 is present nanomolar 
concentrations of genistein induce an anti-proliferative effect (Chang, et al., 2008). 
Similar outcomes have been observed in women of child bearing age (e.g. high E2 
levels) experiencing protective effects against breast cancer when exposed to 
genistein compared to post-menopausal women (e.g. low E2 levels) who experience 
promotive effects when exposed to genistein (Rice, et al., 2006).  
 
Daidzein 
Daidzein is also a major isoflavone found in soy and soy based products (Coward, et 
al., 1993). Daidzein also preferentially binds to ERb and has similar protective effects 
to genistein (Kostelac, et al., 2003). Daidzein and genistein are very similar 
structurally and only differ by the extra hydroxyl group at carbon atom 5 on genistein 









Equol is a metabolite of daidzein produced by bacteria present in the human gut 
(Moors, et al., 2007). Two isomers of equol exist, but the gut bacteria only produce 
the S-isomer which is estrogenic (Fig. 1.21). It is more estrogenic than daidzein 
(Sathyamoorthy, et al., 1997). Interestingly, only about 30-50% of people have the 
intestinal bacteria that make equol, so equol is only found in a certain percentage of 
the human population (Sanchez-Calvo, et al., 2013). The S-isomer of equol 



















Kaempferol is a flavonoid found in fruit and vegetables such as broccoli, apples, 
strawberries and beans (Somerset, et al., 2008). Kaempferol has not received a lot of 
attention until recently when studies have suggested it has anti-cancer properties. 
Kaempferol has been demonstrated to invoke the downregulation of various cell 
signalling pathways that inhibit cancer development (Ramos, 2007). Studies in MCF-
7 cells have shown that kaempferol has both estrogenic and anti-estrogenic activity. 
As for the observed responses with other phytoestrogens, kaempferol induces MCF-7 
cell proliferation at low concentrations, with anti-proliferative effects at high 
concentrations or in combination with E2 (Oh, et al., 2006). Therefore, it has also 
been earmarked as a potential breast cancer therapeutic. Unsurprisingly, kaempferol 
also has a preference for ERb over ERa (Kuiper, et al., 1998).  
 
Curcumin 
Curcumin is the principal curcuminoid of turmeric and is often sold as a herbal 
supplement.  It is also used in cosmetics, food flavouring, and food colouring 
(Aggarwal, et al., 2003). Curcumin is a tautomeric compound existing in enolic form 
in organic solvents and as the keto form in water (Fig.1.22) (Bertolasi, et al., 2008, 
Nie, et al., 2008). Curcumin has been extensively studied in laboratory and clinical 
studies and is thought to be a potential cancer therapeutic (Adiwidjaja, et al., 2017). 
Again, like other phytoestrogens, it has been shown to have concentration-dependent 
proliferative/anti-proliferative effects in MCF-7 cell studies (Lv, et al., 2014). 
However, the bioavailability is low and therefore, curcumin has not progressed into 
therapeutic clinical studies to date (Hatcher, et al., 2008, Ireson, et al., 2001, Ireson, et 






















Tetrahydrocurcumin is a metabolite of curcumin, but is much more stable, and easily 
absorbed by the gastrointestinal tract due to the lack of double bonds beside the keto 
groups (Okada, et al., 2001). It is thought that tetrahydrocurcumin is one of the 
genuinely bioavailable forms of curcumin, and therefore, the compound responsible 
for the anticancer properties observed in some curcumin studies (Han, et al., 2016). 
However, its potential anticancer properties have only recently been observed, and are 
not well understood. Tetrahydrocurcumin is known to have dose-dependent anti-
proliferative effects in MCF-7 cells (Han, et al., 2016). Although these anti-
proliferative effects have been suggested to be a result of the activation of apoptosis, 






















Figure 1.22: Structures of the curcumin enolic and keto stereoisomers. 
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1.4.2. Synthetic Xenoestrogens 
Synthetic xenoestrogens are widely used in industrial compounds, such as BPA, and 
pharmaceuticals, such as EE2. Synthetic xenoestrogens elicit their effects via ERs 
which lead to down-stream biological effects such as cell proliferation. Interestingly, 
the public often perceive synthetic xenoestrogens to be more risky than natural 
xenoestrogens, even though they act via the same mechanism.  
 
Bisphenol A 
Bisphenol A (BPA) is a monomer used to manufacture polycarbonate plastics (Fig. 
1.2 and 1.23) and epoxy resins used in protective coatings of food cans and sealants in 
dentistry (Calafat, et al., 2005). BPA is the xenoestrogen that has received the most 
public attention, leading to WHO enquiries into its safety (EFSA, 2015, WHO, 2010). 
Although it is deemed safe due to its high rate of metabolism, many countries 
including Canada, USA, China, and Brazil have made an unprecedented move to ban 
BPA from being used to manufacture polycarbonate plastic babies’ bottles on the 
grounds that milk formula-fed babies are likely to be a key target group due to their 
sensitive developmental stage, high BPA intake per body weight, and their sole source 
of food likely contaminated with BPA (Almeida, et al., 2018, JRC/IHCP, 2010). 
Unlike most xenoestrogens, BPA does not have an ER isoform preference, and binds 
ERa and ERb with similar affinity.   BPA is 1000-2000 fold less potent than E2 itself 








Ethinylestradiol (EE2) is the synthetic estrogen used in the oral contraceptive (OC) or 
“The Pill”. The primary role of the OC is to control ovulation and in turn prevent 
implantation and pregnancy (Tata, 2005). It is designed to be a potent estrogen, with 











structural analogy with E2 (Levin, 2005). EE2 preferentially binds to ERa and is 4 
times more potent than E2. EE2, although well known for its use in preventing 
pregnancy, is also known for its effects on aquatic environments. It is not well 
degraded in sewage treatment plants and thus gets released into the aquatic 
environments where it comes into contact with fish and aquatic species. It has been 
shown that male fish living in such areas synthesise vitellogenin, a protein normally 
synthesised by females during the development of the ovum, and bizarrely, early stage 
egg production in the testes (Kidd, et al., 2007, Sumpter, et al., 1995). Although 
second hand human exposure is minimal, the effluents do have a tendency to leach 
into drinking water supplies. A well-known example is the River Thames in London, 
England. The River Thames is the main water source for the city, however, it also has 
352 sewage treatment plants treating sewage from around 5.4 million people, 
discharging into the river every year (Williams, et al., 2009). Therefore, the 
bioaccumulation of EE2 could mean populations are being exposed to increasing 
concentrations of EE2 in their drinking water, although these concentrations are still 
in the nanomolar order of magnitude. 
 
Parabens 
Parabens (esters of 4-hydroxybenzoic acid) are used as preservatives in cosmetics, 
topical pharmaceuticals and personal care products such as moisturisers and 
shampoos, and in foods such as jams and baked goods (Rudel, et al., 2009). They 
prevent bacterial and fungal growth in these products (Darbre, et al., 2008). Parabens 
are widely used due to their low toxicity and low estrogenicity (Anderson, 1994, 
Anderson, 1995, Soni, et al., 2001, Soni, et al., 2002). The longer chained parabens 
are more estrogenic than their shorter chained counterparts, owing this increased 
estrogenicity to better occupancy of the ERs (Karpuzoglu, et al., 2013).  
 
Methylparaben 
Methylparaben is the methylester of hydroxybenzoic acid. It is widely used in a 
variety of cosmetics and personal care products. It is one of the most commonly used 
parabens due to its seemingly non-existent estrogenicity. Therefore, it is considered 
safe by The Food and Drug Administration (FDA) for food and cosmetic antibacterial 






Butylparaben is butylester of 4-hydroxybenzoic acid. It is a highly successful 
antimicrobial preservative in cosmetics. It is also used in medication suspensions and 
flavouring additives in foods. Butylparaben has displayed estrogenicity in most 
competitive binding assays and is more estrogenic compared to the short chain 
parabens (methyl, ethyl and propyl) (Terasaki, et al., 2009).  
Benzylparaben 
Benzylparaben is the benzylester of hydroxybenzoic acid and is one of the more 
recent parabens used in cosmetics as an antimicrobial preservative. Benzylparaben 
has been reported as having estrogenic potential but no anti-estrogenic potential in a 
panel of ER mediated assays, including MCF-7 cells (Darbre, et al., 2003). It is not 
surprising that benzylparaben has estrogenic properties given that the possible 
cytochrome P450 generated metabolite of a hydroxyl group added to the benzyl ring 
(Fig. 1.24). If this occurred this would make benzylparaben the most similar to E2 of 










1.4.4. Exposure to Xenoestrogens 
Clearly, xenoestrogens are found in a lot of common products, to which humans are 
exposed in their day-to-day lives. Graham (2012) compiled an extensive literature 
search which demonstrated the levels of xenoestrogens found in the urine of adults 
(Fig. 1.25). Urine was chosen as it is the most common method of determining 
xenoestrogen exposure in adults. The total concentration (free + conjugated) is most 
often reported. These data represent cohorts of different sizes and nationalities, and 
thus a great diversity in lifestyles. The data shown in Fig. 1.25 includes almost all of 







Figure 1.24: Structures of benzylparaben and its potential metabolite. 
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Figure 1.25: Range of reported total xenoestrogen concentrations in adult human 
urine. Lines indicate range of reported values, bars indicate lowest and highest median 
reported values (from Graham 2012 with permission). 
 
1.4.5. Exposure to Xenoestrogen Cocktails 
It is clear from the information above that co-exposure to xenoestrogens and possible 
bioaccumulation are realistic scenarios, because humans are constantly exposed to 
various xenoestrogens simultaneously through the environment and diet. Therefore, in 
linking negative health effects to xenoestrogen exposure, it may be more relevant to 
consider mixtures rather than single substances. Exposure to xenoestrogens is an 
exposure mixture of changing composition and concentration. Because the endpoint 
of concern is hormonal signalling, there is no safe threshold below which there is no 
activity (Brucker-Davis, et al., 2001). When assuming a similar mode of action for 
mixture components, researchers have concluded that these mixture effects are often 
described most accurately by the concept of the concentration addition model (CA) 
postulated by Loewe and Muischnek in 1926, making it the most commonly used 
model in xenoestrogen mixture research. This simplest approach to assessing the total 
estrogenic effect of mixtures is where each component adds to the total proportion of 
the concentration weighted by its relative potency. Rajapakse et al demonstrated in 
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principle that every xenoestrogen, however weak, may add incrementally to the total 
estrogenic effect, even at very low concentrations, and even in the presence of potent 
endogenous steroidal estrogens (Rajapakse, et al., 2002).  
 
However, there are inherent mathematical limitations to the concept of CA regarding 
the prediction of effects caused by mixtures of substances differing in efficacy 
(maximal response). This limitation to the maximal effect level of the mixture 
component with the lowest efficacy which leads to predictive blind zones (Liu, et al., 
2015). Furthermore, if mixture components have no effect, the predictivity of CA is 
disturbed. Currently, the accepted CA model (discussed further in Chapter 5) relies 
upon the theory that since estrogenic compounds are likely to be working through the 
same mechanism (i.e. binding to the ER) they have got to be at least additive. 
However, this is perhaps flawed because it does not consider their binding constants. 
This could modify the additive effect.  
 
1.4.6. Measurement of Xenoestrogens 
Many in vitro assays measure endocrine activity at the molecular level e.g. nuclear 
receptor activation. Whether such activation indeed leads to biologically relevant 
adverse outcomes depends on key events in the respective adverse outcome pathways. 
Adverse health effects, such as compromised reproduction and carcinogenesis, have 
been attributed to the disruption of the E2 signalling pathway (Diamanti-Kandarakis, 
et al., 2009). ER activation and E2-induced proliferation of ER positive cells are 
considered hallmarks of estrogenic activity. Well established on the one hand are ER 
mediated reporter gene assays that measure ER binding and transactivation by the 
substance of interest, thus estimating its impact on the genomic ER pathway. On the 
other hand, the E-SCREEN assay, based on the ER-expressing breast cancer cell line 
MCF-7, responds with increased proliferation to estrogenic compounds and thus is 
commonly used to estimate the proliferative potential of xenoestrogens. This response 
can be mediated by both genomic and non-genomic ER pathways. Interestingly, both 
assays have been frequently used independently, but few studies consider both 
together (Evans, et al., 2012).  
 
It remains to be clarified if findings derived from ER-dependent reporter gene assays 
are sufficient to predict effects at higher levels of cellular organisation.  It is also 
possible for mixtures to have a higher potency than that predicted by the simple 
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additivity model of CA. This behaviour is described as synergy. For example, 
mixtures of benzophenones (xenoestrogens found in sunscreens and lotions), alone or 
including E2, showed synergy, with substantial increases in observed effect in the 
YES assay even though each UV filter was present at its no observable effect 
concentration (NOEC) level (Kunz, et al., 2006). In addition, mixtures with 
phytoestrogens, particularly genistein, have been well documented to induce a 
supramaximal effect (i.e. an effect greater that are greater than 100%) in luciferase-
based reporter gene assays, which can be confused with synergism (Sotoca, et al., 
2010). However, although it appears synergistic, it is unlikely that genistein would 
induce that level of response, especially in comparison to E2. Therefore, the effect is 
likely an artefact of the assay (Montano, et al., 2010). This poses a concern when 
using gene reporter assays to regulate xenoestrogen mixtures and thus care should be 
taken when using data from these experiments.   
 
1.4.7. Assessing the risk of Xenoestrogen cocktails 
The complexity of dealing with mixtures in exposure assessment is recognised, but 
appropriate methodologies for the assessment risk due to exposure mixtures are still 
hotly debated (Filby, et al., 2007, Kortenkamp, 2007, Kortenkamp, 2008, 
Kortenkamp, et al., 2007, Payne, et al., 2000, Rajapakse, et al., 2002). Nevertheless, 
some regulatory frameworks are beginning to consider groups of chemicals that act 
via the same mechanism collectively rather than evaluating the potential risks 
individually.   
 
One approach to simplifying the topic of endocrine disruption is to treat the effects of 
exposure individually according to the signalling pathway, e.g. E2 signalling 
disruption separate from androgen or thyroid disruption. While this approach 
disregards the potential for the different signalling pathways to interact, e.g. anti-
androgenic effects contributing to an overall estrogenic outcome, there is insufficient 
information available at this time to completely address the problem. An example of 
this is the parabens. They simultaneously upregulate ER gene expression, 
downregulate AR gene expression and inhibit aromatase activity, thereby supressing 
the biosynthesis of estrogens. Parabens can contribute to the common effect 
(feminisation) via two distinct mechanisms (estrogenicity and anti-androgenicity) and 
also contribute to a contradicting effect (masculinisation) via supressing endogenous 
estrogen biosynthesis (Engeli, et al., 2017, Vo, et al., 2009). Similar behaviour is 
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likely present with other classes of compounds of interest to estrogenic signalling 
disruption, but the data are currently lacking.  
 
This study will be limited to assessing xenoestrogen mixtures in the context of 
estrogen signalling using a variety of the ER model systems discussed above. This 
will be done by using the CA model, gene reporter assays that examine both ERa and 
ERb individually, and the breast cancer cell line, MCF-7 to encompass the effects 
individually by ERs and in the context of breast cancer.  
 
1.4.8. Xenoestrogens as Cancer Risk Factors 
Arguably, one of the deadliest linkages between xenoestrogens and human health is 
cancer. While there are some well-known associations (e.g. breast cancer) (Jenkins, et 
al., 2012), there is mounting evidence that suggests a wider range of cancers could be 
influenced by xenoestrogen exposure, thus xenoestrogens could be risk factors for 
multiple cancers (Fucic, et al., 2012). Lung cancer has long been linked to smoking, 
however, with the number of smokers decreasing a clear gender bias is emerging. The 
ratio between ERa and ERb in the lung tissue seems to be relevant for lung cancer 
development and might explain the higher incidence of lung adenocarcinoma in 
women compared to men (Whitrow, et al., 2003). Currently, ERb positive lung cancer 
in men is associated with a significantly lower mortality rate compared to ERb 
negative lung cancer (Schwartz, et al., 2005). Interestingly, women taking HRT have 
shown an increased lung cancer incidence, highlighting a correlation between lung 
cancer and estrogens (Slatore, et al., 2010). Of course, it is possible that mutations in 
other genes (e.g. EGRF) could lead to increased expression and therefore, increased 
proliferation (da Cunha Santos, et al., 2011). Xenoestrogens may also play a role in 
lung cancer incidence and could be a risk factor.  
 
There is also ample evidence that suggests estrogens may play a critical role in 
predisposing or even causing prostate cancer. However, studies have shown mixed 
results (Nelles, et al., 2011) with one study finding an association between elevated 
plasma estrogens and an increased risk of prostate cancer, and another study finding 
the opposite where a decrease in estradiol levels was associated with prostate cancer. 
It is not hard to envision the influence of estrogens/xenoestrogens on the prostate 




Similar mechanistic correlations have been made for kidney (Kabaria, et al., 2016, 
Tanaka, et al., 2003), pancreatic (Konduri, et al., 2007, Lowenfels, et al., 2006, 
Sauerland, et al., 2009), colon (Caiazza, et al., 2007, Hartman, et al., 2010, Rudolph, 
et al., 2012) and brain (Batistatou, et al., 2006) cancer. Therefore, although the 
primary focus of this thesis is on breast cancer, it is important to consider the 
observed effects in the context of many other cancers.  
 
1.5 Breast Cancer 
Cancer originating in the mammary gland is the most common type of cancer in 
women. The lifetime risk for a woman in developed countries has been calculated at 
around 1 in 7 to 1 in 10. When it comes to New Zealand, the latest analysis reports an 
accumulated lifetime risk of developing breast cancer to be 1 in 9 with approximately 
600 women dying from the disease every year (MOH, 2015). This means around 11% 
of the New Zealand female population will be diagnosed with breast cancer at some 
point in their life (calculated from the average lifespan 0-74 years; e.g. the risk of 
developing breast cancer before the age of 74 years). 
 
1.5.1. Breast Cancer Biology 
At normal physiological conditions, the epithelium is a well-defined structure where 
epithelial cells form the lining of ducts that are responsible for milk transport during 
lactation (Fig. 1.26). Ductal carcinoma is the most common type of breast cancer, 
occurring both in women and men, although the incidence in men is low. Contrasting 
with healthy tissues, cells within solid tumours acquire several pathophysiological 
characteristics that confer them survival, proliferative and migratory capabilities. 
Tumour progression is characterised by a mass formed by multiple populations of 
cells with mechanisms capable of inhabiting apoptosis, while promoting survival 
pathways and the invasion of healthy tissues through the blood and lymphatic system. 
Morphologic and functional alterations of epithelial cells, as well as alterations of 




When normal epithelium has begun malignant transformation, it undergoes a first 
stage of excessive proliferation known as hyperplasia followed by the appearance of 
cells showing aberrant characteristics (atypical ductal or lobular hyperplasia). At a 
later stage, known as carcinoma in situ, these cells acquire a full malignant phenotype, 
except the ability to invade the surrounding parenchyma through the basal membrane. 
Nonetheless, in its final phase the carcinoma cells break through the basal membrane 
and become an invasive carcinoma (Fig. 1.27). Breast cancer progression is a 
complex process. Clinical evidence has shown that, even pre-malignant lesions, which 
are closest in similarity to invasive carcinoma, may progress to invasive carcinoma. 
However, it has been estimated that less than 50-60% of these will progress to 
invasive carcinoma (Erbas, et al., 2006). Hence, atypical hyperplasia and carcinoma 
in situ are non-obligate precursors of breast cancer. Since breast cancer originates in 
normal breast epithelium it can be suggested that stimuli that normally result in breast 
gland proliferation will also boost the growth of breast cancer cells, intrinsically 
characterised by their proliferation advantage (Visvader, 2009). Mammary gland 
epithelium proliferation presents a marked dependence on hormones (Brisken, et al., 
2010, Macias, et al., 2012). This way, glandular units of the female breast present a 
Figure 1.26: Breast Parenchyma (from https://www.britannica.com) 
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cyclic growth and atrophy throughout the menstruation cycle, with the most marked 
hyperplasia during pregnancy and lactation, and regression during menopause (Russo, 
et al., 2014).  
Since estrogen is of great importance in breast epithelium growth and E2 interacts 
directly with ER to direct cell biology, it can be deduced that most mammary 
epithelial cells are ERa positive at one point in time (Allred, et al., 2001, Clarke, et 
al., 1997). Yet in malignant conversion through atypical hyperplasia and carcinoma in 
situ towards invasive breast cancer (Shoker, et al., 1999), the ER positivity is 
increased, with around two thirds to three quarters of ductal carcinoma in situ and 
invasive breast cancers showing positivity (Li, et al., 2003). Interestingly, a 
significant minority of cases of ER+ve breast cancers can be explained by an ESR1 
(ERa) gene amplification (Holst, et al., 2007). This suggests that for a majority of 
breast cancers, high ERa expression is a result of other mechanisms such as post-












Figure 1.27: A schematic representation of breast cancer progression. The transformation of breast epithelial cells gives rise to metastatic breast 
cancer. During this multistage process, control of proliferation, survival, differentiation and migration become deregulated, and aberrant tumour-
stromal cell interactions facilitate this process. To form metastases, cells must invade through the basement membrane, survive in the absence of 










1.5.2. Staging of Breast Cancer 
The Union for International Cancer Control (UICC) categorises cancer into four 
stages based on the size of the tumour and the extent of spread. Stage 1 is small and 
confined within the breast. Stage 2 usually means the cancer has not spread to the 
lymph nodes close to the tumour. Stage 3 is a larger cancer with some spread to the 
surrounding tissue and lymph nodes. Stage 4 is the spread of the cancer to other 
organ/s. Advanced disease is defined as stages 3 and 4. In addition, breast cancer is 
further classified by the cellular expression of human epidermal growth factor 
receptor 2 (HER2), progesterone receptor (PR) and ERs (Yersal, et al., 2014). This is 
then used to identify appropriate treatments.  
 
The high incidence, complexity, and the economic cost of treatment for breast cancer 
make it one of the most relevant health problems in our society today. Wide-spread 
population-based screening programs implemented in Western countries over the last 
30 years have allowed the diagnosis of the disease at earlier stages, which has led to 
reduced mortality. However, since the establishment of screening programs there has 
been debate over the magnitude of the harm (e.g. overdiagnosis) that may come from 
screening. For example, the consequence of overdiagnosis is that women have their 
cancer treated by surgery, and in many cases medication and radiation, but neither 
women nor her doctor can know whether that particular cancer would have become 
apparent in the absence of screening (Marmot, et al., 2013). In addition, treatments 
such as surgery, radiotherapy, chemotherapy, and the development of hormonal 
treatment, have significantly improved. Tamoxifen has significantly improved quality 
of life and often extends a patient’s life for up to 20 years (Davies, et al., 2017).  
 
Substantial advances have been made in the treatment and detection of breast cancer, 
however, the age-standardised incidence of breast cancer still continues to increase in 
some countries (e.g. U.S.A.) (DeSantis, et al., 2015). This age-standardised incidence 
is projected to continue to rise for these countries over the next 20 years. Clearly, 








1.5.3. Breast Cancer Risk Factors 
Since the incidence of breast cancer increases with increasing age, this can give the 
impression that it is a disease of predominantly middle-aged and older women. In a 
sense that is true, indeed for the clinical part of the disease. However, it means that 
early life exposures must also be explored (i.e. at puberty and adolescence) to 
understand risk. From a breast cancer perspective, the ‘lifecycle’ of the breast can be 
divided into five windows of vulnerability: in utero, pubertal, pregnancy, postpartum 
involution and age-related involution (Fig. 1.28), representing identified times of risk 
throughout a woman’s life. The unique biology of the breast begins in utero with 
breast ductal anlagen development. After birth, the ductal architecture grows slowly 
before ductal side branches and alveoli ensue during puberty, filling the mammary fat 
pad, poised to respond to pregnancy hormones. Pregnancy drives alveolar 
proliferation and differentiation and terminal differentiation of the gland with full 
term pregnancy and lactation. Post-partum, when lactation has ceased, the mammary 
gland undergoes involution where it remodels to a state morphologically and 
functionally similar to pre-pregnancy. Finally, with declining ovarian function, the 
mammary gland begins age related involution during peri-menopause where alveolar 
lobules regress. Involution is complete when a woman has gone through menopause 
and the parenchyma disappears (Fig.1.28) (Adami, et al., 1995, Brisken, et al., 2010, 
Colditz, et al., 1995, Hilakivi-Clarke, et al., 2006, Milanese, et al., 2006, Pike, et al., 
1983, Schedin, 2006). Interestingly, many first clinical breast cancers appear when 
breasts begin the involution process (Russo, 2016). Therefore, the risk of developing 
breast cancer later in life is likely to increase during these lifecycle windows. In 
addition, nulliparity (i.e. not having children) also increases breast cancer risk with no 




Figure 1.28: Lifecycle windows of risk for breast cancer. Schematic presentation of the lifecycle of breast development in women. The 
pregnancy, lactation, and involution cycle of the breast is offset to distinguish parous from women who have never been pregnant (nulliparous). 
The four windows of cancer vulnerability are defined by bold black lines: fetal, puberty, postpartum involution, and age-related involution (from 
(Martinson, et al., 2013) with permission). 
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After sex and age, familial predisposition is the most important risk factor for breast cancer, 
however, not even 10% of the breast cancer patient population has an inherited germ line 
gene mutation. Germ line mutations of the breast cancer susceptibility genes, BRCA1 and 
BRCA2, are well known and responsible for a large part of the familial breast and ovarian 
cancer syndrome. A child born with a germ line mutation in BRCA1 has a 70-80% lifetime 
risk of developing breast cancer. For BRCA2, the penetrance is somewhat less but still 
amounts to almost 60% (Rebbeck, et al., 2015). Most BRCA1 cancers have the basal cell 
phenotype, whereas this phenotype is rarely found in BRCA2 carcinomas that tend to be 
ER+/PR+ (Honrado, et al., 2005). 
 
Exposure to estrogens, whether endogenous or exogenous, is the main determinant of breast 
cancer risk. They have a dual effect: direct hormone action and genotoxicity. The prevailing 
model proposes that estrogens increase the rate of cell proliferation by stimulating ER 
mediated transcription, and thereby the number of errors occurring during DNA replication 
(Martinez-Ramirez, et al., 2013).  
 
An alternative hypothesis proposes that estrogens can be metabolised into quinone 
derivatives which react with DNA and then remove bases from DNA via depurination. The 
error prone DNA repairs then result in point mutations. Interestingly, metabolism of 
diethylstilbestrol, (a synthetic estrogen formerly used to reduce the risk of miscarriage and 
premature labour in pregnancy), causes high production of quinone derivatives compared to 
E2, whereas EE2 produces fewer quinone derivatives compared to E2 (Zhu, et al., 1993). 
Phytoestrogens in general seem to form more 2-catechol estrogens (CE), which results in 
lower quinone production. Soy products are even able to change estrogen metabolism to less 
toxic CE, but the effects are presumably much more complex (Lehmann, et al., 2008). 
 
Age 
The majority of breast cancer cases occur among women aged 50 years or older. However, 
according to the New Zealand Ministry of Health, about 1 in 10 breast cancers develop in 
women younger than 45 and about 1 in 2 breast cancers are found in women between 45-64 
years (MOH, 2015). Age is not a unique risk factor for breast cancer, it is a risk factor for 
most diseases. This is due to the fact that the longer a person lives, the more opportunities 





Exogenous estrogens (HRT) 
Current or recent users of hormonal replacement therapy (HRT) have a higher risk of 
developing breast cancer. Many postmenopausal women took HRT to alleviate 
postmenopausal symptoms such as hot flashes and fatigue. However, since the link between 
HRT and breast cancer was established the number of women taking HRT has dropped 
dramatically (Ravdin, et al., 2007). There are two types of HRT available: combination HRT 
(containing both estrogen and progesterone) and estrogen-only HRT. Current users of 
combination HRT approximately double their breast cancer risk (Rossouw, et al., 2002). In 
contrast, current users of estrogen-only HRT have a 30% increase in risk.  The risk increases 
with duration of use, but declines rapidly after cessation of HRT use (Banks, et al., 2003, 
Chlebowski, et al., 2003, Colditz, et al., 1995, Ross, et al., 2000, Rossouw, et al., 2002, 
Schairer, et al., 2000). In addition, HRT greatly increases the risk of uterine cancer; thus, 




While there have been substantial advances in understanding breast cancer risk factors, 
especially the role of estrogens and genetics, for a majority of women presenting with breast 
cancer it is not possible to identify specific risk factors (IARC, 2008, Lacey, et al., 2009). 
However, it is thought that increasing adoption of the Western lifestyle may be adding to 
breast cancer risk around the world. Interestingly, women who have migrated from China to 
the U.S.A have an increased risk of developing breast cancer, approaching 80% to that of the 
risk in the U.S.A. The daughters of those migrants will have a breast cancer risk that is 
almost identical to that of women who have lived in the U.S.A for generations (Ziegler, et al., 
1993). Clearly, the environment is a major component of breast cancer risk. 
 
Alcohol and exercise 
Research has consistently shown an association between alcohol consumption and breast 
cancer risk. It has been shown that women who have three alcoholic drinks per week have a 
15% higher risk of developing breast cancer (McDonald, et al., 2013). It is also known that 
physical activity of between 4-7 hr a week lowers breast cancer risk. This is attributed to 
exercise consuming and controlling blood sugar which in turn limits blood levels of insulin-
like growth factor (IGF), a hormone that affects how breast cells grow and behave (Xie, et 
al., 2013). Therefore, people that do not exercise regularly have an increased risk of 




Currently the contribution xenoestrogens play in breast cancer risk is debatable. However, an 
elevated incidence of breast cancer in women has been associated with prolonged exposure to 
high levels of estrogens, especially pre-menarche and post-menopausally (Bernstein, et al., 
1993, Henderson, et al., 1991). However, exposure to xenoestrogens is not limited to these 
two stages in a woman’s life, in fact, exposure can occur throughout a woman’s life (Soto, et 
al., 2007).  
 
1.6 Model Systems for Studying Xenoestrogen Responses 
There are many model systems that can be used to study xenoestrogens. One is a breast 
cancer cell line (MCF-7) that expresses both the ERα and ERβ, another model system is a 
reporter gene assay (e.g. Chemically activated luciferase expression (CALUXâ) and another 
is a computational model system, namely Schrodinger.  These are described in detail below. 
 
1.6.1. The MCF-7 Model System 
The MCF-7 cell line was first isolated in 1970 from a 69-year-old Caucasian woman who had 
breast cancer. The cell line has been used extensively for research, as it was the first 
mammalian cancer cell line capable of surviving in culture for longer than a few months. 
MCF-7 cells, in addition to their longer life span, were the first ER-positive (ER+) and 
estrogen responsive breast cancer cell line to be documented. These cells have been widely 
used in xenoestrogenic studies as they have both ERα and ERβ, allowing them to rapidly 
grow when exposed to E2 (Levenson, et al., 1997). The MCF-7 model system, as mentioned 
above, has both ER isoforms and is a breast cancer cell line. This is the closest in vitro 
system that models a breast cell, therefore, when xenoestrogen exposure studies are carried 
out it is likely to give the most representative results. However, these cells can be difficult to 
manipulate, hence, other systems have also been developed.  
 
1.6.2. CALUXâ Reporter Gene Assay 
CALUXâ is a bioassay used as an effect-based screening method that is able to measure the 
total effect a ligand has on its receptor. The assay consists of a cell that has been genetically 
modified with a luciferase reporter gene, producing luciferase – a light generating enzyme. In 
gene reporter assays the DNA sequences containing the EREs are linked to the gene of an 
easily measurable protein, for example firefly luciferase. In this case, the ligand-activated 
receptor will activate luciferase transcription, and the transcribed luciferase protein will emit 
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light when a substrate is added (e.g. luciferin), see Fig. 1.29. The signal will dose 
dependently increase as a result of increasing concentrations of xenoestrogen, allowing 






Figure 1.29: Principle of the CALUXâ reporter gene assays. Estrogenic chemicals ( ), as a 
component of a cocktail, cross the cell membrane and bind to ERs. The ligand-bound ER 
dimer enters the nucleus, binds to DNA receptor binding elements, resulting in up-regulated 
luciferase and luciferase protein synthesis. The addition of luciferin (substrate) results in light 
production, where the number of photons produced is proportional to the estrogenicity of the 
xenoestrogen cocktail. In the endogenous situation, the molecular mechanism is identical, 
except other estrogen responsive genes are up-regulated since luciferase is not present (from 
Biodetection Systems Ltd with permission).  
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The ERα and ERβ CALUXâ reporter gene assays are constructed in U2OS (human 
osteosarcoma) cells. The U2OS cells are an ideal cell to choose as they exhibit no or very low 
expression of endogenous receptors. Therefore, this assay requires the genetic modification to 
express luciferase and the desired receptor (e.g. ER a or b). The advantage of such a system 
is that cross-talk between various nuclear hormone receptors cannot occur, resulting in highly 
selective and responsive assays (Sonneveld, et al., 2005). These assays have been proven to 
accurately predict estrogenic activity of chemicals and pharmaceuticals. Reporter gene assays 
have several advantages over classical in vivo assays for estrogenicity, not only by increasing 
speed and reduced costs but also reduced use of animals and the use of human cells and 
human receptors (Sonneveld, et al., 2006, van der Burg, et al., 2010). Furthermore, reporter 
gene assays are ideally suited to accurately and quantitatively measure the combined effect 
exerted by all chemicals present in complex mixtures (van der Burg, et al., 2013). However, 
it is a more simplified method for studying xenoestrogenic compounds and does not fully 
represent the in vivo situation. Therefore, it is important to also do the MCF-7 experiments to 
ensure the most accurate representation of a human breast cell is attained.   
 
1.6.3. Schrodinger 
Another model system is computational models. Schrödinger is an advanced computational 
modelling system where the docking of xenoestrogens can be simulated. It has been widely 
used in the study of xenoestrogens to explore the binding interactions of specific 
xenoestrogens with ERs (Celik, et al., 2008, D'Ursi, et al., 2005, Lambrinidis, et al., 2006). 
Much of the computational docking done with the ER has been for drug development (Knox, 
et al., 2006, Knox, et al., 2008) for the treatment of breast cancer, osteoporosis and prostate 
diseases. Docking studies maybe able to shed light on the small local changes that occur upon 
ligand binding that are then amplified through the protein structure resulting in large 
conformational changes. Since the objective of this study was to use the tool to study the 
intimate interactions of xenoestrogens with the ERs, computational docking was used in 










1.7. Goals and Objectives 
• Characterise and perfect the MCF-7 cell culture system.  Determine optimum growth 
conditions by observing MCF-7 growth characteristics following modification of culture 
media (e.g. changes in non-essential amino acids (NEAAs)).  Determining optimum 
tryspin methodology to de-adhere cells from culture vessels. 
• Investigate the effects of xenoestrogens and combinations of xenoestrogens on MCF-7 
cells in culture by exposing cultured MCF-7 cells to varying concentrations of selected 
xenoestrogens both individually and in combinations and plotting growth curves. 
• Investigate the estrogenic potency of individual and combinations of xenoestrogens on 
both ER isoforms (ERa and ERb) of the CALUXâ assay by exposing ERa and ERb 
CALUXâ cells to varying concentrations of selected xenoestrogens both individually and 
in combinations and determining EC50 values.  
• Use in silico modelling (Schrödinger platform) to investigate the biomolecular 
interactions of xenoestrogens with ER ligand binding sites (LBC and AF-2) and explore 
the interplay between the two binding sites. Using ligand-receptor docking to study the 
biological chemistry of biomolecular interactions of selected xenoestrogens with ERs, 
and determine the importance of ligand structure in predicting interactions with LBC and 
AF-2.  
• Assess women’s and pre-pubertal girls’ exposures to xenoestrogens using a dietary and 
lifestyle questionnaire, and determine the contribution of xenoestrogen exposure to the 
theoretical total estrogenic load.   
• Determine serum markers of xenoestrogen exposure (e.g. BPA, genistein, butylparaben), 
based on women’s exposures from the dietary and lifestyle questionnaire study, by taking 
blood samples from a group of women and determining serum levels of a selection of 
xenoestrogens by LC-MS. 
• Bring together data from the cell culture, CALUXâ, in silico and exposure studies to 
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Chapter 2 Materials and Methods 
 
 
2.1. Materials  
A list of materials used in cell culture and blood analysis are presented in Table 2.1  
 
Table 2.1: Materials used in cell culture and blood analysis 
Material Supplier/model Location 
Cell culture   
Chemicals   
b-Estradiol (E2) Sigma-Aldrich Auckland, NZ 
Estrone Sigma-Aldrich Auckland, NZ 
Estriol Sigma-Aldrich Auckland, NZ 
17a-Ethinyl estradiol (EE2) Sigma-Aldrich Auckland, NZ 
Bisphenol A (BPA) Sigma-Aldrich Auckland, NZ 
Genistein LC-Laboratories  Massachusetts, 
USA  
Daidzein LC-Laboratories  Massachusetts, 
USA  
Kaempferol Sigma-Aldrich Auckland, NZ 
Curcumin Sigma-Aldrich Auckland, NZ 
Tetrahydrocurcumin Sigma-Aldrich Auckland, NZ 
Methyl 4-hydroxybenzoate Sigma-Aldrich Auckland, NZ 
Butyl 4-hydroxybenzoate Sigma-Aldrich Auckland, NZ 
Benzyl 4-hydroxybenzoate Sigma-Aldrich Auckland, NZ 
Streptomycin sulphate salt Sigma-Aldrich Auckland, NZ 
Penicillin G sodium salt Sigma-Aldrich Auckland, NZ 
Commercial phosphate buffered saline 
(PBS) packet (total weight = 9.55 g 
comprising sodium chloride (8 g), potassium 
phosphate, monobasic (0.2 g), sodium 
phosphate, dibasic (1.15 g) and potassium 
chloride (0.2 g)) 
Sigma-Aldrich Auckland, NZ 
Gibco MEM non-essential amino acids 
(NEAA) 
Thermofisher Scientific Christchurch, NZ 
Analytical grade ethanol ECP Ltd Auckland, NZ 
Sodium bicarbonate ECP Ltd Auckland, NZ 
Ethylenediaminetetracacetic acid (EDTA) ECP Ltd Auckland, NZ 
Ground dextran coated charcoal Sigma-Aldrich Auckland, NZ 
Magnesium chloride hexahydrate ECP Ltd Auckland, NZ 
Sucrose ECP Ltd Auckland, NZ 
4-(2-Hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) 
ECP Ltd Auckland, NZ 
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Trypan Blue Sigma-Aldrich Auckland, NZ 
Tris Sigma-Aldrich Amsterdam, NL 
Dithiothreitol (DTT) Sigma-Aldrich Amsterdam, NL 
1,2-diaminocyclohexane-N,N,N´,N´-
tetraacetic acid (CDTA) 
Sigma-Aldrich Amsterdam, NL 
EDTA Sigma-Aldrich Amsterdam, NL 
Glycerol Sigma-Aldrich Amsterdam, NL 
TritonâX-100 Sigma-Aldrich Amsterdam, NL 
Tricine Sigma-Aldrich Amsterdam, NL 
Mg(CO2)4Mg(OH)2.5H2O Sigma-Aldrich Amsterdam, NL 
MgSO4.7H2O Sigma-Aldrich Amsterdam, NL 
Dextran T500 Sigma-Aldrich Amsterdam, NL 
Biological products   
RPMI-1640 powder Life Technologies Auckland, NZ 
Gibco phenol red-free RPMI-1640 Life Technologies Auckland, NZ 
Fetal bovine serum Life Technologies Auckland, NZ 
Trypsin powder Sigma-Aldrich Auckland, NZ 
Gibco trpLEä express Life Technologies Auckland, NZ 
MCF-7 human breast cancer cells American Type Culture 
Collection (ATCC) 
Manassas, USA 
ERa-CALUXâ cells BioDetection Systems Amsterdam, NL 
ERb-CALUXâ cells BioDetection Systems Amsterdam, NL 
D-Luciferin Sigma-Aldrich Amsterdam, NL 
ATP Sigma-Aldrich Amsterdam, NL 
Dulbecco’s Modified Eagle Medium: 




Gibco Sodium pyruvate (1 M) Life Technologies Auckland, NZ 
Equipment   
T-75 sterile cell culture flasks In Vitro Technologies  Auckland, NZ 
T-25 sterile cell culture flasks Sigma-Aldrich Auckland, NZ 
Glass vials (4 mL, 7 mL and 20 mL)   
24 Well plate Sigma-Aldrich Auckland, NZ 
White 384 well plate Sigma-Aldrich  Amsterdam, NL 
50 mL Centrifuge tubes   
Automatic pipette and tips   
Sterile filter (Steritop-GP, 0.22 µm, 









Autoclave   
Laminar flow cabinet Cytoguard CG2000 
series, model CGA-180 
Sydney, AUS 
Inverted microscope CKX41, Olympus Melbourne, AUS 
Microscope camera ProSciTech Kirwan, AUS 
Toup camera software ProSciTech Kirwan, AUS 
Veriplast plastic counting chambers Thermo Fisher 
Scientific 
Melbourne, AUS 
Centrifuge  MultiFuge 1 S-R Hanau, Germany 
Glassware   
Hot-plate stirrer   
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Microwell plates (24, 384 wells) ThermoFisher 
Scientific 
Auckland, NZ 
Schott bottles (100 mL, 500 mL, 1000 mL)   
Cytomat Incubator ThermoFisher 
Scientific 
Amsterdam, NL 
Hamilton Robot STARlet Bonaduz 
Switzerland 
EL406 Washer-Dispenser BioTek Amsterdam, NL 
Luminometer Tecan Mannedorf, 
Switzerland 
Blood analysis   
Chemicals   
Analytical grade acetonitrile  ECP Ltd Auckland, NZ 
Analytical grade Methyl tert-butyl ether Sigma-Aldrich Auckland, NZ 
Analytical grade chloroform ECP Ltd Auckland, NZ 
Sodium sulphate ECP Ltd Auckland, NZ 
Equipment   
Sterile needles Becton Dickinson Auckland, NZ 
Vacutainer  Becton Dickinson Auckland, NZ 
50 mL Centrifuge tubes   
Centrifuge  MultiFuge 1 S-R Hanau, DE 
High performance liquid chromatography 
(HPLC) vials 
Micro-Analytix Auckland, NZ 
Whatman filter paper ThermoFisher 
Scientific  
Auckland, NZ 
Glassware   
Speed Vac ThermoFisher 
Scientific  
Auckland, NZ 
Glass vials   
LC-MS   
C18 reverse phase HPLC column Phenomex North Shore, NZ 
 
2.1.1 MilliQ Water 
All water used in MCF-7 and Blood analysis experiments was purified using the Milli-Q® 
system (Merck Millipore, Auckland, New Zealand).  Resistivity (25⁰C) = 18.2 MΩ.cm. 
 
 
2.1.2. Demineralised Water 
All water used in CALUXâ assay experiments was purified using a HOH RO 51 Reverse 
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2.1.2. Computational Modelling 
2.1.2.1. Receptor Models 
Computational docking relies on models of the receptor protein structure. These models are 
developed from published x-ray crystal structures. For this work, the x-ray crystal structures 
of the ER LBD (Table 2.2) were obtained from the RSCB Protein Data Bank (PDB; 
http://www.rcsb.org). The models developed from the crystal structure are identified by the 
PDB code. 
 









1ERE ERa E2 3.10 A no (Brzozowski, 
et al., 1997) 
3OLS ERb E2 2.20 A yes (Mocklinghoff, 
et al., 2010) 
 
2.1.2.2. Ligand Structures 
Computational docking requires a model for each ligand which is developed from their 3D 
structures. The 3D structures for all ligands were constructed using the software tools (see 
Section 2.2.10.1.) from the Schrodinger Suite. Models of 16 xenoestrogens (estrone, E2, 
estriol, progesterone, testosterone, genistein, daidzein, equol, kaempferol, curcumin, 
tetrahydrocurcumin, EE2, BPA, methylparaben, butylparaben and benzylparaben (see Figs. 
1.1 and 1.19) were required for the study.  
 
All ligands were energy minimised using the Schrödinger software to achieve an optimised 
conformation of the ligand that had the lowest internal energy. This calculation searched the 
entire conformation space of the ligand, including ring conformations (e.g., 6-member ring 
boat/chair conformations) and rotational degrees of freedom. For the ring conformation 
search, only ligands with minimised energy within 50 kJ/mol of the lowest energy 
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2.2. Methods 
MCF-7 culture studies 
2.2.1. Sterilisation 
2.2.1.1. Glassware and Consumables 
All glassware and consumables including glass pipettes, micropipettes, Pasteur pipettes, 
Schott bottles and Eppendorf tubes were autoclaved at 120 °C, 15 psi for 80 min.  
 
2.2.1.2.  Maintaining an Aseptic Work Surface 
All cell culture procedures were conducted in a laminar flow cabinet with an internal work 
surface pre-sterilised by UV radiation (254 nm, 2 h). Immediately prior to any cell culture 
work, the internal surface was sterilised with 70% v/v ethanol aerosol. All equipment and 
reagents were sprayed with ethanol aerosol and immediately transferred inside the laminar 
flow cabinet. 
 
2.2.2. Preparation of Cell Culture Media and Related Reagents 
2.2.2.1. Preparation of Phosphate Buffered Saline (PBS) 
A packet of PBS powder was added to a 1 L Schott bottle. MilliQ (900 mL) was added and 
the PBS dissolved by vigorous shaking. The pH was adjusted to 7.4 using 1 M HCl or NaOH 
as appropriate. The pH adjusted solution was topped up to 1 L with MilliQ water. The 
solution was sterilised via ultra-filtration through a 0.22 µM filter and stored at 4°C. 
 
2.2.2.2. Preparation of Antibiotics for Addition to Culture Media 
Benzyl penicillin (3.0 g) and streptomycin (2.8 g) were made up to 100 mL of sterile MilliQ 
water and stirred using a magnetic stirrer for 24 h. The solution was stored at 4°C for up to 6 
months. 
 
2.2.2.3. Preparation of Trypsin Protease 
NaCl (8.5 g) was dissolved in MilliQ water and made up to 1 L. Trypsin powder (25 g) was 
added to the 0.85% (w/v aq) NaCl (1 L) and stirred (using a magnetic stirrer) at room 
temperature for 1 h. The trypsin solution was sterilised by syringe filtration and dispensed 
into 10 mL aliquots and stored at -20°C. EDTA (3.72 g) was dissolved in PBS (1 L) and 
sterilised by filtration. This PBS/EDTA (PE) solution was diluted 10-fold with PBS and 90 
mL of the diluted PE was mixed with trypsin solution (10 mL) to produce the final trypsin 
solution (2.5% aq). This solution was stored at 4°C for up to 3 weeks.  
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2.2.2.4. Heat Inactivation of FBS 
FBS (500 mL) was thawed at 4°C overnight. The thawed serum was gently warmed in a 
37°C water bath for 30 min with gentle inversion every 10 min to ensure even temperature 
distribution. After the serum reached 37°C it was placed in a 56°C water bath for 60 min with 
gentle inversion every 10 min. The serum was left to rest at room temperature for 30 min. 
Aliquots (100 mL) were transferred to Schott bottles and stored at -20°C.  
 
2.2.2.5. Preparation of Charcoal-dextran Stripped FBS 
MgCl2(H2O)6 (0.3 g), sucrose (85.6 g), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES, 2.4 g) was added to a 1 L Schott bottle. MilliQ water (1 L) was added to the bottle 
and shaken vigorously. The solution was divided into 50 mL aliquots. Two aliquots were 
added to two 50 mL plastic centrifuge tubes each containing dextran coated charcoal (0.137 
g). The centrifuge tubes were inverted 10 times to ensure even distribution of charcoal-
dextran. The tubes were incubated for 24 h at 4°C. Following incubation, the charcoal-
dextran solution was centrifuged at 500 xg for 10 min and the supernatant was discarded. 
Inactivated FBS (50 mL) was added to each pellet. The tubes were inverted 10 times and 
incubated for a further 24 h at 4°C. The FBS-charcoal solution was then centrifuged at 1700 
xg for 10 min and the stripped FBS decanted into a 100 mL Schott bottle and stored at -20°C.  
 
2.2.2.6. Preparation of Phenol Red RPMI-1640 Medium Containing 10% v/v Inactivated FBS 
Heat inactivated FBS was thawed at 4°C overnight. Phenol red RPMI-1640 powder (9.6 g) 
and NaHCO3 (2.0 g) were added to a 1 L Schott bottle. MilliQ (900 mL) was added and the 
powder dissolved via vigorous shaking. The pH was adjusted to 7.4 (see Section 2.2.2.1.) and 
MilliQ (100 mL) was added. Sodium pyruvate solution (1 M; 1 mL) was added to the RPMI-
1640 solution and 900 mL was sterilised via ultra-filtration through a 0.22 µM Millipore 
filter. Ultrafiltration sterilised anti-biotics (5 mL) and FBS (100 mL) were added in that order 
to the RPMI-1640 culture medium. The complete RPMI-1640 culture medium solution (1 L) 
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2.2.2.7. Preparation of Phenol Red Free RPMI-1640 Medium Containing 10% v/v Stripped 
FBS 
Charcoal-dextran stripped FBS (100 mL) was thawed at 4°C overnight. Gibco phenol red free 
(PRF) RPMI-1640 culture medium solution (900 mL) was sterilized via ultra-filtration using 
a 0.22 µM Millipore filter, followed by antibiotics (5 mL) and FBS (100 mL), respectively 
and stored at 4°C.  
 
2.2.3. Cell Maintenance and Passaging 
2.2.3.1 MCF-7 Cell Seeding  
A 1 mL cryo-vial containing frozen MCF-7 cells was removed from storage in liquid 
nitrogen (-196°C) and thawed at room temperature for 15 min. Phenol red RPMI-1640 (5 
mL) was added to a sterile 25 cm2 culture flask using a flame sterilised 10 mL glass pipette. 
The defrosted cell suspension (100 µL) was added to the RPMI-1640 using a micro pipette 
with a sterile tip. The cells were incubated at 37°C in 5% v/v CO2 until they reached 
confluence (approx. 5 days). When confluent, the cells were passaged into sterile 75 cm2 
culture flasks as described in Section 2.2.3.2. 
 
2.2.3.2. Maintenance of MCF-7 Cell Culture 
MCF-7 cells were routinely passaged when the cultures reached at least 70% confluence 
(approx. 107 cells). Confluence refers to the percentage of the surface of a culture flask that is 
covered by adherent cell, in this case a 70% coverage was required before routine passage.   
Spent phenol red RPMI-1640 culture medium was vacuum aspirated using a flame sterilised 
Pasteur pipette. PBS (4 mL) was added to wash away any residual RPMI-1640 culture 
medium from the flask. Gibco TrpLEâ express (a proprietary trypsin solution, 3 mL) was 
added to detach the cellular monolayer. The culture flasks were incubated at 37°C with 5% 
v/v CO2 until the cells were seen to be beginning to detach under an inverted microscope. 
RPMI-1640 (6 mL) was added to inactivate the TrpLEâ express and the cell suspension was 
transferred to two new sterile 75 cm2 culture flasks. Further RPMI-1640 (12 mL) was added 
to each flask to give a total volume of 18 mL. The cell cultures were incubated at 37°C (see 
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2.2.4. Cell Counting  
2.2.4.1. Vetriplastâ Plastic Counting Chambers 
Vetriplastâ Plastic Counting Chambers were used to count large volumes of cells samples at 
any given time. A 20 µL aliquot from each sample of cell suspension was collected from a 
known volume and mixed 1:1 with trypan blue. A 9 µL aliquot of each sample was added to 
the 9 x 9 grids (10 per chamber). The same 5 squares were counted for each of the 10 
samples under an inverted microscope at 100x magnification. The total cell number was 
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2.2.5. MCF-7 Exposure Experiments 
Exposure experiments were used to determine the exposure concentration of the 
combinations of xenoestrogens to be used in the MCF-7 growth curve experiments (see 
Section 2.2.6.). A confluent flask was removed from incubation and the cells detached using 
4 mL of 2.5% trypsin solution and incubated for 5-10 min. Fresh PRF-RPMI-1640 (10 mL) 
was added to each flask. The cell suspension from the flask was transferred to a 50 mL 
centrifuge tube and vortex mixed until a homogenous suspension was produced. Three 20 µL 
aliquots were removed for counting (see Section 2.2.4.2.), the remaining cell suspension was 
kept on ice to prevent cell aggregation. Once the total number of cells were determined, they 
were seeded into a 24 well plate and diluted to ensure a final concentration of 105 cells in 
each well. Fresh medium with the desired exposure compound/s was added to give a final 
volume of 2 mL of medium/well in a series of eight serial dilutions. The plate was incubated 
at 37°C with 5% v/v CO2 for five days and counted in triplicate. 
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2.2.6. MCF-7 Growth Curve Experiments 
Growth curve measurements were carried out in triplicate over 10 days. Confluent cells (3 
flasks) were removed from incubation and the cells detached, vortex mixed, counted and 
seeded into a 24 well plate (see Section 2.2.5.). Fresh media was added to give a final volume 
of 2 mL of media/well. The plates were incubated at 37°C with 5% v/v CO2. The 24 wells 
were counted in triplicate on days 1, 3, 5-8 and 10.   
 
2.2.7. Cryopreservation 
A flask of confluent MCF-7 cells was removed from incubation. The monolayer was 
detached (See Section 2.2.3.2.) and transferred to a 50 mL centrifuge tube. The suspension 
was centrifuged at 4000 xg for 5 min and the supernatant was vacuum aspirated. The pellet 
was suspended in phenol red RPMI-1640 containing 17% v/v DMSO (100 µL). Aliquots 
(100 µL) were added to sterile 1 mL cryovials. Each cryovial was wrapped in cotton wool 
and placed at -80°C for 24 h before being stored in liquid nitrogen (-198°C).  
 
CALUXâ Studies  
2.2.8. Preparation of Cell Culture Media and Related Reagents 
2.2.8.1. Preparation of Phosphate Buffered Saline (PBS) 
A packet of PBS powder was added to a 1 L Schott bottle. MilliQ water (900 mL) was added 
and the PBS dissolved by vigorous shaking. The pH was adjusted to 7.4 (as described in 
Section 2.2.2.1.). The pH-adjusted solution was topped up to 1 L with MilliQ water. The 
solution was sterilised using ultra-filtration through a 0.22 µM Millipore filter and stored at 
4°C. 
 
2.2.8.2. Preparation of Trypsin Protease 
Trypsin stock solution was diluted to a concentration of 0.05% using PBS (without calcium 
and magnesium) containing 0.2 g/L ETDA. The solution was sterilised using ultra-filtration 
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2.2.8.3. Preparation of Cell Lysis Buffer 
Demineralised water (500 mL) was added to a 1 L glass beaker. Tris, DTT and CDTA (see 
Table 2.3), glycerol (100 mL) and TritonâX-100 (10 mL) were added to the beaker and 
adjusted to pH 7.8 (see Section 2.2.2.1.). The final volume was adjusted to 1 L with 
demineralised water and aliquoted (40 mL) into 50 mL centrifuge tubes. The tubes were 
stored at -20°C for up to 1 year or 4°C for up to 1 month.  
 









2.2.8.4. Preparation of BioDetection Systems Illuminate Mix 
Tricine and magnesium hydroxide carbonate pentahydrate (as per Table 2.4) were added to 
demineralised water (500 mL) and stirred using a magnetic stirrer until the solution was clear 
(approx. 1 h). Illuminate was warmed to room temperature and added along with magnesium 
sulphate-heptahydrate, EDTA and DTT (as per Table 2.5) to the solution in a dark room to 
prevent illuminate mix degradation. ATP (as per Table 2.5) and demineralised water (400 
mL) was added and the solution was adjusted to pH 7.8 (see Section 2.2.2.1.). The final 
volume was adjusted to 1 L with demineralised water and mixed carefully. Aliquots (100 
mL) were transferred into Schott and stored at -20°C for up to 3 months or at -80°C for up to 
a year.  
 
Table 2.4: Composition of illuminate mix 
Compound Weight (g) Molarity 
Tricine 3.580 20.0 mM 
(MgCO2)4Mg(OH)2.5H2O 0.520 1.07 mM 
MgSO4.7H2O 0.658 2.67 mM 
EDTA 0.037 0.100 mM 
DTT 0.231 1.50 mM 
Compound Weight (g) Volume (mL) Molarity 
Tris 3.0  25 mM 
DTT 0.31  2.0 mM 
CDTA 0.73  2.0 mM 
Glycerol  100 10% 
TritonâX-100  10 1% 
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D-Luciferin 0.151 0.539 mM 
ATP 3.026 5.49 mM 
 
2.2.8.5. Preparation of Dextran-Coated Activated Charcoal 
Tris (0.6 g) was dissolved in demineralised water (500 mL) in a glass beaker and adjusted to 
pH 8.0 (see Section 2.2.2.1.). A further 450 mL of demineralised water was added to the Tris 
solution. Dextran T500 (0.25 g) and activated charcoal (2.5 g) were added to the buffer and 
stirred using a magnetic stirrer at 4°C overnight.  
 
2.2.8.6. Preparation of Charcoal-dextran Stripped FBS 
FBS (500 mL) was thawed and 200 mL aliquoted into a glass bottle by sterile pipetting prior 
to refreezing. The remaining FBS (300 mL) was gently warmed in a 56°C water bath for 30 
min. Dextran-coated charcoal suspension (950 mL) was divided equally between 12 
centrifuge tubes (50 mL) and centrifuged at 1000xg for 10 min. The supernatant was 
discarded leaving behind dextran-coated charcoal pellets. FBS was divided equally into 6 
centrifuge tubes and incubated in a 45°C water bath for 45 min with continuous shaking. The 
serum-charcoal solution was centrifuged at 1000 xg for 20 min. The serum was decanted into 
the remaining 6 centrifuge tubes and incubated again at 45°C for 45 min and centrifuged at 
1000 xg for 20 min. The stripped FBS was decanted into six clean 50 mL centrifuge tubes 
and centrifuged at 1000 xg for a further 20 min. Stripped FBS was pooled, sterilised by ultra-
filtration and aliquoted (26.4 mL) into 50 mL centrifuge tubes and stored at -20°C for up to 6 
months.  
 
2.2.8.7. Preparation of DMEM/F12 Phenol Red Free Medium Containing 5% v/v Stripped 
FBS 
FBS (41 mL) was thawed in a 37°C water bath and added with Gibco non-essential amino 
acids (NEAAs; 5.5 mL) and penicillin-streptomycin solution (1 mL; see Section 2.2.2.2.) to 
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2.2.9. Cell Maintenance and Passaging  
2.2.9.1. Maintenance of U2OS CALUXâ Cell Culture 
U2OS CALUXâ cells were routinely passaged when cultures reached at least 70% 
confluence (see section 2.2.3.2). Spent DMEM/F12 medium was removed from the flask and 
the cells were washed using PBS (5 mL) twice to inactivate any residual DMEM/F12. 
Trypsin (2 mL) was added to the flask to just cover the cells and then decanted before 
incubating the cells at 37°C with 5% v/v CO2 until the cells were seen to begin to detach 
under an inverted microscope (approx. 1-3 min). DMEM/F12 (10 mL) was added to 
inactivate the trypsin and the cell suspension was transferred into four new sterile 75 cm2 
culture flasks. Further DMEM/F12 (7 mL) was added to each flask and the cells incubated at 
37°C until confluent. 
 
2.2.9.2. ERa and ERb CALUXâ Exposure Studies  
The response of CALUXâ to xenoestrogen combinations to assays was determined and 
repeated in triplicate. For both the ERα and ERβ CALUXâ assays, cells were seeded into 
white 384-well plates at a density of 3000 cells/well and allowed to attach for 24 h. The 
Assay medium was removed from each well using an EL406 washer/dispenser (BioTek) and 
exposure medium applied with the desired xenoestrogen/s. To get the required combinations, 
ERα or ERβ CALUXâ cells were exposed to increasing concentrations of each of the test 
compounds at a final DMSO concentration of 0.1% v/v, and in the ‘background’ a second 
compound was added at fixed concentration ([DMSO] = 0.01% v/v), giving an overall 
[DMSO] = 0.11% v/v. The fixed concentration was always around the EC10 concentration of 
the particular compound. Additionally, two DMSO blanks and a full dose response curve of 
the relevant reference compound (e.g. E2) were included on each plate. The preparation of 
the compound dilution series (e.g. the second exposure mixture) was performed on a 
Hamilton Starlet liquid handling robot coupled to a Cytomat incubator. After another 24 h, 
the medium was removed and Tritonâ X-100 lysis buffer (10 μL/well) was added using the 
BioTek EL406 washer/dispenser. Finally, illuminate mix was added to each well and the light 
signal was measured in a luminometer (TECAN Infinite Pro) for 0.017 min/well (i.e. ~1 s).  
 
2.2.9.3. Cytotox CALUXâ Studies 
The response of the Cytotox CALUXâ assay to selected xenoestrogen combinations were 
determined. Cells were seeded into white 384-well plates at a density of 3000 cells/well and 
allowed to attach for 24 h. The Assay medium was removed from each well using an EL406 
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washer/dispenser (BioTek) and exposure medium applied with the desired xenoestrogen/s. To 
get the required combinations, Cytotox CALUXâ cells were exposed to increasing 
concentrations of each of the test compounds at a final DMSO concentration of 0.1% v/v, and 
in the ‘background’ a second compound was added at fixed concentration ([DMSO] = 0.01% 
v/v), giving an overall [DMSO] = 0.11% v/v (as per Section 2.2.9.2). Additionally, two 
DMSO blanks were included on each plate. The preparation of the compound dilution series 
(e.g. the second exposure mixture) was performed on a Hamilton Starlet liquid handling robot 
coupled to a Cytomat incubator. After another 24 h, the medium was removed and Tritonâ X-
100 lysis buffer (10 μL/well) was added using the BioTek EL406 washer/dispenser. Finally, 
illuminate mix was added to each well and the light signal was measured in a luminometer 
(TECAN Infinite Pro) for 0.017 min/well (i.e. ~1 s). 
 
2.2.9.3 Graphs and Statistics 
MCF-7 Exposure Studies 
Cell counting data were processed as follows; the background (ethanol control) values were 
subtracted from all raw data before plotting using GraphPad Prism software (version 7.0a for 
mac, GraphPad Software, La Jolla California, USA, www.graphpad.com). All results are 
presented as mean ± standard error of n experiments (SEM). 
 
ERa and ERb CALUXâ assays 
Luminometer data were processed as follows; the background (DMSO control) values were 
subtracted from all raw data before plotting using GraphPad Prism software (version 7.0a for 
mac, GraphPad Software, La Jolla California, USA, www.graphpad.com). A sigmoidal dose-
response curve was fitted to the data and EC50 values and Hill slopes were determined using  
non-linear regression analysis. 
 
For the combined exposures, the ‘fixed’ concentration of the compound present in the 
background was recalculated to the corresponding concentration of the dose-response-curve 
compound. This was done using its EC50 values as a measure of relative potency. For 
example, if compound A is a 10x more estrogenic than compound B, 1.0 x 10-9 M of 
compound A can be recalculated to 1.0 x 10-8 M of compound B. This way, a dose-response 
curve could be plotted with the total estrogenic potency present in the mixture on the x-axis, 
expressed as the concentration of the dose-response-curve compound and light emission (or 
E2 response equivalents) on the y-axis.  
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In addition, in order to correctly assess the total estrogenicity of the mixtures, the CA model 




























R is the predicted response of the mixture in ‘percentage activation’ relative to E2, Ci is the 
concentration of each individual chemical in the mixture, and EC50i is the EC50 value of each 
individual chemical in the mixture. Observed and predicted data for mixture exposures were 
plotted in GraphPad Prism using a nonlinear regression curve fit.  
 
Cytotox CALUXâ assay 
Luminometer data were processed as follows; the background (DMSO control) values were 
subtracted from all raw data before plotting using GraphPad Prism software (version 7.0a for 
mac, GraphPad Software, La Jolla California, USA, www.graphpad.com). Data was plotted 
using regression analysis.  
 
2.2.10. Schrödinger Modelling 
2.2.10.1. Software Tools 
The Schrödinger Suite 2017 is a proprietary software package for studying biomolecular 
interactions. The various modules and workflows of the suite are accessed through a 
graphical interface (Maestro). For this work, the applications and workflows listed in Table 
2.5 were used. The Schrödinger Suite has been extensively tested and compared to other 
software tools and its performance is consistently in the top half of the group of tested 
software tools (Cheng, et al., 2009, Englebienne, et al., 2009, Halgren, et al., 2004, 
Kellenberger, et al., 2004, Perola, et al., 2004, Repasky, et al., 2007) and often one of the 
top-ranked tools for docking calculations. 
 
Materials and Methods 
 70 




Graphical interface for all Schrodinger applications and 
workflows 
LigPrep  Generation of accurate 3D molecular models for ligand 
molecules, including tautomeric, stereochemical, and 
ionisation variation optimised for further computational 
analyses. These tools are based on well-known bond 
length, bond angle and atom size parameters and 
molecular geometry and bonding rules.  
Glide  An extensive validated ligand placement algorithm and 
scoring function package to accurately predict binding 
mode for ligand-receptor complexes.  
Prime  Protein structure predictions, protein structure 





Correcting common structural problems (e.g. missing 
residues or residue side chains) and creating reliable, all 
atom protein models.  
Induced Fit 
Docking 
A novel method for fast and accurate prediction of 
ligand induced conformational changes in receptor 
active cavities. Combines Glide and Prime to 
exhaustively consider possible binding modes and the 
associated conformational changes within the receptor 
binding cavity. 
 
The process for docking as implemented in the Schrodinger Suite is illustrated in Figure 2.1. 
The ensemble of poses obtained as output from this process were further evaluated to obtain 
information from force field scoring functions.  
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Assign bond orders and formal charges
Fill missing side chains of residues using primary amino acid sequence
Add hydrogen atoms





















Figure 2.1: Schrodinger Suite ligand docking process. 
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2.2.10.2. Receptor Model Development  
The x-ray crystal structures of the ER LBDs listed in Table 2.2 were used to develop models 
for docking. Where multiple polypeptide chains were present in the PDB file, chain A was 
arbitrability selected (because even single polypeptide proteins have chain A) for the 
experiment. All water molecules except for the one involved in the hydrogen bond bridge 
with Glu353 and Arg394 in ERa models and Glu305 and Arg346 in ERb models were 
removed. Protein Preparation Wizard was used to assign bond orders, add hydrogen atoms 
and fill in missing side chains within the protein structure. The modified protein structure was 
then energy minimised to optimise bond distances and angles.   
 
2.2.10.3. Ligand Structure Development  
For each ligand, LigPrep was used to determine the ionisation state for carboxylic acids and 
amines at pH 7 ± 2 (this is close to the cellular pH of 7.4); generate tautomers (e.g. keto-
enol); generate alternative chiralities for all stereocentres and sample ring conformations to 
find lowest (i.e. the most thermodynamically stable) energy conformations. Finally, the 
geometry of each structure was optimised which involved allowing the structure to relax in 
all dimensions to achieve a low energy conformation. Not all possible isomers were produced 
because of internal filtering to eliminate structures which violate geometric restrictions such 
as for fused ring systems or conflict with natural product chiralities such as for the steroid 
framework. For some ligands LigPrep produced more than one stereoisomer (e.g. 17a- and 
17b-estradiol were produced). For those ligands where it was known which stereoisomer was 
the desired or correct option, only that stereoisomer was used for docking (e.g. only E2 was 
used). For equol, 2 possible isomers were produced; however, only the S isomer is found in 
vivo; therefore, the S-isomer was used in the study. 
 
2.2.10.4. Rigid Receptor Docking – RRD 
RRD was carried out using Glide and was run within Maestro using the applications menu. 
The first step in Glide docking was to generate a receptor grid. The LBC binding cavity was 
defined automatically based on the size, shape and location of the co-crystallised ligand of 
the particular receptor model used (e.g. 1ERE). For the AF-2 site the centroid of the residues 
Lys362 and Glu542 in ERa models and Lys314 and Glu493 in ERb models were used to 
define the location of the binding cavity. The size was determined by specifying ligands to be 
docked less than 20 Å in length because it must fit the receptor site. The receptor grid was 
kept rigid – with no van der Waals radius or change scaling of receptor atoms. The ligand 
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was docked flexibly, allowing nitrogen inversions and ring conformations. No constraints 
(e.g. required hydrogen bonds or covalent bonds to metal atoms) were specified and all 
receptor hydroxyl groups were allowed to rotate. 
 
Glide XP was used for docking using default parameters. The core, constraints and similarity 
options were not used. The core options allow for constraint of ligand poses within the 
binding cavity based of a reference ligand. The similarity options incorporate a similarity 
between a docked ligand and a reference ligand – a measure of how alike or unlike the two 
molecules are. Both the core and similarity options are useful in virtual screening application 
for drug target development to aid in the identification of strong binding ligands from a pool 
of potential candidates, which were not applicable to the task at hand. All the ligands listed in 
Table 3.3 were docked with receptor models listed in Table 3.2. For RRD, poses were ranked 
by XPGlideScore which was reported in units of kcal/mol and converted to kJ/mol.  
 
2.2.10.5. Induced-fit Receptor Docking - IFD 
IFD was run from within Maestro using the workflow menu (Table 2.6). For the LBC, the 
Glide grid was defined automatically based on the size and orientation of the co-crystallised 
ligand. The AF-2 site Glide grid was defined using the centroid of the residues Lys362 and 
Glu542 in ERa models and Lys314 and Glu493 in ERb models estimating the location of the 
binding cavity and the size was determined by specifying ligands to be docked less than 20 Å 
in length. Initial Glide docking allows residue side chains to be trimmed (temporarily 
removing them from the protein structure) automatically, based on the B-factor. The B-factor 
is also called the temperature factor and the higher the value, the more mobile the residue 
side chain. The more mobile side chains were trimmed as their spatial positions were less 
certain. The parameters used are summarised in Table 2.6. During the induced fit refinement 
step, the residues that were allowed to adapt to the placement of the ligand were those within 
5 Å of the co-crystallised ligand.  
 
For IFD, poses were ranked by IFDScore. The IFDScore is defined as the sum of 
XPGlideScore and 5% of the Prime energy (i.e. the total energy of the receptor-ligand 
complex), so this ranking accounts for the overall energy of the complex, not just a 
favourable binding energy. The calculated binding energy is given by the scoring function 
XPGlideScore. 
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Table 2.6: IFD parameters. 
Glide Grid Setup 
Box Centre Centroid of ligand 
Box Size Automatic based on co-crystallised 
ligand for LBC docking, centroid of 
Lys362/314 and Glu542/493 for AF-
2 docking 
Step 1: Initial Glide docking 
Protein Preparation constrained 
refinement 
Yes 
Trim side chains Yes, automatic based on B-factor 
Receptor van der Waals scaling 0.7 
Ligand van der Waals scaling 0.5 
Number of poses retained per ligand 5 
Step 2: Prime induced fit refinement 
Refine residues Within 5 Å of ligand 
Step 3: Glide re-docking  
Glide Docking  XP mode; re-dock into structures 
within 30 kcal/mol of best structure 
and within the top 5 structures 
overall 
 
2.2.10.6. XP GlideScore 
XPGlideScore was used in both RRD and IFD to estimate binding energy of the ligand with 
the receptor. XPGlideScore is optimised to identify and estimate ligand poses that have 
unfavourable energies based on well-known principles of physical chemistry (e.g. 
inappropriate hydrophobic interactions, poor hydrogen bonding interactions, etc.) to weed out 
false positives. As a result, more precise poses are produced than with standard GlideScore; 
however, the cost for this increased precision is computational time. Standard GlideScore is 
used for ligand database enrichment to quickly identify good candidates; however, for a more 
thorough study XPGlideScore was used.  
 
2.2.11. Questionnaire Study 
2.2.11.1. Study Design 
This was a two-part Canterbury population based cross sectional study. A cross sectional 
study is a study that assesses disease and exposure in a measured population. In this study, 
two groups of participants were selected: (1) Women aged between 18-69 years who were 
randomly selected from the New Zealand Electoral Roll and asked to complete a daily habits 
questionnaire, and (2) women from the University of Canterbury (UC) staff and students’ 
lists were randomly selected to complete a daily habits questionnaire and donate a blood 
sample for analysis of xenoestrogens. Additionally, women in both groups were asked to 
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complete a questionnaire on behalf of their daughters, if they had a daughter who had not had 
her first period (e.g. menarche), to assess the pre-pubertal exposure to xenoestrogens in girls. 
If a woman had two daughters who had not had their first period, she was asked to complete 
the questionnaire for her eldest daughter.  
 
2.2.11.2. Study Area 
The study was conducted in Canterbury, a province of Aotearoa-New Zealand which has a 
land area of 45,346 km2 and population of 539,436 according to the 2013 Census. The 
questionnaire was in English which is spoken by most New Zealanders and immigrants.   
 
Undertaking a cross-sectional study in Canterbury was appropriate to get access to 
participants, and to estimate xenoestrogen exposure, using a random sample of the population 
(Group 1) and to compare to the findings from the questionnaire with the blood analysis 
component in Group 2. Also streamlining access to the Canterbury population was relatively 
easy due to all New Zealand citizens and permanent residents 18 years and above being 
required to register on the parliamentary electoral roll. UC staff and students’ lists were easily 
accessible and encompassed the desired stratification of age frequencies required for Group 
2. Also, of interest for the current study, breast cancer is the most common cancer diagnosed 
in women in New Zealand and Canterbury, making it highly relevant to our target population.  
 
2.2.11.3. Study Population 
The study population consisted of women aged 18-69 years and their pre-pubertal daughters 
who resided in the Canterbury province. Breast cancer is generally a disease of post-
menopausal women, with menopause occurring between the ages of 42-56 years. Our 
assessment of women across a broad range of ages is important in the context of 
xenoestrogen mimic exposure and its potential breast cancer risk. Although women below the 
age of menopause (mean 51.5 years) are less likely to have developed breast cancer, their 
food and lifestyle habits now could be influencing their overall breast cancer risk later in life. 
By the age of 69 years the number of potential participants in the population significantly 
decreases; therefore, women over 69 years were not sought for the study. Additionally, 
women were asked to fill in an additional questionnaire on behalf of their daughter, only if 
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2.2.11.4. Inclusion and Exclusion Criteria 
Women in Group 1 were randomly selected from the General and Māori Electoral Rolls for 
the Canterbury province using a statistical analysis system (SAS) random number generator. 
All males were removed from the lists. Women whose name was not on the electoral rolls or 
who were 70 years and older were excluded from the study. All participants gave informed 
consent to participate in the study and, if applicable, gave consent on behalf of their pre-
pubertal daughter. Women in Group 2 between the ages of 18-69 were selected from UC staff 
and student lists. All women were capable of completing a self-administered questionnaire, 
gave consent to participate in the study and gave consent on behalf of their daughter if 
appropriate. Participants in this group were also capable of donating a 20 mL blood sample.  
 
2.2.11.5. Sampling  
There was sequential recruitment of participants until the target of each of the studies was 
achieved. The participants for the questionnaire study (Group 1) were selected randomly 
from the electoral rolls. Each person who met the inclusion criteria (see Section 2.2.11.4.) 
was assigned a random number between 0 and 1. They were then assigned a unique ID that 
incorporated the random number and their age (as at midnight on the 21st of September 
2016). This was then used to select participants in the correct frequency matched 5-year age 
groups. Participants in the blood analysis study were sequentially recruited through the use of 
UC staff and student email lists until the desired sample size was achieved in the correct 
frequency matched 5-year age groups. Samples of the letters to both groups of women are 
provided as Appendix 6.  
 
2.2.11.6. Sample Size 
When deciding the sample size, it was important to consider the number of study participants 
required to answer the study objectives. A small study may fail to detect important effects on 
the outcome of interest, whereas a study larger than necessary wastes resources. Furthermore, 
the study must be appropriate to be completed in the time frame of this PhD. Taking account 
of these considerations the first group target was 250 participants and the second group were 
50 participants. The following equation has been used to estimate sample sizes for surveys 
(Schaeffer et al., 1990) and was used to estimate an appropriate sample size (n) for the 
questionnaire study (Group 1):  
 
= = D1@@ I5cDd
1.96d (I − 1) + 5c
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N is the population size, p is the estimated proportion, q is 1-p, d is the desired absolute 
precision, and deff is the design effect. The value of 1.96 is based on the fact that 95% of the 
area of a normal distribution is within 1.96 standard deviations of the mean. 
 
At the start of the study there were limited data available on the prevalence of xenoestrogen 
exposures in New Zealand; however, a 2005 study (Thomson, 2005), which investigated 
dietary xenoestrogen exposures, suggests people are likely exposed to a number of dietary 
xenoestrogens on a daily basis. Therefore, taking this into consideration with other possible 
xenoestrogen exposures (e.g. parabens), a conservative hypothesised frequency of 80% was 
selected. The estimated population size of women in Canterbury is 184, 700 (based on 2013 
NZ Census data) and the design effect was set to one as this is a random simple sample. 
Using this data, it was determined that a sample size of 250 would provide statistically 
significant sample with 95% confidence intervals.   
 
The blood analysis study was not intended to be statistically robust but rather to give an 
indication of xenoestrogens present in women’s blood. It was decided to set up a study with 
the University of Canterbury Medical Centre to take blood samples from 50 women who 
were attending the medical centre for other reasons and agreed to take part in the study or had 
responded to a UC staff and student email. It was decided to include 50 women in this study 
because that was considered appropriate number to sample in a working day. The number 
was not statistically driven as this was a pilot study.  
 
2.2.11.7. Data Collection Instrument 
The data were collected using a structured self-administered questionnaire (Appendix 6) 
covering the following areas:  
1. Socio-demographic characteristics of the study participants: these included age, 
occupation, area of residence and weight. These were to help judge whether the selected 
group represented the population by comparing to other studies including the New 
Zealand Dietary survey. Additionally, their weight was asked to help us calculate the 
average amount of blood for a person in that particular age group.  
2. History of breast cancer: this covered their personal experience to having breast cancer 
and what subtype of breast cancer they had (e.g. ER+ve, ER-ve etc.). This provided 
insight into their food and lifestyle habits and allowed adjustment for possible changes in 
diet related to a previous/current breast cancer diagnosis.  
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3. Hormone medication: this covered current usage of contraceptives, hormone replacement 
treatment and/or fertility treatments. By taking any of these medications, the overall 
estrogenic load experienced by participants is significantly increased and may make other 
exposures negligible.  
4. Food and lifestyle habits: this included questions on food consumption, food packaging 
use, personal care product usage, dietary supplementation regimes and other non-
hormonal medication usages. These covered all the main routes of xenoestrogen 
exposure.  
5. Elimination of xenoestrogens: this covered whether the participant had heard of 
xenoestrogens prior to the questionnaire and whether they had taken any steps to 
eliminate them from their daily routine. 
 
The questionnaire included questions derived from the NZ Census and questions seeking 
further information sourced from suitable questionnaires including those used in previous 
dietary surveys. The use of questions based on information provided by the NZ Census 
allowed for comparison to the source population. The questionnaire was pilot tested and 
revised before being used in the study. The participants were also given the option of 
receiving a report of the study results but not a report of their individual results.  
 
2.2.11.8. Data Collection Procedure 
Recruitment of study participants and data collection was done Canterbury wide. All women 
were taken from both the General and Māori Electoral Rolls and placed into a spreadsheet in 
age order as of the 21st September 2016. Each woman was assigned a random number using a 
SAS random number generator. The women were then ordered numerically according to their 
randomly assigned number. The first 750 women were selected for recruitment to the study. 
The selected women were sent an information sheet detailing the study, a consent form, a 
copy of the food and lifestyle habits questionnaire and a copy of the daughter’s questionnaire 
and a postage paid addressed envelope for returning the questionnaire/s and consent form 
(Appendix 6) (Fig. 2.2).  
 
Access to electronic data about people on the New Zealand Electoral roll for purposes of 
health research is allowed under section 112 (3) of the (NZ) Electoral Act 1993. To facilitate 
responses, women who did not respond to the initial questionnaire and consent form within 3 
months from the dispatch date, were sent a second questionnaire package. The second round 
of dispatches also included an Ethics Committee amendment, which allowed an online option 
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for questionnaire completion. Those selected were informed that by pressing the submit 
button, they were consenting to the information provided to be used in the study. Those 
participants who returned completed questionnaires without a signed consent form were 
considered to have consented.  
 
The recruitment of study participants and data collection for Group 2 was done within the UC 
staff and student lists. Women were informed of the study and asked to participate in the 
study via email. Participants were asked to come to the University of Canterbury Health 
Centre on specified days and the first five willing participants of each age frequency were 
















Figure 2.2: Questionnaire and blood analysis data collection processes 
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2.2.11.9. Ethical Considerations 
Ethics committee approval was received for this part of the research from the University of 
Canterbury Human Ethics Committee (Approval number 2016/45). The approval letter 
(Appendix 7) and information sheets, consent forms and questionnaire are included in 
Appendix 6. In addition, the study proposal was assessed by the University of Canterbury 
Māori Research Advisory Group. 
 
2.2.11.10. Data Management and Analysis 
Questionnaire  
Questionnaire data (both groups) were entered into an excel spreadsheet. Frequency tables 
were then constructed in order to aid in identifying data entry errors. These errors were 
corrected by referring to the answers in the questionnaires. All identifying information was 
coded before analysis.  
 
Data were analysed using the IBM Statistical Package for the Social Sciences (IBM SPSS 
statistics). Descriptive statistics were used to compute frequencies in each of the five-age 
frequencies.  
 
Blood Xenostrogen Concentration Data 
New Zealand data (see Appendix 5) were used to estimate the xenoestrogen concentrations in 
foods and personal care products whenever they were available for population consistency 
with consumption and application data. Where New Zealand data were not available, data 
from the world scientific literature were employed. Attempts were made to use data from 
populations that are as culturally similar (e.g. Australia) to New Zealand as possible. 
 
Quantifying Food Servings and Personal Care Product Applications 
Food serving information from the 2009 New Zealand Total Diet Survey (Vannoort, et al., 
2009) was used to determine serving sizes for a simulated New Zealand typical diet for 
specified subgroups (Section 7.2.1.). However, the number of foods included in the New 
Zealand Total Diet Survey limits the usefulness because it does not include every possible 
food that is consumed by New Zealanders. Therefore, if a food was not included in the New 
Zealand Total Diet Survey the serving size for a similar food was used to estimate the serving 
size. For example, parsnip was not included in the 2009 New Zealand Total Diet Survey, but 
carrots were; therefore, based on the similarity in serving size and the fact that carrots and 
parsnips are both root vegetables, it was assumed the serving size for parsnip was similar as 
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for carrots. In addition, personal care product application size (Appendix 5) were taken from 
world scientific literature and applied to the xenoestrogen exposure assessment. Attempts 
were made to use data from populations that are culturally similar to New Zealand as 
possible.  
 
Relative Estrogenic Potency Data 
Relative estrogenicity (in estrogen equivalents (EQ)) was based on in vitro competitive 
binding or gene expression assays because they assess the basic binding to ERs without the 
higher level of biological complexity (e.g. xenobiotic metabolism) often associated with cell 
proliferation assays, such as the MCF-7 proliferation assay. EQ is the concentration of E2 
required to achieve 50% of the maximal response (EC50) divided by the concentration of the 
test compound required to achieve the same effect. EQ estimates are widely used to 
characterise and compare the potency of a wide variety of compounds, in this case 
xenoestrogens. For internal consistency, results from ERa and ERb CALUXâ experiments in 
Chapter 5 were also used. Using EQ, the total daily estrogenic load for each subgroup was 
calculated. This was carried out by calculating the mass (e.g. dose) of the food or personal 
care product, how much was eaten or used (e.g. serving or application size) and the 
concentrations of xenoestrogens in the food or personal care product, and therefore how 
much xenoestrogen participants were exposed to relating to their consumption/product usage. 
EQs were then determined for the calculated xenoestrogen concentrations (X) from literature 
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Circulating Concentrations of Xenoestrogens  
The average total blood volume for each subgroup of women was calculated using the 
following formula (Nadler, et al., 1962):  
 
o2::D	0:2>71 = o:Dp	q1Brℎ;	(Er) × 	sK16<r1	o2::D	0:2>71(78Er) 
 
The average blood volume/body weight (mg/kg), where the density of blood was assumed to 
be 1 mg/mL (Vitello, et al., 2015), was based on published literature values (Morgan, et al., 
2002): namely, 65 mg/kg for women and 80 mg/kg for pre-pubertal girls. In the 
questionnaire, women were asked to report their weight from which an average weight was 
calculated for each subgroup group. 
 
Once the total blood volume was calculated, the total concentration of xenoestrogens (as 
EQ)/L blood was calculated for each subgroup of women and pre-pubertal girls. The daily 
xenoestrogen intake had been calculated previously. This was assumed to be equally 
distributed in the circulatory system. Therefore, the circulating xenoestrogen concentration 






Circulating E2 Concentrations 
The estimated concentration of circulating E2 were determined from the scientific literature 










Materials and Methods 
 84 
Table 2.7: Circulating E2 concentrations 
Subgroup (age range) E2 concentration range (M) 
Women 
18-19 9.9 x 10-11 – 1.6 x 10-9 
30-39 9.9 x 10-11 – 1.6 x 10-9 
40-49 9.9 x 10-11 – 1.6 x 10-9 
50-59 0.0 – 1.5 x 10-10 
60-69 0.0 – 3.7 x 10-11 
Pre-pubertal girls 
0-12 months 0.0 – 1.5 x 10-11 
1-3 0.0 – 1.5 x 10-11 
5-6 0.0 – 1.5 x 10-11 
11-14 0.0 – 1.3 x 10-9 
 
The total concentration of E2 was determined, the total estrogenic loads for each subgroup of 
women and pre-pubertal girls were calculated. It was assumed that E2 and the xenoestrogens 
were equally distributed in the circulatory system. The total estrogenic loads were calculated 
by adding the calculated xenoestrogen concentration in EQ (M) to the determined E2 (M) 
concentration.  
 
2.2.12. Blood Analysis  
2.2.12.1. Sample Collection 
Blood samples (20 mL) were collected using a vacutainer and needle from each of the 
participants in Group 2. The samples were left for a minimum of 30 min at room temperature 
to clot before being stored at 4°C. 
 
2.2.12.2. Serum Preparation 
Blood samples were processed in batches of 12. The samples were centrifuged (2000 xg for 
10 min), on the same day they were collected. The serum layer was removed using a Pasteur 
pipette, transferred into a glass scintillation vial (20 mL) and stored at -20°C until analysed.   
 
2.2.12.3. Serum Extraction  
The serum samples were thawed at room temperature. Aliquots (10 mL) of serum were 
extracted using methyl tert-butyl ether (10 mL). The serum/ether mix was inverted 10 times 
and allowed to settle. The ether (upper) layer was transferred using a glass Pasteur pipette 
into a clean test tube (20 mL) containing anhydrous sodium sulfate (approx. 10 g). The 
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sodium sulfate was used to remove any remaining water from the samples. The solution was 
filtered using whatman filter paper (grade 2, 8µm) and transferred to a clean scintillation vial 
(20 mL). The samples were dried using a vacuum concentrator (SpeedVac SPD121P, 
Thermofisher) at 37°C for 20 min. The extracts were stored at 4°C overnight. The sample 
extracts were dissolved in analytical grade acetonitrile. If the samples did not fully dissolve a 
few drops of chloroform were added. The dissolved extracts were transferred to HPLC vials 
and analysed for the target analytes using LC (Dionex Ultimate 3000, ThermoFisher) coupled 
with a MS (maXis 3G UHR-Qq-TOF, Bruker Daltonik GmbH, Bremen, Germany).   
 
2.2.12.4. Serum Analysis 
For detection of all analytes, each sample was analysed using LC-MS coupled with the 
Bruker Compass Data Analysis software program (Bruker Daltonik GmbH, Bremen, 
Germany). The LC-MS system was equipped with an electrospray ion source (ESI) and was 
running in positive mode. The sample (5 µL) was injected onto a C18 reverse phase HPLC 
column (Dionex). The flow rate was 200 µL/min, and the column temperature was 25°C. 
Solvents were A: 0.1% v/v (aq.) acetic acid and B: 0.1% acetic acid in acetonitrile. Table 2.8 
shows the solvent programming. An analyte was positively detected if the mass ion was 
identified within 2 decimal places of the analyte standard’s accurate molar mass and had the 
same retention time.  
 
Table 2.8: Solvent gradient: A, 0.1% acetic acid in water; B, 0.1% acetic acid in acetonitrile 
Time (min) 0.0 1.5 1.6 6.0 6.1 10.0 10.1 12.0 15.5 15.6 17.0 
Solvent A (%) 95 95 73 70 55 55 30 10 10 95 95 
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MCF-7 cells are the most studied human breast cancer cell line in the world (Lee, et al., 
2015). Results from these studies have made a fundamental impact upon breast cancer 
research, particularly for ERa positive breast cancer. To date there have been nearly 25,000 
published reports on this cell line, rivalled only by the nearly 80,000 publications using the 
HeLa cell line (Lee, et al., 2015). The popularity of the MCF-7 cell line for breast cancer 
research reflects its reliability to many aspects of breast cancer in a clinical setting, 
particularly in the understanding of postmenopausal women with hormone receptor positive 
breast cancer.  
 
3.1.1. A Brief History of MCF-7 Cells 
The MCF-7 cell line was established in 1973 by Dr. Soule and colleagues at the Michigan 
Cancer Foundation (Soule, et al., 1973). MCF-7 cells, named after the Michigan Cancer 
Foundation and representing Dr. Soules seventh attempt at generating a cancer cell line, were 
isolated from the pleural effusion of a 69 year old women with metastatic breast cancer 
disease. The patient had undergone a conservative radical mastectomy for malignant breast 
adenocarcinoma three years earlier. Local recurrences were controlled for the subsequent 
three years with radiotherapy and an unrecorded hormone therapy, most likely the synthetic 
estrogen diethylstilbestrol. Two months after widespread nodular recurrences, cells were 
excised from chest wall nodules and from a pleural effusion. The chest wall cells quickly 
became overgrown in culture by fibroblasts; however, the pleural effusion cells initially grew 
in suspension and then ultimately formed a monolayer on plastic culture flasks that grew in 
continuous culture, a technique where cells are maintained in a particular phase of growth 
(e.g. log phase; Fig. 3.1). At this time cell culture was still in its infancy, with the first cancer 
cell line (HeLa) being established some 20 years earlier. Many laboratories documented 
technical difficulties in generating homogenous breast cancer cell populations without 
significant stromal contamination and overgrowth by fibroblasts. Several laboratories had 
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tried to isolate cells using different substrates and nutrients with many cell lines only capable 
of being cultured for a few months at a time (Levenson, et al., 1997, Soule, et al., 1973). 
 
3.1.2. MCF-7 and the ERs 
The MCF-7 cell line has made important contributions to both breast cancer research and our 
current understanding of the ERs. This cell line is one of very few established breast cancer 
cell lines able to express substantial levels of ERa, akin to a majority of invasive breast 
cancers. The maintenance of ER expression in cultured cells lines is difficult and has resulted 
in far more ER-ve than ER+ve human breast cancer cell lines to date. Evidence of this loss in 
ER expression in cultured breast cancer cells points towards the role of extracellular matrix 
and inappropriate growth substrate (i.e. two-dimensional plastic). Interestingly, it appears Dr. 
Soule did not perform any modifications to the standard isolation technique at the time to 
specifically isolate an ER+ve cell line. In the original description of MCF-7 cells, Dr. Soule 
did not make reference to the ERa +ve expression. This finding was subsequently described 
in another publication in 1973 where Soule and his colleagues reported the finding of 
“specific estrogen receptor in MCF-7…” (Brooks, et al., 1973). The importance of ER 
Figure 3.1: Historical image of MCF-7 cells (image from Levenson and Jordan 1997 with 
permission). 
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expression and how this would impact the basic understanding of ERs at the time was also 
recognised, with the authors acknowledging the potential to “add to present knowledge 
regarding intracellular binding constants, transport mechanisms and the mode of nuclear 
uptake”. However, it was not until 1975 when Lippman (Lippman, et al., 1975) and Horwitz 
(Horwitz, et al., 1975) first reported the ER status and biological function of MCF-7 cells, 
with both clearly realising and stating the importance the cell line would have in breast 
cancer research in the future.  
 
3.1.3. Early MCF-7 Studies 
While it appeared straightforward to use the MCF-7 cell line to understand the actions of the 
ER, the simple demonstration of stimulation of MCF-7 cell growth by E2 was more 
challenging and not as reproducible as anticipated (Osborne, et al., 1983, Sutherland, et al., 
1983). In 1986, the Katzenellenbogens discovered that phenol red, used in tissue culture 
media as an indicator of pH, was a weak estrogen and was sufficient to induce activation of 
the ER at the high concentration used in media. The removal of phenol red eliminated the 
confounding variable and was a critical step forward in understanding how estrogen activated 
the ER and stimulated breast cancer cell growth (Berthois, et al., 1986). Solving this 
predicament was absolutely critical for future research into ER action in MCF-7 cells. 
Comparatively, early studies on anti-estrogens were much more straight forward with 
inhibition being reported of the MCF-7 cell cycle at the G0/G1 block aid, leading to cell 
proliferation inhibition (Osborne, et al., 1983, Sutherland, et al., 1983).  
 
In addition, MCF-7 cells were central to the development of ER antibodies with the first 
monoclonal antibody for human ER being purified from this cell line (Greene, et al., 
1980).The antibodies aided in the cloning and sequencing of ESR1(Walter, et al., 1985) and 
the clarification of prominent nuclear localisation of ER (King, et al., 1984) thus providing 
key insights into the ER mechanism of action upon E2 activation.  
 
It is also important to note that while MCF-7s are viewed as the “work horse” for studies of 
estrogen action in breast cancer, these cells also express androgen, progesterone and 
glucocorticoid receptors (Horwitz, et al., 1975). MCF-7 cells have served as a valuable model 
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3.1.4. Genomics of MCF-7 Cells 
Understanding the variability and isolation of MCF-7 is critical, as fundamental concepts of 
breast cancer have been developed from this single cell line. In the original report on the 
isolation of MCF-7, chromosome number was assessed in passage two of the pleural effusion 
and found to range from 70-144 (Soule, et al., 1973). However, analysis of the MCF-7 cell 
line at passage 39 showed that the chromosome number had narrowed to a range of 77-99. 
Remarkably, this number has stabilised further over the last 45 years with the current number 
of chromosomes in MCF-7 cells provided by the American Type Culture Collection (ATCC) 
is 82 (range 66 to 87) (Lee, et al., 2015). 
 
When considering the increased understanding of breast cancer cell heterogeneity and 
evolution it is not surprising that there is a considerable amount of genomic instability. Some 
studies have also shown different gene expression and genomic profiles, while others have 
shown karyotype differences between MCF-7 cell line variants (Osborne, et al., 1987). 
Indeed, this genomic instability is akin to breast cancer in a clinical setting where, in a patient 
over time, the breast cancer cells exhibit similar genomic instability, whether that be from 
therapies (e.g. hormonal treatment) or spontaneously.  
 
One of the most disconcerting aspects of MCF-7 cells in the laboratory has been their ability 
to adapt and evolve over time, such that many different variants of the original cell line have 
been identified. These adaptations have led difficulty to replicate results from different MCF-
7 variants from different laboratories around the world (Lorsch, et al., 2014). Initially, cross-
contamination was thought to be the general issue, like with many other cell lines; however, 
it is now thought that genomic instability of the cell line is responsible for the variation 
between MCF-7 culture variants. It was Osborne and colleagues who first reported the 
American type culture collection (ATCC) MCF-7 cell line to be cytogenetically dissimilar to 
the original MCF-7 cell line described by Dr. Soule (Osborne, et al., 1987). Since then 
investigators from other laboratories have also identified this issue and have even noted 
different responses between MCF-7 cell line variants in biologic assays. Many laboratories 
now distinguish their MCF-7 cell line by naming their own variants including MCF-7 L 
(Lippman, B (Benz), KP (Kent Osborne), BK (Benita Katzenellenbogen), and many more. 
Therefore, with the likelihood of many different MCF-7 cell line variants around the world, it 
is obvious many different adaptations have been developed for culture media formulation for 
culturing MCF-7 cells. 
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3.1.5. The MCF-7 Culture System 
Culture medium is the most important factor in cell culture technology, it supports cell 
survival and proliferation, as well as cellular functions; obviously this means that the quality 
of the medium directly affects research results. An array of different culture media and a 
diverse range of nutrient formulations have been established for culturing MCF-7 cells over 
the last 45 years. A commonly used culture medium formulation, as described by Comsa and 
colleagues, includes low glucose DMEM containing 10% FBS, 2 mM glutamine, 0.01 
mg/mL insulin and 1% penicillin/streptomycin mix and incubated at 37ºC in an atmosphere 
of 5% CO2 v/v in air (Comsa, et al., 2015). The addition of 1% non-essential amino acid 
supplementation is also common in culture media used to culture MCF-7 cells (Adams, 
1990).  
 
Cell culture has developed in leaps and bounds, with many breakthroughs leading to cell 
culture equipment being easily accessible to any scientist wanting to work with cultured cells. 
Despite the clear limitations, the value of MCF-7 cells to the understanding of ER action 
cannot be overstated. The pivotal work using this cell line continues unabated and when used 
in the right way remains a powerful experimental tool and continue to lead to improved 
outcomes in breast cancer patients (Lee, et al., 2015). However, the influence of the culture 
system on MCF-7 proliferation has not been fully understood.  
 
The aim of this chapter was to understand the culture system that optimised MCF-7 cell 
growth in a laboratory setting and aligned with international literature with minimal 
background variability which could influence the results presented in Chapter 4. 
Additionally, the impact of two trypsin enzyme solutions used during cell maintenance and 
experimental procedures was investigated to reduce any influence on cell variability and 
reproducibility.  
 
3.2. Experimental Approach 
Since the MCF-7 cell line is one of the most used cells in laboratories around the world, there 
are plethora of different culture media available for MCF-7 cell culture. For example, culture 
media with different nutrient supplements (e.g. glutamine), the inclusion of NEAA (e.g. 
glycine, serine), and key energy sources (e.g. glucose). However, the scientific literature 
gives little guidance on which medium to use for a particular application – published studies 
using MCF-7 cells rarely explain their choice in culture medium. For this reason, I embarked 
Understanding the MCF-7 Model System 
 91 
upon an investigation on the most appropriate media for the model system I wanted to 
develop (see Chapter 4).  
 
Cell culture media composition used in MCF-7 cell culture was evaluated and compared to 
determine if there were any significant differences between the compositions. MCF-7 cells 
were then challenged with the different culture media and proliferation was measured using 
cell counting techniques as previously described (Section 2.2.4.). Three different culture 
media were tested: MEM, DMEM and RPMI-1640.   
 
Furthermore, the metabolic pathways in MCF-7 cells were investigated with different culture 
medium supplementations. It is well known that metabolic reprogramming in cancer cells is 
required to drive biosynthetic pathways which enables rapid cell proliferation. Therefore, two 
of the most used substrates, glucose (metabolised by glycolysis) and pyruvate (a carbon 
source for the tricarboxcyclic acid (TCA) cycle) were investigated to evaluate the effect of 
this category of supplements on MCF-7 cell proliferation.  
 
Trypsin is a serine protease which cleaves two amino acids, arginine and lysine, on cell 
surface proteins (i.e. cadherin) thus, interferring with cell-cell and cell-matrix (e.g. plastic 
culture flask) interactions. Treatment with trypsin allows the cells to dissociate from the 
plastic culture flask and each other to achieve a single cell suspension which is important in 
reducing variability during dose response and growth curve experiments (see Chapter 4). 
Two main forms of trypsin are available to use: TrypLEä  Express, a recombinant fungal 
enzyme produced by fermentation, and porcine trypsin isolated from the pancreas of pigs. 
The difference between the two types of trypsin is that TrypLEä  Express is described by its 
manufacturers to be ‘gentler’ at cleaving the cell surface proteins in addition to its increased 
stability and storage longevity compared to porcine isolated trypsin. Therefore, TrypLEä  
Express and a 2.5% trypsin protease solution were tested to determine which trypsin was 
most effective in the dissociation of MCF-7 cells without affecting cell growth. If either of 
the trypsin solutions were to affect MCF-7 cell growth prior to an experiment, it could mask 
any differences observed in subsequent chapters. MCF-7 cells were exposed for 5, 10 and 30 
min to TrypLEä  Express (1x). Cells were also exposed to a 2.5% trypsin protease solution 
and monitored under an inverted microscope. Since the trypsin protease was being used, they 
were only observed for 5 min to prevent cell death.  
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The MCF-7 culture system used in this thesis was developed on a modification of the 
previous culture method used in the Human Toxicology Research Group (Webber, 2013), the 
general culture media composition described above (Section 5.1.3.) and the method used at 
the Christchurch District Health Board (CDHB) where the cell line originated. The culture 
media compositions selected for testing are shown in Table 3.1.  
 
Table 3.1: Culture media formulations (1) (2) and (3) indicate the culture conditions used. 















MEM (1) ü ü ü    
DMEM ü ü ü  ü  
DMEM 
(2) 
ü ü ü    
RPMI-
1640 
ü ü ü   ü 
RPMI-
1640 (3) 
ü ü ü ü  ü 
 
3.3. Results 
3.3.1. Effect of Culture Medium on MCF-7 Cell Proliferation 
To understand the effects of the culture media on MCF-7 cell proliferation, the cells were 
passaged into each of the culture media formulations described in Table 3.1. For test (1) the 
cells proliferated slowly (e.g. the cells did not reach confluence until day 10) and presented 
with a low level of adherence to the culture flask. This is uncharacteristic of MCF-7 cells as 
they are known to be an adherent cell line and have previously been shown to reach 
confluence at day 6 (Webber, 2013); therefore, no further experiments were carried out using 
this culture medium. The next test (2) increased proliferation compared to test (1). However, 
cells did not rapidly proliferate as expected and exhibited a low level of adherence. 
Therefore, this culture media formulation was not routinely used, however, it was used in a 
later experiment to investigate the impact of high and low glucose supplementation on MCF-
7 cell growth (see Section 2.2.6.). Finally, test (3) was carried out and the cells reached 
confluence as expected with a high level of adherence. The MCF-7 cells exhibited an 
increase in proliferation compared to proliferation observed with tests (1) and (2). The 
growth curve experiment carried out using this culture method also produced a specific (i.e. 
middle of log phase reached at day 5) sigmoidal growth pattern characteristic of MCF-7 cells 
(see Fig. 3.2). 




Furthermore, when comparing the culture media compositions (Table 3.2) it is clear that there 
is a high degree of composition commonality between MEM and DMEM. However, RPMI-
1640 included non-essential amino acids (L-asparagine, L-aspartic acid, L-glutamic acid, L-
proline and hydroxyproline) which were not part of MEM and DMEM’s composition. The 
DMEM culture medium had additional supplementation, including L-serine, glycine, ferric 
nitrate and pyridoxine hydrochloride, compared to MEM; however, it was unclear whether 
these compounds affected cell proliferation with both experiments displaying low cell 
Figure 3.2: A schematic sigmoidal growth curve in culture based on how one would expect 
cells to grow. The cells would be expected to exhibit a typical three phase growth pattern: 1) 
the lag phase – cell population grows slowly; 2) the log or exponential growth phase – the 
cell population undergoes a rapid period of growth 3) the plateau or stationary phase – cell 
population growth becomes static and cell proliferation = cell death, this is referred to as the 
carrying capacity (from Bioninja with permission).  
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adhesion to the culture flask in the presence of both culture media formulations. Interestingly, 
when comparing the culture media compositions with the non-essential amino acids solution 
available to add to MEM and DMEM culture media, it is clear that the amino acid differences 
between MEM/DMEM and RPMI-1640 are the same as those included in the NEAAs 
solution (Table 3.2). 
 
Table 3.2: Comparison of culture media composition.  
Component MEM DMEM RPMI-1640 NEAAs 
Amino Acids      
Glycine  ü ü P 
L-Arginine hydrochloride ü ü   
L-Cysteine 2HCl ü ü ü  
L-Glutamine ü ü ü  
L-Histidine hydrochloride-
H2O 
ü ü   
L-Isoleucine ü ü ü  
L-Leucine ü ü ü  
L-Lysine hydrochloride ü ü ü  
L-Methionine  ü ü ü  
L-Phenylalanine ü ü ü  
L-Serine  ü ü P 
L-Threonine  ü ü ü  
L-Tryptophan ü ü ü  
L-Tyrosine disodium salt 
dihydrate 
ü ü ü  
L-Valine ü ü ü  
L-Arginine   ü  
L-Asparagine   ü P 
L-Aspartic Acid   ü P 
L-Glutamic Acid   ü P 
L-Histidine   ü  
L-Hydroxyproline   ü  
L-Proline   ü P 
L-Alanine    P 
Vitamins     
Choline chloride ü ü ü  
D-Calcium pantothenate ü ü ü  
Folic Acid ü ü ü  
Niacinamide ü ü ü  
Pyridoxine hydrochloride  ü ü  
Riboflavin ü ü ü  
Thiamine hydrochloride ü ü ü  
i-Inositol ü ü ü  
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Pyridoxal hydrochloride ü    
Biotin   ü  
4-Para aminobenzoic acid   ü  
Vitamin B12   ü  
Inorganic Salts     
Calcium chloride ü ü   
Ferric nitrate  ü   
Magnesium sulfate ü ü ü  
Potassium chloride ü ü ü  
Sodium bicarbonate ü ü ü  
Sodium chloride ü ü ü  
Sodium phosphate 
monobasic 
ü ü   
Calcium nitrate   ü  
Sodium phosphate dibasic 
anhydrous 
  ü  
Other Components     
D-glucose ü ü ü  
Phenol red ü ü ü  
Glutathione   ü  
 
3.3.2. Effect of Sodium Pyruvate and Glucose Supplementations on MCF-7 Cell Proliferation 
To gain further insights into the influence of culture media supplementation on MCF-7 cell 
proliferation, MCF-7 cells were grown in DMEM with a high glucose supplementation, and 
RPMI-1640 with sodium pyruvate supplementation. All culture media used in these 
experiments contained low glucose (Table 3.2), therefore it was not possible to do a low 
glucose experiment.  When comparing MCF-7 cell proliferation between the groups, no 
difference was found between a high glucose supplemented culture medium and a low 
glucose supplemented culture medium. However, the was a significant increase in MCF-7 
cell proliferation when sodium pyruvate was present in the culture medium.  
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Figure 3.3: Proliferation (± SEM, n=3) of MCF-7 cells exposed to high glucose (a) and 
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3.3.3. TrypLEä  Express and Trypsin Protease Dispersal of MCF-7 Cells 
MCF-7 cells were exposed to TrypLEä  Express (2 mL) for 5, 10 or 30 min. Cells exposed 
to TrypLEä Express for 5 min began to detach, with a majority of the cells remaining 
adhered to the bottom of the culture flask. However, when the cells were exposed to 
TrypLEä  Express for 10 min the cells were detached enough to the point where when the 
culture medium was added, the force from the expelled liquid using the automatic pipette was 
enough to fully remove the cells from the bottom of the flask. However, when the cells were 
seeded into 24 well plates to begin an experiment, the cells still adhered to one another 
(clumped), making an even dispersal almost impossible. This led to a high cell count 
variability. However, for cell maintenance, complete cell-cell dissociation was not necessary; 
therefore, an approximate 10 min exposure to TrypLEä  Express was sufficient unless 
preparing for an experiment where a single cell suspension was required to get an even 
distribution of cells in each of the wells. If the cell-cell dissociation was unsuccessful the 
results often had a high variability between replicates. When cells were exposed to TrypLEä  
Express for 30 min the cells completely detached from the bottom of the flask; however, the 
cells dissociated in large clumps which were near impossible to separate without causing 
damage to the cells. If the cells became damaged they would not adhere to the flask, instead 
the cells would float in suspension. Eventually this led to cells growing in large floating 
clumps rather than a monolayer on the bottom of the flask. In addition, cells exposed to 
TrypLEä  Express for 30 min spent a longer time in the lag phase, resulting in the log phase 
being delayed for up to three days (Fig. 3.4).   



















TrypLEä  Express was demonstrated to separate cells sufficiently following 10 min 
exposure, thus, because it is gentler on the cells it was continued to be used for cell 
maintenance (Section 2.2.3.2.). However, when observing the cell suspension under a 
microscope, the TrypLEä  Express did not sufficiently separate the cells, thus a single cell 
suspension could not be achieved. Additionally, when cells were seeded using the TrypLEä  
Express solution in the protocol, high variability was observed between replicates (Fig. 3.5). 
Therefore, the trypsin protease solution was used to prepare a single cell suspension for cell 
seeding (Section 2.2.4.). However, the cells were much more closely monitored under the 
microscope when exposed to trypsin protease solution to minimise any effects of prolonged 
exposure such as a delayed log phase or low adherence due to the breakdown of cell surface 
adhesion molecules. When the cells had completely dissociated from the flask, a single cell 
suspension could be achieved using the force from expelled liquid in the automatic pipette.  
Figure 3.4: Proliferation (± SEM, n=3) of MCF-7 cells exposed to TrypLEä  
Express (30 min), highlighting the delay in the log phase to day 6/7. 



















It is clear, even from a brief literature search, that there are many different cell culture 
systems used around the world. This is not surprising when one considers the deviation of the 
MCF-7 cell line since it was first isolated in 1973. Although, remarkably, the cell line has 
stabilised over the last 45 years the ability of MCF-7 cells to adapt and evolve over time, this 
is a concern in the context of historical data from MCF-7 cell experiments. This has led to an 
difficulty to replicate results in MCF-7 variants across laboratories which has caused concern 
for people using the MCF-7 cell line for their research (Lorsch, et al., 2014). However, from 
the perspective of my work the MCF-7 cells still responded to an E2 stimulus as anticipated. 
In this section of my research I wanted to identify the best culture medium for my MCF-7 
model system – this was achieved.  
 
3.4.1. Effect of Culture Medium on MCF-7 Cell Proliferation  
Sufficient concentrations of nutrients in the medium are prerequisites for cells to behave 
consistently. Some cell types require higher concentrations of nutrients than others, 
depending on their metabolic activity and proliferation rate. Therefore, it is not surprising that 
MCF-7 cells responded differently to each of the culture media; with cells cultured in MEM 
culture media having the slowest growth response and low adherence to the culture flask. 
Figure 3.5: Proliferation (± SEM, n=3) of MCF-7 cells exposed to TrypLEä  
Express, highlighting the variability cause by prolonged exposure (i.e. 30 min). 
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MEM culture medium is the least supplemented of the three tested, based on basal medium 
Eagle (BME). Non-essential amino acids, which MCF-7 cells can biosynthesise, are not 
included in the MEM formulation. DMEM is modified to include additional non-essential 
amino acids serine and glycine. MCF-7 cells grown in DMEM culture medium proliferated at 
a higher rate compared to MEM, which suggests the addition of glycine and serine was 
necessary for cell growth and proliferation. However, the RPMI-1640 culture media had a 
positive effect on proliferation compared to MCF-7 cell cultured in both MEM and DMEM, 
while a high level of adherence to the culture flask was also observed. One of the most 
significant differences between MEM/DMEM and RPMI-1640 is the addition of eight 
NEAAs to RPMI-1640. The NEAAs are important in the cell’s intermediary biochemistry 
(see Fig. 3.6) and by extension are important in cell health and proliferation. In general, 
NEAAs can be biosynthesised in cells (Yao, et al., 2017), thus, they are not included in some 
basal media such as MEM. It is likely that MCF-7 cells cannot produce sufficient amounts of 
NEAAs in the cultured state to support proliferation, thus rely on high concentrations of 
NEAAs in the culture media. The addition of NEAAs in the RPMI-1640 appears to ensure 
more favourable culture conditions and thus might alleviate the biosynthetic pressure of the 
cells. Interestingly, the majority of methods that use MEM or DMEM to culture MCF-7 cells 
add NEAAs (Yao, et al., 2017), highlighting the importance of correct nutrient 
supplementation for MCF-7 cell culture.  
 
Glutamine, one of the essential amino acids, is an energy source in mammalian cells in 
culture, in addition to being required for protein synthesis. The glutamine requirements for 
cell culture are ~3-40 fold greater than those of other amino acids (Eagle, 1959). However, 
ammonia is released into the culture media as a result of consumption of glutamine by the 
cells where glutamine undergo the chemical decomposition to pyrrolidonecarboxylic acid. 
Ammonia is cytotoxic to cells and has been shown to inhibit cell growth (reviewed by 
(Schneider, et al., 1996)), however, for many years glutamine has been known to be a major 
energy source for mammalian cells grown in culture (Yao, et al., 2017). It’s possible that cell 
death seen after long term (e.g. 10 days or more) is related in part to depleted glutamine in 
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3.4.2. Effect of Sodium Pyruvate and Glucose Supplementation of MCF-7 Cell Proliferation 
In general, the genetic differences between normal and cancer cells lead to significant 
phenotypic differences; therefore, an altered metabolic phenotype would be required for the 
normal function of the cancer cell, thus some metabolic precursors are necessary for 
increased proliferation, providing a growth advantage over normal, non-cancerous cells 
(DeBerardinis, 2009). From the results, it is clear that glucose did not support the replication 
and proliferation of the MCF-7 cells, whereby, no change in proliferation was observed 
between glucose and non-glucose supplemented medium. Although the medium used in this 
experiment was DMEM which lacks NEAAs; however, one would expect the glucose present 
in the culture medium to be sufficient to support increased proliferation. Interestingly, when 
MCF-7 cells were cultured in sodium pyruvate supplemented RPMI-1640, increased 
proliferation occurred compared to cells exposed to RPMI-1640 without sodium pyruvate 
supplementation. Pyruvate is a key metabolic intermediate (see Fig. 3.6). It is biosynthesised 
from glucose through glycolysis and can supply energy to cells through the tricarboxylic acid 
(TCA) cycle when oxygen is present (Berg, et al., 2002). Without the constant supply of 
metabolic energy, the frequent replication characteristic of cancer cells would not be 
possible.  
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Figure 3.6: Simplified schematic of a cell’s metabolic pathways: glycolysis, the citric acid 
(TCA) and pentose phosphate pathway and the role in of these pathways in amino acid 
synthesis. The pentose phosphate (red) and TCA (blue) demonstrates how glucose and 
pyruvate supplementation could circumvent the biosynthesis of glycine, serine and cysteine 
in MCF-7 cells. 
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The results from the experiments describe above support those of Diers and colleagues 
(2012) who also observed rapid proliferation in MCF-7 cells in the presence of pyruvate, 
compared to cells cultured in glucose-containing medium. The culture media used in these 
studies was DMEM without NEAA supplementation, which suggests even though my studies 
were carried out in two different culture media, the presence of the NEAAs did not influence 
the outcome (Diers, et al., 2012). Clearly, glucose and thus glycolysis, is not sufficient to 
support rapid proliferation in MCF-7 cells compared to mitochondrial metabolism. However, 
glycolytic metabolism can provide a growth advantage through several different mechanisms 
(reviewed in (Kim, et al., 2006)). These include generating ATP at a faster rate than oxidative 
phosphorylation, providing biosynthesis substrates needed for rapid proliferation (e.g. 
NADPH and ribose-5-phosphate) and supporting cell growth under hypoxic conditions.  
 
Interestingly, a study conducted by Drabovich and colleagues (2012) showed elevated 
expression of fructose-1, 6-bisphosphatase (FBP1), fructose-1, 6-bisphosphatase-2 (FBP2) 
and glucose-6-phosphate dehydrogenase (G6PD) in MCF-7 cells compared to a non-
cancerous breast cell line (MCF-10A) (Drabovich, et al., 2012).  The elevation of these 
enzymes increases glucose flux from glycolysis to the pentose phosphate pathway (PPP), 
redirecting cellular energy metabolism toward increased biosynthesis (Jiang, et al., 2011). 
This likely explains the low induction of rapid proliferation by glucose-supplemented culture 
media, with glycolysis being redirected into the PPP. Therefore, even if MCF-7 cells are 
cultured in a high glucose containing medium, the pathway could be redirected to drive 
synthesis of ribose 5-phosphate, a precursor for the synthesis of nucleotides and other 
macromolecules, leaving glycolysis with minimal substrates to produce pyruvate. It is not 
surprising that the cells drive the production of ribose 5-phosphate (see Fig. 3.6) considering 
their rapid proliferation and high dependence on the synthesis of nucleotides, and thus DNA 
synthesis. This pathway favourability could also explain the induction of rapid proliferation 
of cells cultured in pyruvate containing media, where the exogenous pyruvate to the culture 
medium bypasses glycolysis, and thus the redirection into PPP, allowing for effective 
biosynthesis of the TCA macromolecules.  
 
Interestingly, an emerging concept in the field of cancer metabolism suggests the importance 
of mitochondrial metabolism, particularly tricarboxylic acid (TCA) activity, in providing 
intermediates required for the biosynthesis of cellular macromolecules (e.g. fatty acids, 
NEAAs).   It has been shown that metabolism of mitochondrial substrates such as glutamine 
and pyruvate are necessary to support the rapid proliferation of multiple cells types, and a 
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functional link between mitochondrial respiration and proliferation capacity (Pike, et al., 
2011, Weinberg, et al., 2010). This suggests that pyruvate might be required for MCF-7 cells 
to have the necessary energy reserves thought to be critical for effective cell function in 
adverse conditions (Dranka, et al., 2010, Jekabsons, et al., 2004). 
 
It is likely that the energy required to produce the NEAAs is directed towards the 
biochemistry associated with replication if the NEAAs are provided in the culture medium – 
indeed NEAAs could be regarded as essential for cancer cells which divide frequently. This 
also highlights the need for NEAAs media supplementation (see Section 3.4.1.). In addition, 
glycine and serine are biosynthesised from glucose via glycolysis (Fig. 3.5) which further 
supports the need for NEAA supplementation. If glucose was supplemented to give the cells 
the metabolic wherewithal to biosynthesise NEAAs the metabolic flux would redirect glucose 
to the PPP which would not achieve the goal NEAA biosynthesis. On the other hand, if 
pyruvate is supplemented it directly enters the TCA and bypasses glycine and serine 
biosynthesis. In short glucose does not provide the cell its NEAAs needs and pyruvate 
bypasses the biosynthesis of two key NEAAs and therefore NEAAs is required by MCF-7 
cells in culture. 
 
3.4.3. TrypLEä  Express and Trypsin Protease Dispersal of MCF-7 Cells 
Trypsin or TrypLEä  Express cleaves peptide bonds with lysine and arginine on the c-
terminal side unless they are followed by proline. They are the most common enzyme 
preparations in tissue culture used to release adherent cells from culture flasks (i.e. the 
matrix) and/or each other (Heng, et al., 2009). Cell-cell and cell-matrix interactions depend 
on adhesion molecules such as cadherin which, in turn, relies on calcium for activity. 
Cadherin is important in the formation of adhesion junctions which mediate cell-cell and cell-
matrix interactions. Since Ca2+ and Mg2+ are important for growth and development and 
biochemistry in general, this of course facilitates adhesion processes. In the context of cell 
culture, unfortunately trypsin is inhibited by Ca2+ Mg2+, for this reason EDTA is usually 
added to trypsin solutions because it chelates Ca2+ and Mg2+ which facilitates trypsin activity 
(Dainiak, et al., 2007). 
 
This study compared the dissociation of adherent MCF-7 cells with either TrypLEä  Express 
or trypsin protease, the most commonly used enzyme for dissociation of cultured cells in 
vitro. The TrypLEä  Express is designed to be gentler on cells, and this was evident from the 
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experiments. The TrypLEä  Express exposed cells required a longer exposure to get the 
desired dissociation. However, it did not separate the cells to get a single cell suspension 
required for the experiments as described (Section 2.2.4.). However, prolonged exposure (30 
min) to the trypsin protease solution affected cell proliferation by decreasing initial adhesion 
of the cells to the flask and delaying the log phase for up to three days. This is not surprising 
considering the enzymes mechanism of action cleaving peptide bonds. Prolonged exposure 
leaves the cell surface stripped of proteins which would at the very least change the 
morphology of the cell or could even cause cell death.  
 
When TrypLEä  Express is used in routine cell culture, it effectively removes the cells from 
the matrix but to some extent reduced cell-cell adhesion. The degree cell-cell and cell-matrix 
dissociation was sufficient for the purposes of routine passage. On the other hand, trypsin 
was very effective in reducing cell-cell and cell-matrix adhesion usually resulting in 
liberation of single cells; this is required for MCF-7 cell experiments. Therefore, TrypLEä  
Express was used for routine passaging and trypsin was used for experiments where a single 
cell suspension was required.  
 
3.5 Concluding Remarks 
The results presented in this Chapter highlights the importance of understanding the 
biochemistry of cultured cells. In the MCF-7 cell line it is clear that the metabolic 
requirements are vast, and therefore, important in developing and understanding the culture 
system. Whilst MCF-7 cells have been fundamental in breast cancer research, limited 
information is available on the rationale behind the multitude of culture systems used. 
Therefore, this chapter provides insights into culturing the MCF-7 cell line which is 
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The ER evolved in a pristine environment in which it developed a highly specific relationship 
with estrogens, particularly E2. Sequence analysis indicates that the ER evolved before other 
nuclear receptors such as AR and PR, with an ancestral ER identified in basal animals (e.g. 
sponges, coral, etc.) but not plants, yeast and bacteria (Baker, 2005, Baker, 2008, Bertrand, et 
al., 2011, Bertrand, et al., 2004, Bridgham, et al., 2010, Sladek, 2011). However, with the 
industrial revolution came the development of a myriad of chemicals, many of which would 
be found to be E2 mimics. In turn, the ER was found to be surprisingly promiscuous with the 
accommodation of a broad array of ligands at the LBC binding site. The development of 
chemicals did not stop there with millions of chemicals being registered every year many of 
which have unknown estrogenicities. For example, in 1995 there were 211,934 chemical 
abstract service (CAS)-registered chemicals, this increased to 88, 758, 285 by 2006 (Binetti, 
et al., 2008). Improvements in industrial productivity over the last 70 years have meant that 
large quantities of structurally diverse, persistent chemicals have been released into the 
environment (Bitman, et al., 1968, Colborn, et al., 1993). Over 800 compounds are known to 
disrupt the endocrine system, with over 160 of these compounds identified as being 
xenoestrogens (Brody, et al., 2006, Brody, et al., 2003, Brody, et al., 2007). However, this 
number is likely a vast underestimate with only a select number of chemicals being tested to 
date, many of whom have been selected based on toxicological evidence.  
 
Many xenoestrogens are found in the environment and foods; however, their in vivo 
predictability has come under scrutiny with the development of different techniques and tools 
used for assessing their estrogenic effects (Graham, 2012, Thomson, 2005). The major routes 
of exposure for humans are assumed to be via the regular diet of food containing natural 
phytoestrogens, compounds leaching from food wrapping materials, and residues of 
pesticides, as well as personal care products such as wash off products (shampoos and soaps) 
that are used regularly, often daily (Aurela, et al., 1999, Erlund, et al., 2002, Franke, et al., 
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1998, Saito, et al., 2002). Thus, a normal diet and daily habits already result in exposure to 
complex mixtures of xenoestrogens, resulting in systematic circulation in the body (van 
Meeuwen, 2008). Therefore, while xenoestrogens are generally found at low concentrations 
in the environment, the overall impact of xenoestrogen mixtures could lead to biological 
effects that are at least additive. There is wide concern about the increasing exposure of 
humans to xenestrogens. In this respect, several xenoestrogens have been suggested to pose a 
possible risk to humans and concern has been raised because of a suggested link with breast 
cancer (Siddiqui, et al., 2016). 
 
Many common environmental chemicals are mammary gland carcinogens in animal studies, 
activate relevant hormonal pathways, or enhance mammary gland susceptibility to 
carcinogenesis. The long latency and multifactorial aetiology of breast cancer have made 
evaluation of these chemicals as possible carcinogens in humans challenging (Rodgers, et al., 
2018). However, the possibility that the bioaccumulation of xenoestrogens may cause breast 
cancer has been raised by past epidemiological studies on environmental and occupational 
exposure. Associations have been reported between breast cancer risk and serum or fatty 
tissue levels of 1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene (DDE) or 2,2-bis-(p-
chlorophenyl)-1, 1, 1-trichloroethane (DDT), sometimes linked to ER positive tumours 
(Djordjevic, et al., 1994, Falck, et al., 1992, Wolff, et al., 1993). Major risk factors for breast 
cancer include sex, age, genetic predisposition, reproductive history and lifetime exposure to 
breast tissue estrogens as well as modifiable risk factors such as obesity, lack of physical 
activity and high alcohol intake (see Section 1.5.3.). Exposure to xenoestrogens early in life 
is also thought to alter breast development and increase adult susceptibility to breast cancer. 
For example, the synthetic estrogen diethylstilbestrol (DES) has been associated with breast 
cancer after age 40 in a U.S. cohort of women who were exposed in utero (Hoover, et al., 
2011). However, the age-standardised breast cancer incidence rates are increasing in some 
developed and developing countries, which cannot be explained by these major risk factors 
(DeSantis, et al., 2015, WHO, 2013). 
 
The questions posed by Safe and colleagues (2018) summarised the current controversy in 
the field: “The important toxicological question concerning these chemical xenoestrogens is 
whether they differ only in potency which is governed by their intrinsic estrogenicity and 
bioavailability based on their metabolism and pharmacokinetics. On the other hand, since the 
estrogenic activity of these compounds is ER dependent, is the estrogenic activity of 
structurally diverse xenoestrogens more unique and not necessarily governed by intrinsic ER 
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binding affinities and pharmacodynamics factors?”  Indeed, results from X-ray 
crystallographic analysis clearly demonstrate that both ER agonists and ER antagonists 
differentially bind the ER and induce compound-specific changes in the bound complex, 
leading to different transactivation induction (Bernstein, 2002). Not only that, they also have 
different ER isoform preferences such that genistein and other phytoestrogens preferentially 
bind ERb, while synthetic xenoestrogens, such as EE2, preferentially bind ERa (see Section 
1.4.). This indicates that the potential associated risk of xenoestrogen combination and breast 
cancer, are very much dependent on the mixture composition. However, not all 
xenoestrogens have negative implications for human health, in fact, phytoestrogens (plant 
derived xenoestrogens) are well known to exhibit a litany of health benefits including lower 
risk of osteoporosis, heart disease and breast cancer (Patisaul, et al., 2010). 
 
4.1.1. Phytoestrogens 
Humans are exposed to high concentrations (e.g. µM concentrations) of isoflavones in their 
day-to-day lives. Isoflavones are a good indicator of phytoestrogen intake because 
isoflavones are the main component of consumed phytoestrogens (e.g. genistein, daidzein 
and equol). A meta-analysis by Lim and Shaw (2016) shows that isoflavone intake in China 
varies from 5.7 mg/day to 89.3 mg/day, while in the USA intakes vary from 0.8 mg/day to 
13.7 mg/day. Intake data from the USA likely represent Western diets, while Chinese data 
likely represent Asian diets. Interestingly, data from both diets are converging, with an 
increase in Western diets to 13.7 mg/day and a significant decrease in Asian diets to 15.6 
mg/day (Lim, et al., 2016). Interestingly, Asian populations historically had lower rates of 
breast cancer compared to Western populations, however, breast cancer incidence is 
increasing in Asian countries which has been linked to soy consumption (Adlercreutz, et al., 
1997). Soy is the corner stone of a traditional Asian diet, an observation which had long 
fuelled the widely held belief that consumption of soy reduces the risk of breast cancer. This 
makes is sound really simple, however, it is far more complex because now we know more 
about phytoestrogen intake it looks like the breast cancer incidence is not only related to soy 
consumption. Phytoestrogens, especially genistein and daidzein, are largely attributed as the 
compounds responsible for the reduced breast cancer risk and have particularly gained a lot 
of interest in the area since the 1980’s after findings of epidemiological studies that compared 
Western and Asian diets. Results indicate that a diet with high phytoestrogen content may 
give some prevention against predominant Western diseases such as breast cancer 
(Adlercreutz, 2002, Cassidy, et al., 2000). However, with a significant decrease in soy 
consumption and rising breast cancer incidences in Asia, one could speculate that there may 
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be a negative relationship between soy consumption and breast cancer incidence. Age-
standardised incidence is going up in some countries around the world (Fig. 4.1) which could 
be related to dietary xenoestrogen exposures, however causation cannot be inferred from 
descriptive data alone. It is much more complicated that simple soy consumption; this graph 
shows developed and developing nations where it so happens that some developing countries 
eat a lot more soy than the developed countries. However, there are other factors such as 
differences in regulatory status of chemicals and therefore, exposure of populations to 
environmental chemicals, such as pesticides or components of cosmetics can vary greatly 




At present, several mechanisms underlying this possible beneficial effect of phytoestrogens 
have been suggested: (i) specifically binding and activating ERb more than ERa, although 
generally with less affinity than E2 (Kostelac, et al., 2003, Kuiper, et al., 1997, Kuiper, et al., 
1998), (ii) acting as a SERM (selective estrogen receptor modulator) (Diel, et al., 2001), (iii) 
reducing ER expression (Chen, et al., 2003, Miodini, et al., 1999, Sathyamoorthy, et al., 
1997), (iv) competing as agonist with other endogenous estrogens on the ER, (v) inducing 
apoptosis (Pagliacci, et al., 1994), (vi) lowering estrogen levels in circulation (Ibarreta, et al., 
Figure 4.1: Incidence of breast cancer in individuals grouped by geographical area between 
1980 and 2010 (Forouzanfar, et al., 2011). 
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2001), (vii) reducing angiogenesis and tumour invasiveness (Chen, et al., 2003, Magee, et al., 
2004), and (viii) scavenging radicals (Brownson, et al., 2002, Nijveldt, et al., 2001, Zand, et 
al., 2000). Clearly, there are many possible mechanisms of action attributed to the possible 
beneficial effects of phytoestrogens; thus, understanding their role in xenoestrogen endocrine 
disruption is important in unravelling the cocktail effect of xenoestrogens as breast cancer 
risk factors.  
 
4.1.2. Xenoestrogens as Endocrine Disruptors  
There are several mechanisms of disruption that can affect estrogen signalling (Fig. 4.2). The 
mechanisms can be categorised as ER mediated (e.g. genomic and non-genomic signalling) 
and non-ER mediated (e.g. competition at SHBG). Xenoestrogens are able to interfere with 
multiple steps illustrated in Figure 4.2 that evidently will lead to altered gene expression. To 
further complicate matters xenoestrogens may simultaneously act via more than one 
mechanism (see labelled numbers 1-12 in Figure 4.2). For example, a xenoestrogen may 
interfere with E2 biosynthesis, compete for binding to the SHBG and compete for binding at 
the ER LBC compounding the estrogenic effects.  For these reasons, a phenotypic definition 
of xenoestrogens as endocrine disruptors is difficult to provide. Thus, with such a complex 
nature, regulation of the use and exposure of xenoestrogens has been limited to individual 















[Figure legend on next page] 
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Thus, in order to fully understand the estrogenic or anti-estrogenic activities of 
xenoestrogens, studies will have to consider multiple mechanisms of actions of ER-
xenoestrogen complexes. Risk assessment of these compounds is complex and dependent on 
all the variables mentioned above. Moreover, since individual xenoestrogens exhibit unique 
biologies, the overall impact of mixtures of these compounds may not be additive. These 
factors highlight the challenges faced by scientists and regulators in addressing the health 
risks and benefits of estrogenic compounds (Safe, et al., 2018). 
 
In addition, assessing xenoestrogen cocktails, particularly in women who are most at risk of 
developing breast cancer, is not as straightforward as it first appears. Circulating E2 levels 
vary significantly throughout a woman’s life which can impact on the effects of xenoestrogen 
mixtures; therefore, the proportion E2 contributes to a mixture varies depending on the day in 
the estrus cycle and stage of development (e.g. pre-puberty, post-menopausal, etc.) of a 
woman, thus it is important to consider the circulating E2 levels when assessing xenoestrogen 
cocktail risk. Women who are of child-bearing age have high circulating E2 levels (20-250 
pg/mL) compared to postmenopausal women or pre-pubertal girls who have low circulating 
E2 levels (<20 pg/mL). Such varying concentrations of E2 might significantly impact on the 
activity and estrogenic effect xenoestrogen exposures might have at the individual level.  
 
4.1.3. Current Understanding of Xenoestrogen Cocktails 
MCF-7 cells, which are ER+ve, are often used to study xenoestrogen, as they exploit the 
principle that MCF-7 human breast cancer cells proliferate in the presence of chemicals that 
directly or indirectly activate the ERs. In previous MCF-7 cell proliferation studies, 
combinations of benzylbutyl phthalate, BPA, DDE and hexachlorobenzene and E2 with 
either BPA or pentachlorophenol have been reported to give a synergistic proliferative 
Figure 4.2: Potential mechanisms of xenoestrogen endocrine disruption. (1) Up/down regulation of 
testosterone biosynthesis leads to changes in E2 biosynthesis. (2) Up/down regulation of aromatase 
leads to altered E2 biosynthesis in the ovaries. (3) Changes in E2 feedback mechanisms leads to 
altered E2 biosynthesis. (4) Xenoestrogens gastrointestinal (GI) tract metabolism leads to a more or 
less potent xenoestrogen. (5) Competition for hormone carrier proteins (e.g. steroid hormone binding 
globulin, SHBG) increases the concentration of free E2. (6) Agonist xenoestrogens compete for ER 
binding altering genomic (8) and non-genomic (9) signalling pathways. (7) Antagonist xenoestrogens 
compete for ER binding altering genomic (8) and non-genomic (9) signalling pathways. (10) Changes 
in epigenetic modification (e.g. transcriptional and post-translational) leads to altered gene expression. 
(11) Altered E2 metabolism by competition for phase II enzymes (e.g.sulfotransferase (SULT) and 
uridine 5’-diphospho- glucuronosyltransferase (UGT)) alters free E2 concentrations. (12) Up/down 
regulation of phase II metabolic enzymes alters free E2 concentrations (concept of the GI tract, 
circulation and bile sections of this diagram were taken from (Kodavanti, et al., 2010). 
MCF-7 Exposure Studies 
 113 
response (Suzuki, et al., 2001). In contrast, mixture experiments with nonyl and octylphenol 
and E2 and benzylbutyl phthalate have been reported to negatively affect MCF-7 cell 
proliferation (Rajapakse, et al., 2004). Additionally, multiple studies by Kortenkamp and 
colleagues have shown xenoestrogen mixtures to be additive in MCF-7 cell studies (Evans, et 
al., 2012, Kortenkamp, 2007, Kortenkamp, 2008, Kortenkamp, et al., 2007, Payne, et al., 
2000, Rajapakse, et al., 2002, Rajapakse, et al., 2004, Silva, et al., 2002). Additivity in the 
context of this work describes the case in which chemicals act together to produce effects 
without enhancing or diminishing each other’s actions.  
 
The identification of xenoestrogens in the environment, coupled with human exposures to 
these compounds, has generated public, regulatory and scientific concern regarding their 
potential hormonal toxicity resulting in human health risks and risks to wildlife. While there 
has been an increased interest in xenoestrogens, they still remain regulated individually due 
to the complexity of their mechanisms of endocrine disruption. In addition, the hypothesis 
that environmental/dietary xenoestrogens may increase breast cancer incidence is 
controversial and the significance of these compounds on human health is not resolved. 
However, recent research has started to propose the involvement of xenoestrogens via 
interfering with estrogenic pathways, as one of the causes of increasing incidence rates of 
breast cancer (WHO, 2013). 
 
Clearly, exposure to xenoestrogens is far more complex that the concept of simple additivity; 
thus, the overall effects of mixtures still remains inconclusive. However, in view of the 
suggested adverse effects of xenoestrogens on human health and wildlife, it is important for 
the risk assessment process to establish the types of mixture interactions that may occur with 
exposure to combinations of these natural and synthetic xenoestrogens. The aim of this 
chapter is to assess xenoestrogen combinations to determine the effect on MCF-7 cell 
proliferation, in order to understand the mixture effects in a breast cancer model system. 
Phytoestrogens are present in food at fairly high concentrations, thus we are all exposed to 
them every day. There is also a very large literature on their biochemistry and toxicological 
effect; for example, the mixed proliferative/anti-proliferative effects of genistein in cultured 
breast cancer cells. This makes them interesting candidates for study. Therefore, it was 
reasonable to included them as a major part of the study.   
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4.2. Experimental Approach 
Xenoestrogens (Table 4.1) were selected for MCF-7 exposure studies based on previous 
published studies which showed a high likelihood of women being exposed throughout their 
day-to-day lives. There was a focus on phytoestrogens because (1) they are present in a 
significant proportion of foods people consume every day, (2) they are likely to induce 
simple additivity, and (3) they have potential to exert breast cancer preventive effects. Two 
studies were carried out in order to assess xenoestrogen mixtures: a dose response study 
which coupled eight increasing concentrations of xenoestrogens with either E2 or another 
xenoestrogen, and 10-day growth curve studies which examined the impact of exposure to a 
combination of xenoestrogens where the individual components of the mixture were selected 
at fixed concentrations. 
 
Table 4.1: Xenoestrogens selected to be studied in MCF-7 exposure studies: E2, EE2, 

































4.2.1. MCF-7 Dose Response Studies 
Initially, MCF-7 dose response experiments were carried out to determine the combination 
concentration for the 10-day growth experiments (see Section 2.2.6.). Cells were exposed to 
increasing concentrations (n=8) of each of the eight xenoestrogens with and without E2 (1.0 x 
10-11 M) in a 24 well plate. Additionally, methylparaben/butylparaben and E2/BPA/genistein 
combinations were also studied (Table 4.2). Cells were exposed to the combinations for five 
days and then counted in triplicate and repeated in triplicate using a Vetriplast cell counting 
chamber as described (Section 2.2.4.1). The five-day exposure period was chosen based on 
the time taken for cells to reach the middle of the log phase without any xenoestrogens 
present (see Fig. 3.3). From the results, a concentration combination for each of the eight 
xenoestrogen/E2 combinations was selected to be used for 10-day growth curve experiments 
(Section 2.2.6.). The concentration combination was selected based on the lowest 
concentration where an effect was seen (e.g. where there was a clear positive or negative 
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Table 4.2: Selected concentrations of each xenoestrogen for MCF-7 dose response 
experiments. Varied compounds are tested at eight increasing concentrations with a fixed 
compound added for combination studies. The tick indicates the xenoestrogen combination 
used in each experiment.  
Fixed compounds (M) } 
Varied compounds (M) 
 6 
E2 
(1.0 x 10-11) 
Butylparaben  
(1.0 x 10-8)  
Genistein 
(1.0 x 10-8)  
BPA  
(1.0 x 10-8)  
E2  
(1.0 x 10-8.5- 1.0 x 10-12) 
   P P 
E2  
(1.0 x 10-8.5- 1.0 x 10-12)  
  P  
EE2 
 (1.0 x 10-9.5- 1.0 x 10-13) 
P    
Genistein  
(1.0 x 10-5.5- 1.0 x 10-9) 
P    
BPA  
(1.0 x 10-5.5- 1.0 x 10-9) 
P    
Methylparaben  
(1.0 x 10-4.5- 1.0 x 10-8) 
 P   
Butylparaben  
(1.0 x 10-5.5- 1.0 x 10-9) 
P    
Tetrahydrocurcumin  
(1.0 x 10-6.5- 1.0 x 10-10) 
P    
Kaempferol  
(1.0 x 10-5.5- 1.0 x 10-9) 
P    
Estriol  
(1.0 x 10-7.5- 1.0 x 10-11) 
P    
 
4.2.2. MCF-7 10-day Growth Curve Studies 
The effects of the xenoestrogen combinations selected from the dose response experiments 
were examined over a 10-day exposure period. MCF-7 cells were exposed to the selected 
combination (Table 4.3), and cell proliferation was determined in triplicate (e.g. each well 
was counted three times and each daily time point was repeated three times) on days zero, 1, 
3, 5-8 and 10 using a vetriplast counting chamber (2.2.4.1.). In addition, cells were exposed 
to a combination of all eight xenoestrogens/E2 and counted in triplicate. The 10-day exposure 
period was selected because MCF-7 cells reach the plateau/stationary phase at day 10 (see 
model system chapter Fig. 3.2). Cell numbers were compared at day 6 as this is where the 
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cell growth stabilised, which was selected based on the time taken to reach the top of the log 
phase (see Fig. 3.3).  
 
4.3. Results 
4.3.1. Individual Xenoestrogen Dose Responses 
Each xenoestrogens studied showed a definite dose-response effect (Fig. 4.3). If the 
concentrations were sufficiently low, then a classic dose-response curve was seen. In most 
cases it is obvious.  
 
4.3.2. Xenoestrogen Combination Dose Responses 
The growth of the MCF-7 cells following exposure to varying concentrations of xenoestrogen 
combinations is shown in Figure 4.3. Dose responses for the xenoestrogen combinations 
show differing patterns of response compared to the corresponding individual response 
experiments. Two clear categories of responses emerged, those that positively increased the 
MCF-7 proliferative response and those that decreased proliferation. Xenoestrogen 
combinations that positively affected proliferation included EE2/E2 and BPA/E2, while the 
remaining combinations negatively affected the proliferative response to varying degrees. 
Most surprisingly, when comparing the combination responses to the response elicited by 
exposure of E2 (1 x 10-11 M), the combinations that had a negative effect on proliferation 
showed a significant decrease in cell number, whereas the combinations that had a positive 
effect on proliferation only increased the response initially before following a similar trend to 
the individual xenoestrogen response. Tetrahydrocurcumin and estriol, both in the presence 
of E2, decreased MCF-7 cell proliferation so much that the response was similar to the 
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Figure 4.3: also see pages 119 and 120 
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Figure 4.3: also see page 120 











From the graphs shown in Figure 4.3, the exposure concentrations of the xenoestrogen 
combinations were selected for the 10-day growth curve experiments. The 
concentration at which there was either a definite increase or decrease in the 
proliferation response was selected for all xenoestrogens except genistein. In the 
genistein dose response curve there was an unexpected and unexplained peak. 
However, upon comparison with the docking experiments (Chapter 6) it was clear that 
the calculated binding energy for genistein did not support the definite 
increase/decrease observed, whilst they did for all the other xenoestrogens. Thus, 
because the calculated binding energy for genistein was very similar to butylparaben 
and BPA, the same concentration was selected for genistein to take account of the 









Figure 4.3 (also see pages 118 and 119): MCF-7 proliferation (± SEM, n=3) 
response to individual and combinations of xenoestrogens. EE2 and BPA 
combinations exhibited had a positive effect on proliferation at low 
concentrations, while genistein, butylparaben, E2, tetrahydrocurcumin, estriol 
and methylparaben combinations negatively affected proliferation compared to 
individual responses.  












E2 + BPA + Genistein
E2
E2 + BPA + Genistein
BPA   
Genistein
Control
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Table 4.3: Exposure concentrations of xenoestrogens to be tested in 10-day MCF-7 
growth curve experiments. 
Compound Exposure concentration (M) 
Genistein 1.0 x 10-8 
BPA  1.0 x 10-8 
EE2 1.0 x 10-12 
Butylparaben 1.0 x 10-8 
Kaempferol 1.0 x 10-8 
Tetrahydrocurcumin 1.0 x 10-9 
Estriol 1.0 x 10-10 




4.3.3. 10-Day Xenoestrogen Combination Growth Curve Responses 
MCF-7 cells were grown in culture over 10 days and were shown to have a typical 
sigmoidal growth curve (Fig. 3.2). Seven individual MCF-7 exposure experiments 
containing two xenoestrogens followed by 1 combination exposure experiment with 
eight xenoestrogens were studied (see Figs. 4.4, 4.5 and 4.6). Results were similar to 
the dose response experiments where two clear groupings emerged, those that had a 
positive effect on proliferation and those that had a negative effect on proliferation 
compared to the control.  
 
The EE2 and BPA combination studies again showed additivity in MCF-7 cell 
proliferation of 21.4% and 16.9%, respectively when compared to the control 
response at day 6, and an increase of 1.8%-2.4% compared to the respective 
individual xenoestrogen in the combination. When comparing proliferation induced 
by these two combinations, both combinations approached the response of E2 with 
only a 7.1%-15.1% difference. Whether this is biologically significant is uncertain, 
however, in the context of a cocktail of chemicals when one might be exposed to 20-
30 xenoestrogens in a day it might be expected to have a biologically significant 
effect.  
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BPA   
BPA + E2  
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Control
Figure 4.4: MCF-7 proliferation (± SEM, n=3) response to individual and 
combinations of EE2 and BPA. EE2 positively affected proliferation compared 
to E2 and the control. BPA positively affected proliferation compared to the 
control and elicited a similar response to that of E2. 
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Cell proliferation resulting from treatment with the remaining xenoestrogens 
(genistein, butylparaben, kaempferol, tetrahydrocurcumin and estriol) in combination 
with E2 all showed a significant decrease in proliferation. Genistein decreased cell 
proliferation by 47.4% when compared to E2, while butylparaben decreased cell 
proliferation by 28.8%. Tetrahydrocurcumin and kaempferol decreased proliferation 
by 46.6% and 54.8%, respectively, while the only other endogenous estrogen included 
in this study (estriol) decreased proliferation by 48.9%. Interestingly, when the 
combinations are compared with the control growth curve at day 6, all combinations 
negatively affected proliferation with a decrease by 31.0%-38.5%, except for the 
butylparaben combination which caused a 7.8% decrease (Table 4.4). Additionally, 
when compared to their respective individual xenoestrogen responses, the 
xenoestrogens showed between a 41.8% - 46.5% decrease in proliferation. It’s also 
important to consider the variability around the individual cell counts to understand 
the significance of the difference in Tables 4.4 and 4.5. Individual data are shown in 
Appendix 8. This table highlights the small variability between replicates. 
 
Table 4.4: Summary of the % change between the combination and E2, control and 
the respective individual xenoestrogen tested in the combination at their maximum 
response (day 6). Yellow = % decrease and green = % increase. * = represented in 
Table 4.5. 






EE2 + E2 15.1 21.4 1.8 
BPA + E2 7.1 16.9 2.4 
Genistein + E2 47.4 31.9 43.0 
Butylparaben + E2 28.8 7.8 41.8 
Tetrahydrocurcumin + E2 46.6 30.8 42.7 
Kaempferol + E2 54. 9 38.4 46.5 
Estriol + E2 48.9 30.8 45.1 
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Figure 4.5: also see page 126 
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Intriguingly, the combination study which included all 8 xenoestrogens from the two 
combination studies, had a similar growth response to the control (Fig. 4.6). It appears 
that the positive effect on proliferation induced by E2, EE2 and BPA was 
counteracted by the negative effects of genistein, butylparaben, tetrahydrocurcumin, 
kaempferol and estriol. Therefore, when comparing the combination study to the 
control, there was only a 0.2% difference in proliferation.  
 
Table 4.5: % Decrease of the combination study compared to individual xenestrogen 
responses as at day 6 when the maximum response was observed. 









Figure 4.5 (see page 124): MCF-7 proliferation (± SEM, n=3) response to individual 
and combinations of genistein, butylparaben, tetrahydrocurcumin, kaempferol and 
estriol. All of the xenoestrogens had a negative effect on MCF-7 cell proliferation 
compared to E2, individual compounds and the control. 




















Additionally, Figure 4.7 highlights the similarities between the individual 
xenoestrogen responses compared to the combination responses. It is clear that 
individually all the compounds elicit a similar proliferative effect, however, they do 
not behave similarly in combinations. This is illustrated by the cells’ response to the 
combinations where a negative (ameliorative) proliferative response by the cells was 























Figure 4.6: MCF-7 proliferation (± SEM, n=3) response to the combination of 
all eight xenoestrogens. The combination had a negative effect on proliferation 
compared to E2 and All of the xenoestrogens and estriol had a negative effect 
on MCF-7 cell proliferation compared to E2, individual compounds and the 
control. 
















Individual compounds Genistein    
Butylparaben    
EE2   
BPA   
Tetrahydrocurcumin   

















Combinations Genistein + E2  
Butylparaben + E2  
EE2 + E2  







Figure 4.7: Summary of MCF-7 proliferation response (± SEM, n=3) to individual 
xenoestrogens and combination studies. Individually, the xenoestrogens induce a 
similar proliferative response at the selected concentrations. However, in combination 
with E2 there are clear groupings with EE2 and BPA eliciting a response akin to E2, 
while the remaining compound combinations elicit a response akin to or below the 
control. This also highlights the eight-component combination which is represented in 
the middle of the two combination groupings showing how the two categories of 
xenoestrogens can counteract each other.  
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4.4. Discussion 
In this chapter, the estrogenic responses of individual and combinations of 
xenoestrogens were characterised in both dose response experiments and 10 days 
growth curve experiments. Due to the persistence of xenoestrogens in the 
environment and food, their individual estrogenicity has long been appreciated. 
However, a normal diet and basic daily habits result in exposure to complex mixtures 
of xenoestrogens. This leads to uptake, blood levels, and possibly a cellular response 
to these mixtures in the body. Therefore, the effects of mixtures are important for the 
risk assessment of xenoestrogen cocktails, particularly as possible breast cancer risk 
factors.  
 
All of the xenoestrogens studied satisfy the basic criteria used to define potential 
estrogenicity, yet they exhibited differences in both the dose response experiments 
and in the 10-day growth curve experiments, when in combination with other 
xenoestrogens.  In terms of their individual responses, MCF-7 cell proliferation 
profiles were as expected. However, when the cells were challenged with different 
combinations of xenoestrogens, whether by dose response experiments or growth 
curve experiments, two distinct proliferative responses were observed – those that had 
a positive effect on proliferation and those that had a negative effect. When 
comparing the 2D structures of the xenoestrogens that had a negative effect on MCF-
7 proliferation, all except estriol, had at least one keto group in their structure. 
Interestingly, this is characteristic of many phytoestrogens which have been shown to 
have anti-proliferative effects on breast cancer cells, such as MCF-7. Butylparaben in 
combination with E2 was not expected to have a negative effect on proliferation; 
however, when one considers the high degree of structural similarity between 
butylparaben and genistein (Fig. 4.8) it is obvious that butylparaben could have the 
same effect as genistein on purely structural grounds. This is highlighted by the 





























Previous studies have shown that phytoestrogens have anti-proliferative effects in 
breast cancer cell model systems. Genistein is a classic example; it has been shown to 
positively affect proliferation at low concentrations (e.g. nM) and negatively affect 
proliferation at high concentrations (e.g. µM) (Lavigne, et al., 2008, Lecomte, et al., 
2017). Epidemiological studies have also shown genistein to be protective against 
breast cancer in women of child-bearing age (who have high circulating E2 levels) but 
not for postmenopausal women (who have low circulating E2 levels) (Adlercreutz, 
1995, Messina, et al., 2006). In this study, genistein had anti-proliferative effects on 
MCF-7 cells at lower (e.g. nM) concentrations in conjunction with E2, compared to 
individual studies which saw the anti-proliferative effect at high concentrations (e.g. 
µM). This is the case for the other anti-proliferative xenoestrogens, which had a 
positive effect on proliferation individually but a negative effect in combination with 
E2. However, when you consider the concept of simple additivity, where 
xenoestrogens act via the ER’s LBC, one would not expect there to be different 
proliferation responses because they all bind to the one site, LBC. It is clear that 
mixtures of xenoestrogens behave differently depending on the structures of the 


















Figure 4.8: Structural comparison between genistein (black) and butylparaben (blue), 
highlighting the clear similarities showing the structural alignment of keto and 
hydroxyl moieties. 
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The phytoestrogens are the most studied group of xenoestrogens that have anti-
proliferative effects on MCF-7 cells, and multiple mechanisms of action have been 
proposed. Firstly, of all the compounds that were shown to have negative proliferative 
effects in the MCF-7 cell studies, almost all of them have been shown to have an ERb 
preference (Morito, et al., 2001). It is well documented that ERb has modulatory 
effects on ERa-mediated signalling, thus, this could logically explain the anti-
proliferative effects (Matthews, et al., 2006, Zhou, et al., 2001); however, MCF-7 
cells express very low levels of ERb compared to ERa; thus, it is unlikely that the 
low level of ERb expression would be enough to cause the 40-50% decrease in 
proliferation, which was observed in these studies. In addition, Tetrahydrocurcumin 
has not been extensively studied in the context of ER binding; therefore, it is the only 
compound where an ER isoform preference is not known.  
 
Another possible mechanism that could explain the decrease in cell proliferation is 
direct competition for ERa LBC. However, binding at the LBC is not simply a case of 
binding, it involves an equilibrium between bound (e.g. hydrogen bonds with LBC 
amino acid residues) or an unbound state (Fig. 4.9). This equilibrium is displaced 
towards the bound state if the ligand has a higher binding affinity for the LBC. For 
example, E2 binds with high affinity to the LBC, which leads to an equilibrium shift 
towards the bound state. However, for a ligand that has a lower binding affinity (e.g. 
genistein) the equilibrium will favour the unbound state in comparison to E2. 
Therefore, depending on individual ligand concentrations, lower LBC affinity 
xenoestrogens can outcompete E2, overwhelming the LBC and leading to an overall 
negative effect on proliferation. However, when you compare the combination 
proliferation response to the individual xenoestrogen proliferation response, you 
would not expect to see a 40-50% decrease with such high theoretical LBC 
occupancy. Therefore, direct competition at the LBC is not likely to be the 
mechanism responsible for the negative proliferative effects.  
 




Figure 4.9: Illustration of equilibria involved in ER/ligand interactions. A) shows the binding equilibria for a high LBC affinity binding ligand 
in which binding to the LBC is favoured over AF-2. B) shows the binding equilibria for a low LBC affinity binding ligand in which the binding 
affinities for LBC and AF-2 are similar, thus LBC binding affinity is favoured less compared to the high LBC affinity binding ligand. C and D 
both show the complex binding equilibria for combinations. C shows a combination with a high and low LBC binding affinity ligand which 
shows that the high LBC affinity binding ligand will outcompete the low LBC binding affinity ligand for the LBC binding site, facilitating AF-
2 spill over. On the other hand, D shows that both ligands have similar binding affinities for both binding sites, therefore a high concentration of 
at least one ligand is going to be required to facilitate AF-2 spill over.  
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Another possible explanation for the mixed proliferative/anti-proliferative effects is 
akin to that previously described for 4-OHT’s mechanism of action (Jensen, 2001, 
Jensen, et al., 2004). 4-OHT also shows the same mixed proliferative/anti-
proliferative effects observed in my studies, where at low concentrations it acts as an 
agonist and this positively affects MCF-7 cell proliferation, whereas at high 
concentrations it acts as an antagonist, negatively affecting MCF-7 cell proliferation. 
A two-site model has been proposed to explain 4-OHT’s actions on proliferation 
(Jensen, et al., 2004, Wang, et al., 2006). In this model it is suggested that a primary, 
high affinity site is responsible for the agonist activity and a secondary, low affinity 
site is responsible for the antagonist activity (Wang, et al., 2006). In addition, Wang 
and colleagues (2006) carried out structural investigations which support the two-site 
model hypothesis; they showed that 4-OHT binds classically to the LBC and a second 
4-OHT molecule binds to the AF-2 site, a hydrophobic groove in ERb. While this 4-
OHT study focuses on ERb, analysis of amino acid residues involved in the 
interaction of 4-OHT at AF-2 indicates that the amino acids are conserved between 
the two ER isoforms, suggesting ERa may also have the capacity to interact with 
more than one small, non-peptide molecule rather than the normal peptides of co-
activator proteins that are normally used to study the AF-2. Assuming the ER 
translocates to the nucleus when bound by two 4-OHT molecules, binding at the AF-2 
site is likely to significantly affect the recruitment of coactivator proteins and the 
formation of the coactivator complex. Coactivators have specific enzyme activity (see 
Section 1.3.1.2) which leads to ER-mediated transcription; therefore, this could be 
disrupted by AF-2 binding, blocking histone modifications, or preventing rapid 
degradation by the proteasome. Ligand binding rapidly signals ER ubiquitylation, and 
ubiquitylated ER cycles on and off the ERE promoter site to control target gene 
transcription. Emerging evidence suggests that interactions between genomic and 
non-genomic signalling pathways mediated ER ubiquitylation. For example, SRC-
mediated phosphorylation at Tyr537 (ERa) primes ER E6AP recruitment. E6AP is an 
E3 ligase, a protein that recruits a ubiquitin-conjugating enzyme which assists in the 
transfer of ubiquitin to the ER and is recruited as part of the coactivator complex. The 
ubiquitylated ER is then signalled to the proteasome for degradation (Zhou, et al., 
2014). Therefore, disruption of this ubiquitylation and AF-2 occupancy by 4-OHT 
could prevent key protein recruitment which are involved in catalysing the ‘opening’ 
chromatin, rendering the ER promoter site ‘unavailable’ to transcriptional machinery. 
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This would likely downregulate ER-mediated transcription and reduced cell 




Figure 4.10: Illustration of the 4-hydroxytamoxifen (4-OHT) two site binding model 
and the potential downstream implications on ER-mediated transcription and 
proteolysis. The ER monomer is activated upon 4-OHT binding, facilitating 
dimerisation and translocation to the nucleus. The ER dimer binds to the estrogen 
response element (ERE) on the DNA but the 4-OHT/AF-2 interaction disrupts 
coactivator (CoA) recruitment and ER degradation at the proteasome (Prot) leading 
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It is tempting to speculate that the proposed two-site model for 4-OHT could explain 
the proliferation responses seen in my studies, both on individual compounds and in 
mixtures. This study shows a number of xenoestrogens having the same proliferative 
response as seen in the previously reported 4-OHT study; therefore, the anti-
proliferative effect could be caused by an interaction of some xenoestrogens at AF-2. 
It has been suggested that the AF-2 site is the secondary, low affinity site which aligns 
with the experimental results presented here. If the LBC is the primary, high affinity 
site then logically it would need to be fully occupied before any compound would 
bind to the second, low affinity site (i.e. AF-2). This could explain the high 
xenoestrogen concentration dependence before any anti-proliferative effects are seen. 
However, when E2 is added to the mixture, the concentration of xenoestrogen 
required to have a negative anti-proliferative effect decreases. Since E2 has a high 
affinity for the LBC, it would, in theory, compete with the xenoestrogen in the 
mixture for LBC binding, reducing the required amount of xenoestrogen to reach full 
LBC occupancy. This would facilitate AF-2 spill over at lower concentrations. In a 
manner akin to the proposed 4-OHT two-site model, the same outcomes would be 
expected for xenoestorgen ER-mediated actions in MCF-7 cells (see Fig. 4.11).  






Figure 4.11: Illustration of the xenoestrogen two site binding model and the potential 
downstream implications on ER-mediated transcription and proteolysis. The ER 
monomer is activated upon E2 binding, facilitating dimeristaion and translocation to 
the nucleus. The ER dimer binds to the estrogen response element (ERE) on the DNA 
but the xenoestrogen/AF-2 interaction disrupts coactivator (CoA) recruitment and ER 
degradation at the proteasome (Prot) leading to altered gene transcription. 
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The studies reported here show that the xenoestrogens studied can be categorised by 
their responses in dose response and 10-day growth curve experiments. A majority of 
the xenoestrogens selected were chosen due to their previously reported mixed 
agonist/antagonist responses and their persistence in the environment and in food, 
which meant that they were akin to daily human exposures. These studies confirmed 
and further support the hypothesis that some xenoestrogens have a concentration-
dependent anti-proliferative effect, which is amplified in the presence of E2. This 
appears to be the first time butylparaben has been reported to have a mixed 
agonist/antagonist effect in MCF-7 cells. However, when comparing xenoestrogen 
structures, it is clear that butylparaben has a high structural analogy to genistein and 
other flavonoids and therefore, it is not surprising to find a similar proliferation prolife 
for butylparaben.   
 
Interestingly, the combination study, which incorporated eight different 
xenoestrogens, had the same effect on proliferation as the control, however, this 
combination study exhibited a 22.97% decrease when compared to E2 proliferation. 
For the first time, a two-site model has been suggested to explain the 
agonist/antagonist activity exhibited by genistein, kaempferol, tetrahydrocurcumin, 
butylparaben and estriol, which display the same mixed proliferation response as the 
breast cancer drug metabolite, 4-OHT. Therefore, if xenoestrogens do function via a 
two-site model, it could have a profound pharmacological significance in the search 
for a drug to prevent breast cancer. This will be investigated further in Chapters 5 and 
6.  
 
4.5. Concluding Remarks 
The results from this chapter clearly show the MCF-7 proliferative response to the 
xenoestrogen combination, with two clear categories of xenoestrogens emerging. EE2 
and BPA clearly had an additive effect on MCF-7 cell proliferation, while genistein, 
butylparaben, tetrahydrocurcumin, kaempferol and estriol all had anti-proliferative 
effects on MCF-7 cells. In my opinion, these effects are likely ERa-mediated since 
MCF-7 cells are known to express high levels of ERa which facilitates cell 
proliferation. Therefore, it is possible that the xenoestrogens that had anti-proliferative 
effects on MCF-7 cells are binding the AF-2 site (a secondary, low affinity binding 
site) on the ER. This two-site binding model has previously been proposed to explain 
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the mixed agonist/antagonist effect of 4-OHT, thus it is plausible that xenoestrogens 
are behaving in a similar manner. However, it is also conceivable that other 
mechanisms not involving ERa are also involved in facilitating the anti-proliferative 
effects. In order to study this, experiments were performed using ERa and ERb 
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There has been considerable effort over the last two decades to develop in vitro assays 
capable of screening the estrogenic activity of environmental pollutants, industrial 
chemicals, natural chemicals and pharmaceuticals (Charles, 2004, Mueller, 2002, 
Mueller, 2004, Scrimshaw, et al., 2004, Soto, et al., 2006, Zacharewski, 1997). While 
many studies have identified effects emanating from individual xenoestrogens, there 
is scientific evidence that suggests mixtures of xenoestrogens will predominantly 
elicit additive effects because they bind to the ERs in vitro as well as in vivo. 
Individual xenoestrogens are usually present in low concentrations, mostly below 
their individual maximum detected levels, but have been shown to act additively, 
thereby eliciting an effect, even when applied in combination with the individual 
compounds at concentrations below their No Observed Adverse Effect Level 
(NOAELs). Interestingly, most of these studies have analysed individual and 
combination effects of xenoestrogens at ERa, while few have dealt with effects of 
individual and combinations of xenoestrogens at ERb, reviewed by (Gustafsson, 
1999). However, the ERa and ERb subtypes can interact with a wide variety of 
different xenoestrogens, with some exhibiting different relative affinities for the ER 
subtypes. Therefore, the expression of ER isoforms, and the cells and tissues in which 
they are expressed, are important for understanding estrogen-mediated cellular 
functions (Lee, et al., 2012). Thus, the intracellular ratio of the two receptors is 
important in understanding xenoestrogen combinations as breast cancer risk factors. 









5.1.1. Genomic and Non-Genomic Mechanisms of ER Binding  
E2 determines its effects by binding to ERa or ERb which act as ligand transcription 
factors regulating the transcription of ERE-containing genes. In addition, E2 is also 
able to elicit the rapid activation of extra-nuclear signalling pathways via interactions 
with membrane-localised receptors. Integration of nuclear and extra-nuclear ER-
dependent actions as well as of ERa and ERb specific signalling co-ordinately 
contributes to the regulation of the E2 physiological actions (Ascenzi, et al., 2006, 
Marino, et al., 2012). All the E2 effects occur in parallel with transcriptional and post-
translational modulation of ER intracellular concentrations, which are finely 
modulated by E2-induced extra-nuclear (Caiazza, et al., 2007, La Rosa, et al., 2012) 
and epigenetic signalling (e.g. ER promoter methylation) (Thomas, et al., 2011). For 
example, the relative concentrations of ERa and ERb are significantly altered during 
the development of breast cancer with an increase in ERa levels and a decrease in 
ERb concentration (Roger, et al., 2001). In addition, E2 protective effects against 
colon cancer growth rely on E2-induced ERb up-regulation. In addition, ERa 
degradation is also required for the transcription of E2 responsive genes (Caiazza, et 
al., 2007). As a whole, this evidence points to the control of ERa as a critical step in 
endocrine-dependent cell growth and consequently, the identification of molecules 
that modulate these molecular circuities is a demanding issue(Leclercq, et al., 2006, 
Reid, et al., 2003).  
 
Xenoestrogens are heterogeneous chemicals known to bind to ERa and ERb, which 
can interfere with many aspects of estrogen-dependent control of body homeostasis 
including the balance between cell growth/apoptosis (Diamanti-Kandarakis, et al., 
2009, Zoeller, et al., 2012). Although xenoestrogens act via the same binding site (i.e. 
LBC), they interfere with ER-mediated signalling, driving breast cancer cells to 
different functional outcomes (Bolli, et al., 2008, Bulzomi, et al., 2010, Marino, et al., 
2012). In particular, some xenoestrogens (e.g. genistein) cause proliferative effects in 
breast cancer cells at nanomolar concentrations, but anti-proliferative effects at 
micromolar concentrations, and have even been shown to have protective effects 
against breast cancer in women of child bearing age (see Section 1.4.1.) (Chang, et 
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al., 2008). Therefore, understanding the individual ER isoform effects is important in 
understanding xenoestrogens as breast cancer risk factors.  
 
5.1.2. ERa and ERb Ratio in Humans 
While estrogens and ERs are primarily associated with female reproductive 
development, the role of ERs in the body is often overlooked. The ER’s expression 
patterns and functions vary in receptor subtype and in cell- and tissue-specific 
manners, leading to growth and differentiation in both males and females. ERs are 
expressed early in fetal development, with trophoblast cells (i.e. cells that eventually 
develop into the placenta) being the first cells during embryonic development to have 
aromatase activity, indicative of estrogen production (see Fig. 1.3) (Stocco, 2012, 
Vasquez, et al., 2013). At 9 weeks, the placenta becomes the primary source of fetal 
estrogen production and the embryonic sex organs begin to differentiate. Interestingly, 
the expression of the ERs, in particular ERb, during development is not limited to 
reproductive development, indicating the importance of ERb dependent E2 signalling 
in the fetus (Berkane, et al., 2017, Devroey, et al., 1990).  However, aberrant estrogen 
signalling, caused by xenoestrogens, can lead to birth defects in both males and 
females. Indeed, the administration of DES to pregnant women in the 1950s led to 
increased risk of reproductive tract development abnormalities in both male and 
female babies (Hoover, et al., 2011). Interestingly, while breast cancer is often 
thought of as a gender-related cancer, breast cancer cells respond to estrogens in a 
growth and development context, similar to that observed in the fetus, rather than as 
purely a female reproductive response (Gillies, et al., 2010, Heldring, et al., 2007). 
Therefore, considering breast cancer cells as primordial cells rather than as breast 
cells could help understand disease risk. 
 
5.1.3. ERa and ERb Ratio in the Breast 
In general, the ERa isoform expression occurs mainly in tissues related to 
reproductive activity (e.g. uterus and mammary gland), ERb is more widely 
distributed (see Section 1.1.). Conversely, in the clinical setting ERa is the primary 
focus with approximately 75% of diagnosed breast cancers being identified as ERa 
positive tumours (Lim, et al., 2016); however, the ERb isoform is often overlooked. 
Contrary to the clinical setting of breast cancer, ERb is highly expressed in the normal 
breast epithelium and declines during breast tumourgenesis (i.e. in precancerous and 
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cancerous lesions) (Abdel-Fatah, et al., 2008, Chantzi, et al., 2014, Hung, 2004, 
Jarvinen, et al., 2000, Roger, et al., 2001, Shaaban, et al., 2003, Speirs, et al., 2002). 
Interestingly, higher levels of ERb expression in breast tumours have been found to 
be associated with the expression of good prognostic markers or better clinical 
outcomes (Guo, et al., 2014, Haldosen, et al., 2014, Kim, et al., 2012). Clearly the 
intracellular ratio between ERa and ERb is important during breast cancer 
development. ERb is also regarded as a negative regulator of ERa (Bottner, et al., 
2014); thus, the risk emanating from an estrogenic substance depends on its activity at 
both ER subtypes. This emphasises the importance of identifying the ability of 
xenoestrogens (individual and combinations) to activate ERa and ERb-mediated 
transcription in the cumulative risk assessment of xenoestrogens (Seeger, et al., 
2016). This will be especially important for xenoestrogens such as genistein, which 
have a binding affinity preference for ERb over ERa.  
 
The aim of this study was to understand the importance of the intracellular ratio of the 
two receptors ERa and ERb for the xenoestrogens: E2, EE2, genistein, BPA, 
methylparaben and butylparaben. To this end, the activity of individual and 
combinations of xenoestrogens to activate either ERa or ERb-mediated transcription 
was characterised and compared to that of E2, using the ERa and ERb CALUXâ 
assay. 
 
5.2. Experimental Approach 
ERa and ERb CALUXâ cell lines were kindly provided by Biodetection Systems 
(Amsterdam, The Netherlands). Each cell line had been genetically modified to 
express the ER isoform (a or b) along with a luciferase reporter gene as described 
earlier (Section 2.2.9.2.).  
 
5.2.1. ERa and ERb CALUXâ Assay 
The ERa and ERb CALUXâ assays were performed on individual compounds to 
evaluate the individual effects of each xenoestrogen on ERa and ERb. Full dose 
response (13 increasing concentrations) curves were tested for each compound and 
the EC50 values were determined (see Section 2.2.9.2). The calculated EC50 values 
were applied to predict the responses of mixtures using the well-known concept of 
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CA, based on the work of Loewe and Muischnek (Loewe, et al., 1926). CA applies 
the concept of pure additivity, thus if a correlation was observed between 
experimental and the predicted CA responses, additivity was assumed (Kortenkamp, 
2007). In addition, xenoestrogen mixtures (Table 5.1) were studied in both ERa and 
ERb CALUXâ assays (see Section 2.2.9.2.). The mixtures were designed to include a 
full dose-response (13 increasing concentrations) of one xenoestrogen (varied) with a 
fixed concentration of either one or two additional xenoestrogens (see Tables 5.1, 5.2 
and 5.3). The concentrations selected for both the varied xenoestrogen and fixed 
xenoestrogens were based on initial experimental data from individual response 
curves, with the fixed concentrations selected based on EC10 values (Table 5.2).  
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Table 5.1: Xenoestrogen combinations studied in both ERa and ERb CALUXâ assays. 
 Fixed6 
Varied 6 E2 EE2 Genistein BPA Methylparaben Butylparaben Combination 1 Combination 2 
E2  P P P P P P P 
EE2 P  P P P P P P 
Genistein P P  P P P P P 
BPA P P P  P P P P 
Methylparaben P P P P  P P P 
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Table 5.2: Fixed concentrations of xenoestrogens/E2 added to each combination in the 
ERa and ERb CALUXâ assays. 
Xenoestrogen ERa ERb 
E2 (M) 3.0 x 10-12 2.0 x 10-10 
EE2 (M) 3.0 x 10-13 7.0 x 10-10 
Genistein (M) 3.0 x 10-8 6.0 x 10-10 
BPA (M) 1.0 x 10-7 1.0 x 10-7 
Methylparaben (M) 3.0 x 10-7 1.0 x 10-5 
Butylparaben (M) 3.0 x 10-8 3.0 x 10-7 
 
Table 5.3: Compositions and concentrations of Combinations 1 and 2. 
  BPA Genistein Methylparaben Butylparaben 
Combination 
1 
ERa 1.0 x 10-7 3.0 x 10-8   
ERb 1.0 x 10-7 3.0 x 10-10   
Combination 
2 
ERa   1.0 x 10-7 2.2 x 10-8 
ERb   1.0 x 10-5 3.0 x 10-7 
 
5.2.2. Data Analysis 
The solvent controls were subtracted from the raw luminescence values and 
normalised to the response of E2 in the respective assay (e.g. ERa or ERb). The data 
were then plotted using non-linear regression in the software package Graphpad 
Prism, and EC50 values were calculated.  
 
5.2.3. Cytotoxicity Testing  
Cytotoxicity was studied to ensure the responses elicited by the xenoestrogens tested 
were not a result of cytotoxicity, but rather ERa and ERb-mediated effects (Section 
2.2.9.3.). The cytotox CALUXâ assay consists of a general genetic modification of 
U2OS cells (same as ERa and ERb CALUXâ cells) to constitutively express a high 
level of luciferase. The luciferase response is not directly related to a specific pathway 
but serves as measure of cytotoxicity and as a control for non-specific activation or 
inhibition of luciferase expression or activity. If cells are exposed to cytotoxic 
compounds the resulting amount of luciferase expressed will decrease (van der 
Linden, et al., 2014). All individual xenoestrogens were tested, along with 
combination 1 (ERa) and combination 2 (ERa and ERb) (Table 5.3). Three 
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component combinations were selected based on the likelihood that cytotoxicity 
would be observed at higher total xenoestrogen concentrations.  
 
5.3. Results 
The estrogenic potencies of individual and combinations of xenoestrogens were 
measured using the ERa and ERb CALUXâ assays, and compared to the activity of 
the natural ligand, E2. Treatment of both cell lines resulted in mixed responses, with a 
wide range of maximal luciferase responses being observed for both individual 
xenoestrogens and mixtures. Interestingly, genistein and butylparaben induced a 
luciferase response that exceeded the maximum response elicited by E2; additionally, 
a number of combinations also exhibited this response, known as a supramaximal 
effect.  
 
5.3.1. Dose-response Analysis of Individual Xenoestrogens 
Concentration response curves for the individual xenoestrogens are shown for ERa 
and ERb CALUXâ assays in Fig. 5.1. It shows that the xenoestrogens tested in the 
ERa CALUXâ assay exhibited a wide range of potencies, with EC50 values ranging 
from picomolar to high micromolar concentrations (Table 5.4). It was shown that the 
most potent xenoestrogens tested were EE2 and E2 and the least potent was 
methylparaben. Fig. 5.1 shows that the xenoestrogens tested in the ERb CALUXâ 
assay exhibited a narrower range of potencies compared to the ERa CALUXâ assay, 
with EC50 values ranging from nM to high µM concentrations. As in the ERa 
CALUXâ assay, EE2 and E2 were the most potent xenoestrogens tested, with 
methylparaben being the least potent. Additionally, genistein also had a similar 
potency to E2 and EE2, which was not observed in the ERa CALUXâ assay. 
Supramaximal responses (responses greater than the maximal response for the natural 
ligand E2) were observed in both the ERa and ERb CALUXâ assay. Genistein, 
123.4% and 197.0%, and butylparaben 185.3% and 176.0% both had supramaximal 
luciferase responses in the ERa and ERb CALUXâ assays, respectively. In addition, 
BPA also exhibited a supramaximal luciferase response of 127.3% in the ERa 
CALUXâ assay but not in the ERb CALUXâ assay. Clearly, the supramaximal effect 
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varied between both assays and xenoestrogens with responses up to almost 200% 




























Methylparaben   





















Butylparaben   
Figure 5.1: Graphs show the results of individual xenoestrogen responses in the ERa 
and ERb CALUXâ assays. Each individual xenoestrogen was tested in triplicate and 
results are presented as a non-linear regression with errors expressed as SEM. 
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Table 5.4: Experimental EC50 values and maximal luciferase responses for individual 
xenoestrogens in the ERa and ERb CALUXâ assay. 
 ERa ERb 
 EC50 (M) Maximal response 
(%) 
EC50 (M) Maximal response 
(%) 
E2 2.5 x 10-11 100.0 3.9 x 10-10 90.7 
EE2 7.1 x 10-12 98.1 1.3 x 10-9 111.5 
Genistein 4.4 x 10-9 123.4 3.8 x 10-9 197.0 
BPA 2.8 x 10-7 127.3 1.0 x 10-6 94.5 
Methylparaben 3.8 x 10-7 95.5 2.2 x 10-5 89.7 
Butylparaben 7.0 x 10-7 185.3 3.8 x 10-6 176.0 
 
5.3.2. Dose-Response Analysis of Xenoestrogen Combinations 
Combinations of different xenoestrogens exhibited a wide range of potencies, 
depending on the xenoestrogen combination and ER subtype tested (see Tables 5.5 
and 5.6). In addition, the maximal responses of the combinations varied depending on 
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Table 5.5: Comparison of experimental (E) and CA predicted (P) ERa CALUXâ EC50 values for the xenoestrogen combinations. * indicates a 
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Table 5.6: Comparison of experimental (E) and concentration CA predicted (P) ERb CALUXâ EC50 values for the xenoestrogen combinations. * 
indicates a response was not converged using non-linear regression. 




Varied 6 E P E P E P E P E P E P E P E P 
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Table 5.7: Calculated maximal luciferase response change (%) for xenoestrogen combinations compared to the varied component of the mixture 
in the ERa CALUXâ assay. * indicates a response was not converged using non-linear regression (yellow). Green shading indicates a decreased 
maximal response and blue shading indicates an increased maximal response.  
ERa Activation of xenoestrogen combinations (%) 
 Fixed6 
Varied 6 E2 EE2 Genistein BPA Methylparaben Butylparaben Combination 1 Combination 2 
E2  * 18.5 20.52 * 82.3 62.1 86.5 
EE2 31.8  20.8 1.00 50.2 63.6 22.9 69.3 
Genistein 64.7 6.9  80.65 37.0 22.7 63.0 1.3 
BPA 22.3 25.7 12.6  52.0 62.2 65.5 63.5 
Methylparaben 17.4 74.1 10.9 38.72  72.9 66.7 81.7 
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Table 5.8: Calculated maximal luciferase response change (%) for xenoestrogen combinations compared to the varied component of the mixture 
in the ERb CALUXâ assay. Green shading indicates a decreased maximal response and blue shading indicates an increased maximal response.  
ERb activation of xenoestrogen combinations (%) 
 Fixed6 
Varied 6 E2 EE2 Genistein BPA Methylparaben Butylparaben Combination 1 Combination 2 
E2  47.3 7.1 63.7 51.9 10.0 28.3 4.8 
EE2 5.8  40.1 50.2 47.2 27.6 49.6 12.0 
Genistein 15.2 30.5  33.4 11.6 50.6 52.1 30.5 
BPA 10.2 44.8 2.1  49.7 17.2 45.0 37.0 
Methylparaben 19.9 38.4 10.9 55.2  41.9 41.0 24.6 
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5.3.2.1. E2 
Testing in the ERa CALUXâ assay (Fig. 5.2 and Appendix 1) revealed the E2 
combination with BPA to induce a supramaximal luciferase response of 122.4% 
compared to E2; however, combinations with genistein (79.3%) and butylparaben 
(17.2%) revealed a decrease in the supramaximal response when compared to the 
effect elicited by the individual mixture components. Data for the EE2 and 
methylparaben combinations could not be converged using non-linear regression in 
the graphpad prism software (data not shown). Interestingly, the remaining data sets 
did not have a good correlation between the experimentally determined luciferase 
responses and the corresponding predicted CA responses in the ERa CALUXâ assay. 
In comparison, in the ERb CALUXâ assay (Fig. 5.2 and Appendix 2), combinations 
with EE2 (224.0%), BPA (228.9%) and methylparaben (187.0%) exhibited an 
increased supramaximal luciferase responses and poor correlations with the predicted 
CA responses. Both genistein (97.6%) and butylparaben (81.6%) combinations 
showed a decrease in the maximal luciferase response but had a good correlation with 

















































 Figure 5.2: Example data for E2 (varied) in combination with genistein and BPA in both ERa and ERb CALUX
â assay. Results are 
presented using non-linear regression analysis with errors expressed as SEM. 
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5.3.2.2. EE2 
Testing of EE2 in the two component combination studies showed a wide variety of 
responses compared with individual xenoestrogen responses. In the ERa CALUXâ 
assay (Fig. 5.3 and Appendix 1) all combinations had a maximal luciferase response 
equal to or lower than the maximal luciferase response elicited by the individual 
components of the combinations. The only combination to have a confirmed good 
correlation with the predicted CA response was the BPA combination. All other 
responses had a poor correlation with the predicted CA responses. Interestingly, in the 
ERb CALUXâ assay (Fig. 5.3 and Appendix 2) combinations with BPA (224.0%) 
and methylparaben (211.2%) exhibited a supramaximal luciferase response and a poor 
correlation with the predicted CA responses.  In comparison, E2, butylparaben and 
genistein combinations revealed a good correlation with the predicted CA response 
but genistein and butylparaben combinations showed a significant reduction of the 










































Figure 5.3: Example data for EE2 (varied) in combination with genistein and E2 in both ERa and ERb CALUXâ assay. Results are 
presented using non-linear regression analysis with errors expressed as SEM. 
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5.3.2.3. Genistein 
Concentration response curves for genistein combinations also revealed a wide variety 
of responses in both ERa and ERb CALUXâ assays (Fig. 5.4 and Appendix 1). When 
tested in the ERa CALUXâ assay, genistein (varied) combinations with E2, EE2 and 
methylparaben exhibited a supramaximal response compared to the individual 
responses of the mixture components; interestingly, these responses showed a good 
correlation with the predicted CA responses. In comparison, when the ERa CALUXâ 
cells were exposed to genistein in combination with BPA the maximal response 
exceeded 200.0%, which is very much higher than either of the individual maximal 
luciferase responses and the predicted CA response. Exposure to genistein in 
combination with butylparaben (57.8%) resulted in a decrease in the maximal 
luciferase response compared with the individual xenoestrogen maximal responses. 
Also, a poor correlation between the experimental and predicted CA response was 
observed for the genistein + butylparaben combination. ERb CALUXâ cells 
responded differently to the genistein combinations, with supramaximal luciferase 
responses being observed in both methylparaben (222.9%; Appendix 2) and BPA 
(280.8%; Fig. 5.4) combinations. Interestingly, when ERb CALUXâ cells were 
exposed to combinations of genistein with E2, EE2 and butylparaben, a decrease in 
luciferase response of 221.3 %, 137.0 % and 93.3 % (Fig. 5.4 and Appendix 2), 
respectively, was observed. All ERb genistein combinations had poor agreement with 



































Figure 5.4: Example data for genistein (varied) in combination with E2 and BPA in both ERa and ERb CALUXâ assay. Results are 
presented using non-linear regression analysis with errors expressed as SEM. 
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5.3.2.4. BPA 
Comparisons of the BPA containing combinations in both ERa and ERb CALUXâ 
(Fig. 5.5 and Appendices 1 and 2) assays revealed similar changes to the 
supramaximal luciferase responses observed in previous combinations. In the ERa 
CALUXâ assay responses of BPA in combination with E2, EE2, methylparaben and 
butylparaben all elicited a decrease in the maximal luciferase response equal to or 
lower than the maximal E2 response (e.g. 100.0%). However, when ERa CALUXâ 
cells were exposed to BPA in combination with genistein, a supramaximal luciferase 
response was observed. Furthermore, poor correlations were observed between the 
predicted CA responses and the corresponding combination in the ERa CALUXâ 
cells. Studies in the ERb CALUXâ cells showed increased supramaximal responses 
with BPA (varied) in combination with EE2 (316.5%) and methylparaben (187.7%), 
while responses below 100% were observed for the remaining E2, genistein and 
butylparaben combinations; however, for both the genistein and butylparaben 
containing combinations the maximal luciferase response was significantly decreased 








































Figure 5.5: Example data for BPA (varied) in combination with E2 and genistein in both ERa and ERb CALUXâ assay. Results are 
presented using non-linear regression analysis with errors expressed as SEM. 
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5.3.2.5. Methylparaben 
A decrease in the maximal luciferase responses to methylparaben-containing 
combinations with E2, EE2, genistein and butylparaben in the ERa CALUXâ assay 
(Fig. 5.6 and Appendix 1) was observed in comparison to the maximal luciferase 
responses elicited by the corresponding individual xenoestrogens components of the 
mixture. A supramaximal response was observed from the methylparaben/BPA 
combination, with a maximal luciferase of 155.9% (Appendix 1). Poor agreement 
with predicted CA responses was observed for all ERa methylparaben combinations 
(Fig 5.6 and Appendix 1). Interestingly, the methylparaben/BPA combination 
exhibited a supramaximal luciferase response in the ERb CALUXâ assay (200.9%; 
Appendix 2), while the genistein combination exhibited a response of 100.9% (Fig. 
5.6). On the other hand, the E2 combination’s maximal luciferase response did not 
reach that of the maximal luciferase response of E2 alone or the predicted CA 
response. The methylparaben/butylparaben combination significantly decreased the 
maximal luciferase response observed in the ERb CALUXâ cells compared to 
butylparaben (176.0%), methylparaben (89.7%) and the predicted CA response 












































Figure 5.6: Example data for methylparaben (varied) in combination with E2 and genistein in both ERa and ERb CALUXâ assay. 
Results are presented using non-linear regression analysis with errors expressed as SEM. 
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5.3.2.6. Butylparaben 
Supramaximal responses and poor agreement with the corresponding predicted CA 
responses were observed in butylparaben combinations with EE2 (327.1%), genistein 
(133.7%), BPA (354.2%) and methylparaben (215.1%) in the ERa CALUXâ assay 
(Fig. 5.7 and Appendix 1). However, the butylparaben/E2 combination elicited a 
decreased maximal luciferase response compared to E2 (100%), butylparaben 
(185.3%) and the predicted CA response (98.9%). In comparison, in ERb CALUXâ 
assay (Fig. 5.7 and Appendix 2), supramaximal luciferase responses were observed in 
butylparaben combinations with E2 (177.3%), EE2 (235.5%), BPA (317.2%) and 
methylparaben (267.1%). However, when exposed to the butylparaben/genistein 
combination, the maximal luciferase response decreased compared to the maximal 
luciferase response of both butylparaben (176.0%) and E2 (90.7%). Poor correlations 
were also observed between all combinations tested in the ERb CALUXâ assay and 
























































Butylparaben + E2 ERα
Butylparaben
E2
Butylparaben + E2  
Butylparaben + E2 
predicted 















Buthylparaben + E2 ERβ
Butylparaben
E2
Butylparaben + E2  
Butylparaben + E2 
predicted 















Butylparaben + Genistein ERα
Butylparaben




















Butylparaben + Genistein ERβ
Butylparaben
Genistein    
Butylparaben + Genistein   
Butylparaben + Genistein 
predicted 
Figure 5.7: Example data for butylparaben (varied) in combination with E2 and genistein in both ERa and ERb CALUXâ assay. 
Results are presented using non-linear regression analysis with errors expressed as SEM. 
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5.3.3. Dose-response Analysis of Three Component Xenoestrogen Combinations 
5.3.3.1. Combination 1 
Comparisons between the responses of the ERa CALUXâ assay (Fig. 5.8 and 
Appendix 3) revealed a decreased maximal luciferase response for combinations with 
E2 (36.9%), EE2 (52.7%), BPA (43.9%) and methylparaben (31.8%) to below 50.0% 
of the maximal luciferase response exhibited by E2. These responses all had a poor 
correlation with the corresponding predicted CA response. However, genistein and 
butylparaben combinations had good agreement with the corresponding predicted CA 
response and both exhibited a maximal luciferase response similar to E2 (e.g. 
100.0%). Interestingly in the butylparaben combination, the supramaximal response 
elicited by individual xenoestrogens in the mixture disappeared when they were tested 
in combination. In comparison, in the ERb CALUXâ assay (Fig. 5.8 and Appendix), 
combinations with EE2 (68.8%), BPA (52.0%) and methylparaben (53.1%) all 
exhibited a slight decrease in the maximal response compared to the response for E2; 
therefore, poor agreement was observed between the predicted CA responses and the 
corresponding combination responses. In addition, both E2 and genistein 
combinations had a similar response to the corresponding predicted CA responses, 
thus, a similar maximal luciferase response was observed between both combinations 
and the individual E2 response. Interestingly, the butylparaben combination exhibited 




































Figure 5.8: Example data for E2 and butylparaben (varied) in combination with genistein and BPA (fixed) in both ERa and ERb 
CALUXâ assay. Results are presented using non-linear regression analysis with errors expressed as SEM. 
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5.3.3.2. Combination 2 
Combinations with E2 (13.1%), EE2 (30.1%), genistein (44.1%), BPA (46.5%) and 
methylparaben (17.5%) all exhibited a lower luciferase maximal response compared 
with the response to E2 in the ERa CALUXâ assay (Fig. 5.9 and Appendix 3). 
Therefore, poor agreement between the responses and the corresponding predicted 
CA responses was observed. However, the butylparaben combination exhibited a 
similar response to its corresponding predicted CA response. Interestingly, the 
supramaximal response observed for butylparaben alone disappeared when tested in 
combination with the other mixture components (Fig. 5.9). In the ERb CALUXâ 
assay (Fig. 5.9 and Appendix 3), good correlations were observed between maximal 
luciferase responses for the E2, EE2 and methylparaben combinations and the 
predicted CA responses. However, supramaximal responses were observed for 
genistein (137.0 %), BPA (120.5 %) and butylparaben (137.2 %) combinations and 
obviously poor correlations between predicted CA responses and experimental 








































 Figure 5.9: Example data for E2 and butylparaben (varied) in combination with genistein and BPA (fixed) in both ERa and ERb 
CALUXâ assay. Results are presented using non-linear regression analysis with errors expressed as SEM. 
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5.3.4. Cytotoxicity Testing  
Cytotoxicity testing was carried out for individual xenoestrogens and three component 
studies. The same concentration combinations were used for cytotoxicity testing as in 
the ERa and ERb assays (see Tables 5.2 and 5.3). A positive result for cytotoxicity is 
indicative by a decrease in luciferase response. Therefore, a cytotoxic response was 
observed for methylparaben alone and methylparaben and EE2 each with combination 
2 (ERa). Interestingly, individual exposures and combinations with genistein and 
butylparaben both exhibited increased luciferase responses in the cytotox CALUXâ 
assay. In addition, E2 with combination 1 (ERa) and combination 2 (ERb), 
methylparaben with combination 2 (ERb), and BPA with combination 2 (ERb) (Table 
5.3) all exhibited increase luciferase responses (Fig. 5.10). This suggests that 
cytotoxicity did not interfere with most of the results presented above for the ERa and 
ERb CALUXâ assays. It also suggests that the supramaximal effects observed in the 
ERa and ERb CALUXâ assays were not directly related to ER-mediated transcription 
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Figure 5.10: also see page 171 
 




















Figure 5.10: Results of individual and selected combinations of xenoestrogens in the cytotoxicity CALUXâ assay. Results are 
presented using linear regression analysis with errors expressed as SEM. 
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5.4. Discussion 
In this chapter, the estrogenic potencies of individual and combinations of 
xenoestrogens were examined in both the ERa and ERb CALUXâ assays. The results 
showed a wide range of responses, including supramaximal responses in both 
individual and combination experiments, with poor correlations between combination 
responses and their corresponding predicted CA responses.   
 
5.4.1. Estrogenicities of Individual Xenoestrogens 
As discussed above (Section 5.1) there has been a considerable effort over the last two 
decades to develop in vitro assays capable of screening and assessing the estrogenic 
activity of xenoestrogens. During this time a wide range of xenoestrogens has been 
tested to determine the individual estrogenic potencies, however, few studies 
incorporate ERb in the test regimes, especially when assessing the estrogenic effects 
of xenoestrogens in a breast cancer context. Since the ERb may act as a counterpart of 
the ERa, it is of great relevance for the risk assessment process to limit the analysis of 
mixture effects to ERa, especially since most ERa ligands also bind ERb. Indeed, 
some xenoestrogens (e.g. phytoestrogens) have a higher binding affinity for ERb 
compared to ERa, highlighting the importance of the intracellular ER receptor ratio in 
the breast. This is evident from the results presented in this chapter with the individual 
xenoestrogen responses in both ERa and ERb exhibiting a wide range of potencies. 
Therefore, to give a more precise comparator, estrogen equivalents (EQs) were 
calculated for xenoestrogens (X) from the EC50 values as follows (Table 5.9) (Soto, et 







The EQ values clearly show that EE2 is the most potent xenoestrogen studied, indeed 
it is 3.54-fold more potent than E2 in ERa. In addition, there are significant 
differences between ERa and ERb responses– EE2 is 12.24-fold more potent in ERa 
compared to ERb. On the other hand, genisteins ERa/ERb EQ ratio is 0.055 showing 
that it binds preferentially to ERb. It is clear from these and previously published 
results that individual xenoestrogens will have different estrogenic effects on cells, 
CALUX Exposure Studies 
 172 
and further, will have different effects according to the ER isoform to which they 
preferentially bind. The toxicological implications of exposure to xenoestrogen 
cocktails depends on whether or not their effects are additive or perhaps synergistic 
(see Section 1.4.5.).   
 
Table 5.9: Calculated estrogen equivalents (EQ) for individual xenoestrogens tested in 
the ERa and ERb CALUXâ assay. The ERa/ERb binding preference is also shown. 
 ERa EQ ERb EQ ERa/ERb ratio 
EE2 3.5 0.3 12.2 
Genistein 0.006 0.1 0.06 
BPA 0.00009 0.0004 0.2 
Methylparaben 0.00007 0.000002 37.7 
Butylparaben 0.00004 0.0001 0.4 
 
5.4.2. Estrogenicities of Xenoestrogen Combinations in the ERa and ERb CALUXâ 
Assay 
The combination studies presented in this chapter exhibit a wide range of responses in 
both the ERa and ERb CALUXâ assays. Individually, genistein, butylparaben and 
BPA (ERa only) exhibit supramaximal effects; however, supramaximal effects were 
not seen in combinations with E2 and EE2 (i.e. high LBC binding ligands). 
Interestingly, in the presence of a lower LBC binding affinity ligand (e.g. 
methylparaben) the supramaximal effect was amplified. In addition, some ERb 
CALUXâ assay combination experiments exhibited a supramaximal effect (e.g. BPA 
+ methylparaben) where no supramaximal effect was observed for the individual 
xenoestrogen responses. Therefore, for interpretation of the CALUXâ results, it is 
important to understand whether this effect is related to the real supramaximal 
response of gene expression that might also occur in vivo or whether it is an artefact 
of the assay. For example, it has been suggested that supramaximal effects are a result 
of a direct luciferase interaction, whereby some xenoestrogens (e.g. genistein) 
stabilise the degradation of the enzyme, resulting in a supramaximal response – this 
will be discussed in more detail later.  
 
The presence of supramaximal effects (effects that exceed the maximal effect elicited 
by the natural ligand, E2) has been noted in in vitro assays for over 20 years, with the 
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first reported in 1994 (Makela, et al., 1994). However, supramaximal effects are not 
consistently reported in the scientific literature, and sometimes reports appear to be 
contradictory (Montano, et al., 2010). Many authors only mention the presence of a 
maximal effect, while others do not describe supramaximal effects in their results or 
mention them in the discussion, even when a supramaximal response is apparent. 
Other authors will acknowledge the presence of a supramaximal effect and normalise 
the results, so they cannot exceed 100% activation of the natural ligand E2 (Jonker, et 
al., 2005, Murk, et al., 1996, Vrabie, et al., 2009). Several xenoestrogens, including 
genistein, have been reported to induce a supramaximal response in luciferase reporter 
gene assays. Many possible explanations have been put forward over the years, 
including an ER-mediated response, and post-transcriptional mechanisms such as a 
non-ER-mediated mechanism and stabilisation of luciferase leading to an increased 
half-life of the enzyme and thus a supramaximal response.  
 
Sotoca et al., (2010) extensively investigated some of the possible mechanisms that 
might explain the supramaximal response. They found much higher concentrations of 
ER antagonists were required to block the supramaximal luciferase induction by 
genistein compared to E2. This suggests that, although higher concentrations of 
inhibitor are required to inhibit induction of luciferase, the supramaximal effect 
induced by genistein is ER-mediated. However, they also found that the 
supramaximal effect induced by genistein in reporter gene assays is not mirrored at 
the cell proliferation level (e.g. superproliferation). This illustrates that the 
phenomenon of the supramaximal effect is not reflected at the biologically relevant 
endpoint (e.g. in vivo) and therefore, it is likely an artefact of the assay.  
 
This is further supported by Sotoca and colleague’s studies which examined the 
correlation between luciferase activity and real luciferase mRNA induction, to 
determine whether the supramaximal effect was a true reflection of transcriptional 
activity. Interestingly, no correlation was found between luciferase activity and 
mRNA induction when exposed to genistein. This suggests that xenoestrogens that 
induce a supramaximal effect are doing so via an alternative mechanism.  
 
Finally, the possible direct interaction between genistein and the luciferase enzyme 
was examined. It had been previously proposed that certain compounds can directly 
bind to, and stabilise, the luciferase enzyme, thereby increasing the half-life. Sotoca 
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and colleagues showed that in a cell-free biochemical assay, genistein and resveratrol 
(a xenoestrogen found in red grapes) stabilised the luciferase enzyme. Therefore, the 
increased bioluminescent signal induced during the cell-based assays is likely a result 
of luciferase stabilisation.  
 
This stabilisation hypothesis likely explains the supramaximal effects observed in the 
results presented in this chapter for both the ERa and ERb CALUXâ assays. 
However, it does not explain the findings for all of the combinations that were tested. 
Some combinations did not induce a supramaximal luciferase response even though at 
least one xenoestrogen capable of inducing such effect was present. For example, 
when E2 (varied) was tested with genistein (fixed) the maximal luciferase response 
was 78.9% compared to the individual responses for E2 (100.0%) and genistein 
(132.2%). In theory, with genistein being the lower LBC binding affinity ligand in the 
combination, it would be expected that at higher concentrations E2 would outcompete 
genistein for the LBC, resulting in an increase in unbound genistein; therefore, more 
genistein would be freely available to stabilise the luciferase enzyme, inducing a 
supramaximal effect. However, the maximal luciferase response not only suggests 
that there is no genistein available to stabilise the luciferase enzyme, but also that the 
presence of genistein in the mixture decreases the ER-mediated transcription of the 
luciferase itself.  
 
A possible explanation for this phenomenon is the potential of a two-site binding 
model, as proposed in the previous chapter (Chapter 4). The lack of the supramaximal 
response suggests that genistein is bound to a protein in the cell that was not 
previously available when genistein was tested individually. Therefore, if E2 could be 
inducing a conformational change at the LBC, making binding at the AF-2 site more 
favourable for genistein, not only would a supramaximal effect no longer be observed, 
but also a decrease in transcription of the luciferase enzyme via a possible disruption 
of coactivator protein recruitment at the ER (Fig. 5.11). 
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Figure 5.11: Proposed two-site model for xenoestrogens ( ,  and ) in the ERa and ERb CALUXâ assays. Two mechanisms are proposed: (A) shows 
the decreased luciferase response as a result of a high affinity and in combination with a low affinity LBC binding ligand and (B) shows an increased 
luciferase response (supramaximal) as a result of a xenoestrogen mixture with two low affinity LBC binding ligands. (Elements of this diagram were derived 
from BioDetection Systems Ltd. The concept of the entire diagram is the authors). 
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However, not all combinations exhibited this effect, and an increased supramaximal 
response was observed in many lower LBC binding affinity ligand combinations. For 
example, the combination with butylparaben (varied) and BPA (fixed) induced a 
supramaximal effect of 332.9% compared to the individual maximal luciferase 
responses for butylparaben (162.6%) and BPA (122.6%). The significantly increased 
supramaximal response is not surprising considering both butylparaben and BPA 
induce supramaximal effects individually; therefore, it would be expected that in 
combination there would be a higher supramaximal response due to the increased 
presence of unbound xenoestrogens.  
 
Furthermore, genistein and butylparaben both exhibited increased supramaximal 
luciferase responses in the cytotox CALUXâ assay, which further supports the 
hypothesis of luciferase enzyme stabilisation by these compounds. All genistein and 
butylparaben combinations exhibited the same increased luciferase response in the 
cytotoxicity assay in addition to methylparaben, BPA and E2 in combination with 
BPA butylparaben and methylparaben and E2 and EE2 in combination with BPA and 
genistein. Interestingly, for almost all of the combinations that exhibited an increased 
luciferase response in the cytotoxicity assay, a decrease in the maximal luciferase 
responses was observed in the ERa and ERb CALUXâ assays. This suggests that the 
luciferase enzyme stabilisation that was observed in the cytotoxicity assay is not 
occurring. Since the only difference between the cytotoxicity assay and the ERa and 
ERb assays is the presence of the ER, it is likely that the decrease in the maximal 
luciferase response is ER-mediated. This also aligns with the possible two-site 
binding model proposed above, where only in the presence of an ER will a decrease in 
the supramaximal effect be observed.  
 
It is clear that the changes in supramaximal response are mixture-dependent, in that 
only certain mixtures elicit supramaximal responses, while other mixtures have a 
submaximal (e.g. below 100.0%) response. A possible explanation for this mixture-
dependent response is the availability of the AF-2 site. Indeed, when comparing the 
ERa surface topography of E2, BPA and butylparaben-bound receptor it is clear that 
there are differences in charge distribution depending on the bound ligand (Fig. 5.12); 
therefore, the subtle differences in ligand binding at the LBC appear to have a 
significant influence on AF-2 surface topography.  Thus, if ligands are binding at the 
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AF-2 site, the binding at the LBC could influence these interactions and account for 




Indeed, E2 binding to the ER is known to induce a specific conformational change in 
the tertiary structure of the ER, which subsequently affects the alignment of the highly 
conserved amphipathic a-helix (H12) within AF-2 (Danielian, et al., 1992). The 
correct agonist alignment of H12 exposes amino acid residues at the AF-2 site that 
interact with coregulatory proteins (Klinge, et al., 1996). In addition, it has been 
shown that xenoestrogens can induce distinct conformational changes in the tertiary 
structure of the ERs following ligand binding at the LBC, likely a result of differences 
in steric and electrostatic properties of the various ligands (Paige, et al., 1999, 
Routledge, et al., 2000). Furthermore, it has been reported that different 
xenoestrogens recruit different coregulatory proteins at the ERs. For example, 
Routledge and colleagues found BPA to recruit fewer coregulatory peptides (e.g. 
peptides derived from coregulatory proteins) compared with E2 (Routledge, et al., 
2000). Interestingly, they also found ERb had an enhanced ability to recruit 
coregulatory proteins compared with ERa in the presence of xenoestrogens, 
suggesting clear ER isoform differences. Indeed, this might explain the mixture-
dependent supramaximal effects in the ERa and ERb CALUXâ assay studies 
E2 BPA Butylparaben
Figure 5.12: Illustration of the electrostatic charges on the surface of ERa complexed 
with E2 (left; from 5HYR), BPA (middle; from 3UU7) and butylparaben (right; from 
4MG9). Blue represents negative and red represents positive electrostatic charges. 
Note a higher charge is indicated by a higher intensity of colour, while grey 
represents a neutral charge. Yellow dashed circles represent the approximate AF-2 
binding site. 
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presented in this chapter.  I suggest that differential ligand binding at the LBC 
explains the changes in supramaximal responses by recruitment of ligands to AF-2 as 
a secondary binding site on the ER ligand binding domain.  
 
5.4.3. CA Correlations 
In a natural exposure scenario, it is not possible to experimentally test every possible 
xenoestrogen mixture; therefore, mathematical models such as CA, are often used to 
predict the effects of mixtures. Researchers have concluded that CA most accurately 
predicts mixture effects, assuming that the mixture components act by a similar mode 
of action (e.g. the ER’s LBC). However, there are inherent mathematical limitations 
to the CA model, most importantly the inability to predict mixture effects that elicit a 
maximal response greater than 100.0% (Scholze, et al., 2014). This inability to deal 
with responses greater than 100.0% leads to predictive blind zones, and thus poor 
mixture predictability (Liu, et al., 2015). This could explain the under-reporting and 
inconsistencies across the literature for supramaximal effects (Montano, et al., 2010). 
However, it is clear from the results in this chapter that the supramaximal effects are 
an important aspect of a mixture’s response. By not limiting the maximum luciferase 
response to 100.0%, it has led to an inability to predict mixture effects in this chapter. 
In general, poor correlations were observed between experimental and predicted EC50 
values (Fig. 5.13), suggesting that the CA model may not be as robust in predicting 
xenoestrogen mixture effects as first thought. Indeed, the CA model assumes a similar 
mode of action for different components of a mixture; therefore, in my opinion, the 
responses presented in this chapter are a result of more than one mode of action (e.g. 
the two-site model) and therefore it was not surprising to find poor correlations 
between experimental and predicted EC50 values.  
 
 
















































































Figure 5.13: Correlation of experimental EC50 values and concentration addition (CA) 
predicted EC50 values in the ERa (top) and ERb (middle) CALUXâ assay. The 
second ERb correlation (bottom) shows a zoomed in view of the responses in the red 
box from the above graph. The solid red line represents a 1:1 correlation. 
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The consequence of the unpredictability by CA and the uncertainty of the 
supramaximal phenomenon could result in over- or under-estimation of the estrogenic 
potency if the supramaximal effect is a molecular artefact of the cell model.  
 
5.5. Concluding Remarks 
 
From the results presented in this chapter, it is clear that simple additivity was not 
observed for all xenoestrogen combinations. The results from the mixture studies 
support the growing consensus (Evans, et al., 2012) that additivity (CA) occurs when 
mixtures of xenoestrogens bind to the LBC. Genistein and butylparaben induced a 
supramaximal effect in the ERa and ERb CALUXâ assays; however, this 
phenomenon was not observed in all of the mixtures. Whilst the supramaximal effect 
is likely an artefact of the assay, the reduction in luciferase response appears to be 
ER-mediated. In my opinion this is likely a result of the two-site binding model 
previously proposed in Chapter 4, whereby some xenoestrogens could also bind to the 
AF-2 site on the ER, downregulating ER-mediated transcription and thus, E2-
mediated cellular functions. Finally, the consideration of the ER-mediated reduction 
in luciferase response is necessary to accurately predict the outcomes of complex 
xenoestrogen exposure scenarios. In order to study this, investigations into LBC and 
AF-2 interactions will need to be performed to understand the interplay between these 
two binding sites. The Schrödinger computational docking platform was used to study 
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Chapter 6 In silico Predictions of 




A wide range of adverse outcomes in humans have been associated with exposure to 
xenoestrogens as presented in Chapter 1; an increased risk of developing breast cancer 
is one of the most significant health effects thought to be a result of exposure to 
environmental and dietary xenoestrogens. However, this hypothesis remains 
controversial with limited, often inconsistent, evidence reported on the effects of 
xenoestrogens, in particular phytoestrogens. As previously discussed, phytoestrogens 
may also have beneficial effects on human health which could reduce breast cancer 
risk. Indeed, it is clear from Chapters 4 and 5 that some xenoestrogens exert 
concentration-dependent agonist/antagonist effects, which appear to be ER-mediated; 
thus, understanding the mechanism is important for predicting the biological 
outcomes of xenoestrogen exposure cocktails. Previously I have speculated that the 
agonist/antagonist effects of some xenoestrogens are mediated by a two-site binding 
model, in which the agonist effects are mediated by LBC binding and the antagonist 
effects are mediated via AF-2 interactions. Therefore, the aim of this chapter is to 
investigate the interplay between xenoestrogens and the ER LBD binding sites.  
 
6.1.1. Theoretical Background of the ER Binding Mechanism of Action 
The binding of the ligand to the LBC represents a key priming step for the subsequent 
binding of ER, via the DBD, to gene promoters. Importantly, the LBD binds to E2 as 
a monomer with a twofold symmetry, wherein each monomer is largely comprised of 
a triple-layered antiparallel a-helical sandwich capped at one end by a small two-
stranded anti-parallel b-sheet (Brzozowski, et al., 1997). Within this a-helical 
sandwich, the central layer comprises H5, H6, H9 and H10 a-helices, flanked by one 
layer of H1, H3 and H4 a-helices on the left and one layer of H7, H8 and H11a-
helices on the right as viewed from the direction of the sole b-sheet or the C-terminal 
a-helix H12 (Fig. 6.1). Subsequently, the ligand binds within the core of the globular 
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LBD with recognition of E2’s A and D ring. This is achieved through intermolecular 
hydrogen bonding of E2’s 3 OH with the carboxylate moiety of the glutamate residue 
from H3 and the guanidinium group of arginine residue from H5 as well as the E2’s 
17b-OH with imidazole sidechain of the histidine residue from H11. Additionally, 
van der Waals interactions are established as a result of sandwiching of the A/B-ring 
interface of E2 with amino acid residues alanine and leucine on one side and 
phenylalanine on the other side, as well as sandwiching of the E2’s D ring with an 




Figure 6.1: Crystal structures of ERa (PDB: 1ERE; left) and ERb (PDB: 3OLS; right) 
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Figure 6.2: Key amino acid residue interactions at the LBC in ERa (top) and ERb 
(bottom). 
 
A “mouse trap” model has been proposed (Moras, et al., 1998) in which an agonist 
accesses the core of the LBD via a pore and once bound is “trapped” by a 
conformational shift of H12, a structural component of the LBD itself. This carboxyl-
terminal a-helix folds against the surface of the LBD which is recognised by 
transcriptional coactivators that mediate the agonist-dependent transactivation 
properties of the ERs. The coactivator recognition surface or activation function (AF)-
2 of the ER is created by a-helices 3, 4, 5 and 12 of the LBD and is composed of a 
hydrophobic groove that is capped on either side by two charged residues (charge 
clamp), a lysine residue from H3 and glutamate residue from H12 (Nolte, et al., 1998, 
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Shiau, et al., 1998). The coactivator motif that is recognised by this groove within the 
LBD is a conserved amphipathic a-helical structure with the consensus sequence 
LxxLL (L=leucine and x=any other amino acid) (Ding, et al., 1998, Heery, et al., 
1997, LeDouarin, et al., 1996, Savkur, et al., 2004, Torchia, et al., 1997). The 
recognition of the LxxLL motif by the LBD is facilitated by interactions between the 
hydrophobic side chains of the leucine amino acid residues displayed on one face of 
the co-activator protein with the hydrophobic surface of the LBD AF-2 site, and 
hydrogen bonding between the charge clamp residues at the AF-2 site and backbone 
carbonyl groups of the co-activator protein LxxLL motif (Nolte, et al., 1998, Shiau, et 
al., 1998). Thus, these ligand-regulated protein-protein interactions are crucial for the 
mediation of transcriptional activation by ERs (Wang, et al., 2006). 
 
6.1.2. Ligand Structure and ER Binding  
Graham (2012) extensively reviewed the literature on the theory of ligand binding 
requirements, transcription, receptor protein structure and conformation and the 
applicability to computational docking. To summarise, there are a number of complex 
control mechanisms for estrogen target gene transcription, such as different 
expression of ER isoform combined with varying types of coregulatory proteins 
present in specific cell types. The molecular structures of endogenous estrogens are 
rigid and induce a precise 3D conformation in the ER upon binding. This precise 
conformation is observed in solved protein crystal structures and is described as the 
agonist conformation. This leads to distinct patterns in gene transcription. As 
mentioned in Section 1.3.1.4., pharmaceuticals such as tamoxifen, have been designed 
to block transcription by inducing the occupancy of the AF-2 site with H12 (Gangloff, 
et al., 2001). Interestingly, genistein has similar properties to tamoxifen in ERb 
(Barkhem, et al., 1998), where the conformation adopted is antagonist in the absence 
of a coregulatory peptide (Pike, et al., 1999); however, in the presence of this peptide, 
designed to mimic specific coregulatory proteins, ERb adopts an agonist 
conformation. It is thought that the peptide is providing additional stabilisation 
necessary to produce the agonist conformation (Manas, et al., 2004). Conversely in 
ERa, genistein induces an agonist conformation without the stabilisation of a co-
regulatory peptide. This is likely because of the higher energy barrier between he 
agonist and antagonist conformation for ERa (Fig. 6.3); therefore, the energy barriers 
between these ER isoform conformations could be important when attempting to 
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predict the biological outcomes of xenoestrogen exposure cocktails (Gangloff, et al., 









6.1.3. Requirements of Ligand Binding  
The LBC requires key molecular characteristics of E2 to facilitate ligand interaction. 
This binding can be described as a 3D lock and key model, where only the correct key 
(i.e. ligand) will ‘open’ the lock (i.e. the ER). Therefore, it is known from the 
structure of E2 that two hydroxyl groups in the right spatial arrangement, one 
aromatic and the other aliphatic, separated by 9.6 Å of hydrophobicity are required to 
‘open’ the ER. However, these requirements can be exploited by xenoestrogens which 
exhibit similar characteristics to E2; e.g. genistein has two aromatic hydroxyls 
separated by 13.13 Å of hydrophobicity. Ligands that more closely imitate E2 have 
greater estrogenic activity. Thus, this highly efficient and specific binding of ligands 
to the LBC are prerequisites for the desired ER-mediated biological activity. The 
specificity of these interactions is mediated by hydrogen bonds between key 
functional groups on the ER and on the ligands, namely Glu353/305, Arg394/346 and 
H2O which forms a hydrogen bonded triumvirate with E2’s aromatic hydroxyl, and 
His524/475 which hydrogen bonds with the aliphatic hydroxyl group of E2. Once the 
ligand is docked, hydrophobic interactions are created between the ligand and LBC 
amino acid residues pulling the a-helices towards the ligand and inducing ER 
conformational changes. These conformational changes are responsible for facilitating 
receptor dimerisation, nuclear translocation, and coactivator complex formation (e.g. 









Figure 6.3: Illustration of proposed relative stability of the agonist and antagonist 
conformations of the two ERs (from Graham, 2012 with permission). 
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These specific interactions are also what is exploited in computational modelling 
when ligands are docked. 
 
6.1.4. Computational Docking Background 
Computational docking is the computer simulation used to predict binding of a ligand 
within the receptor binding cavity and to estimate the binding energy (affinity). It can 
be used for virtual screening of collections of potential drug candidates or screening a 
library of possible candidate chemicals, this approach is often utilised in 
pharmaceutical research (Knox, et al., 2006, Knox, et al., 2007, Knox, et al., 2008, 
Sousa, et al., 2006). Computational docking has been used extensively in the study of 
endocrine disrupting chemicals (EDCs), to enable an understanding of the specific 
interactions with the ER; for example, phytoestrogens (Lambrinidis, et al., 2006), 
polychlorinated biphenyls, dichlorodiphyenyltrichloroethane (DDT) and its 
metabolites (D'Ursi, et al., 2005), polyphenols (Lambrinidis, et al., 2006), diphenyl 
ethers (Yang, et al., 2010) and pesticides (Celik, et al., 2008) have all been 
investigated using computational docking methods. However, most of the 
computational docking research has been applied to drug development for breast 
cancer, osteoporosis and prostate diseases (Knox, et al., 2006, Knox, et al., 2008).  
 
The basis of computational docking is the lock-and-key model first described by 
Fischer (Fischer, 1894). The 3D structures of the ligand and the receptor are both 
considered rigid and complement each other like a key fits into a lock (see Section 
6.3.1.). It is based on the static models of the receptor and ligand, understanding how 
the ligand can adopt a shape that best complements and interacts with the binding 
cavity of the receptor. However, docking calculations do not consider the kinetic 
energy of the system, thus, large scale movements of the receptor that may occur as a 
result of ligand binding cannot be modelled using computational docking methods 
(Graham, 2012). Therefore, small-scale conformational changes in the protein 
structure in the vicinity of the binding cavity, termed flexibility, are now being 
considered in docking applications (Sousa, et al., 2006). Thus, computational docking 
provides a means to study the intimate interactions of ligands with ERs without the 
high costs associated with other structural techniques such as x-ray crystallography.  
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The aim of this study was to employ the established Schrödinger modelling platform 
to examine xenoestrogen binding at both LBC and AF-2 sites of both ER isoforms in 
order to determine potential binding affinities at both sites.  
 
6.2. Experimental Approach 
The xenoestrogens selected for this study include those already examined in Chapters 
4 and 5, plus daidzein, equol, curcumin, benzylparaben, testosterone, progesterone 
and estrone (Table 6.1). These additional ligands were selected based upon relevance 
(e.g. naturally occurring steroid hormones) or persistence in the environment and 
foods. Each of the ligands were docked into each ER crystal structures: 1ERE and 
3OLS. RRD and IFD docking methods were both used to investigate ER-ligand 
interactions.  
 
Table 6.1: Structures of xenoestrogens selected for computational docking studies. 











































































The docking process begins with choosing or developing geometric and chemical 
descriptions of the separate receptor and small molecule structures. The receptor 
models are derived from the coordinates of ER x-ray crystal structures with co-
crystallised ligands. The ligand model was developed using a 3D chemical structure 
drawing tool (2D sketcher, Maestro) (see Section 2.2.10.1). Energy minimisations of 
both receptors and ligands structures were carried out, and then using search 
algorithms and force field interactions, the docking process sought to find optimal 
placements of the ligands in the receptor binding cavity. A scoring function is used to 
calculate the energy of the receptor-ligand complex and ranks the poses of a given 
ligand relative to one another to allow the comparison of poses of different ligands 
(see Section 2.2.10.3). Ideally, the numerical value of the scoring function should 
correspond directly to the binding affinity of the ligand for the protein so that the 
ligands with the best scores are the best binders (Graham, 2012).  
 
6.2.1. RRD and IFD Docking 
Two docking methodologies were employed to study the xenoestrogen binding 
affinities, RRD and IFD. RRD is the simpler of the two methodologies, where the 
receptor cannot move so the degrees of freedom of the docking is that of the ligand: 
three translational, three global rotational and, one internal dihedral rotation for each 
rotatable bond (see Section 2.2.10.4). It was assumed that the ligand was able to adapt 



















On the other hand, it is well known that the ER experiences some degree of 
conformational change during the binding process, especially at the AF-2 site upon 
LBC binding (see Section 1.3.1.4.) (Zilli, et al., 2009). Therefore, the xenoestrogens 
were also studied using IFD where different representations and simplifications of 
protein flexibility were implemented that avoid direct generation and search 
thousands of potential protein structure conformations (Graham, 2012). The 
Schrödinger platform uses an iterative approach of docking with a soft receptor 
followed by energy minimisation of the entire protein-ligand complex. An ensemble 
of candidate poses was generated per xenoestrogen within the receptor binding cavity. 
The candidate poses are then ranked, and a selection of the top-ranked poses were 
subjected to energy minimisation which allows the protein structure to relax around 
the ligand. These minimised receptor-ligand complexes were then re-scored to 
produce an ensemble of the most favourable complexes (see Section 2.2.10.6.).  
 
6.2.2. Scoring Function  
The scoring functions are used to estimate the free energy of binding (e.g. the binding 
affinity). A general scoring function was chosen because the objective of the study 
was to evaluate both multiple poses or clusters of similarity and the difference among 
the selected ligands, rather than being able to reliably use the information to refine the 
structure of the ligand to improve binding (Graham, 2012). Each of the scoring 
functions for each method, receptor and binding site, were compiled in empirical 
order. This was reported as the GlideScoreXP in units of kcal/mol and converted to 
kJ/mol where 1 kcal/mol = 4.2 kJ/mol (Bash, et al., 1996, Mulholland, 2007) 
Figure 6.4: Illustration of the rigid receptor-flexible ligand docking concept (from Graham 
2012 with permission). 
Rotational degrees of freedom allow the ligand to adapt to the 
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6.3. Results 
Several ligands were used to dock at both LBC and AF-2 sites in both ER isoforms, 
ERa and ERb, in order to validate binding and capture subtle variations caused by the 
different ligands. A total of two models were developed and two docking processes 
were used to evaluate binding. Rigid docking holds the models’ static, and IFD allows 
the models to mutually adapt. With rigid docking, the subtleties among the different 
models are retained and the docking calculation determines how favourably the 
particular ligand interacts with a given model. Thus, for less flexible ligands, the 
ligands were only docked into models that they were able to fit. Poor fitting was 
evident for less favourable calculated binding energies. More flexible the ligands were 
able to adapt to the fixed binding topography of the binding site compared to the rigid 
ligands. The calculated binding energies indicate how ‘uncomfortable’ a particular 
binding site is for a particular ligand. Among the flexible ligands, the relative 
differences in calculated binding energies indicate which of the different receptor-
ligand complex conformation is more favourable. In contrast, IFD allowed the 
receptor model to adapt to a ligand pose and one would expect similar models to 
converge to a common conformation for a given ligand, if the ligand is effective in 
influencing the receptor conformation.  
 
6.3.1. RRD and IFD Validation 
The first step in the studies was to validate both the RRD and IFD docking methods. 
The ability of the docking procedure to correctly place the ligand and correctly predict 
the binding energy was evaluated in both the 1ERE and 3OLS models. Graham 
(2012) extensively validated both docking methods, comparing the calculated binding 
energies with experimental binding energies from the literature. Thus, correlations 
between binding energies of ligands from Graham’s studies (E2, genistein and 
methylparaben) were compared to those generated in the current study in order to 
validate the methods used in the studies. The results showed a strong correlation 
between the RRD and IFD docking scores (Fig. 6.5) with R2 values of 0.98 for ERa 
and 0.95 for ERb, in both RRD and IFD. 
 




6.3.2. LBC Docking Studies 
The calculated RRD binding energies for the top ranked poses for both ERa and ERb 
LBCs are given in Table 6.2. RRD was able to dock all the ligands into the correct 
pose in both ERa and ERb models. IFD had the same success for docking the ligands 

































































Figure 6.5: Correlation of Graham (2012) calculated binding energies and calculated binding 
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Table 6.2: Calculated binding energies (kJ/mol) for the top-ranked poses for LBC 
obtained by RRD and IFD in both ERa (PDB: 1ERE) and ERb (PDB: 3OLS). 
 ERa binding energies 
(kJ/mol) 
ERb binding energies 
(kJ/mol) 
 RRD IFD RRD IFD 
Estrone  -35.4 -44.8 -44.9 -46.2 
E2 -48.4 -47.5 -47.2 -49.5 
Estriol -50.2 -51.7 -50.7 -54.5 
Testosterone  -43.5 -46. -42.4 -45.7 
Progesterone -22.0 -40.5 -35.5 -47.8 
EE2 -41.4 -51.7 -41.2 -50.2 
BPA -37.1 -37.9 -42.2 -40.0 
Methylparaben -25.5 -24.9 -23.6 -26.4 
Butylparaben -29.8 -31.5 -28.5 -29.2 
Benzylparaben -37.4 -40.7 -37.0 -41.0 
Genistein -40.3 -45.2 -45.0 -49.5 
Daidzein -31.8 -42. -35.9 -47.0 
Equol -39.5 -45.21 -43.4 -48.2 
Kaempferol -42.7 -48.0 -41.2 -50.2 
Curcumin -31.4 -55.7 -38.2 -57.7 
Tetrahydrocurcumin -51.5 -53.3 -40.4 -49.0 
 
Correlation of the RRD and IFD calculated binding energies are shown in Figure 6.6. 
R2 = 0.41 for ERa and 0.57 for ERb. Although both R2 values show a weak 
correlation, the P values of 0.0077 and 0.0007 respectively indicate a significant 
correlation for ERa and ERb models. 
 
 






ERβ IFD vs RRD











































ERα IFD vs RRD
Calculated RRD ΔGbind (kJ/mol)
Figure 6.6: Correlation of RRD calculated binding energies and IFD calculated binding energies 
in ERa and ERb models, 1ERE (left) and 3OLS (right). 
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To further validate the results, correlations between the calculated binding energies 
with experimental ∆Gbind (Table Appendix 4) are shown in Figure 6.7 for both RRD 
and IFD ERa and ERb models. Both RRD and IFD predict the experimental binding 
energies for these ligands within the stated uncertainty of ±12.5 kJ/mol. There are 



































































































Figure 6.7: Correlation of experimental and calculated binding energies for RRD (a and c) and IFD 
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Methylparaben, benzylparaben, curcumin and tetrahydrocurcumin do not have 
literature values for experimental binding affinities kaempferol and testosterone have 
only been studied in ERb and ERa, respectively. Therefore, data were not included if 
there were no experimental data to determine the correlation.  
 
Furthermore, there are significant differences in potencies between some 
xenoestrogens for RRD and IFD docking methodologies (Table 6.3). For example, 
estradiol and tetrahydrocurcumin have an RRD ERa/ERb ratio of 1.03 and 1.27, 
respectively, showing that they bind preferentially to ERa LBC using RRD docking. 
On the other hand, genistein and daidzein have RRD ERa/ERb ratios of 0.89 and 0.9, 
respectively, showing that they preferentially bind to ERb LBC. Interestingly, IFD 
appears to reduce the variability of the ERa/ERb ratios showing ligands to have lower 
ER isoform binding preference.  
 
Table 6.3: RRD and IFD ER isoform preference from calculated binding energies 
(kJ/mol). 
Ligand RRD preference ratio ERa/ERb 
IFD preference ratio 
ERa/ERb 
Estrone  0.8 1.0 
E2 1.0 1.0 
Estriol 1.0 1.0 
Testosterone 1.0 1.0 
Progesterone 0.6 0.9 
EE2 1.0 1.0 
BPA 0.9 1.0 
Methylparaben 1.1 1.0 
Butylparaben 1.0 1.1 
Benzylparaben 1.0 1.0 
Genistein 0.9 0.9 
Daidzein 0.9 0.9 
Equol 0.9 0.9 
Kaempferol 1.0 1.0 
Curcumin 0.8 1.0 
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6.3.3. AF-2 Docking Studies 
The calculated binding energies from RRD ligand binding studies at ERa and ERb 
AF-2 are summarised in Table 6.4. Literature values for experimental binding 
affinities for some ligands were not available; therefore, the most favourable binding 
energy when docked is shown. Some ligands were not successfully docked using 
RRD in the ERa model, these included estrone, testosterone, methylparaben, 
butylparaben, benzylparaben, genistein, daidzein and equol. In addition, no docked 
ligands were returned for IFD docking studies in the 1ERE and 3OLS models. 
Instead, the Schrödinger modelling platform docked the ligands at the more 
favourable LBC binding site. This was also observed with the ligands that were not 
docked in the RRD ERa model.  
 
Table 6.4: Calculated binding energies (kJ/mol) for the top-ranked poses for AF-2 
obtained by RRD in both ERa (PDB: 1ERE) and ERb (PDB: 3OLS). ND=not docked 
and indicates the ligand was not docked in the ER models. 
 AF-2 RRD binding energies (kJ/mol) 
Ligand ERa ERb 
Estrone  ND -7.0 
E2 -6.6 -14.6 
Estriol -13.6 -13.8 
Testosterone  ND -10.4 
Progesterone -10.0 -12.4 
EE2 -5.6 -7.7 
BPA -10.1 -10.1 
Methylparaben ND -11.9 
Butylparaben ND -12.00 
Benzylparaben ND -10.9 
Genistein ND -11.8 
Daidzein ND -11.0 
Equol ND -10.5 
Kaempferol -14.4 -12.4 
Curcumin -14.8 -10.2 
Tetrahydrocurcumin -16.2 -10.7 
 
Interestingly, the docking results showed there were clear key amino acid interactions 
at the AF-2 that were consistent between both ERa and ERb models (e.g. with charge 
clamp amino acid residues). For many of the docked ligands, either a hydrogen bond 
or van der Waals interaction was formed at Gln375/327. In addition, most of the 
docked ligands formed either hydrogen bond or van der Waals interaction with at 
least one of the charge clamp residues (Lys362/314 and Glu542/493). Other 
consistent van der Waals interactions that emerged from the AF-2 docking studies 
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were observed with amino acid residues Met358/309, Leu372/324, Val376/328, 
Leu379/331 and Leu539/490. Interactions of ERb ligands with AF-2 amino acid 
residues also included Ile310, Phe319, Glu332 and Met494; however, these 
interactions were not observed in ERa AF-2 docking studies. Example data for 
tetrahydrocurcumin and curcumin are shown in Figure 6.8 which highlights hydrogen 












Figure 6.8: Hydrogen bonding interactions at the AF-2 site with tetrahydrocurcumin 
(ERa; top) and curcumin (ERb;bottom). 
In silico Predictions of Xenoestrogen Interactions with ERs 
 198 
Surprisingly, some ligands (i.e. kaempferol and tetrahydrocurcumin) exhibited 
hydrogen bonding interactions between both charge clamp amino acid residues (i.e. 
Lys362/314 and Glu542/493) and the OH moieties on the ligands, imitating co-
activator interactions at the AF-2 site. Example data are shown for kaempferol (ERa) 










Figure 6.9: Hydrogen bonding interactions with kaempferol (ERa; top) and 
tetrahydrocurcumin (ERb; bottom) with the charge clamp amino acid residues at the 
AF-2 site. 
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6.3.4. LBC and AF-2 Binding Preference  
Comparisons between the LBC and AF-2 calculated binding energies demonstrate 
ligand binding is significantly favoured towards the LBC. This suggests that the LBC 
is a high affinity binding site and the AF-2 is a lower affinity binding site. The ratios 
show that some ligands (i.e. E2 and EE2) have much greater LBC favourability (i.e. 
7.4 times more favourable) compared to other ligands (e.g. kaempferol or curcumin) 
where the LBC binding affinity is only between 2 and 3 times more favoured. These 
ratios are summarised in Table 6.5.  
 
Table 6.5: ERa and ERb binding site preference ratio (LBC/AF-2). ND = not docked 
and indicates the ligand was not docked in the model.  
Ligand ERa preference ratio (LBC/AF-2) 
ERb preference ratio 
(LBC/AF-2)  
Estrone  ND 6.5 
E2 7.4 3.2 
Estriol 3.7 3.7 
Testosterone ND 4.1 
Progesterone 2.2 2.9 
EE2 7.4 5.4 
BPA 3.7 4.2 
Methylparaben ND 2.0 
Butylparaben ND 2.4 
Benzylparaben ND 3.4 
Genistein ND 3.8 
Daidzein ND 3.2 
Equol ND 4.1 
Kaempferol 3.0 3.3 
Curcumin 2.1 3.7 





Although there is a good theoretical and physical basis for the calculations in 
computational docking, the complexity of the systems necessitates assumptions and 
simplifications in order to make the problem more tractable and computationally 
possible with our current computer systems. While more sophisticated systems are 
available they are incredibly expensive; therefore, it was not possible to gain access to 
these systems for these studies. For example, the Schrödinger modelling platform 
assumes that only the amino acid residues within 20 Å of the docking site are able to 
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move. The assumptions and simplifications can result in errors and disagreement 
between computational results. For the present study, the scoring function 
implemented in the Schrödinger Suite is a good choice because ERα is one of the 
systems used (Friesner, et al., 2004, Friesner, et al., 2006, Halgren, et al., 2004) in the 
calibration of the GlideScore scoring function and validation of the Glide docking 
methodology. Glide has been shown to perform better than many other docking 
software packages in both accuracy of predicted binding energies and in accuracy of 
ligand placement (Friesner, et al., 2004, Friesner, et al., 2006, Halgren, et al., 2004). 
Therefore, it is not unreasonable to expect that the calculated binding energies and 
ligand poses obtained from the Schrödinger Suite for this study of ERα and ERβ are 
likely to be representative of the in vivo situation. However, for the purposes of this 
work, it is still important to recognise that computational results may not always agree 
numerically with experimental results but should reflect the trends demonstrated by 
experimental results. For these reasons, validation of the model results using known 
test scenarios is essential to gain confidence in the computations for predicting 
behaviour of unknown systems (Graham, 2012). 
 
With the RRD receptor model, the binding cavity residues are held fixed and the 
ligand is required to adapt to the binding cavity to find a low energy conformation. 
Therefore, the positions of the key binding cavity amino acid residues are important in 
determining ligand positioning within the binding cavity because of the corresponding 
interacting moieties on the ligand and in the binding cleft. When performing IFD, it is 
reasonable to expect that any given ligand would be docked into any of the sites on 
the models, provided that the adjustment of the models by the induced-fit procedure 
allows the model to adapt to the ligand. However, in the case of AF-2 docking the 
induced-fit procedure grappled with the less definitive site and facilitated ligand 
docking to the more specific, defined site of the LBC; thus, IFD was not the docking 
method of choice when attempting to dock ligands at the AF-2 sites of the models.   
 
6.4.2. LBC Binding Studies 
The validation of the LBC docking demonstrated that:  
• Both RRD and IFD can correctly place the ligands into the models and place 
the ligands in known orientations within the binding cavity of the models 
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• The scoring function can calculate the experimental binding energy within the 
stated uncertainty of ± 12 kJ/mol.  
 
There were good correlations between the calculated LBC binding affinities using 
both RRD and IFD for both the ERa and ERb models. Correlations were also found 
between calculated binding affinities and experimental binding data from the 
literature (Table A1). Interestingly, the IFD returned an overall stronger correlation 
compared to RRD for both ER models. However, the difference in correlation was not 
significant. This suggests that either of the protocols can be used to calculate ER 
ligand binding affinity. For some of the ligands it was not possible to find 
experimental binding affinities; however, due to the good correlation between 
calculated and experimental binding energies it is likely the LBC binding data is 
representative of those ligands for ERa and ERb.  
 
Surprisingly, estriol and tetrahydrocurcumin returned the best binding affinities for 
ERa. This was unexpected as EE2 is usually the superior binder; however, docking 
returned a binding affinity of -41.39 kJ/mol using RRD compared to -50.21 kJ/mol 
and -51.45 kJ/mol for estriol and tetrahydrocurcumin, respectively. RRD was unable 
to reliably dock EE2 at the LBC, with a lack of His524 hydrogen bond formation. 
This was surprising because EE2 is a pharmaceutical designed to interact with key 
elements of the LBC. This likely explains the lower calculated binding affinity (Fig. 
6.10). In comparison, estriol had the highest binding affinity (-50.70 kJ/mol) followed 
by E2 (-47.15 kJ/mol) and genistein (-45.01 kJ/mol) in the RRD ERb model. In 
general, the IFD method returned higher binding affinities compared to RRD. This is 
likely due to the ER protein models being ‘softened’ allowing the model to adapt to 
the ligand rather than the ligand having to adapt to the rigid protein. In short, in IFD 
receptor plasticity and ligand plasticity allow for the mutual adaptation of both the 
receptor and ligand facilitating optimum binding of the ligand to the binding site. 
However, it does not indicate the reliability of the model to represent the in vivo 
situation. Thus, a greater binding affinity does not necessarily correlate to better in 
vivo accuracy. It is clear from the ERa/ERb ratios that IFD does not show the correct 
ER isoform preference for ligands such as E2; therefore, RRD likely more closely 
represents in vivo binding affinities.  
 
In silico Predictions of Xenoestrogen Interactions with ERs 
 202 
 
Figure 6.10: LBC docking of EE2, illustrating the absence of hydrogen bonding 
between the aliphatic hydroxyl and His524 in ERa. 
 
6.4.3. AF-2 Binding Studies 
Ligands were successfully docked at the AF-2 site in both ER models using RRD; 
however, in the ERa model not all ligands were successfully docked compared to 
ERb where all ligands were docked. For the first time this provides evidence for 
xenoestrogen interactions at the AF-2 site. Interestingly, when comparing the docking 
results presented in this chapter with the study by Wang et al., (2006), which reports 
studies on 4-OHT co-crystallised at the ERb AF-2 site - the amino acid interactions 
they showed are strikingly similar to those seen in the present studies. For example, 
Wang and colleagues found the AF-2 interactions to be mainly hydrophobic or van 
der Waals interactions which were emulated in the ERb docking studies (Wang, et al., 
2006). In addition, the amino acid residues involved in ligand interactions shown in 
the present study are very similar to those described by Singh et al., (2015) (Table 
6.6). Interestingly, the ligands (candidate development drugs) studied by Singh et al., 
(2015) had significant structural similarities to curcumin (i.e. one of the strongest AF-
2 binders in the present studies). This agreement between data between different 
groups at different times strongly support the proposed xenoestrogen AF-2 
interactions. This suggests that the AF-2 interactions presented in this chapter could 
also be occurring in vivo.  
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Table 6.6: AF-2 amino acid residue studies presented in this thesis comparisons 
between docking studies and published AF-2 interactions in ERa and ERb. The tick 
indicates that the amino acid residue was involved in the ligand interaction with AF-2. 
ER AF-2 amino 
acids (ERa/ERb) 




Leu354/306  ü  
Met358/309 ü ü ü 
Ile359/310 ü ü ü 
Lys362/314 ü ü ü 
Phe367/319 ü   
Leu372/324 ü  ü 
Gln375/327 ü ü ü 
Val376/328 ü ü ü 
Leu379/331 ü ü  
Glu380/332 ü ü  
Trp383/335  ü  
Leu496/447  ü  
Arg497/448  ü  
Leu539/490  ü  
Glu542/493 ü ü ü 
Met543/494 ü  ü 
Met546/497  ü  
 
6.4.3.1. Interactions with Gln375/327 
It is clear that particular amino acids play key roles in AF-2 docking as seen in Table 
6.6. Interestingly, Gln375/327 has previously been found to play an important role in 
stabilisation of AF-2 binding (Singh, et al., 2015). Singh and colleagues found that 
the ligands that exhibited weak antagonist effects in cultured MCF-7 breast cancer 
cell exposure studies did not interact with Gln375, highlighting the importance of 
ligand interactions with this amino acid. Furthermore, all the ligands that were docked 
at the AF-2 site either had a hydrogen bond or a strong van der Waals interaction with 
Gln375/327 highlighting its possible importance in facilitating AF-2 site binding. 
Therefore, Gln375/327 is likely a key amino acid involved in small ligand (e.g. 
xenoestrogens) interactions at the AF-2 site via the formation of either a hydrogen 
bond or van der Waals interaction. 
 
6.4.3.2. Charge Clamp Amino Acid Residue Interactions 
In addition to the importance of a hydrogen bond or van der Waals interaction with 
Gln365/327, the charge clamp amino acid residues Lys362/314 and Glu542/493, 
which are known to facilitate key interactions between the coregulatory protein 
LxxLL binding motif and the AF-2 site, are also key in facilitating ligand docking in 
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this study. A majority of ligands that were docked at AF-2 in both ERa and ERb 
model had at least one strong interaction with these charge clamp residues, with some 
ligands (e.g. curcumin and tetrahydrocurcumin) hydrogen bonding at both charge 
clamp amino acid residues. While these amino acid residues are usually responsible 
for recognition of the coactivator LxxLL motif, it is likely that the hydrogen bonding 
interactions between the charge clamp amino acid residues and the OH moieties on 
the ligands are anchoring ligand binding, facilitating the stabilisation of the ER-ligand 
complex (see Fig. 6.7). This stabilisation induced by AF-2 binding is likely important 
in disrupting the co-activator-DNA complex formation, which could affect ER-
mediated gene transcription (see Chapter 4). Indeed, the studies by Singh et al. (2015) 
demonstrated that the interactions between charge clamp amino acid residues and the 
ligand was important in facilitating a more potent anti-proliferative effect in breast 
cancer cell lines. Therefore, understanding interactions between the AF-2 site and 
xenoestrogens could be important in determining the anti-proliferative effects which 
could be used to treat and reduce breast cancer risk, this will be discussed further in 
Section 6.4.5.  
 
6.4.3.3. Additional AF-2 Amino Acid Interactions 
There are a number of other amino acid residues that are consistent with previous 
studies, namely Met358/309, Leu372/324, Val376/328, Leu379/331 and Leu539/490 
in both ERa and ERb models. Additional interactions with ERb included Ile310, 
Phe319, Glu332 and Met494 which were consistent with the findings of Wang et al. 
(2006) and Singh et al., (2015). The example of kaempferol bound at ERa AF-2 is 
shown in Figure 6.11. The way a molecule interacts with the ER can determine its 
biological activity (e.g. in terms of agonism or antagonism); therefore, some 
xenoestrogens could facilitate their mixed agonist/antagonist effects via a two-site 
binding model. The two-site binding model, previously discussed in Chapters 4 and 5, 
is demonstrated by the results reported here, where the LBC is the primary, high 
affinity binding site and the AF-2 is the secondary, low affinity binding site. Thus, the 
mixed agonist/antagonist effects could be explained by the two-site binding model. In 
addition, some xenoestrogens exhibited similar binding characteristics to the ligands 
investigated by Singh and colleagues; therefore, it is reasonable to assume that some 
xenoestrogens, which were also shown in this thesis to have ER-mediated anti-
proliferative effects, are probably facilitating anti-proliferative effects in breast cancer 
cells via binding to the AF-2 site. The logical downstream effects of binding, as 
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discussed in Chapters 4 and 5, could interfere with ER-mediated transcription and 
thus gene expression and ER-mediated cellular signalling pathways (e.g. cell cycle 
and apoptosis). Therefore, understanding the mechanism of action of mixed 
agonist/antagonist effects and the biological implications for exposures to 
xenoestrogens combinations is important in understanding xenoestrogens exposure 
cocktails as breast cancer risk factors.  
 
6.4.3.4. AF-2 Binding Energies 
Tetrahydrocurcumin, estriol, kaempferol and curcumin had the highest calculated 
binding energies for AF-2 in the ERa model, while E2, estriol, kaempferol and 
progesterone had the highest calculated binding energies for AF-2 in the ERb model. 
Interestingly, the ligands that had the highest AF-2 calculated binding energies in the 
ERa models, were also the ligands that had the greatest anti-proliferative effects in 
MCF-7 cell studies (see Chapter 4). This is not surprising given the high expression of 
ERa in MCF-7 cells (Al-Bader, et al., 2011); therefore, a correlation between AF-2 
binding energies and MCF-7 cell studies was not surprising.  
Figure 6.11: Key amino acid residue interactions with kaempferol at the ERa AF-2 
site. 
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Whilst all ligands were docked in the ERb model, only some of the ligands were 
successfully docked in the ERa model using RRD. The main difference between the 
AF-2 sites of the ERa and ERb models is that ERb is co-crystallised with a co-
regulatory peptide while ERa is not. As discussed above, ERb has a lower energy 
barrier between the agonist and antagonist conformations compared to ERa; 
therefore, ERb requires a coactivator peptide to provide stabilisation of the agonist 
conformation. Upon closer examination of the key AF-2 amino acid residues, it is 
clear ERb’s coactivator peptide influences the distances between the key AF-2 site 
residues (i.e. Lysine, glutamate and glutamine) (Fig. 6.12). While the differences 
between the amino acid residues is small (i.e. < 1	Å) between ERa and ERb models, it 
appears to be sufficient to differentiate between a docked and ‘not docked’ ligand. 
Although this is not the only reason for influencing ligand docking at AF-2, it is likely 
to be one of the major contributing factors.  
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Figure 6.12: Distances (Å) between the key AF-2 amino acid residues Lys362/314, 
Gln375/327 and Glu542/493 in ERa (top) and ERb (bottom) models. This outlines 
the differences between the key amino acid residues of the models. 
 
In addition to AF-2 amino acid residues’ positions, the length and flexibility of a 
ligand (NB this is RRD docking) may also influence ligand docking at AF-2. 
Comparisons between key ligand moieties (e.g. hydroxyl or carbonyl groups) prior 
and post docking illustrate how a ligand might adapt to the AF-2 site in the docking 
process (Table 6.7). The ability of a ligand to adapt to the AF-2 site could influence 
the binding and even the strength of binding (i.e. binding energy); thus, an optimum 
distance between ligand moieties of 9-12 Å appears to result in docking to the ER AF-
2 site. Furthermore, the positioning of the key amino acid residues (see above) may 
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separation of key kaempferol hydroxyls is 12.2 Å prior to docking and reduced to 
11.1 Å post docking, clearly indicating the ability of the ligand to adapt to the 
optimum AF-2 binding separation (i.e. 9-12 Å). However, some ligands did not have 
sufficient plasticity to adapt to the docking requirements of the ERa AF-2 site. For 
example, genistein which has a hydroxyl separation of 13.1 Å prior to docking, could 
not be docked in the ERa model but was successfully docked in the ERb model. This 
suggests that the combination of a greater distance between amino acid residues and 
greater genistein hydroxyl separation prohibited its docking in the ERa model.  
 
In addition, ligand rigidity is likely to influence the ability of a ligand to be docked at 
AF-2. RRD utilises a rigid receptor with a flexible ligand, where the ligand has to 
adapt to the rigid binding site requirements for AF-2. Therefore, some ligands which 
have a greater moiety separation (e.g. curcumin) were docked in preference to ligands 
that had smaller separation (e.g. genistein) because of their greater molecular 
flexibility. Curcumin has greater flexibility compared to genistein, with a key moiety 
separation of 9.09 Å post docking. This is well within the ideal range of separation for 
binding to the AF-2 site. In view of this, it is not surprising that curcumin was docked 
and ligands such as genistein and daidzein were not. On the other hand, while RRD 
had limited success docking ligands in the ERa model, IFD was not successful in 
docking any of the ligands in both ERa and ERb models. Whilst receptor flexibility is 
likely more representative of the in vivo situation compared to RRD, the AF-2 site is a 
much broader, less defined binding site. Therefore, using the Schrödinger platform it 
was not possible to determine a favourable docking position at AF-2 for some ligands 
(e.g. genistein), which results in them being docked in the more defined and specific 
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Table 6.7: Ligand moiety separation prior and post docking in the Schrödinger 
computer modelling platform. 
Ligand Ligand separation 








E2 10.2 11.9 11.1 
Estrone 11.0  11.4 
Estriol 11.5 10.5 11.1 
EE2 10.1 9.7 9.9 
Testosterone 10.1  10.6 
Progesterone 10.2 10.1 8.7 
Genistein 13.1  10.0 
Daidzein 13.1  11.3 
Kaempferol 12.2 11.1 11.1 
Equol 8.9  12.4 
Curcumin 13.5 9.1 8.5 
Tetrahydrocurcumin 12.2 9.7 7.4 
Methylparaben  8.5  8.5 
Butylparaben 12.6  9.7 
Benzylparaben 12.2  10.7 
BPA 10.4 10.5 10.1 
 
6.4.4. LBC/AF-2 Binding Affinity Ratios 
The LBC/AF-2 ratios (Table 6.5) indicate the favourability of ligands for LBC 
compared to AF-2. The ligands can be grouped according to their LBC/AF-2 ratios 
(i.e. high LBC binding affinity and low AF-2 binding affinity) and those that have a 
low ratio (i.e. lower LBC binding affinity and low AF-2 binding affinity). For 
example, E2 in the ERa model has a high LBC/AF-2 ratio of 7.4 compared to estriol 
and tetrahydrocurcumin which have ratios of 3.7 and 3.2, respectively. This might 
find use in the prediction of the biological effects of estrogen mimic cocktails. For 
example, a mixture containing a high ratio ligand and a low ratio ligand could have a 
different effect when compared to a mixture with two low or two high ratio ligands. 
Thus, the lower the LBC/AF-2 ratio the more likely the ligand is to favour AF-2 
binding which could result in anti-proliferative effects. However, the LBC/AF-2 is 
still dependent on the individual binding affinities; for example, if the ligand had a 
low binding affinity to AF-2, the chance of it inducing an anti-proliferative affect 
would be low because the binding equilibrium will be favoured towards the unbound 
state (see Section 4.4).  
 
The results from this study further support the initial idea of a two-site model as an 
explanation for the mixed agonist/antagonist effects observed in MCF-7 and CALUX 
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studies reported in this thesis. The two-site model proposes a primary high affinity 
site, and a secondary low affinity site. The calculated binding energies from the 
docking studies reported above support this model, with high affinities being found 
for ligand binding at the LBC and low ligand binding affinities found for the AF-2 
site. The results presented here clearly demonstrate the possibility of dual ER 
interactions by xenoestrogens; thus, the two-site binding model could be important in 
explaining and understanding the biological effects of xenoestrogen combinations. 
This is highlighted by Figure 6.13 which shows E2 bound to the LBC and 
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6.4.5. Implications for Breast Cancer 
Numerous ER structural studies (e.g. x-ray crystallography) have revealed key 
insights into the function of ER proteins and have provided a platform for the design 
of pharmaceutical ER- modulators, particularly for the treatment of breast cancer. 
However, inconsistencies between the biological and structural data highlight that this 
approach to studying the structure-function relationship does not always paint a 
complete and accurate picture that fully describes the activity of a ligand in the unique 
chemical microenvironment of the ER. Indeed, a number of studies, including those 
presented in Chapter 4, have shown a concentration-dependent mixed 
agonist/antagonist activity of some xenoestrogens (e.g. genistein) in cultured breast 
Figure 6.13: Tetrahydrocurcumin bound to the AF-2 (red) site (ERa with E2 
complexed at the LBC - green) illustrates the potential for two different ligands to 
interact with both ER binding sites simultaneously.  
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cancer cells (e.g. MCF-7). In silico studies provide a way forward in respect to 
uncovering the intimate ER/ligand interactions that might help explain this 
phenomenon.   
  
The in silico studies reported in this thesis provide insight into the possible 
mechanism of mixed agonist/antagonist activity of some xenoestrogens, and supports 
a departure from the traditional paradigm of xenoestrogen binding to the LBC to a 
mechanism that involves complex interplay between ER’s LBC and the AF-2 site. 
The AF-2 site is known to play a pivotal role in the activation of ERa and 
ERb - mediated gene transcription (Marino et al., 2006); thus, the interplay between 
xenoestrogens and the LBC and AF-2 sites could have important implications for 
downstream ER-mediated biological activity. For example, xenoestrogen interactions 
at AF-2 could interfere with the DNA-coactivator-complex formation, which, in turn, 
may alter ER-mediated gene expression (see Section 4.4). Alternatively, some 
xenoestrogens could prevent the recruitment of the coactivator protein via their 
binding to the AF-2 site. Coactivator proteins have enzymatic activity which can 
facilitate ER degradation via the ubiquitin proteasome degradation pathway; thus, 
interfering with this process could extend ER occupancy of the target gene promoters 
which will impact gene transcription (see Section 4.4).  
 
In the context of breast cancer risk, the complex interplay between the dual effects of 
xenoestrogen interactions with the ER binding sites makes predicting the outcomes of 
xenoestrogen cocktails almost impossible. For example, the facilitation of AF-2 
occupancy, and thus ‘spill over’ from the LBC site, is likely to be dependent on 
multiple factors (e.g. xenoestrogen exposures concentration and cocktail composition) 
which are likely to have high inter-individual variability. Therefore, one person’s 
xenoestrogen cocktail exposure could increase their breast cancer risk (i.e. AF-2 
occupancy is not achieved), whilst that same exposure level to one or more particular 
xenoestrogen cocktail could reduce another person’s breast cancer risk (i.e. AF-2 
occupancy is achieved). Thus, the total estrogenicity of xenoestrogen cocktails does 
not necessarily lead to breast cancer development, but could lead to amelioration of 
the developmental process. This also poses a conundrum when attempting to 
implement new strategies to reduce breast cancer risk, where the classic approach for 
regulating chemicals (i.e. by limiting exposure) no longer applies. Indeed, the results 
reported in this study illustrate the importance of higher xenoestrogen exposure (i.e. a 
In silico Predictions of Xenoestrogen Interactions with ERs 
 213 
minimum exposure level) to facilitate AF-2 interactions, depending on the 
xenoestrogen.  
 
Clearly, understanding the complexity of xenoestrogen cocktails and the interplay 
between the individual components of these often-complex exposure mixtures at the 
ER’s LBC and AF-2 is important when designing strategies for reducing breast cancer 
risk. In addition, the present study also highlights the potential for rational drug 
design approaches involving small E2-mimicking molecules targeted at the 
functionally important AF-2 site to circumvent competition with the cognate LBC 
site. This approach could not only improve the treatment of breast cancer but could 
also be used in preventative strategies to reduce breast cancer risk. 
 
6.5. Concluding Remarks 
The results presented in this chapter clearly show the possible AF-2 binding of 
xenoestrogens, further supporting the two-site binding model presented in chapters 4 
and 5. The results highlight the high binding affinity of ligands with the LBC and low 
binding affinity at the AF-2 supporting the requirements of the two-site binding model 
and the dose-dependence of the responses (i.e. low and high concentrations elicit 
agonist and antagonist effects, respectively). However, these experiments were 
performed in silico which begs the question: do they predict the in vivo effects? While 
these studies are computationally simulated they do furnish a logical explanation for 
the mixed agonist/antagonist effects which is supported by previous work on 4-OHT 
(Jensen, et al., 2004, Wang, et al., 2006). Therefore, this work could be important in 
the context of breast cancer risk and furthermore supports the idea that phytoestrogens 
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Exposure to xenoestrogens might lead to a number of adverse outcomes, including an 
increased risk of breast cancer development, as reviewed in Chapter 1. Exposure to 
xenoestrogens is complex, whereby they do not always simply act in unison with one 
another (e.g. additivity; see Chapters 4, 5 and 6). Xenoestrogens can bind to ERs, 
activating ER-mediated signalling pathways; however, some xenoestrogens can 
modulate these effects, opposing the proliferative actions of other xenoestrogens, 
depending on the exposure concentration and mixture composition (e.g. mixed 
agonist/antagonist effects; as discussed in Chapters 4, 5 and 6). Therefore, predicting 
the outcome of exposures to complex mixtures of xenoestrogens is difficult. To 
complicate matters further, the same exposure may have different effects on pre-
pubertal girls, women of childbearing age, and postmenopausal women, because of 
differences in circulating E2 levels. The aim of this chapter is to investigate 
xenoestrogen exposure via daily food intake and lifestyle habits of women and pre-
pubertal girls, in order to determine whether the predicted magnitude of exposure is 
cause for concern in the context of breast cancer risk. Knowledge and understanding 
of these highly complex exposure cocktails may provide a novel opportunity to 
develop new preventive strategies for reducing breast cancer risk in New Zealand. 
 
7.1.1. Breast Cancer 
Breast cancer is one of the most commonly diagnosed cancers in women in both the 
developed and developing world. It is estimated that worldwide 1.7 million women 
were diagnosed with breast cancer in 2016 and 535,000 women died from breast 
cancer in 2016 (the leading cause of cancer death for women in 2016) (Morange-
Serrano, 2018). In New Zealand (estimated female population of 2.3 million in 2013) 
there were 3020 new registrations (28% of all cancer registrations) and 633 deaths 
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(15% of all cancer deaths) from breast cancer in 2013 The age-standardised incidence 
of breast cancer was 98.4 per 100,000 standardised to the WHO World Standard 
Population (MOH, 2012). Interestingly, survival from breast cancer has improved 
over time with New Zealand exhibiting some of the highest 5-years net survival rates 
compared to other developed nations (Allemani, et al., 2018). However, breast cancer 
outcomes vary significantly across the New Zealand population, with the worst 
outcomes seen in Māori (Cunningham, et al., 2010), Pasifika and people living in 
socially deprived areas (Haynes, et al., 2008). This suggests that more should be done 
to improve breast cancer care and prevention in New Zealand. There are other 
important factors, particularly social factors such as early diagnosis, which could 
influence the risk of death; for example, participation rates in BreastScreen Aotearoa 
(New Zealand’s breast screening program) are lower among Māori women (Robson, 
et al., 2017). 
 
7.1.2. Breast Cancer Initiation, Promotion and Progression 
Breast cancer is regarded as a systemic disease that initially presents local 
manifestations and later may advance, in a multistep process, with various hallmarks 
including rapid proliferation, resistance to cell death, neoangiogenesis, local invasion, 
remote metastasis, etc. (Fig. 7.1) (Barrett, 1993, Grizzi, et al., 2006, Liu, et al., 2015, 
Siddiqui, et al., 2015). Initiation is the first step in breast cancer development. 
Initiators are often chemicals, also known as mutagens, which cause permanent 
damage to DNA. These can include exposure to environmental risk factors such as 
carcinogenic chemicals, radiation or even physical stimuli. On the other hand, 
initiation can occur from internal metabolic processes (e.g. DNA metabolism, see 
Section 7.1.3.) (Liu, et al., 2015). Promotion is the second step that occurs in the 
initiated breast cancer cells. The promoters often refer to the compounds that promote 
the proliferation of the cell into a large number of daughter cells containing the 
mutation. Promoters do not directly interact with the DNA like initiators, they often 
bind to receptors on the cell surface (e.g. ERs) that affect intracellular pathways 
increasing cell proliferation (see Chapter 4). Whilst promoters do not necessarily 
cause breast cancer on their own, they do increase the clonal expansion of initiated 
cells that ultimately leads to malignancy (Klaunig, et al., 2000). The third step, 
progression, refers to the transformations from a benign tumour through to 
malignancy. Progression is often associated with karyotype changes coupled with 
increased growth rate, invasiveness, metastasis and alterations in biochemistry and 
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Figure 7.1: Three phases of breast cancer carcinogenesis: initiation upon exposure to a carcinogen, promotion via a proliferative stimuli and 
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7.1.3. Breast Cancer Risk 
Breast cancer risk factors are often thought of as non-modifiable (e.g. genetics, age, 
etc.); however, modifiable risk factors (e.g. socioeconomic status) are also important 
(Hiatt, et al., 2018). Whilst this thesis primarily focuses on the adverse effects of 
xenoestrogen exposures, and the downstream biological implications, the role of the 
social environment must not be forgotten. For example, a woman’s socioeconomic 
status may influence her food and lifestyle choices, in turn, affecting exposure to 
xenoestrogens. However, from a biological perspective, breast cancer is thought to 
develop as a result of accumulated damage induced by both internal (e.g. genetic) and 
external (e.g. exposure to carcinogens) triggers resulting in initial cell transformation 
events. The affected cells and tissues then progress through multiple stages, with 
accompanying alterations in the surrounding tissue likely playing a role in whether the 
damage leads to breast cancer. These events may occur spontaneously as a by-product 
of errors in normal processes, such as DNA replication, or potentially though effects 
of environmental exposures (Hiatt, 2011).  
 
The early procarcinogenic events from endogenous and exogenous processes may be 
augmented by physiologic conditions such as obesity and other risk factors such as 
environmental xenoestrogens. It is possible that many such initiative procarcinogenic 
events may never be entirely preventable because, although potentially modifiable, 
they are consequences of basic biologic processes (Hiatt, 2011); for example, DNA 
bases are metabolised to xanthene which is further metabolised by xanthene oxidase 
to 8-hydroxyguanosine coupled with the release of superoxide (O2·–), a highly reactive 
species which can result in oxidative DNA damage. Although such biological 
‘background’ DNA damage is unavoidable, highly efficient protective pathways, such 
as DNA repair and immune surveillance, are effective at reducing the impacts of 
procarcinogenic events (Bissell, et al., 2011).  
 
Although more needs to be learned about both the mechanisms of breast cancer and 
the array of risk factors that influence risk; a great deal has already been established 
(Fig. 7.2). For example, the major factors generally accepted as increasing a woman’s 
risk are older age, inherited genetic mutations (e.g. BRCA1 and BRCA2), and 
previous breast cancer or benign breast disease.  Other risk factors include having a 
child at an older age (e.g. over 35 years) or never having a child , current/recent use of 
oral contraceptives or HRT, lack of physical activity (see Section 1.5.2.) and exposure 
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to ionising radiation (ACS, 2010). While these key breast cancer risks have been 
identified, for the majority of women diagnosed with breast cancer it is not possible to 
identify the specific risk factors; however, it is thought that exposure to environmental 
chemicals may be a key component (IARC, 2008, Lacey, et al., 2009). Interestingly, 
the observation that the female offspring of immigrants from low-incidence countries 
within a few generations experience the high incidence rates of countries to which 
they migrate, illustrates that whichever environmental factors are in play can act to 
increase rates in genetically similar people in two generations (Hiatt, et al., 2018). 
Indeed, a US case-control study of Asian women, found that migrants who had lived 
in the West for a decade or longer had a breast cancer risk 80% higher than more 
recent migrants (Ziegler, et al., 1993). Therefore, understanding possible 
environmental and food exposure risk factors could help to mitigate breast cancer risk 
through implementing food and lifestyle changes. This understanding will help us 
devise better strategies to help reduce breast cancer risk. 




















 Figure 7.2: Illustration of an evidence-based complex systems model of postmenopausal breast cancer causation. This model 
displays multiple factors associated with postmenopausal breast cancer causation in four broad domains and shows their 
interconnections across levels (genes-society) by arrows that indicate strength. This is based on current understanding in the strength 
of the associations and quality of the data (from (Committee on Breast Cancer and the Environment, 2012) with permission). 
 
Human Xenoestrogen Exposure Study 
 221 
7.1.4. Xenoestrogens as Breast Cancer Risk Factors 
Estrogen levels in the body are tightly controlled by enzyme feedback mechanisms 
and gene regulatory processes. This is very important to ensure appropriate control of 
estrogen-mediated biological activity (Hall, et al., 2001). It is very likely that most 
xenoestrogens, despite their high structural analogies to E2, may not interact in the 
same way as E2. This means that xenoestrogens are uncontrolled in terms of their 
contribution to the total estrogenic load. Xenoestrogens can bind to ERs and imitate 
endogenous estrogens, exerting estrogenic effects which can interfere with the 
regulation of growth and proliferation of the cells by endogenous estrogens 
(Slomczynska, 2008). Again, it must be realised that a single component of a mixture 
may act via different mechanisms within the ER signalling pathway from another 
component of the mixture, and these mechanisms can act in unison with or in 
opposition to one another, thus, predicting the outcome of the exposure to complex 
xenoestrogen cocktails is difficult (Graham, 2012). One of the most difficult problems 
relating to xenoestrogens is establishing risk assessment strategies for potential 
adverse human health effects - this is the case for breast cancer. Current toxicological 
assessments in most jurisdictions take into consideration the biologic potency of an 
individual xenoestrogen as well as known exposure scenarios for that xenoestrogen 
(Slomczynska, 2008); but xenoestrogens are not usually specifically regulated, which 
means their use, or exposure to them, are not specifically limited. If toxicological 
testing does pick up estrogenicity (e.g. increased uterine wall thickness in standard 
animal toxicity testing) it will be considered in the risk assessment. However, the 
regulatory authorities do not usually consider the possibility of a combined effect of 
the xenoestrogens; thus, it is possible that the human daily exposure to estrogenic 
effects of xenoestrogens is a lot higher than anticipated, which could be affecting 
breast cancer risk.  
 
There are many complicating factors when understanding the combined effects of 
xenoestrogens: gender and age-related susceptibility to damage (e.g. circulating E2 
levels), additional exogenous burden from both natural (e.g. genistein) and synthetic 
(e.g. BPA) xenoestrogens in food and the environment, and complicated estrogen-
mediated biological activity. However, cause-effect relationships between 
xenoestrogens and breast cancer risk have not been established, except in the case of 
daughters of women who used DES during pregnancy (Singleton, et al., 2003). It has 
been shown that DES causes alterations in mammary gland structure and gene 
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expression in rodents, and was associated with increased breast cancer incidence after 
the age of 40 in a U.S. cohort of women who were exposed in utero (Hoover, et al., 
2011).  
 
7.1.5. Importance of Xenoestrogen Regulations 
Interestingly, most jurisdictions (e.g. USA, EU) have not limited the use of most 
xenoestrogens because risk assessments based on exposure to individual compounds 
(e.g. BPA (EFSA, 2015, WHO, 2010)) have not provided sufficient grounds for 
regulatory control.  Canada, the USA, and many more countries have, however, made 
an unprecedented move to ban BPA used to manufacture babies’ bottles on the 
grounds that milk formula-fed babies are likely to be a key target group due to their 
sensitive developmental stage, high BPA intake per body weight, and their sole source 
of food is likely to be contaminated with BPA (Almeida, et al., 2018, JRC/IHCP, 
2010). This will be discussed in greater detail in Section 7.4.6.1. 
 
7.1.6. Human Health Benefits of Xenoestrogens  
Just because something is estrogenic does not necessarily mean it will have adverse 
health effects. Some groups of xenoestrogens, particularly phytoestrogens, might have 
beneficial effects which could reduce the risk of breast cancer in women, help to 
alleviate postmenopausal symptoms, and reduce the risk of cardiovascular disease, 
atherosclerosis and cancer generally (Thomson, et al., 2003). However, because of the 
persistence of many xenoestrogens in the environment, high potential for human 
exposure, and the accumulation in biological matrices, interest should be maintained 
in both determining modes of action and establishing the risk from these chemicals 
(Singleton, et al., 2003). On the other hand, there is great concern surrounding the 
link between combinations of xenoestrogens and breast cancer – particularly in adults. 
Breast cancer incidence currently varies widely around the world, with incidence rates 
increasing in some countries (e.g. some northern and western European countries) 
whilst incidence rates in other countries (e.g. France and Norway) are decreasing. 
These differences in trends are likely a result of different patterns of risk factors 
(DeSantis, et al., 2015) which could be, in part, linked to exposure to environmental 
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7.1.7. Exposure to Xenoestrogens 
The most common mode of exposure to xenoestrogens is via the diet; e.g. ingestion of 
foods containing naturally occurring xenoestrogens (e.g. phytoestrogens) and leeching 
of monomers from polycarbonate plastics from food packing (e.g. BPA) (Allmyr, et 
al., 2006, Allmyr, et al., 2008, Dayan, 2007, Muller, et al., 1998, Waring, et al., 
2008). In addition, the dermal application of personal care products such as 
sunscreens and ‘wash off’ products (e.g. shampoos and soaps), can also result in 
exposure to estrogenic antimicrobial agents (e.g. parabens) via absorption through the 
skin (Chedgzoy, et al., 2002, Darbre, et al., 2008, Dayan, 2007, Hayden, et al., 1997, 
Janjua, et al., 2004). In addition, dietary supplements are another main source of 
xenoestrogens (Parnell, et al., 2006) that are often overlooked. Dietary supplements 
are regulated differently around the world. In New Zealand they are deemed foods 
and are regulated under the guidelines of the Food Act 1981. Under this Act food does 
not have to be approved for marketing and does not require efficacy or toxicity 
testing, it simply has to be fit for purpose; thus, dietary supplements are treated in the 
same manner. However, this has also led to a significant public misunderstanding 
where dietary supplements can be thought of as a safer alternative to medicines. For 
example, soy dietary supplements are often marketed as “safe alternatives for 
hormone replacement treatments for those battling symptoms of menopause”. 
However, these supplements often have much higher concentrations of soy 
phytoestrogens (e.g. genistein) compared to the concentrations found in whole soy 
products (e.g. soy beans) (Burke, et al., 2000). The total estrogenic effect of soy 
dietary supplements is likely higher, thus leading to an effect that could be akin to 
available pharmaceuticals used to treat menopause. Therefore, women could be 
unwittingly exposing themselves to high levels of xenoestrogens which could 
potentially be adding to breast cancer risk.  
 
7.1.8. Understanding the Role of Xenoestrogens in Breast Cancer Prevention 
Prevention strategies are crucial if the global breast cancer burden is to be reduced. It 
has recently been suggested that about one third to a half of diagnosed breast cancers 
in the Western world could be avoided by practicing healthy lifestyles, such as eating 
a healthy diet rich in plant-based products (remember genistein is a plant 
phytoestrogen) (Bouker, et al., 2000, Chang, et al., 2013, Ingram, et al., 1997). 
Indeed, diets containing plenty of fruits and vegetables have been related to a 
decreased risk of carcinogenesis, and phytoestrogens are thought to exert 
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chemopreventive effects (Chang, et al., 2013, Iwasaki, et al., 2008, Magne Nde, et al., 
2015). Some cell culture experiments and animal studies have suggested an anti-
cancer action of phytoestrogens, while epidemiological studies have found limited, 
inconsistent and even controversial associations between dietary phytoestrogen 
consumption and breast cancer risk (Adebamowo, et al., 2005, Chang, et al., 2013, 
Fink, et al., 2007, Magne Nde, et al., 2015, Touvier, et al., 2013, Travis, et al., 2008, 
Wang, et al., 2014, Yamamoto, et al., 2003, Zamora-Ros, et al., 2013, Zhu, et al., 
2011). 
 
The lower age-standardised incidence rates of breast cancer in some Asian countries, 
and the increase in breast cancer incidence in Asian women who have migrated to the 
West having adopted western dietary habits, have suggested a possible protective 
effect of dietary phytoestrogens. Some investigators have attributed the health 
benefits for Asian regions to the traditionally high intake of soy foods containing high 
levels of phytoestrogens (e.g. genistein) (Goodman, et al., 2009, Hedelin, et al., 2008, 
Lee, et al., 2009, Magne Nde, et al., 2015, Peeters, et al., 2003, Verheus, et al., 2007).  
 
A recent review of dietary intake of phytoestrogens and breast cancer risk found 
inconsistent associations between the consumption of phytoestrogens and decreased 
incidence of mammary tumours in Asian populations (i.e. high soy consumption) 
compared to Western countries (i.e. low soy consumption) (Sak, 2017). Interestingly, 
this study showed the protective association of phytoestrogens with breast cancer (see 
Section 1.4.1) might only occur in females who had consumed soy foods during 
childhood and adolescence. This suggests the consumption of soy phytoestrogens is 
particularly important during breast development. Thus, understanding these 
important windows for phytoestrogen exposure could help develop new breast cancer 
prevention strategies (Sak, 2017, Zhang, et al., 2010).   
 
7.1.9. Biological Regulation of Xeneostrogens 
When considering the effects of xenoestrogens one must consider not only exposure 
to these compounds but also the role of endogenous estrogens. The levels of 
endogenous E2 vary significantly throughout a woman’s life, from 0 – 1.4 x 10-10 M 
at pre-puberty and post menopause (Cummings, et al., 1998, Elmlinger, et al., 2002) 
to between 9.9 x 10-11 – 1.6 x 10-9 M (Cummings, et al., 1998) in a woman’s child 
bearing years. Therefore, one cannot fully assess the biological impact of 
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xenoestrogens without considering circulating E2 levels. For example, xenoestrogens 
are likely to significantly contribute to a postmenopausal woman’s total estrogenic 
load compared to a woman of child-bearing age based on their circulating endogenous 
E2 levels (Patisaul, et al., 2010). In addition, xenoestrogens likely circumvent the 
normal E2-mediated feedback mechanisms, evading biological control. Thus, for 
postmenopausal women and pre-pubertal girls, only a small proportion of their 
estrogenicity is, in theory, controlled by these mechanisms and a majority of their 
estrogenicity can only be ‘switched off’ via metabolic processes (e.g. glucuronidation) 
(Liehr, et al., 1998). Therefore, postmenopausal women and girls could be more 
susceptible to the biological influences of xenoestrogens.  
 
Further adding to the complexity is the individual variability between xenoestrogen 
uptake, metabolism and excretion. Xenoestrogens are frequently taken up from the 
gastrointestinal tract, transported to the liver where they are metabolised – often by 
hydroxylation or glucuronidation – and then normally excreted as inactivate 
glucuronides in the urine or bile. This could mean that the effects of xenoestrogens 
are lesser in women who metabolise xenoestrogens rapidly compared with women 
who are slower metabolisers. Therefore, a ‘one size fits all’ approach is unlikely to be 
relevant when devising new risk assessment strategies for xenoestrogen exposures 
(Thomson, 2005).  
 
7.1.10. Risk Assessment of Xenoestrogen Exposures 
If a person is not exposed to a hazard, in this case a xenoestrogen, then they will 
suffer no adverse effects as a result of that hazard, and there is no risk to them. Risk 
assessment is a scientifically based process, invaluable for defining the importance of 
any particular hazard (Thomson, 2005). In terms of xenoestrogen exposure 
assessments, one must collectively consider exposure (e.g. level, frequency) which 
determines the dose, and the individual variables (e.g. genetic makeup, age) to 
determine the risk associated with that particular exposure (Fig. 7.3) (Thomson, 
2005). In this Chapter a comprehensive risk assessment combines new and existing 
data on food concentration and food consumption for each xenoestrogen. Exposure is 
combined with relative estrogenic potency information, from published bioassay data 
and data presented in this thesis (Chapter 5), to estimate risk, relative to normal 
circulating endogenous E2 levels, to determine total estrogenic loads for women and 
pre-pubertal girls.  







The aims of this study were (i) to estimate the exposure of a random sample of 
Canterbury women (and the daughters of women with pre-pubertal daughters) to 
xenoestrogens, using a daily life habits questionnaire and, (ii) in a smaller non-
random sample of women, to compare the findings from the questionnaire with a 
blood analysis study. 
 
7.2. Experimental (Survey) Approach 
A survey of food and lifestyle habits, using a self-administered questionnaire, was 
carried out to assess xenoestrogen exposure in women and pre-pubertal girls (Group 
1).  Adult participants (target n=250) were randomly selected from the general and 
Māori Electoral Rolls and were asked to fill in the questionnaire (see Section 2.2.11.). 
If applicable the women also completed a questionnaire on behalf of their pre-pubertal 
daughters. Women were only asked to fill in a ‘daughter questionnaire’ if their 
daughter had not had her first period (e.g. menarche). If a woman had more than one 
pre-pubertal daughter she was asked to fill in the questionnaire for her eldest 
daughter. In addition, a smaller group of women (Group 2; target n=50) were 
recruited from UC staff and student email lists to complete the same questionnaire as 
the other women in conjunction with a blood analysis study, to investigate links 
between daily diet and lifestyle habits, and circulating xenoestrogens in the blood. As 
Figure 7.3: Schematic representation of xenoestrogen risk assessment. An individual’s 
response is based on exposure which leads to a specific dose, combined with 
individual characteristics, gives an estrogenic response. 
Human Xenoestrogen Exposure Study 
 227 
in Group 1, the women were asked to complete a questionnaire on behalf of their pre-
pubertal daughters, if applicable; however, their daughters were not required to 
provide a blood sample.  
 
7.2.1. Study Population  
The study population and sub-populations are described below. Young women were 
included in the study because of the possibility that risk factors operate much earlier 
than people had initially thought. The electoral roll only includes people from 18, 
thus, the first subgroup included 18 and 19-year olds. The age-range for the adult 
women (18-69 years) was chosen based on available data from the New Zealand 
Electoral Roll which includes women from age 18 years. The female population 
begins to decline from about age 69 years; which limited the size of the older (e.g. 69 
years and older) sub-population. Therefore, the upper age limit was set at 69 years. 
The subgroups selected for pre-pubertal girls were based on the available data in the 
New Zealand Total Diet Survey. Pre-pubertal girls were included to obtain an 
indication about the similarities between the mother and child’s daily habits (i.e. do 
their daily habits reflect their mothers). Therefore, with a small group of pre-pubertal 
girls to choose from all pre-pubertal girls were included in the total population 
calculations; thus, data were also collected for 7-10 years and 4 years subgroups and 
estimates included data ranges using the parameters from each of the subgroups 
outlined below.  
 
Exposure assessments were undertaken for the following sub-populations: 
• Adult females 18-29 years, 30-39 years, 40-49 years, 50-59 years and 60-69 
years. 
• Pre-pubertal girls 0-12 months, mean body weight 9 kg 
• Pre-pubertal girls 1-3 years, mean body weight 13 kg 
• Pre-pubertal girls 5-6 years, mean body weight 23 kg 
• Pre-pubertal girls 11-14 years, mean body weight 55 kg 
 
 
7.2.2. Questionnaire study 
The basic design was based on a questionnaire study which determined daily exposure 
to xenoestrogens. These were then multiplied by the quantified food servings or 
personal care product application and xenoestrogen concentration data. Blood 
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volumes were calculated and used to determine circulating xenoestrogen 
concentrations (in EQ) and endogenous E2 concentrations. The sum of the circulating 
xenoestrogen concentration and endogenous E2 concentration determined the total 
daily estrogenic loads (see Section 2.2.11.10.). 
 
Two possible xenoestrogen exposure scenarios were considered, representing the 
average and worst-case scenario exposure situations. In the average exposure 
scenario, the total estrogenic load was calculated by adding the calculated average 
circulating xenoestrogen (in EQ) levels with the calculated circulating endogenous E2 
level. In the WCS, the total estrogenic load was calculated by adding the calculated 
maximum circulating xenoestrogen exposure levels with the calculated circulating 
endogenous E2 level.  
 
7.2.3. Blood Analysis Study 
A 20 mL blood sample was taken from each participant (see Section 2.2.12.1.). The 
serum from each sample was removed (see Section 2.2.12.2.) and ether-extracted (see 
Section 2.2.12.3.) to isolate the xenoestrogens. Each sample was tested and analysed 
for the 13 xenoestrogens using LC-MS (see section 2.2.12.4.). Bruker LC-MS 
Software was used to observe the collected data and determine whether the 
xenoestrogens were present in the samples. A positive detection of a xenoestrogen 
was determined if the mass ion from the blood sample had the same mass ion (within 
two decimal places) to the standard, in addition to having the same retention time (see 
Section 2.2.12.4.).  
 
7.3. Results 
The questionnaire results from Groups 1 and 2 clearly demonstrate the increase in 
total estrogenic loads from xenoestrogen exposures. This calculated xenoestrogen 
exposure has a significant impact on the postmenopausal women and pre-pubertal girl 
subgroups. Hormone-based medicines clearly contribute significantly to the total 
estrogenic loads in all subgroups of women, which was expected. In addition, the 
blood analysis part of the study clearly demonstrates the complex exposures from 
women’s daily food and lifestyle habits.  
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7.3.1. Questionnaire Response Rates – Group 1 
There were 750 participants selected from the electoral roll. Of these, 35 were not 
currently residing at the address indicated on the electoral roll and 3 were living 
overseas. Of the remaining 712 women, 227 (32%) returned a completed 
questionnaire and 34 (15%) of these women also returned a completed questionnaire 
on behalf of their pre-pubertal daughter. The numbers of responses and percentages of 
total responses for each subgroup in Group 1 are presented in Tables 7.1 and 7.2 
 
Table 7.1: Responses by age distribution for women participants 
Participants  
(age range) 
Number of responses 
returned 
Percentage of total responses 
18-29 20 9 
30-39 31 14 
40-49 51 22 
50-59 71 31 
60-69 54 24 
Total 227 100 
 
Table 7.2: Responses by age distribution for pre-pubertal girls included in the study 
Participants  
(age range) 
Number of responses 
returned 
Percentage of total responses 
0-12 months 3 9 
1-3 years 4 12 
4 years 2 6 
5-6 years 6 17 
7-10 years 12 36 
11-14 years 5 14 
Age unknown* 2 6 
Total 34 100 
*Date of birth not given 
 
7.3.2. Exposure to Xenoestrogens – Group 1 
7.3.2.1. Women 
The results of the calculated xenoestrogen exposures in EQ, circulating E2 levels and 
total estrogenic loads, also in EQ, are presented in Table 7.3 for each of the 
subgroups. Each subgroup had similar calculated xenoestrogen exposure ranges; 
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however, they had different percentage contributions to the daily estrogenic loads. For 
example, the calculated xenoestrogen exposures made up a higher proportion of the 
total estrogenic loads for postmenopausal subgroups (e.g. >50 years) compared to 
subgroups of child-bearing age (e.g. <50 years). Not surprisingly, the calculated WCS 
xenoestrogen exposures had a much greater contribution to the total estrogenic loads 
compared with the average xenoestrogen exposure calculations.  
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Table 7.3: Calculated total daily xenoestrogen exposure in EQ, circulating E2 and total estrogenic loads for women (Group 1) based on average 




exposure in EQ (M) 
Calculated WCS xenoestrogen 
exposure in EQ (M) 
Circulating E2 levels 
(M) 
Calculated total daily 
estrogenic load in EQ (M) 
Calculated total daily WCS 
estrogenic load in EQ (M) 
18-29 2.0 x 10-11 – 4.0 x 10-11 7.3 x 10-10 9.9 x 10-11 – 1.6 x 10-9 1.2 x 10-10 – 1.7 x 10-9 8.4 x 10-10 – 2.3 x 10-9 
30-39 3.3 x 10-11 – 4.4 x 10-11 2.3 x 10-9 9.9 x 10-11 – 1.6 x 10-9 1.3 x 10-10 – 1.7 x 10-9 2.5 x 10-9 – 4.0 x 10-9 
40-49 3.3 x 10-11 – 4.4 x 10-11 2.4 x 10-9 9.9 x 10-11 – 1.6 x 10-9 1.3 x 10-10 – 1.7 x 10-9 2.5 x 10-9 – 4.0 x 10-9 
50-59 3.4 x 10-11 – 4.4 x 10-11 2.4 x 10-9 0.0 – 1.5 x 10-10 3.4 x 10-11 – 1.9 x 10-10 2.4 x 10-9 – 2.6 x 10-9 
60-69 2.6 x 10-11 – 4.4 x 10-11 1.4 x 10-9 0.0 – 3.7 x 10-11 2.6 x 10-11 – 8.1 x 10-11 1.4 x 10-9*  
All ages 3.4 x 10-11 – 4.4 x 10-11 2.4 x 10-9 0.0 – 1.6 x 10-9 3.4 x 10-11 – 1.7 x 10-9 2.4 x 10-9 – 4.0 x 10-9 
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In addition, daily xenoestrogen exposures were calculated for women who were using 
hormone-based contraceptives or HRT. The resulting xenoestrogen intakes for the 5 
subgroups are shown in Tables 7.4 and 7.5. Interestingly, some postmenopausal 
women included in the study were taking hormone-based contraceptives as a form of 
HRT to treat menopausal symptoms; thus, calculations for all subgroups are included. 
As expected, both hormone-based medications increased the total estrogenic load 
significantly, with an increase of between 1.4 - 7.1 x 104 for the average exposure 
with hormone-based contraceptives. On the other hand, HRT increased the average 
daily total estrogenic load 1000 fold. Whilst the calculated WCS xenoestrogen 
exposures increased the total estrogenic loads, the increases were negligible compared 
to the increases observed for hormone-based medications. Therefore, the percentage 
contribution of the WCS calculated xenoestrogen exposures to the total estrogenic 
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Table 7.4: Calculated total daily xenoestrogen exposure in EQ, circulating E2 and total estrogenic loads for women (Group 1) using hormone-




exposure in EQ (M) 
Calculated WCS xenoestrogen 
exposure in EQ (M) 
Circulating E2 
levels (M) 
Calculated total daily 
estrogenic load in EQ (M) 
Calculated total daily WCS 
estrogenic load in EQ (M) 
18-29 1.4 x 10-8 – 2.4 x 10-8 1.5 x 10-8 – 2.5 x 10-8 9.9 x 10-11 – 1.6 x 10-9 1.4 x 10-8 – 2.6 x 10-8 1.5 x 10-8 – 2.7 x 10-8 
30-39 1.4 x 10-8 – 2.4 x 10-8 1.6 x 10-8 – 2.6 x 10-8 9.9 x 10-11 – 1.6 x 10-9 1.4 x 10-8 – 2.5 x 10-8 1.6 x 10-8 – 2.8 x 10-8 
40-49 1.4 x 10-8 – 2.4 x 10-8 1.6 x 10-8 – 2.7 x 10-8 9.9 x 10-11 – 1.6 x 10-9 1.4 x 10-8 – 2.6 x 10-8 1.6 x 10-8 – 2.8 x 10-8 
50-59 1.4 x 10-8 – 2.4 x 10-8 1.6 x 10-8 – 2.6 x 10-8 0.0 – 1.5 x 10-10 1.4 x 10-8 – 2.4 x 10-8 1.6 x 10-8 – 2.7 x 10-8 
60-69 1.5 x 10-8 – 2.6 x 10-8 1.6 x 10-8 – 2.7 x 10-8 0.0 – 3.7 x 10-11 1.5 x 10-8 – 2.6 x 10-8 1.6 x 10-8 – 2.7 x 10-8 
All ages 1.4 x 10-8 – 2.4 x 10-8 1.6 x 10-8 – 2.7 x 10-8 0.0 – 1.6 x 10-9 1.4 x 10-8 – 2.6 x 10-8 1.6 x 10-8 – 2.8 x 10-8 
 
Table 7.5: Calculated total daily xenoestrogen exposure in EQ, circulating E2 and total estrogenic loads for women (Group 1) using HRT based 




exposure in EQ (M) 
Calculated WCS xenoestrogen 
exposure in EQ (M) 
Circulating E2 levels 
(M) 
Calculated total daily 
estrogenic load in EQ (M) 
Calculated total daily WCS 
estrogenic load in EQ (M) 
18-29 * * 9.9 x 10-11 – 1.6 x 10-9 * * 
30-39 * * 9.9 x 10-11 – 1.6 x 10-9 * * 
40-49 4.7 x 10-7 – 1.5 x 10-6 4.7 x 10-7 – 1.5 x 10-6 9.9 x 10-11 – 1.6 x 10-9 4.7 x 10-7 – 1.5 x 10-6 4.7 x 10-7 – 1.5 x 10-6 
50-59 4.7 x 10-7 – 1.5 x 10-6 4.7 x 10-7 – 1.5 x 10-6 0.0 – 1.5 x 10-10 4.7 x 10-7 – 1.5 x 10-6 4.7 x 10-7 – 1.5 x 10-6 
60-69 5.0 x 10-7 – 1.6 x 10-6 5.0 x 10-7 – 1.6 x 10-6 0.0 – 3.7 x 10-11 5.0 x 10-7 – 1.6 x 10-6 5.0 x 10-7 – 1.6 x 10-6 
All ages 4.7 x 10-7 – 1.5 x 10-6 4.7 x 10-7 – 1.5 x 10-6 0.0 – 1.6 x 10-9 4.7 x 10-7 – 1.5 x 10-6 4.7 x 10-7 – 1.5 x 10-6 
* women not receiving HRT
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7.3.2.2. Pre-pubertal Girls 
The results of the calculated xenoestrogen exposures in EQ, circulating E2 levels and 
total estrogenic loads, also in EQ, for the pre-pubertal girls are presented in Table 7.6. 
As for the women, average and WCS xenoestrogen exposures were calculated for 
each subgroup of pre-pubertal girls. The ranges of calculated xenoestrogen exposures 
were more variable than those for the women in the study. Girls in the 11-14 year 
subgroup were exposed to a similar range of xenoestrogen concentrations as the 
women. The calculated xenoestrogen exposures for the 1-3 year and 5-6 year 
subgroups were found to have the highest percentage contribution to the total 
estrogenic load. The 0-12 month subgroup was also exposed to similar concentrations 
of xenoestrogens. The calculated WCS xenoestrogen exposures significantly 
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Table 7.6: Calculated total daily xenoestrogen exposure, circulating E2 and total estrogenic loads for pre-pubertal girls (Group 1) based on 




exposure in EQ (M) 
Calculated WCS xenoestrogen 
exposure in EQ (M) 
Circulating E2 
levels (M) 
Calculated total daily 
estrogenic load in EQ (M) 
Calculated total daily WCS 
estrogenic load in EQ (M) 
0-12 months 2.3 x 10-11 – 1.5 x 10-10 7.9 x 10-9 0.0 – 5.1 x 10-11 2.3 x 10-11 – 2.3 x 10-10 7.9 x 10-9 – 8.0 x 10-9 
1-3 years 1.2 x 10-10 – 2.0 x 10-10 4.2 x 10-9 0.0 – 7.3 x 10-11 1.2 x 10-10 – 2.7x 10-10 4.2 x 10-9- 4.3 x 10-9 
5-6 years 8.4 x 10-11 – 1.5 x 10-10 1.3 x 10-9 0.0 – 7.3 x 10-11 8.4 x 10-11 – 2.3 x 10-10 1.3 x 10-9 – 1.4 x 10-9 
11-14 years 2.3 x 10-11 – 5.1 x 10-11 5.1 x 10-10 0.0 – 1.3 x 10-9 2.3 x 10-11 – 1.3 x 10-9 5.1 x 10-10 – 1.8 x 10-9 
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7.3.3. Hormone-based Medications and Dietary Supplement Use – Group 1 
The questionnaire included questions about contraceptives and HRT and dietary 
supplements, as these are some of the main sources of xenoestrogens to which women 
are exposed on a daily basis. Of the 227 participants 32 were using hormone-based 
contraceptives; a majority of these women were under the age of 40 years (Table 7.7). 
In addition, 11 participants were taking a form of HRT, with 100% these women over 
the age of 40 years (Table 7.8). Interestingly, 85 participants (37%) were taking 
dietary supplements, with those over age 40 years being the greatest consumers (78%) 
(Table 7.9).  
 
Table 7.7: Participants from Group 1 who had used hormone contraceptives. 
Participant’s  
age range 
Number of positive 
responses returned 
Percentage of total responses 
18-29 11 34 
30-39 9 28 
40-49 8 25 
50-59 4 13 
60-69 0 0 
Total 32 14 
 
Table 7.8: Participants from Group 1 who had used HRT. 
Participant’s age 
range 
Number of positive 
responses returned 
Percentage of total responses 
18-29 0 0 
30-39 0 0 
40-49 2 18 
50-59 5 46 
60-69 4 36 
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Table 7.9: Participants from Group 1 who had consumed dietary supplements. 
Participant’s age 
range 
Number of positive 
responses returned 
Percentage of total responses 
(%) 
18-29 11 13 
30-39 8 9 
40-49 21 25 
50-59 23 27 
60-69 22 26 
Total 85 37 
 
Of the 36 pre-pubertal girls included in this study, 11 (30.6%) were taking dietary 
supplements. All of the girls taking the supplements were over the age of 5 years 
(Table 7.10).  
 




Number of positive 
responses returned 
Percentage of total responses 
0-12 months 0 0 
1-3 years 0 0 
5-6 years 3 50 
11-14 years 1 20 
Total 11+ 30.6 
+ Total calculations include pre-pubertal girls who were 4 years old and those from 
the 7-10 year age group. 
 
7.3.4. Relationship Between Breast Cancer and Exposure to Xenoestrogens in Group 1 
To attempt to understand whether some of the participants’ food and lifestyle habits 
were influenced by a previous or current breast cancer diagnosis, participants were 
asked if they had breast cancer or had previously undergone treatment for breast 
cancer. Out of 227 participants, 14 women (6%) had either been diagnosed with 
breast cancer or were currently undergoing treatment for breast cancer at the time of 
the questionnaire study. Two of these women (14 %) were under the age of 40 years 
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Table 7.11: Participants from Group 1 who had a history of breast cancer. 
Participant’s age 
range 
Number of positive 
responses returned 
Percentage of total responses 
18-29 1 7 
30-39 1 7 
40-49 0 0 
50-59 6 43 
60-69 6 43 
Total 14 6 
 
In addition, participants were asked whether they had previously thought about the 
possible link between xenoestrogens and breast cancer. Of the 227 participants 73 (32 
%) had thought about xenoestrogens as possible breast cancer risk factors, while 68 
(30 %) had taken measures to eliminate xenoestrogens from their daily food and 
lifestyle habits (Table 7.12). This suggests that five of the participants who had 
thought about xenoestrogens as breast cancer risk factors did not change their food 
and lifestyle habits to reduce breast cancer risk. However, when this was examined in 
the five subgroups, it is clear this was not always the case. For example, in the 18-29 
year subgroup, 7 participants had thought about xeneostrogens as breast cancer risk 
factors, but 8 participants had taken measures to eliminate them from their daily 
habits. This suggests that while information is available encouraging women to 
eliminate xenoestrogens from their diet and lifestyle, people are not always aware of 
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Table 7.12: Participants from Group 1 who had thought about xenoestrogens as breast 
cancer risk factors and had taken measures to eliminate them from their daily habits 
prior to receiving the questionnaire. 
 Number of women who had considered: 
Participant’s age range Breast cancer risk factors Elimination 
18-29 7 8 
30-39 11 8 
40-49 18 19 
50-59 19 18 
60-69 18 15 
Total 73 68 
 
 
7.3.5. Relationship Between Breast Cancer Risk and Exposure to Xenoestrogens for 
Pre-pubertal Girls 
Interestingly, 33.3% of the women who completed the questionnaire on behalf of their 
pre-pubertal daughters had considered xenoestrogens as possible breast cancer risk 
factors for their daughters. However, 36.1% of women had taken measures to 
eliminate xenoestrogens from their daughter’s daily food and lifestyle habits (Table 
7.13).  
 
Table 7.13: Participants from Group 1 who had thought about xenoestrogens as breast 
cancer risk factors for their daughter and had taken measures to eliminate them from 
her daily habits prior to receiving the questionnaire. 
 Number of women who had considered: 
Participant’s age range Breast cancer risk factors  Elimination 
0-12 months 2 2 
1-3 years 1 1 
5-6 years 1 1 
11-14 years 3 3 
Total 12+ 13 
+Total calculations include pre-pubertal girls who were 4 years old and those from the 
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7.3.6. Exposure to Xenoestrogens – Group 2 
7.3.6.1. Women 
The results of the calculated xenoestrogen exposures in EQ, circulating E2 levels and 
total estrogenic loads, also in EQ, are presented in Table 7.14 for each of the 
subgroups. Interestingly, despite the different sampling strategies, the findings from 
the questionnaires suggest that both groups of women have similar xenoestrogen 
exposures. The calculated xenoestrogen exposures made up a higher proportion of the 
total estrogenic loads for postmenopausal subgroups (e.g. >50 years) compared to 
women of child-bearing age (e.g. <50 years). Not surprisingly, the calculated WCS 
xenoestrogen exposures were found to have a much greater contribution to the total 
estrogenic loads compared the average xenoestrogen exposure calculations.  
 
In addition, the calculated daily xenoestrogen exposures for women using hormone-
based contraceptives in Group 2 is presented in Table 7.15. As expected, the 
hormone-based medications increased the total estrogenic load significantly, with an 
increase between 1.5 x 103 – 6.6 x 104 for the calculated average exposure and 1.3 x 
103-6.7 x 107 for the calculated WCS exposure. The calculated WCS xenoestrogen 
exposures increased the total estrogenic loads; however, those increases appear to be 
negligible compared to the increases observed by hormone-based medications. 
Therefore, the percentage contribution of the WCS calculated xenoestrogen exposures 
to the total estrogenic loads were almost uniform across subgroups.   
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Table 7.14: Calculated total daily xenoestrogen exposure in EQ, circulating E2 and total estrogenic loads for women (Group 2) based on average 
and WCS exposures. 
 
Table 7.15: Calculated total daily xenoestrogen exposure in EQ, circulating E2 and total estrogenic loads for women (Group 2) using hormone-




exposure in EQ (M) 
Calculated WCS xenoestrogen 
exposure in EQ (M) 
Circulating E2 levels (M) Calculated total daily 
estrogenic load in EQ (M) 
Calculated total daily WCS 
estrogenic load in EQ (M) 
18-29 1.5 x 10-8 – 2.7 x 10-8 1.8 x 10-8 – 2.9 x 10-8 9.9 x 10-11 – 1.6 x 10-9 1.5 x 10-8 – 2.9 x 10-8 1.8 x 10-8 – 3.0 x 10-8 
30-39 1.5 x 10-8 – 2.6 x 10-8 1.6 x 10-8 – 2.7 x 10-8 9.9 x 10-11 – 1.6 x 10-9 1.5 x 10-8 – 2.8 x 10-8 1.6 x 10-8 – 2.9 x 10-8 
40-49 1.3 x 10-8 – 2.3 x 10-8 1.4 x 10-8 – 2.4 x 10-8 9.9 x 10-11 – 1.6 x 10-9 1.3 x 10-8 – 2.5 x 10-8 1.4 x 10-8 – 2.6 x 10-8 
50-59 1.3 x 10-8 – 2.4 x 10-8 1.4 x 10-8 – 2.4 x 10-8 0.0 – 1.5 x 10-10 1.3 x 10-8 – 2.4 x 10-8 1.4 x 10-8 – 2.4 x 10-8 
60-69 1.4 x 10-8 – 2.4 x 10-8 1.4 x 10-8 – 2.4 x 10-8 0.0 – 3.7 x 10-11 1.4 x 10-8 – 2.4 x 10-8 1.4 x 10-8 – 2.4 x 10-8 





exposure in EQ (M) 
Calculated WCS xenoestrogen 
exposure in EQ (M) 
Circulating E2 
levels (M) 
Calculated total daily estrogenic 
load in EQ (M) 
Calculated total daily WCS 
estrogenic load in EQ (M) 
18-29 4.0 x 10-11 - 1.1 x 10-9 2.9 x 10-9 9.9 x 10-11 – 1.6 x 10-9 1.4 x 10-10 – 3.2 x 10-9 2.7 x 10-9 – 4.0 x 10-9 
30-39 4.4 x 10-11 - 2.5 x 10-11 1.2 x 10-9 9.9 x 10-11 – 1.6 x 10-9 1.4 x 10-10 – 1.8 x 10-9 1.3 x 10-9 – 2.8 x 10-9 
40-49 1.6 x 10-11 - 1.8 x 10-11 7.3 x 10-10 9.9 x 10-11 – 1.6 x 10-9 1.1 x 10-10 – 1.6 x 10-9 8.4 x 10-10 – 2.3 x 10-9 
50-59 2.1 x 10-11 - 3 x 10-11 1.5 x 10-10 0.0 – 1.5 x 10-10 2.1 x 10-11 – 1.8 x 10-10 1.5 x 10-10 – 3 x 10-10 
60-69 1.9 x 10-11 – 3 x 10-11 2.5 x 10-10 0.0 – 3.7 x 10-11 1.9 x 10-11 – 6.6 x 10-11 2.5 x 10-10 – 2.8 x 10-10 
All ages 3.1 x 10-11 – 3.6 x 10-11 2.4 x 10-9 0.0 – 1.6 x 10-9 3.1 x 10-11 – 1.7 x 10-9 1.1 x 10-9 – 2.8 x 10-9 
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7.3.6.2. Pre-pubertal Girls  
The results of the calculated xenoestrogen exposures in EQ, circulating E2 levels and 
total estrogenic loads, also in EQ, for the 8 pre-pubertal girls in Group 2 are presented 
in Table 7.16. Again, average and WCS xenoestrogen exposures were calculated for 
each subgroup of pre-pubertal girls. The ranges of calculated xenoestrogen exposures 
were more variable compared to the women in the group. The 11-14 year subgroup 
were exposed to a similar concentration range of xenoestrogens to the women. 
Interestingly, the calculated xenoestrogen exposures for the 1-3 year and 5-6 year 
subgroups were found to have the highest percentage contribution to the total 
estrogenic load. Of the 47 questionnaires returned, no participants had a daughter 
aged under 12 months. The calculated WCS xenoestrogen exposures significantly 
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Table 7.16: Calculated total daily xenoestrogen exposure in EQ, circulating E2 and total estrogenic loads for pre-pubertal girls (Group 2) based 




exposure in EQ (M) 
Calculated WCS xenoestrogen 
exposure in EQ (M) 
Circulating E2 
levels (M) 
Calculated total daily 
estrogenic load in EQ (M) 
Calculated total daily WCS 
estrogenic load in EQ (M) 
1-3 years 1.2 x 10-10 – 4.0 x 10-9 4.0 x 10-9 0.0 – 5.1 x 10-11 1.2 x 10-10 – 4.1 x 10-9 4.0 x 10-9  
5-6 years 7.0 x 10-11 – 2.4 x 10-10 2.4 x 10-10 0.0 – 7.3 x 10-11 7.0 x 10-11 – 3.1 x 10-10 2.4 x 10-10  
11-14 years 4.8 x 10-12 – 7.3 x 10-11 1.4 x 10-9 0.0 – 7.3 x 10-11 4.8 x 10-12 – 1.4 x 10-9 1.4 x 10-9 – 2.7x10-9 
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7.3.7. Hormone-based Medications and Dietary Supplement Use – Group 2 
Of the 47 participants 12 (26%) were using hormone-based contraceptives, with a majority of 
participants under age 40 (Table 7.17). On the other hand, no participants were using a form 
of HRT. Ten women (21%) had taken a dietary supplement, with an even distribution among 
subgroups (Table 7.18). Only one (11.1%) pre-pubertal girl had taken a dietary supplement 
(Table 7.19).  
 
Table 7.17: Participants from Group 2 who had used hormone contraceptives. 
Participant’s age 
range 
Number of positive 
responses returned 
Percentage of total responses 
18-29 3 30 
30-39 3 33 
40-49 4 44 
50-59 2 20 
60-69 0 0 
Total 12 26 
 
 
Table 7.18: Participants from Group 2 who had consumed dietary supplements.  
Participant’s age 
range 
Number of positive 
responses returned 
Percentage of total responses 
18-29 3 30 
30-39 3 33 
40-49 2 22 
50-59 2 20 
60-69 0 0 
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Table 7.19: Participants from Group 2 whose daughter had consumed dietary supplements. 
Participant’s age 
range 
Number of positive 
responses returned 
Percentage of total responses 
0-12 months * 0 
1-3 years 0 0 
5-6 years 0 0 
11-14 years 0 0 
Total 1+ 11.1 
*indicates no participants in this subgroup; + Total calculation includes pre-pubertal girls 
who were 4 years old and those from the 7-10 year age group. 
 
7.3.8. Relationship Between Breast Cancer and Exposure to Xenoestrogens in Group 2 
To attempt to understand whether some of the participants in Group 2’s food and lifestyle 
habits were influenced by a previous or current breast cancer diagnoses, participants were 
asked if they had breast cancer or had previously undergone treatment for breast cancer. Of 
the 47 participants, one woman (2%), who was in the 60-69 year age-group, had been 
diagnosed with breast cancer at the time of the questionnaire study.  
 
In addition, participants were asked if they had previously thought about the link between 
xenoestrogens and breast cancer. Out of the 47 participants 21 (45%) had thought about 
xenoestrogens as possible breast cancer risk factors, while 17 (36%) had taken measures to 
eliminate xenoestrogens from their daily food and lifestyle habits (Table 7.20). This suggests 
that four participants who had thought about xenoestrogens as possible breast cancer risk 
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Table 7.20: Participants from Group 2 who had thought about xenoestrogens as breast cancer 
risk factors and had eliminated xenoestrogens from their daily habits prior to receiving the 
questionnaire. 
 Number of women who had considered: 
Participant’s age 
range 
Breast cancer risk factors  Elimination 
18-29 3 2 
30-39 6 5 
40-49 3 3 
50-59 4 4 
60-69 5 3 
Total 21 17 
 
7.3.9. Relationship Between Breast Cancer Risk and Exposure to Xenoestrogens for Pre-
pubertal Girls 
Interestingly, 55.6% of participants who completed a questionnaire for their pre-pubertal 
daughters had considered xenoestrogens as breast cancer risk factors for their daughters. In 
addition, 100% of these participants had taken measures to eliminate xenoestrogens from 
their daughters’ daily food and lifestyle habits (Table 7.21). For a majority of participants this 
included the removal of BPA-containing plastic containers and packaging.  
 
Table 7.21: Participants from Group 2 who had thought about xenoestrogens as breast cancer 
risk factors for their daughter prior to receiving the questionnaire. 
 Number of women who had considered: 
Participant’s age range Breast cancer risk factors Elimination 
0-12 months * * 
1-3 years 1 1 
5-6 years 1 1 
11-14 years 2 2 
Total 5+ 5 
*indicates no participants in this subgroup; + Total calculation includes pre-pubertal girls 
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7.3.10. Xenoestrogen Blood Analysis Results 
The forty-seven women selected (see Section 2.2.11.) from the UC staff and student lists 
participated in this part of the study. A 20 mL blood sample was taken from each participant 
and analysed for the 13 xenoestrogens selected for the study by LC-MS (see Section 2.2.12.). 
The results of the blood analyses are shown in Tables 7.21 to 7.25. Interestingly, 10 out of the 
13 xenoestrogens tested were detected in all 47 blood samples. The method used to select the 
women for this part of the study was not statistically based as this was a small pilot study, 
therefore, these results are not statistically based; however, it is interesting that a small 
sample of women all showed varying levels of different xenoestrogens in their blood. This 
suggest widespread exposure.  
 
7.3.10.1. Parabens 
Methylparaben and butylparaben were detected in 100% and 87.2%, respectively, of blood 
samples tested (Table 7.22; Fig. 7.4). It was not surprising to find both parabens in the 
samples given the extensive use of methyl and butylparaben in cosmetics and personal care 
products (see Section 1.4.3.). On the other hand, benzylparaben (Fig. 7.4) was only detected 
in one of the samples (2.1%). This suggests that benzylparaben is not as commonly used as 
an anti-microbial agent in cosmetics and personal care products.  
 
Table 7.22: Blood samples with parabens detected. 
 Methylparaben (%) Butylparaben (%) Benzylparaben (%) 
18-29 100.0 90.0 0.0 
30-39 100.0 77.8 0.0 
40-49 100.0 88.9 10.0 
50-59 100.0 90.0 0.0 
60-69 100.0 88.9 0.0 














7.3.10.2. Endogenous Estrogens 
E2 (68%) was the only estrogen detected in any of the blood samples analysed (Table 7.23; 
Fig. 7.5). Surprisingly, E2 was detected in only 40% of blood samples from the 18-29 year 
subgroup. Comparatively, E2 was detected in 77.8% - 80.0% of blood samples from the 
remaining subgroups of women. However, one would expect to find E2 in all blood samples 
of women up to the age to 50 years based on their theoretical circulating E2 levels and the 
sufficient detection level of the analytical methodology. There was a change made during the 
blood collection in that it was found more convenient to centrifuge directly in the vacutainer 
rather than to transfer it to a centrifuge tube and this could have accounted for that difference. 
This might be due to a more sufficient serum separation.  Estrone and estriol were not 








Figure 7.4: Example chromatogram of a blood sample showing the mass ion peaks for 
methylparaben, butylparaben (top) and benzylparaben (bottom). 
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Table 7.23: Blood samples with endogenous estrogens detected. 
 E2 (%) Estrone (%) Estriol (%) 
18-29 40.0 0.0 0.0 
30-39 77.8 0.0 0.0 
40-49 77.8 0.0 0.0 
50-59 80.0 0.0 0.0 
60-69 77.8 0.0 0.0 




Figure 7.5: Example chromatogram of a blood sample showing the mass ion peak for E2. 
 
7.3.10.3. Synthetic Xenoestrogens 
EE2 was detected in one of the 47 blood samples (2.1%; Table 7.24; Fig. 7.6). When 
compared with the relative questionnaire for that participant, she was taking an EE2 
containing oral contraceptive; therefore, it was not surprising to find EE2 in her serum. On 
the other hand, BPA was not detected in any of the blood samples. This is not surprising as 
BPA is rapidly metabolised and quickly excreted from the body after exposure, this will be 
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Table 7.24: Blood samples with synthetic xenoestrogens detected. 
 EE2 (%) BPA (%) 
18-29 10.0 0.0 
30-39 0.0 0.0 
40-49 0.0 0.0 
50-59 0.0 0.0 
60-69 0.0 0.0 





Phytoestrogens were found in all of the 47 blood samples (Table 7.25). Kaempferol was the 
most prevalent of the phytoestrogens, with it being detected in 89.4% of blood samples. 
Interestingly, the mass ion peak for kaempferol often had a higher intensity (Fig. 7.7) 
compared to the other phytoestrogens (e.g. genistein or daidzein), suggesting that kaempferol 
is present at higher concentrations in blood. Genistein and daidzein were detected in 34.0% 
and 29.8% of samples, respectively. Curcumin was detected in 27.7% of samples and the 
metabolite tetrahydrocurcumin was detected in one sample (2.1%). Interestingly, the sample 
containing tetrahydrocurcumin (Fig. 7.7) had a much higher peak of curcumin than was 
observed in the other samples. This suggests that the detection limits were possibly not low 







Figure 7.6: Example chromatogram of a blood sample showing the mass ion peak for EE2 
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18-29 40.0 20.0 70.0 0.0 0.0 
30-39 22.2 66.7 100.0 44.4 0.0 
40-49 33.3 33.3 100.0 33.3 0.0 
50-59 20.0 22.2 90.0 30.0 11.1 
60-69 33.3 34.0 88.9 30.0 0.0 












Figure 7.7: Example chromatograms showing mass ion peaks for daidzein, genistein, 
kaempferol (top), curcumin and tetrahydrocurcumin (bottom). 
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7.4. Discussion 
This study was effectively composed of three sub-studies. The first was a population-based 
study with randomly selected women (questionnaire study). The second was a group of 
women selected off UC staff and student lists (blood analysis study). The third was pre-
pubertal girls of the women included in groups 1 and 2. They were included because of the 
possibility that risk factors operate much earlier in life than people had initially thought; thus, 
exposure to xenoestrogens pre-puberty could translate into an increased breast cancer 
incidence postmenopausally. In Group 1, postmenopausal women (who have lower levels of 
endogenous E2) were potentially the most susceptible if exposed to xenoestrogens because of 
the low E2: xenoestrogen ratio. The average contribution of the calculated xenoestrogen 
exposures to their total estrogenic loads was considerably higher (65.4%) in these subgroups 
compared with women of child-bearing age (16.9%). This study also demonstrates the 
complexity of xenoestrogen exposures from daily food and lifestyle habits, including 
hormone-based medications and the use of dietary supplements. Indeed, the blood analysis 
part of the study demonstrated that the xenoestrogens from the women’s food and lifestyle 
were clearly high enough to be present in the blood samples. However, upon comparison 
between the questionnaire and blood analysis results from this group of women, there was no 
obvious correlations between a woman’s daily habits and the xenoestrogens detected in her 
blood. For example, genistein and daidzein were not always detected in the blood samples 
from women who consumed bread on a daily basis. However, this was nott a fully validated 
study but rather a preliminary investigation and the limits of determination are not known for 
these studies; therefore, it might be that compounds were present at low concentrations that 
were not detected by the analytical methodology. This is a study that requires significant 
modifications. In addition, detection also depended on a number of variables, including the 
time of presence of a compound in the circulatory system is dependent on the dose and the 
pharmacokinetics of the compounds. The biological half-lives of xenoestrogens vary 
significantly (e.g. BPA ~2 h, genistein ~8 h; Table 7.26); therefore, a compound that has a 
shorter half-life is going to disappear very quickly. However, kaempferol, which also has a 
short half-live, was detected in a high number of serum samples. Kaempferol is found in a 
large number of fruits and vegetables, therefore, it is likely that women were exposed to a 
consistent small dose throughout their day. Whilst the xenoestrogen detected are all potential 
risk factors for breast cancer, since they all are capable of binding to ERs, it is very difficult 
to determine the magnitude of a specific exposure because of inter-individual variability (see 
section 7.4.7.).  
 
Human Xenoestrogen Exposure Study 
 253 
Table 7.26: Biological half-lives of xenoestrogens studied 
Compound Approximate biological half-life (h) Reference 
BPA 2.0 (Stahlhut, et al., 2009) 
Kaempferol 2.8 (Wang, et al., 2003) 
Curcumin 6.5 (Jager, et al., 2014) 
Estriol 7.5 (Kuhl, 1990) 
Genistein 8.2 (Chang, et al., 2013) 
Daidzein 9.5 (Chang, et al., 2013) 
Estrone 12.0 (Wecker, et al., 2009) 
Tetrahydrocurcumin 13.5 (Saradhi, et al., 2010) 
E2 16.9 (Zimmermann, et al., 1998) 
Butylparaben 24.0 (Abbas, et al., 2010) 
Benzylparaben  24.0 (Abbas, et al., 2010) 
Methylparaben <24.0 (Abbas, et al., 2010) 




There are many complicating factors to consider in this exposure assessment, which made 
attempting to predict the effects of xenoestrogen exposure cocktails almost impossible. For 
example, polymorphisms in metabolism may mean that xenoestrogens have different half-
lives depending on the person’s ability to metabolise them. Therefore, simplifications and 
assumptions were applied to the calculation in order to predict and calculate the effect of 
xenoestrogen exposure cocktails. These included assuming the xenoestrogens were 100% 
absorbed, evenly distributed in the blood and not metabolised. Interestingly, even with these 
simplifications and assumptions, it is plausible that exposure to xenoestrogens could account 
for a substantial increase in total estrogenic load. In addition, this assessment has only 
addressed the estimated xenoestrogen exposure in terms of additivity; however, it is clear 
from previous experimental work (e.g. Chapters 4, 5 and 6) that there are many co-operating 
and competing factors at play. Therefore, the calculated total estrogenic effect is only 
theoretical. On the other hand, there are many more xenoestrogens that could not be 
accounted for in the study, and with the list of xenoestrogens continually growing, it is likely 
the theoretical total estrogenic effect is an underestimate of what women are exposed to daily.  
 
7.4.2. Impact of Xenoestrogen Exposure on Total Estrogenicity 
7.4.2.1. Women 
This is based on the findings from Group 1 because they were a random sample of women 
from Canterbury. The percentage contribution of xenoestrogen exposures to the total 
estrogenic loads for Group 1 are shown in Table 7.27.  On average xenoestrogens were 
calculated to contribute 51.3% to the total estrogenic loads of women, and in the WCS an 
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80.0% was calculated. This calculated xenoestrogen exposure could considerably increase the 
total estrogenic loads of women, potentially at least doubling normal circulating endogenous 
E2 levels. Whilst an approximate 51.3% contribution is not observed in all subgroups, even a 
small contribution (e.g. 9.6% in the 18-29 year subgroup) significantly increases the 
estrogenic potency of the blood in women. However, the postmenopausal subgroups of 
women experience a much higher contribution of xenoestrogens to their total estrogenic 
loads; between 61.5% and 77.3%. Not only does this mean that xenoestrogen exposure is at 
least doubling the estrogenic potency of their blood, but also that over 61.5% of the 
estrogenicity is not controlled by estrogen-mediated feedback mechanisms. Therefore, the 
only way to ‘switch off’ that portion of estrogenicity is to rely on metabolism (e.g. 
glucuronidation) (Liehr, et al., 1998); thus, postmenopausal women are likely to be more 
susceptible to ER-mediated xenoestrogenic effects.  
 
Table 7.27: Percentage contribution of xenoestrogens to the daily estrogenic loads of women 
from Group 1. 
 Average % WCS % 
18-29 9.57 59.1 
30-39 13.8 77.8 
40-49 13.8 77.8 
50-59 61.5 97.1 
60-69 77.3 98.7 
All 51.3 80.0 
 
In terms of breast cancer development, the estimated increase in blood estrogenic potency 
observed in Canterbury women could lead to considerable amplification of the promotion and 
progression stages (Safe, 1998). Indeed, an increase in estrogenic potency remarkably 
increases the proliferation power of a breast cancer cell - a hallmark characteristic of cancer 
promotion and progression (Fouad, et al., 2017). In postmenopausal women this increase in 
estrogenic potency (e.g. 67.6%), in conjunction with reduced biological control over the total 
estrogenic load, may partly explain why they are most at risk of developing breast cancer.  
 
7.4.2.2. Pre-pubertal Girls  
Both groups of girls were not randomly selected, therefore, they cannot be assumed to 
represent the wider population of pre-pubertal girls; thus, the two groups were combined for 
analysis. However, even though the daughters (Groups 1 and 2) and women (Group 1) were 
obtained using different sampling strategies, the findings were similar between the groups. 
This may mean xenoestrogen exposures could have biological implications (e.g. precocious 
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puberty, increased risk of breast cancer development post-menopausally) for pre-pubertal 
girls in Canterbury. The percentage contribution of xenoestrogen exposures to the total 
estrogenic loads for Group 1 are shown in Table 7.28. A good agreement between the 
percentage contribution of xenoestrogen exposure to the average total estrogenic load (58.1% 
and 63.5%) was observed; however, poorer agreement was observed between the calculated 
WCS total estrogenic loads (58.7% and 83.64%). This suggests that on average both groups 
of pre-pubertal girls have similar food and lifestyle habits but not at the WCS level. The 
younger (e.g. <6 years) subgroups of pre-pubertal girls were potentially more susceptible if 
exposed to xenoestrogens compared to the 11-14 year subgroup. This is likely because of 
their higher food intake per body weight, and lower circulating E2 levels, so that the 
contribution of xenoestrogens is higher for these subgroups (Aksglaede, et al., 2006). 
Interestingly, these same subgroups of pre-pubertal girls experienced, at a minimum, an 
83.0% contribution from xenoestrogen exposure to their total estrogenic loads. It is 
important, but highly complex, to consider the relatively estrogenicities of xenoestrogens in a 
mixture because this will significantly affect the sum of their interactions with the ERs. I did 
not attempt to investigate this but clearly this warrants further study. This is a significant 
increase in the estrogenic potency of their blood; therefore, they are likely to be more 
susceptible to ER-mediated xenoestrogenic effects compared to the older pre-pubertal girls. 
 
Table 7.28: Average of the percentage contribution of xenoestrogens to the daily estrogenic 
loads of pre-pubertal girls from Groups 1 and 2. Errors are expressed as SEM. 
 Average % SEM WCS % SEM 
0-12 moths 83.9 0.0 99.6 0.0 
1-3 years 92.8 6.3 99.3 0.2 
5-6 years 85.7 2.6 92.8 4.6 
11-14 years 52.3 0.4 69.1 7.3 
All  60.8 2.7 71.2 12.5 
 
Not only is breast cancer complex, but so is breast development. Breast tissue consists of 
multiple cell types, which must remain in close communication. Normal mammary gland 
growth involves intricate crosstalk between the epithelium and surrounding stroma, to 
balance proliferation/apoptosis and remodel the gland at the different stages of life (see Fig. 
1.28) (Macon, et al., 2013). Exposure to xenoestrogens during this highly susceptible time 
could affect mammary gland development, potentially increasing susceptibility to chemical 
carcinogens, and in turn, breast cancer development later in life. The increase in estrogenic 
load calculated from these studies clearly demonstrates the potential to affect mammary 
gland development with the high potential proliferative power of circulating xenoestrogens 
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and limited biological controls (Liehr, et al., 1998) in pre-pubertal girls. However, cause-
effect relationships between pre-pubertal xenoestrogen exposure and increased breast cancer 
risk later in life are yet to be established (Rodgers, et al., 2018).  
 
On the other hand, the pre-pubertal girls could also be more susceptible to other adverse 
health effects, such as precocious puberty (Massart, et al., 2006). Precocious puberty refers to 
the appearance of physical and hormonal signs of pubertal development at an earlier age (e.g. 
8 - 10 years in girls (Carel, et al., 2004)) than is considered normal. The release of E2 in the 
body, which is a result of increased levels of gonadotrophins, is responsible for initiating the 
process of puberty naturally (Mueller, 2004). Therefore, exposure to xenoestrogens could 
initiate this process much earlier than expected. Indeed, a study which examined chronic 
xenoestrogen exposure observed early signs of pubertal development in mice in the absence 
of normally increased levels of gonadotrophins (Massart, et al., 2006). This suggests that 
xenoestrogens could circumvent the natural pubertal control mechanisms, inducing puberty at 
an earlier age. In this study the calculated xenoestrogen exposures for the subgroups of pre-
pubertal girls increased the calculated total estrogenic load. Therefore, the pre-pubertal girls 
included in the study could also be susceptible to precocious puberty. Indeed, the general 
trend of age of menarche (e.g. first period) around the world is decreasing (Fig. 7.8) and 






Figure 7.8: Trends in age of menarche (Sorensen, et al., 2012). 
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Whilst precocious puberty is not often directly associated with an increased breast cancer 
risk, it is well established that the length of time between puberty and a woman’s first full 
term pregnancy (e.g. parity) is associated with an increased risk of breast cancer (Kobayashi, 
et al., 2012). Therefore, decreasing the age of puberty due to xenoestrogen exposure, and 
potentially increasing the age between puberty and parity, could be increasing breast cancer 
risk. Interestingly, it has been shown that an approximate 20% decrease in breast cancer risk 
results from each year of delayed menarche (Feigelson, et al., 1996). On the other hand, 
earlier menarche also means women are able to have children younger (Forman, et al., 2013). 
Whilst the average age for women having their first child is increasing (Shadyab, et al., 
2017), there is also a decrease in the age at which some women are having children (i.e. 
because of earlier menarche) (Forman, et al., 2013). This, however, also creates a gap 
between biological and social maturity in some societies, with individuals becoming 
biologically adult at earlier ages but remaining minors socially and legally (Volgyi, 2008). 
Therefore, girls who are biologically mature are faced with considering the implications of 
environmental exposures, such as the impact of xenoestrogens, which could impact their 
health later in life; yet these girls are unlikely to be mature enough to consider these 
implications. Therefore, the possible impacts of xenoestrogens may be more far reaching than 
previously anticipated. 
 
7.4.3. Comparison of Total Estrogenic Loads of Women and Pre-pubertal Girls 
Interestingly, there is a high degree of commonality between women (Group 1) and pre-
pubertal girls as shown in Table 7.29. As discussed above, postmenopausal women and pre-
pubertal girls are likely to be most susceptible to the adverse effects of xenoestrogen 
exposure. Postmenopausal women are the most likely group of women to develop breast 
cancer, not only because of the high contribution of xenoestrogens to their total estrogenic 
loads, but also, they are the most susceptible to other risk factors, especially age; thus, they 
are more susceptible to cellular transformation (e.g. initiation). The other group of 
participants that are likely to be the most susceptible to the adverse effects of xenoestrogen 
exposure are pre-pubertal girls. Whilst this potential exposure is unlikely to result in an 
immediate breast cancer diagnosis (e.g. within 5 years), it could increase the risk of breast 
cancer development later in life. Indeed, for at least two other known breast cancer risk 
factors (e.g. radiation and migration (Carpenter, et al., 2013, Ziegler, et al., 1993)) it appears 
that exposure to these risk factors during crucial developmental stages (e.g. pre-puberty) can 
translate an increase in breast cancer diagnoses later in life; thus, exposure to xenoestrogens 
during this window of susceptibility could increase breast cancer incidence for these pre-
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pubertal girls. In addition, women of child-bearing age are potentially not as susceptible if 
exposed to xenoestrogens compared to the other groups of postmenopausal women and pre-
pubertal girls; however, they are susceptible to breast cancer initiation. This susceptibility is 
likely a combination of other risk factors including exposure to carcinogens, and high 
circulating endogenous E2 levels (Feuer, et al., 1993). 
 
Table 7.29: Comparison of average total daily xenoestrogen exposure between women and 
pre-pubertal girls. 








All ages (18 18-69 years) 51.3 
Pre-pubertal girls  
0-12 months 58.1 
1-3 years 83.9 
5-6 years 86.5 
11-14 years 83.1 
All ages (0-14 years) 51.9 
 
7.4.4. Impact of Hormonal Medications 
Strong commonality was observed for the percentage contributions of hormone-based 
medicines to the total estrogenic loads between Group 1 subgroups (Table 7.30). This is not 
surprising given the high concentrations (e.g. 5.1 x 10-7 – 8.7 x 10-7 M in hormone-based 
contraceptives) of estrogens present in these medicines, which essentially overwhelm any 
endogenous E2 present. The xenoestrogen exposures appear to be a ‘drop in the bucket’ 
compared to the hormone-based medicines; therefore, they have a small contribution to the 
calculated total estrogenic loads. Thus, the estrogen-mediated biological effects of these 
medicines could have serious implications on human health – such as is the likely case for 
breast cancer risk. Hormone-based contraceptives do increase breast cancer risk; however, 
this increase is small and in a population of women that already have a low risk the increase 
in risk from hormone-based contraceptives is often regarded as negligible (Morch, et al., 
2017). On the other hand, postmenopausal women a small increase in risk from HRT 
medicines could translate into a lot more women developing breast cancer. The calculated 
exposures for hormone-based contraceptives presented here clearly demonstrate the 
significant increase in estrogenic potency of blood. This increase likely increases the 
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proliferative power of the circulating xenoestrogen which could arguably drive the promotion 
and progression stages of breast cancer. Indeed, a recent Danish study found that breast 
cancer risk was higher among women who were currently taking or had recently used 
estrogen contraceptives compared to women that had never used them (Morch, et al., 2017). 
However, a definite link between hormone contraceptives and breast cancer still remain to be 
established.  
 
Table 7.30: Comparison of the percentage contribution of xenoestrogens to the daily 
estrogenic loads of women using hormone contraceptives for Group 1 subgroups.  
Participants Average xenoestrogen contribution 
(%) 
WCS xenoestrogen contribution 
(%) 
18-29 96.6 97.1 
30-39 96.5 96.9 
40-49 96.6 96.5 
50-59 99.7 99.7 
60-69 100.0 99.5 
All 96.9 90.6 
 
In addition, HRT medicines increase the total estrogenic load 100-fold compared to hormone-
based contraceptives, ranging from 1.6 x 10-5 – 5.1 x 10-5 M (Table 7.31). Interestingly, but 
not surprisingly, HRT use in this study was limited, with no women from Group 2 using 
these medicines, perhaps on the account of the widespread knowledge about the link between 
HRT use and increased breast cancer risk (Rossouw, et al., 2002). The significant increase in 
total estrogenic load calculated from these studies clearly demonstrates the high potential 
proliferative power of the circulating exogenous estrogens. In contrast to other xenoestrogens 
(e.g. phytoestrogen, parabens, etc.), these medicines are likely to be controlled by estrogen 
feedback mechanisms. This especially applies to HRT medicines which often consist of E2 
isolated from external sources (e.g. equine urine). Therefore, this could reduce the potency of 
these medicines on breast cancer promotion and progression. Conversely, women who 
generally use HRT medicines are postmenopausal; thus, they likely have a low endogenous 
E2 production to begin with. Therefore, the reduction in potency due to estrogen feedback 
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Table 7.31: Percentage contribution of HRT to the total estrogenic load for Group 1. 
 Average % WCS% 
18-29 0.0* 0.0 
30-39 0.0* 0.0 
40-49 99.9+ 99.9 
50-59 100.0# 100.0 
60-69 100.0# 100.0 
All 99.9+ 99.9 
* This age group does not receive HRT; + represents a 1000 fold increase; # the natural 
estrogen levels in this age-group are incredibly low therefore, it was not possible to calculate 
a fold increase. 
 
E2 is classified as a carcinogen by the International Agency for Research on Cancer (IARC). 
It gained this classification based on data that suggest “E2 is a weak carcinogen and mutagen 
capable of inducing genetic lesions with low frequency” (Liehr, 2000). It is thought E2 
initiates tumour formation by the metabolic conversion of E2 to 4-hydroxyestradiol, which is 
further activated by catechol to catechol estrogens which are hydroxyquinones. These can be 
readily oxidised to DNA-reactive semiquinone/quinone intermediates (Fig. 7.9; see Section 
1.5.3.) (Liehr, 2000). Therefore, HRT medicines are essentially a double-edged sword in the 
context of breast cancer development – inducing DNA damage, which is characteristic of the 
initiation stage, and promotion and progression of tumour growth via ER-mediated 
mechanisms. Hence, it is not surprising that women are at a higher risk of developing breast 
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7.4.5. Impact of dietary supplements 
The term ‘dietary supplements’ once analogous with vitamins and minerals, is now used to 
include botanical supplements such as echinacea, various forms of garlic and a variety of 
physiologically active compounds derived from foods or other biological materials. Although 
there has been a worldwide trend of an increase in the prevalence of dietary supplement use 
(Briefel, et al., 2004, MacLennan, et al., 2002, Tindle, et al., 2005), the necessity for, and 
cost and safety of, dietary supplements continues to be debated (Radimer, 2005). The results 
presented here found dietary supplements were commonly used by women, with 37.4% of 
participants taking at least one form of supplement. Interestingly, dietary supplement use 
significantly increased for the older subgroups with over 75% of participants between the 
ages of 40-69 years. In a 2006 New Zealand study on dietary supplement use, 30.5% of 
women and 5.4% of children were taking a dietary supplement (Parnell, et al., 2006). The 
results presented in this chapter are consistent with these findings for women; however, on 
average 20.9% of pre-pubertal girls were found to be taking at least one form of dietary 
supplement (Table 7.32) – almost quadruple of what was reported in the 2006 study. This 
may be a result of multiple variables between the studies including the non-random sampling 
of pre-pubertal girls in this study, dependence on whether their mother was also taking a 
dietary supplement, the time of year the data were collected (e.g. people are more likely to 
take supplements such as vitamin C in the winter), and that only girls were included in this 
study compared to the 2006 study which also included boys.  
 
Table 7.32: Average number of participants whose pre-pubertal daughters are consuming 
dietary supplements from both groups. 
 Range of number of positive 
responses returned (%) 
Average (%) 
0-12 months 0 0.0 
1-3 years 0  0.0 
5-6 years 0 - 50 25.0 
11-14 years 0 - 20 10.0 
Total 11.1 – 30-6 20.9 
 
Interestingly, dietary supplements could be one of the biggest sources of phytoestrogens; 
however, people may not consider them as risk factors for breast cancer. Upon closer analysis 
of the dietary supplements taken by women and pre-pubertal girls in this study, it is clear 
there are a multitude of phytoestrogens present in the dietary supplements (Table 7.33). This 
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presents a very complex picture when considering dietary supplements in the context of total 
estrogenic load, and therefore, attempting to predict total estrogenicity is almost impossible. 
In addition, there is limited information available on the levels of phytoestrogen in dietary 
supplements; therefore, it was not possible to include them in the calculated total estrogenic 
loads. However, when comparing the structures of the potential phytoestrogens in the dietary 
supplements to E2, it is likely that they would elicit an estrogenic effect based of on their 
structure activity relationship (SAR) (Table 7.33). Therefore, dietary supplements are often 
estrogenically active which could potentially contribute to the promotion and progression 
stages of breast cancer; thus, potentially adding to breast cancer risk.  
 
Table 7.33: List of structures of phytoestrogens found in dietary supplements consumed by 
study participants. 
Phytoestrogen Plant source Structure 
b-Sitosterol Evening primrose, 
dong quai, 5 flavour 
berry and goji 
 
Curcumin Tumeric  
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Quercetin Rosehips and ginkgo  
Ellagic acid Rosehips  
Resveratrol* Grape seed oil  
Epigallocatechin 
gallate 
Green tea  
Eriocitrin Lemon 
 
Hesperidin Lemon  
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Tannin Papaya, celery, black 
cohosh and feverfew 
 
Glycyrrhizin Licorice  
Ginsenoside Ginseng  





Catechin Ginkgo  
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Taraxasterol Dandelion  
Calycosin Huang qi  
Ononin Huang qi  
Acetin Huang qi and black 
cohosh 
 
Biochanin A Red clover  
Genistein Soy and red clover  
Daidzein Soy and red clover  
Catapol Rehmannia  
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Isovitexin Vitex (Chase tree)  
Casticin Vitex (Chase tree)  
Enterodiol 5 flavour berry 
(protein powder) 
 
Enterlactone 5 flavour berry 
(protein powder) 
 
* Resveratrol is also found in wine and other foods; however, this table is only considering 
the dietary supplements women in the studies indicated they were taking.  
 
7.4.6. Relationship between Breast Cancer and Xenoestrogen Exposure  
7.4.6.1. Breast Cancer Diagnosis 
In this study of women aged 18-69 from Group 1 (a population-based sample from the 
electoral roll), 6.0% of participants had been diagnosed with breast cancer at the time of the 
study. For the 50-59 and 60-69 subgroups 9.6% of participants had been diagnosed with 
breast cancer at the time of the study. This is not surprising as breast cancer is the most 
prevalent in post-menopausal women. However, 3.9% of the 18-29 and 30-39 subgroups had 
been diagnosed with breast cancer. This equates to 14.3% of the total number of breast cancer 
diagnoses and is above the 6% average number of women diagnosed with breast cancer under 
the age of 40 years in New Zealand. On the other hand, 70%-75% of women diagnosed with 
breast cancer are over the age of 50 years in New Zealand (NZBCF, 2018). The proportion of 
women in this study that were over the age of 50 were 85.7%. Therefore, the distribution of 
women for the under 40-year-old and over 50-year-old women were slightly higher than the 
national averages; however, suggest that both groups were representative of the New Zealand 
population. Women with breast cancer may be over-represented in the study sample because 
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Surprisingly, 32.2% of women from Group 1 had considered xenoestrogens as breast cancer 
risk factors prior to participating in the study; while 44.5% of women with a pre-pubertal 
daughter had considered xenoestrogens as breast cancer risk factors for their daughter (Table 
7.34). It is remarkable that such a high percentage of women had considered xenoestrogens 
as breast cancer risk factors, suggesting that women are much more aware of this potential 
link than anticipated. In general, the percentage of women that had considered xenoestrogens 
as breast cancer risk factors was similar across subgroups; from 35.5% of the 18-29 subgroup 
to 33.3% of the 60-69 subgroup. This is a surprising knowledge but again might reflect their 
interest in the study. Interestingly, the 50-59 subgroup did have a lower awareness, with 
26.7% of the subgroup considering xenoestrogens as breast cancer risk factors.  
 
Table 7.34: Study average of women who had considered xenoestrogens breast cancer risk 
factors for their daughters (Group 1 and 2) prior to participating in the study. 
 Range of number of positive 
responses returned (%) 
Average (%) 
0-12 months 66.7  66.7 
1-3 years 25.0 – 50.0 37.5 
5-6 years 16.7 – 100.0 58.4 
11-14 years 60.0 – 66.7 63.35 
Total 35.3 – 53.7 44.5 
 
7.4.6.3. Elimination of Xenoestrogens from Daily Food and Lifestyle Habits 
Whilst 32.2% of women from Group 1 had considered xenoestrogens as breast cancer risk 
factors, only 30.0% had taken measures to eliminate them from their daily food and lifestyle 
habits. This illustrates that while information may be available to women on xenoestrogens 
and breast cancer risk, it is only as successful as the person who is willing to change their 
lifestyle. Therefore, one could argue that the most important aspect of encouraging women to 
make lifestyle changes, that could reduce their risk of breast cancer, is not only providing 
them with the information but rather creating a positive mindset equipping them to apply this 
information. In this study, the difference between women who had considered xenoestrogens 
as breast cancer risk factors and those that had followed through to eliminate them from their 
daily food and lifestyle habits is approximately 7.0%. This suggests that a majority of women 
are prepared to create changes in their food and lifestyle habits to reduce breast cancer risk, 
which could have a major follow on effect in reducing the breast cancer burden in New 
Zealand.  
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In comparison, 45.9% of women who completed a questionnaire for their pre-pubertal 
daughter had taken steps to eliminate xenoestrogens from her daily food and lifestyle habits 
(Table 7.35). This is an increase in the percentage of women who considered xenoestrogens 
as breast cancer risk factors for their daughter, demonstrating that they may be eliminating 
xenoestrogens (e.g. BPA plastics) for other reasons than breast cancer risk. 
 
Table 7.35: Study average of women who had taken steps to eliminate xeneostrogens from 
their daughter’s (Group 1 and 2) daily food and lifestyle habits prior to participating in the 
study. 
 Range of number of positive 
responses returned (%) 
Average (%) 
0-12 months 66.7 -  66.7 
1-3 years 25.0 -  37.5 
5-6 years 16.7 -  58.4 
11-14 years 60.0 -  63.35 
Total 38.2 -  45.9 
 
Interestingly, when women were asked to specify the measures they had taken to eliminate 
xenoestrogens from their daily habits, almost all women (95%) had eliminated BPA plastics 
and/or paraben containing cosmetics and personal care products. This clearly demonstrates a 
public awareness (e.g. BPA-free containers and paraben-free cosmetics) of the synthetic 
xenoestrogens and potential breast cancer risk; however, very few women (<5%) had 
eliminated natural xenoestrogens (e.g. phytoestrogens). This may be a result of the 
controversial effects of phytoestrogens (e.g. at low concentrations they increase breast cancer 
risk and at high concentrations are protective against breast cancer) or a clear bias of public 
perception towards synthetic chemicals being risker than natural chemicals. Indeed, BPA has 
been specifically regulated in the use of manufacturing babies bottles in many countries 
(Almeida, et al., 2018, JRC/IHCP, 2010); this could have a significant impact on public 
perception of xenoestrogens. Phytoestrogens have unique estrogenic potencies, which makes 
understanding phytoestrogens in a breast cancer risk context incredibly complex – it is not as 
simple as eliminating them from daily food habits. Therefore, it is not surprising women have 
chosen to focus on the synthetic xenoestrogens which appear to be less complex; however, it 
must not be forgotten that the breast cancer risk of the synthetic xenoestrogens can only be 
determined in the context of the total risk of phytoestrogens from food. Thus, an 
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understanding of the dual effects of phytoestrogens is an important in attempting to create 
new strategies for reducing breast cancer risk. 
 
7.4.7. Detection of Xenoestrogens in Group 2 Blood Samples 
This qualitative analysis detected multiple xenoestrogens in the blood from women in Group 
2, clearly showing that the xenoestrogens predicted to be present from the questionnaire 
analysis were found in the blood samples of the participants. The levels of xenoestrogens 
detected were low, characteristic of chronic exposure rather than acute high-level exposures, 
which are often associated with rapid increases and clearance profiles. Logically one would 
expect xenoestrogen exposures to be chronic considering many products which contained 
xenoestrogens are used/consumed daily, if not multiple times a day. Therefore, it is 
reasonable to assume that the exposures to xenoestrogens are chronic and low-level rather 
than an acute exposure (e.g. workplace exposure) (Graham, 2012). For example, studies on 
workplace exposure to BPA in supermarket cashiers clearly demonstrate this characteristic 
acute dosing profile. The workers experience a rapid increase in BPA in their blood when 
they started their shift that rapidly cleared once their shift finished approximately 8 hr later 
(Ndaw, et al., 2016). On the other hand, if the exposure is very frequent, even though the 
half-life of the compound is short, one could get a pseudo-steady state level. However, in this 
study it is much more likely that exposure to xenoestrogens is intermittent which would lead 
to peaks and troughs. This could have affected the detection of some xenoestrogens in the 
samples.   
 
7.4.7.1. BPA 
BPA was not detected in any of the 47 blood samples analysed. This was not unexpected as 
BPA is metabolised very rapidly (~2 hr) (ref), which makes the chances of detection low. In 
addition, BPA has received a lot of negative public attention, leading to a massive reduction 
in the use of BPA containing plastic products. Therefore, in conjunction with the rapid 
metabolism, the lower exposure likely has led to BPA not being detected in the study.   
 
7.4.7.2. Parabens 
Methyl- and butylparaben were the most commonly detected xenoestrogens in the study, with 
100% and 87.2% of samples detecting the parabens, respectively. This finding is not 
surprising, especially for methylparaben (see Section 1.4.3.), given the extensive use of 
parabens in cosmetics and personal care products. In addition, parabens generally have long 
half-lives (approximately 24 h; (Abbas, et al., 2010)) in comparison to other xenoestrogens 
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(e.g. genistein which has a half-life of 8.2 h; (Chang, et al., 2013)). Interestingly, 
methylparaben has been reported to exhibit only a 5% degradation over 24 h in human serum 
(Abbas, et al., 2010). Therefore, the longer half-lives are likely contributing to the common 
detection of methyl and butylparaben. Benzylparaben was only detected in one of the 47 
blood samples (2.1%); however, it is not as commonly used in cosmetics and personal care 
products. Therefore, it is not surprising to find that it was only detected in 2.1% of samples. 
Interestingly, parabens were the second most common xenoestrogen, next to BPA, that 
women eliminated from their daily food and lifestyle habits; however, they were detected in 
every blood sample. This illustrates the persistence of parabens but also the potential gaps in 
knowledge of how widespread paraben use is in personal care products and cosmetics. On the 
other hand, in this thesis butylparaben has been demonstrated to have similar effects to 
phytoestrogens in breast cancer model systems (e.g. MCF-7 and CALUXâ studies); thus, the 
overall estrogenicity of parabens, in particular butylparaben, may not be as potent as it is 
currently considered. This is certainly something to deliberate when attempting to implement 
new breast cancer prevention strategies by changing food and lifestyle habits.  
 
7.4.7.3. Phytoestrogens 
Phytoestrogens are widely distributed in plants and are found in many food plants (e.g. 
cruciferae, such as brussel sprouts, Rosaceae, such as apples). Therefore, it was not 
unexpected that phytoestrogens were the other group of xenoestrogens that were commonly 
detected in the blood samples. Genistein and daidzein were only detected in 34.0% and 
29.8% of the blood samples, respectively. This is surprising given the widespread use of soy 
flour in baked goods (e.g. bread) and cereals (Rudel, et al., 2009) and the relatively long half-
lives of these isoflavones, 8.2 h and 9.5 h (Chang, et al., 2013), respectively. This suggests 
that soy flour is being used less in baked goods or perhaps people are consuming less baked 
foods and cereals for personal health reasons (e.g. for a gluten intolerance or coeliac disease).  
Interestingly, kaempferol was detected in a much high proportion of blood samples (89.4%). 
It is found in a wide variety of foods including apples, grapes, tomatoes, green tea, potatoes, 
onion, broccoli, squash, blackberries, etc (Calderon-Montano, et al., 2011, Kim, et al., 2013, 
Liu, 2013); therefore, it is not surprising to find kaempferol in a majority of samples 
especially given its much shorter half-live (2.8 h; (Wang, et al., 2003)) compared to other 
phytoestrogens. Interestingly, it is estimated that the total average daily intake of kaempferol 
is 3.91 mg (Liu, 2013). Some of the highest kaempferol containing foods include radish (32.3 
mg/kg) and peas (62.8 mg/kg) (Cao, et al., 2010). Curcumin and tetrahydrocucumin were 
detected in smaller percentages of blood samples, 27.7% and 2.0%, respectively. It was 
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unexpected to find tetrahydrocurcumin as it is one of 5 metabolites of curcumin (Tsuda, 
2018); however, this is an important finding because tetrahydrocurcumin, as shown in 
Chapter 4, has anti-proliferative effects in MCF-7 cells. Because it was only detected in one 
blood sample, the likelihood of women consuming enough turmeric to then have sufficient 
levels of curcumin which then is metabolised to tetrahydrocurcumin is low; therefore, it is 
unlikely that eating turmeric would provide sufficient levels of tetrahydrocurcumin for the 
women in this study to obtain a beneficial effect.  
 
7.4.7.4. Estrogens 
E2 was detected in a high proportion of samples (68%), however, only 40% of the 18-29 
subgroup had detectable levels of E2. This is surprising given the high fluctuating levels (9.9 
x 10-11 – 1.6 x 10-9 M (Elmlinger, et al., 2002)) of E2 during the menstrual cycle in women of 
this age group. In comparison, more women in the 60-69 subgroup had detectable E2 levels, 
even though they have lower circulating E2 levels (0 – 3.7 x 1011 M). This could suggest a 
higher exposure to exogenous E2 from an accumulation of dairy, meat and egg products for 
this subgroup. Indeed, previous studies have reported the presence of estrogens in these 
products (Hu, et al., 2012, Malekinejad, et al., 2015, Shahbazi, et al., 2016). Neither estrone 
nor estriol were detected in any of the 47 blood samples. Again, this is not surprising given 
the lower levels of estrone (2.6 x 10-11 – 7.4 x 10-10 M (Cummings, et al., 1998)) in women, 
which is likely below the limit of detection for the study. Estriol is the primary estrogen 
produced by the placenta during pregnancy; thus, since it was unlikely any of the participants 
were pregnant it was unlikely that estriol would be detected. EE2 was detected in one of the 
samples. This was not surprising given the participant was taking an EE2-containing 
hormone replacement therapy.  
 
7.4.8. Are Xenoestrogens Breast Cancer Risk Factors? 
This human exposure study shows that the predicted xenoestrogens from the questionnaire 
are found in the blood of the participants. The women are clearly exposed to xenoestrogens 
from their daily food and lifestyle habits. Importantly, this study highlights that women are 
not just exposed to one xenoestrogen, but rather to multiple xenoestrogens, with high inter-
individual variability, which illustrates a highly complex xenoestrogen exposure cocktail 
scenario. This complexity makes understanding the xenoestrogen cocktail effect much more 
difficult, especially given the mixed proliferative/anti-proliferative effects of some 
xenoestrogens (e.g. genistein), and an impossibly difficult situation when it comes to 
potentially regulating xenoestrogens.  
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As mentioned above, women are exposed to multiple xenoestrogens. Despite different 
sampling techniques, there was a high degree of commonality between the groups of women, 
and between the women (Group 1) and pre-pubertal girl subgroups; therefore, one may 
expect Canterbury women and pre-pubertal girls to have similar circulating xenoestrogens - 
albeit with inter-individual variability. The estrogenic potency of these circulating 
xenoestrogens could effect the breast cancer promotion and progression stages, with the 
proliferative power of the xenoestrogens driving breast cancer cell growth. Indeed, all the 
xenoestrogens included in this study were previously demonstrated to have ER LBC binding 
capabilities (see Chapter 6); therefore, it would be expected that they would drive 
proliferation which could lead to tumour growth. Thus, based on the calculated xenoestrogen 
exposures and the qualitative blood analyses, Canterbury women could have an increased risk 
of developing breast cancer.   
 
7.5. Concluding Remarks 
Exposure to xenoestrogens is a life-long health risk where the effect may be greater later in 
life because of lower levels of endogenous estrogens and thus, lack of homeostatic control. 
Complex exposures, as demonstrated in this chapter, may play a role in the increase of breast 
cancer incidence, with certain lifetime windows associated with an increase in risk. However, 
simply avoiding xenoestrogens is not necessarily the best way to reduce breast cancer risk. 
Indeed, it is clear that even when women intentionally avoid parabens that methylparaben 
and/or butylparaben are still present in the blood (see Section 7.4.6.2.). On the other hand, 
phytoestrogens have clearly been demonstrated to exert anti-proliferative effects in breast 
cancer cells in this thesis, thus eliminating natural xenoestrogens may be counterintuitive. 
Therefore, much more research is required to truly understand the complexity of 











Chapter 8 Overall Discussion 
 
 
8.1. Overall Discussion  
Since the first inkling that exogenous molecules could interfere with receptor-based sex 
steroid hormone activity in the early 1990’s (Muller, et al., 1995) through to the discovery of 
xenoestrogens in the late 1990’s (Colborn, et al., 1996, Hunter, et al., 1993) and our more 
recent detailed understanding of the complex workings of ERs, many millions of dollars have 
been spent on research to understand the impact on human populations. This represents a 
huge world effort to understand endocrine disruption; in particular estrogen mimicry and its 
impact on ecosystems and humans alike.  These impacts are potentially profound as is 
evidenced by declining human sperm counts around the world (Carlsen, et al., 1992, Levine, 
et al., 2017, Swan, et al., 2000), precocious puberty in girls (Massart, et al., 2006), 
vitellogenin expression in male trout (Kidd, et al., 2007, Sumpter, et al., 1995), disruption of 
breeding cycles in sea bass (Blazer, et al., 2012) and skewed sex ratios in some molluscs 
(Davies, et al., 1997), etc., etc.  
 
As we grapple with the complexity of xenoestrogens’ impact on human populations, it is 
becoming clearer that they might have far reaching effects beyond those originally conceived. 
We now know that E2 is not just a female hormone but plays a key role in growth and 
developmental processes, particularly at the embryonic stage (Stocco, 2012, Vasquez, et al., 
2013). This means that xenoestrogens’ effects are likely to reach beyond control of female 
physiology and biochemistry and extend into growth and developmental phenomena; this 
might have significant implication, in a long-term exposure context, for human growth and 
development and the aetiology of disease. Indeed, xenoestrogens are emerging health risk 
factors; they are being increasing investigated as potential risk factors for developmentally-
based diseases such as breast cancer – the underlying subject of this thesis. 
 
Concerns about the potential for environmental chemicals, drugs, and other stressors to alter 
endocrine physiology have quickly mounted and received a great deal of attention within the 
toxicological community as well as in the public media (Marty, et al., 2011). Xenoestrogens 
have come to the forefront of toxicology over the last 20 years, with prominent government 
and scientific organisations such as the WHO, International Union of Pure and Applied 
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Chemistry (IUPAC) and the US National Research Council reacting to gather 
endocrinologists, toxicologists, and other public health professionals from around the world 
to capture their knowledge and recommend research to address this issue. These efforts are 
documented in a series of comprehensive review papers and reports (Damstra, et al., 2002, 
Lintelmann, et al., 2003, NRC, 1999, UNEP/WHO, 2013), which helped spur on endocrine-
mediated toxicology. The concern at a government level over the possible effects of 
xenoestrogens is also reflected in the millions of dollars allocated by European and American 
agencies to support research on xenoestrogens as endocrine disruptors; for example, $23 M 
by the European Union in 2003 (Lorenz, 2003). Clearly governments are concerned about the 
lasting effects of these chemicals on their populations. This research is wide ranging and 
includes, for example, food safety of phytoestrogens, the screening of many thousands of 
chemicals for estrogenic effects, how these chemicals interact with one another and how they 
influence gene expression. However, the precise impact of xenoestrogens is difficult to 
discern as they can be both beneficial and adverse, producing different effects in different 
tissues at different life stages (Marty, et al., 2011).  
 
The effects of xenoestrogens are not simple. Individual compounds (e.g. genistein) can have 
differential biological effects at different exposure levels; for example, at ‘low’ exposure 
concentrations genistein promotes MCF-7 cell proliferation in culture, whereas at ‘high’ 
concentrations it inhibited growth (see Chapter 4). This means that the effects xenoestrogen 
risk factors are dose dependent and difficult to predict without a significant understanding of 
their complex interactions with ERs’ ligand binding sites. This thesis addresses these issues 
at both the biological activity and in silico-modelled receptor interaction level. 
 
To make the human xenoestrogen exposure scenario even more complex, we are exposed to a 
constant and constantly varying cocktail of xeneoestrogens via food (e.g. genistein in soy), by 
direct interaction with our environment (e.g. pyrethroid pesticide residues) and via personal 
care products (e.g. butylparaben in cosmetics). Since xenoestrogens all interact with the ERs, 
their effects are likely at least additive – this is a major focus of this thesis.  But it is more 
complex than that: some xenoestrogens are ER agonists and other are antagonists, so their 
interactions with biological systems might involve the addition of negative and positive 
effects. One thing is certain, there is well-founded suspicion that xenoestrogens are affecting 




I will attempt to bring this thinking together in this overall discussion, with a view to 
elucidating the bigger picture approach to the effects of xenoestrogens in humans. 
 
8.2 Human exposures to xenoestrogens 
The endocrine system is one of the body’s major homeostatic control systems whose aim is to 
maintain normal functions and development in the face of a constantly changing 
environment. Like all homeostatic control systems, the capacity to maintain physiological 
parameters within normal bounds is finite, and when this capacity is exceeded by chemical 
exposures (e.g. xenoestrogens), adverse consequences can ensue (Marty, et al., 2011). It is 
widely known that humans are continually exposed to xenoestrogens via daily food and 
lifestyle habits (Olea, et al., 1999, Singleton, et al., 2003, Thomson, 2005) which ‘attack’ the 
endocrine system by various mechanisms (see Fig. 4.2). Whilst recognising that there are 
various mechanisms by which environmental compounds might influence the level and 
balance of sex hormones in the body, this thesis focuses on dietary (e.g. natural and 
synthetic) and personal care product (e.g. shampoo) xenoestrogens that are known to bind 
and activate ER via the classical genomic pathway of ligand-dependent activation of the ERs 
(a and b) (Gruber, et al., 2002). Many compounds with in vitro estrogenic activity have been 
detected in a wide range of foods and personal care products. Hence all humans will be 
exposed to xenoestrogens on a daily basis. Naturally occurring xenoestrogens include 
isoflavones (e.g. genistein and daidzein) and the metabolite of daidzein, equol, curcuminoids 
(e.g. curcumin and tetrahydrocurcumin), and the flavonoids (e.g. kaempferol). Exogenous 
estrogens (e.g. natural estrogens found in foods) have also been shown to have estrogenic 
activity including E2, estrone and estriol from dairy products, meat etc. Synthetic compounds 
that have been shown to have estrogenic activity and have been found in food and water 
include industrial chemicals (e.g. BPA), medications (e.g. EE2) and personal care products 
(e.g. methylparaben, butylparaben and benzylparaben) (Caldwell, et al., 2010). 
Xenoestrogens are everywhere. In addition, public perception may present a bias that 
synthetic chemicals are more risky than natural chemicals; the risk of the synthetic 
xenoestrogens can only be determined in the context of the total risk of all xenoestrogens, 
including naturally occurring phytoestrogens.  
In order to understand the magnitude of the human health implications from xenoestrogen 
exposures, we need to know what people are exposed to. Drawing extensively on pre-existing 
data, the risk assessment in this thesis illustrates the extent of xenoestrogen exposures with 
significant inter-individual variability. However, it has also created new knowledge of data 
Overall Discussion 
 276 
gaps, which suggests a more comprehensive ranking of contributing xenoestrogens and an 
estimate of the total level of risk to estrogenic compounds from daily food and lifestyle habits 
is required– this is no small task.  
 
The additive approach taken in this study suggests that combined xenoestrogens from food 
and lifestyle habits could have a significant biological effects, especially when compared 
with the endogenous levels of E2; interestingly, exposures calculated from the Canterbury 
women’s study reported here suggest xenoestrogen exposure could potentially triple the 
circulating levels of estrogenicity for post-menopausal women and pre-pubertal aged girls 
(see Table 7.29) from their daily food and lifestyle choices (Fig. 8.1). The potential tripling of 
the baseline circulating estrogenicity value could mean that, in the context of breast cancer 
cell proliferation, there is three times as much proliferative power. Compared with normal 
circulating estrogen levels this increase in proliferative power is significant and could have a 
pharmacological effect. However, as demonstrated in Chapters 4 and 5, some calculated 
estrogenic loads may have anti-proliferative activity; this suggests that the concept of simple 

































On the other hand, for child bearing age women it is hard to see how an extra 16.9% of 
estrogenicity from food and lifestyle habits could have an effect because a woman’s body is 
physiologically adapted to major cyclic fluctuations of E2 levels during the estrus cycle (Fig. 
8.2). Thus, the contribution from food and lifestyle habits is likely to be small in comparison 
to the level of naturally circulating E2.  
Figure 8.1: The impact of calculated xenoestrogens on the total estrogenic loads 
of pre-pubertal girls (top) and post-menopausal women (bottom). This clearly 
illustrates the significant increase in total estrogenicity by xenoestrogen 
exposures on these populations – this is based on data presented in Chapter 7 







The Canterbury women’s study reported in this thesis represents the diet and life style 
xenoestrogen exposures that Canterbury women would be exposed to on a daily basis. They 
would not be expected to be markedly dissimilar from countries such as the U.S.A and 
Britain so perhaps these data could be extrapolated to these populations; however, it certainly 
would not be similar to people in Africa and most of Asia. As discussed, the diet consists of 
multiple and variable residues over this constitutes a cocktail effect. It’s is the total estrogenic 
intake that causes the biological effect 
 
There is previously published evidence of additivity of effect of low doses of xenoestrogens 
based on experiments using the yeast assay (Payne, et al., 2000, Rajapakse, et al., 2002, 
Silva, et al., 2002) cell proliferation (Rajapakse, et al., 2004) and gene expression assays 
























Figure 8.2: The impact of calculated xenoestrogens on the total estrogenic loads of child 
bearing age women determined from the average E2 levels in a menstrual cycle (blue) (data 
from http://commons.wikimedia.org/wiki/File:Estradiol_during_menstrual_cycle/png) and 
data calculated from 18-29 (red), 30-39 (green), 40-49 (purple), 50-59 (orange) and 60-69 
(black) subgroups. This clearly illustrates that small influence of xenoestrogen exposure on 




estrogenic effects are almost impossible to predict because some xenoestrogens (e.g. 
genistein) have different individual estrogenic effects compared to when they are components 
of mixtures (Gaido, et al., 2003, Rajapakse, et al., 2004). In addition, this estrogenicity may 
vary in different target cells depending on ER isoform expression (Gaido, et al., 2003). 
Indeed, it is clear from the results presented in this thesis that the concept of simple additivity 
is not necessarily the case. For example, the phytoestrogens often had opposing effects as 
seen in CALUXâ (Chapter 5) and MCF-7 studies (Chapter 4). While modelling studies 
(Chapter 6) support binding of xenoestrogens to the LBC, a major finding from my work it is 
clear that they are also able to interact at the AF-2 site. Xenoestrogens have not previously 
been shown to bind to this site, which presents a more complex interaction with the ERs and 
greater uncertainty relating to the overall effect of exposures to xenoestrogen cocktails.  
 
The results presented in Chapters 4 and 5 do not take into account the complexity of the 
potential exposure mixtures reported in the questionnaire and blood analysis studies, thus, 
comparisons between the individual xenoestrogen exposures might shed light on possible 
cocktail effects. Tables 8.1 and 8.2 shows the daily individual xenoestrogen exposures for 
each subgroup of women (Group 1) and pre-pubertal girls in the present study. Table 8.3 
shows the concentrations in MCF-7 studies where an anti-proliferative or proliferative effect 
was observed. Concentrations where a negative effect in the ERa and ERb CALUXâ assays 
was seen are shown in Table 8.4. It is clear from these tables that the xenoestrogen exposure 
concentrations used in MCF-7 and CALUXâ studies were of the same order of magnitude as 
the exposures reported from the questionnaire study; therefore, the responses from the MCF-
7 and CALUXâ studies are likely to be biologically relevant (because they are based on 
intact living cells) and thus, predict the in vivo situation. Furthermore, while the overall 
estrogenic load might have a significant biological effect in some subgroups of women and 
pre-pubertal girls, the exposure concentrations to the individual xenoestrogens could lead to 
quite different effects in vivo. For example, some exposure concentrations would be 
sufficient to reflect the anti-proliferative effects reported in MCF-7 and CALUXâ studies 
(Chapters 4 and 5), while others would reflect the proliferative effects. Whilst some 
xenoestrogen exposures reported from the questionnaire study suggest an anti-proliferative 
biological effect, the assumptions employed (e.g. 100% absorption) when calculating the 
daily exposures might overestimate the total exposure concentration. This overestimation 
would suggest that individual xenoestrogen exposures would not be sufficient to prevent 
proliferation. This will be set in context later in this chapter.  
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Table 8.1: Calculated individual xenoestrogen exposures for the 5 subgroups of women studied. 
 18-29 (M) 30-39 (M) 40-49 (M) 50-59 (M) 60-69 (M) 
Genistein 4.5 x 10-9 1.3 x 10-7 1.26 x 10-7 1.26 x 10-7 2.8 x 10-8 
Estradiol 3.3 x 10-11 1.8 x 10-11 3.2 x 10-11 3.2 x 10-11 3.6 x 10-11 
Estriol 1.9 x 10-11 1.3 x 10-11 1.3 x 10-11 1.3 x 10-11 1.3 x 10-11 
Butylparaben 9.5 x 10-6 9.6 x 10-6 8.9 x 10-6 9.7 x 10-6 7.3 x 10-6 
BPA  1.2 x 10-8 1.2 x 10-8 1.2 x 10-8 1.2 x 10-8 2.9 x 10-9 




Table 8.2: Calculated individual xenoestrogen exposures for the 4 subgroups of pre-pubertal girls studied. 
 0-12 months (M) 1-3 years (M) 5-6 years (M) 11-14 years (M) 
Genistein 6.3 x 10-10 9.8 x 10-7 7.9 x 10-7 1.3 x 10-7 
Estradiol 1.4 x 10-11 9.2 x 10-11 1.0 x 10-10 4.0 x 10-11 
Estriol 1.1 x 10-11 4.5 x 10-11 3.6 x 10-11 2.4 x 10-11 
Butylparaben 3.9 x 10-9 3.0 x 10-8 3.4 x 10-7 2.6 x 10-6 
BPA  1.9 x 10-10 4.8 x 10-9 1.0 x 10-8 1.5 x 10-8 









Table 8.3: Maximum responses for individual xenoestrogens alone and in combination with 
E2 in MCF-7 studies.  
 
Table 8.4: Calculated EC50 values for individual xenoestrogens calculated from data 
collected from the ERa and ERb CALUXâ assays. 
CALUXâ ERa EC50 (M) ERb EC50 (M) 
Genistein 1 x 10-7 1 x 10-8 
E2 1 x 10-10 1 x 10-10 
BPA 1 x 10-6 1 x 10-6 
Butylparaben 1 x 10-6 1 x 10-5 
Methylparaben 1 x 10-6 1 x 10-5 
EE2 1 x 10-12 1 x 10-10 
 
In the Canterbury women’s study, the dose of genistein would not be sufficient to prevent 
breast cancer cell replication in the 18-29 and 60-69 years subgroups, whilst the 30-39, 40-49 
and 50-59 subgroups appear to have a sufficient dose to prevent replication. Interestingly, all 
subgroups of women in the Canterbury women’s study would be exposed to sufficient doses 
of butylparaben to prevent breast cancer cell proliferation. In addition, the exposure 
concentrations for E2, BPA, EE2, Estriol and methylparaben would all be sufficient to induce 
proliferative effects. This is interesting in the context of breast cancer where proliferation of 
transformed cells is crucial to tumour growth. On the other hand, the MCF-7 eight 
component combination study did take into account the complexity of the exposures reported 
in the Canterbury women’s study. The response observed in this experiment clearly shows 
that the proliferative effects of BPA, E2 and EE2 are ameliorated by the anti-proliferative 
effects of genistein, kaempferol, tetrahydrocurcumin, butylparaben and estriol. Therefore, the 
cocktail effect of the calculated xenoestrogen exposures from the Canterbury women’s study 
is likely to be far more complex than just simple additivity. For example, the estrogenic effect 
of xenoestrogen exposure cocktails is related to the identity of the individual components and 
to their exposure concentrations. The biological interaction between xenoestrogens is 
complex– this makes predictions of cocktail effects very difficult.  
 
In addition, the use of hormone contraceptives and HRT significantly increases the overall 
estrogenic load that women are exposed to. The calculated xenoestrogen exposure levels in 
MCF-7 Individual (M) With E2(M) 
Genistein 1 x 10-7 1 x 10-7 
E2 1 x 10-11  
BPA 1 x 10-8 1 x 10-8 
Butylparaben 1 x 10-7.5 1 x 10-7.5 
Estriol 1 x 10-9 1 x 10-11 
EE2 1 x 10-12 1 x 10-11 
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child bearing age women appear to be a ‘drop in the bucket’ compared to the concentrations 
of estrogens in their medications. Therefore, the biological effect of these medicines could 
have serious implications for breast cancer risk. While the pharmaceutical goal of HRT has 
been achieved (i.e. minimising menopausal symptoms), on the other hand there is the 
potential for significant cell-based side effects (e.g. increased breast cancer cell proliferation). 
Indeed, an increase in breast cancer incidence due to the use of hormone replacement 
therapies is well documented (Rossouw, et al., 2002). As a result of this, the use of HRT has 
significantly decreased over the last decade (Antoine, et al., 2014, Canfell, et al., 2008, 
Katalinic, et al., 2009, Lambe, et al., 2010, Park, et al., 2012, Salagame, et al., 2016, Zbuk, et 
al., 2012). Therefore, it is surprising to find that 5.0% of the women in the Canterbury study 
had been prescribed HRT. On the other hand, a recent Danish study also found that the risk of 
breast cancer was higher among women who were currently taking, or had recently used 
hormonal contraceptives compared to women who had never used them (Morch, et al., 2017). 
While Morch et al., (2017) found that the risk increased with longer duration of use, the 
overall risk increase was small (i.e. <5%). When assessing overall estrogenic exposures in 
women prescribed hormone contraceptives it is easy to understand why they might increase 
breast cancer risk. This likely applies to all other xenoestrogens; however, the calculated 
circulating levels of EE2 and E2 in estrogen medications are much higher that endogenous 
circulating E2 concentrations, therefore, the high doses from the medications could outweigh 
the protective effects of some xenoestrogens.  
 
8.3. Understanding the Xenoestrogen Exposure Scenario 
It is clear from the Canterbury women’s exposure study that each woman or pre-pubertal 
daughter is exposed to a complex array of xenoestrogens in their day-to-day lives. To add to 
this complexity, their ‘natural’ circulating E2 levels can vary significantly (Cummings, et al., 
1998, Elmlinger, et al., 2002) depending on the developmental stage, making predicting the 
effects of xenoestrogens exposures very difficult. While a battery of validated assays, both in 
vivo and high-throughput in vitro, have been developed to screen for agonistic and 
antagonistic xenoestrogens, the cost of comprehensively testing the multitude of synthetic 
and natural xenoestrogens to which women might be exposed would be formidable (Falconer, 
et al., 2006), let alone the myriad potential exposure combinations. Over the last decade, 
barely the tip of the iceberg of the potentially estrogenic chemical universe has been tested – 
this would be almost impossible (Birnbaum, 2013, Falconer, et al., 2006). Thus, suffice to 
say that a full xenoestrogen assessment across the plethora of daily chemicals exposures is a 
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daunting prospect. Therefore, computational techniques are becoming increasingly important 
to complement experimental studies. Indeed, I have used in silico modelling in this thesis to 
study complex interactions of xenoestrogen mixtures at ER binding sites with a view to 
predicting biological effects.  
 
In this thesis, rapid in silico screening was used not only to help identify and prioritise which 
xenoestrogens to study, but also to reduce the number of compounds tested. While a number 
of studies have reported models to screen for potential ligands based on docking alone, there 
is still uncertainty whether docking studies adequately represent the in vivo situation 
(Kitchen, et al., 2004, Zhang, et al., 2013).  Therefore, in order to validate the docking 
experiments carried out in this thesis, correlations between theoretical and experimental data 
were determined. For example, correlations between calculated RRD and IFD binding 
energies with the corresponding EC50 values from ERa and ERb CALUXâ assays were 
determined for selected ligands (Chapter 5) (Fig. 8.3). The R2 and P values show a non-linear 
correlation between computational docking and CALUXâ data sets. Therefore, RRD and IFD 
are not good predictors of CALUXâ results and vice versa. As discussed in Chapter 5, some 
CALUXâ data exhibited supramaximal responses, both for individual xenoestrogens and for 
combinations which could explain the correlations. The increase in the maximum response in 
the CALUXâ assay (i.e. supramaximal response) will shift the EC50 value to the right (Fig. 
8.4) which will give artefactually low EC50 values. Thus, this might explain the poor 
correlations between the calculated RRD and IFD binding energies and the corresponding 















































































































Figure 8.3: Correlations for calculated docking scores and CALUXâ EC50 values. A=ERa correlation between RRD 
docking scores and CALUXâ EC50 values; B = ERa correlation between IFD docking scores and CALUXâ EC50 values.   
C = ERb correlation between RRD docking scores and CALUXâ EC50 values. D= ERb correlation between IFD docking 




Figure 8.4: Illustration of supramaximal effects on calculated EC50 values in the ERa 
and ERb CALUXâ assays. 
 
8.4. The Intimate Relationship between Xenoestrogens and ERs 
Decades of research has revealed extraordinary insights into how ERs function - a 
immensely complex picture is emerging. Historically, ERs were thought to be 
standalone transcription factors acting solely through genomic mechanisms that 
impact on nuclear ER function; however, recent research has shown ER activity 
requires the highly co-ordinated accumulation of dozens of coregulatory proteins that 
perform a multitude of functions (e.g. the ability to ‘open’ chromatin, making the 
previously compacted DNA assessible to transcriptional machinery) (Zhou, et al., 
2014). In addition, intracellular concentrations of ERs result in a dynamic balance 
between ER synthesis and ER breakdown/degradation (Glass, et al., 2000, Green, et 
al., 2007). This process requires altered phosphorylation status of ERs and the 
interaction of ERs with several proteins including ubiquitin ligases and ubiquitin 
binding proteins. To add to the complexity, cross-talk between ERs and activated 
growth factor receptors and their downstream kinases (e.g. non-genomic signalling) 
such as the HER2 mediated MAPK pathway, has been shown to play a major role in 
activating ERs. This highly coordinated interplay between genomic and non-genomic 
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signalling pathways plays a crucial role in the processes of cell physiology and 
highlights the role of the intimate intracellular relationship of ER mechanisms of 
action.  
 
The highly coordinated interplay between genomic and non-genomic pathways is 
exploited by xenoestrogens which then exert their estrogenic effects. However, 
xenoestrogens also exhibit concentration-dependent mixed agonist/antagonist effects 
suggesting an even more complex interaction with ERs. Low exposure concentrations 
of some xenoestrogens (e.g. genistein, kaempferol) result in a stimulatory (agonist) 
effect on cell proliferation; however, higher exposure concentrations might result in 
the conversion from agonist to antagonist activity (e.g. inhibition of cell proliferation). 
The two-site binding model could explain this activity, whereby a primary, high 
affinity binding site (e.g. LBC) is responsible for the agonist activity and a secondary, 
low affinity binding site (e.g. AF-2) is responsible for the antagonist activity. This 
model has been proposed previously to explain the mixed agonist/antagonist response 
of the breast cancer drug tamoxifen with studies showing a unified two-site model to 
account for the phenomenon (Jensen, et al., 2004, Kojetin, et al., 2008, Wang, et al., 
2006). Indeed, evidence from in silico studies reported here (Chapter 6) corroborate 
the two-site binding model which is evidenced by high calculated binding energies for 
LBC interactions (e.g. the primary, high affinity site) and low calculated binding 
energies for AF-2 interactions (e.g. the secondary, low affinity site). Therefore, high 
ligand concentration is required to saturate the LBC and allow spill-over to AF-2 and 
initiate conformational change. Thus, with multiple ligands and interacting two 
binding sites to consider, predicting the overall cocktail effect is now even more 
complex. For example, one would need to consider at least three different individual 
binding equilibria from a two component xenoestrogen mixture of E2 and genistein in 
order to begin to predict the biological outcomes of dual interactions with ERs: 1) the 
individual ligand binding equilibria for the LBC; 2) the individual binding 
equilibrium for AF-2; and 3) the individual binding equilibrium between LBC and 
AF-2 (Fig. 4.9). Thus, because E2 binding to the LBC is favoured relative to 
genistein, E2 will outcompete genistein for LBC occupancy; this will increase the free 
genistein concentration, thus, potentially facilitating genistein spill over to AF-2. If 
genistein alone was present in the LBD, since it has a lower LBC binding affinity, a 
higher genistein exposure concentration would be necessary to result in AF-2 spill-
over. Therefore, the higher the LBC ligand binding affinity, the lower the ligand 
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concentration that is required for AF-2 spill over; however, spill over is also 
dependent on AF-2 ligand binding affinities because the higher the AF-2 binding 
affinity the lower the concentration of free xenoestrogens required to bind to the AF-2 
site. This is exemplified by experiments in MCF-7 cells and the ERa and ERb 
CALUXâ assay reported in this thesis in which negative modulatory effects were 
observed on proliferation and luciferase response. Therefore, for a better 
understanding of xenoestrogen cocktail effects, the ratio between AF-2/LBC binding 
energies is crucial. 
 
The LBC/AF-2 binding affinity ratios were determined for ERa from in silico studies 
and compared with the maximum proliferative responses elicited by xenoestrogen 
mixtures in the MCF-7 studies. Excitingly, this illustrates a clear relationship between 
binding energy ratios and MCF-7 cell proliferation. The P value is 0.0008 suggesting 
a statistically significant correlation between the data sets (Fig. 8.5). This supports the 
hypothesis that LBC/AF-2 interplay is a key facet of the biological outcomes of 
exposures to xenoestrogen cocktails. The interactions and interplay between binding 
sites could have significant biological implications and be important in drug 
development approaches involving designing small molecules to target AF-2 directly 





8.5. Biological Consequences of Xenoestrogen/AF-2 
Interactions  
The implications of xenoestrogen interactions at AF-2 could have significant impact 
on ER-mediated genomic and non-genomic mechanisms in the breast. In ER+ve 
breast cancer the presence of E2, and subsequently exposure to xenoestrogens, 
provides ‘permission’ for the cell to proliferate (Goodsell, 2002); however, at high 
concentrations some xenoestrogens (e.g. genistein) could rescind this permission by 
augmenting the reception of the message, e.g. via its interaction with AF-2. These 
AF-2 interactions could have numerous downstream effects on estrogen-related 
biological outcomes which can impact the way breast cancer cells functions (Fig. 8.6). 
For example, in an ER+ve breast cancer cell, ERa is highly expressed while ERb has 
a significantly lower level of expression (Lim, et al., 2016). Increasing the ERa/ERb 
ratio amplifies ERa-mediated cellular signalling (e.g. cell cycle progression); 
however, if a xenoestrogen interacts with the ERa AF-2 site it might block the 
reception of this signal, rendering it invalid. This would result in an inhibitory effect 
on ERa-mediated cellular functions, ultimately leading to overall anti-proliferative 



















Figure 8.5: Correlation for the calculated LBC/AF-2 ratio and the maximum 
proliferative response in MCF-7 studies. 
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effects. Indeed, this was observed in the MCF-7 cell studies reported in this thesis 
where some xenoestrogens showed concentration-dependent anti-proliferative effects. 
There are a number of explanations for the anti-proliferative effects induced by 
xenoestrogens, including crosstalk between genomic and non-genomic signalling 
pathways, ERb antagonism of ERa-mediated responses, and recruitment and 
availability of coregulatory proteins. However, the anti-proliferative effects could also 
be a result of LBC/AF-2 interplay. Indeed, the general consensus of opinion re the 
mechanism of mixed agonist/antagonist effects is that it is a result of ERb preferential 
binding (Lecomte et al., 2017) and its subsequent modulatory effect on ERa. 
Interestingly, the MCF-7 and ERa CALUXâ xenoestrogen exposure studies reported 
here both illustrate the modulatory effects of some xenoestrogens; however, ERb is 
not expressed in the ERa CALUXâ cell line. This suggests that the modulatory 
effects by some xenoestrogens in both studies is not a result of ERb control of ERa 
and eliminates the possibility of ERb modulating ERa-mediated actions in MCF-7 
cells. It also highlights the importance of ERa and ERb ratios in breast cancer. 
Indeed, it is well documented that the ERa/ERb ratio in breast cancer is much higher 
than in normal breast tissue due to dysregulation of ERa and lower expression of 
ERb Kim et al., 2012; Leung et al., 2012; Roger et al., 2001). Therefore, AF-2 
interactions could downregulate ERa-mediated cell signalling, resulting in an 
apparently lower ERa/ERb ratio. The apparent lowering of the ERa/ERb ratio due to 
interactions with AF-2 could restore apparently ‘normal’ function to the breast cancer 
cell; e.g. ERb-mediated control of ERa cell signalling.  
 
On the other hand, it has also been suggested that the recruitment and availability of 
co-regulatory proteins might provide an explanation for the unique mixed 
agonist/antagonist effects of some xenoestrogens. While it has been shown that 
xenoestrogens do recruit different co-activators (Kraichely, et al., 2000, Nishikawa, et 
al., 1999, Paige, et al., 1999, Parker, et al., 2000, Routledge, et al., 2000, Wong, et 
al., 2001), the mechanism of interference is likely more complex, with xenoestrogens 
blocking the assembly of coregulatory protein complexes on the DNA rather than 
differential recruitment alone. Interfering with co-regulatory protein assembly could 
affect transcription and epigenetic mechanisms elicited by ERs resulting in the same 
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effects observed in MCF-7 and CALUXâ studies. This could also be a result of AF-2 
























Figure 8.6: Different ways in which xenoestrogens might alter ER mechanisms of action via 
AF-2 site binding. 1) Modulation of growth factor receptors that ultimately activate gene 
transcription that lead to regulation of apoptosis and the cell cycle. 2) Modulating cell 
signalling pathways that can be activated by cytoplasmic ERs, ultimately leading to changes 
in the regulation of apoptosis and the cell cycle. 3) Modulating cell signalling pathways that 
result in phosphorylation of ERs. 4) Disruption of co-regulatory protein complex formation, 
inducing alterations of epigenetic signals and/or ER degradation. 5) Epigenetic alterations in 
DNA and histone proteins that induce alterations in ER-mediated transcription. 6) 
Inhibiting/stimulating transcription of genes regulating apoptosis and the cell cycle. 
(Elements of this diagram were derived from (Spencer, 2016, Zhou, et al., 2014). The 





While this is the first report that the mechanism of a possible two-site model is used to 
explain such effects, a number of studies have reported non-genomic signalling 
pathways changes that would be expected by such interaction. For example, high 
concentrations of genistein were found to increase the phosphorylation of p38 (Shim, 
et al., 2007), increase the Bax/Bcl-2 ratio (Prietsch, et al., 2014), cause a G2/M phase 
cell cycle arrest so decreasing the duration of the proliferative S-phase (Chen, et al., 
2003), and inhibit the activation of the IGR-1R/AKT and MAPK signalling pathways 
(Uifalean, et al., 2016). Interestingly, Uifalean et al., (2015) reported that low 
exposure levels of genistein in MCF-7 culture experiments resulted in a prolfierative 
effect, akin to E2, by activating IGR-1R/AKT and MAPK signalling pathways. 
Similar effects have been found in cultured MCF-7 cells exposed to curcumin and 
tetrahydrocurcumin where an increase in Bax/Bcl-2 ratio and cell cycle arrest at the 
G0/G1 phase was observed (Han, et al., 2016, Lv, et al., 2014, Patel, et al., 2015). 
Published studies measured biological endpoints (e.g. Bax/Bcl-2) and, therefore, do 
not necessarily explain the mechanism of the underlying gene regulatory changes. 
AF-2 interactions may well be the pivotal to understanding the role of ER in these 
cell-signalling pathways because of the key role that AF-2 plays in ER-mediated 
biological control. 
 
8.6. How could AF-2 Ligand Interactions be Utilised to Treat 
Breast Cancer? 
Current breast cancer drug development strategies focus on developing small 
molecules that bind to the ER LBC. However, with a better understanding of ligand 
binding characteristics and the role of AF-2, perhaps in the future, AF-2 targeted 
drugs are likely to be important. Indeed tamoxifen, which was designed to bind to the 
LBC, also binds to the AF-2 site (Wang, et al., 2006). For many years tamoxifen, and 
other type I anti-estrogens (e.g. raloxifene), were noted to exhibit unusual 
concentration-dependent mixed agonist/antagonist activity in cultured breast cancer 
cells (e.g. MCF-7). These studies and others led to the proposal of a two-site binding 
model to account for this unusual activity (Jensen, et al., 2004), where the occupancy 
of the LBC relates to agonist activity and occupancy of the AF-2 relates to antagonist 
activity (Kojetin, et al., 2008). The same mixed agonist/antagonist effects were seen 
in the xenoestrogen exposure studies reported here. This suggests that, like tamoxifen, 
some xenoestrogens elicit their antagonist effects via the AF-2 site. Therefore, with an 
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increased understanding of xenoestrogen/AF-2 interactions this knowledge could be 
utilised in drug development strategies. 
 
The introduction and widespread use of tamoxifen in the post-menopausal population 
has resulted in significant improvements in the survival of women with ER+ve breast 
cancer (Dowsett, et al., 2015). It is estimated that almost half a million women in the 
UK are alive today because of the use of tamoxifen in the treatment of ER+ve breast 
cancer (Jordan, 2003). Therefore, ER directed therapies represent an important and 
successful cornerstone strategy in the management of ER+ve breast cancer (Lim, et 
al., 2016). However, approximately 30% of patients experience relapse due to 
inherent or acquired resistance to tamoxifen (Lonning, 2000). Still their increased life 
expectancy prior to relapse is significant. 
 
On the other hand, multi-pronged treatments such as aromatase inhibitors to reduce 
E2 biosynthesis with tamoxifen which inhibits the effects of E2 at the ER have been 
introduced. In addition, development of the potent ER antagonist fulvestrant has led to 
stepwise improvements in disease control and outcomes for women with metastatic 
disease (Mehta, et al., 2012, Robertson, et al., 2012). However, breast cancer cells 
circumvent either ER blocking (e.g. following treatment with tamoxifen), low levels 
of ER activity (e.g. following treatment with fulvestrant) or low levels of E2 
(following treatment with aromatase inhibitors) often leading to unresponsive 
metastatic breast cancer. Therefore, it is not surprising that a 3rd line of therapies has 
been introduced. For example, alternative target therapies have recently been used in 
combination with ER-directed therapies to improve survival outcomes.  This 
represents a major advance in the treatment options for patients with ER+ve 
metastatic disease. These third line therapeutics include drugs that target the PI3K cell 
signalling pathway such as everolimus, which is an inhibitor of mTOR downstream of 
PI3K (Bachelot, et al., 2012, Baselga, et al., 2012, Piccart, et al., 2014). There is no 
question about the efficacy of these therapies and the impact they have had on the 
global breast cancer burden, but perhaps we should question the dogma of developing 
more and better LBC antagonists augmented with biochemical means of minimising 




8.7. Breast Cancer Prevention 
The human breast harbours one of the most significant cancers in the world, affecting 
up to one out of eight women. An estimated 1 million people worldwide will be 
identified yearly and about 500,000 new and existing patients worldwide will die 
(WHO, 2013). Currently, the most important determinant of breast cancer treatment 
success is early detection. Late detection significantly reduces treatment success 
because of the potential of metastasis, even though a multitude of treatment regimens 
are available (e.g. surgery, hormone therapy). Once the disease becomes 
disseminated, cure is not possible; although long survivals are well documented. With 
the continuous global escalation in incidence, and the economical limitations of 
progress, there is still risk that overall mortality might increase in the future. Clearly, 
there is an urgent need to slow the incidence rates by affordable means.  
 
While early detection and effective treatments have reduced the global breast cancer 
burden, prevention is an important strategy to minimise the burden further. Prevention 
relies on understanding and identifying breast cancer risk factors. The currently 
acknowledged breast cancer risk factors are genetics, age, lifestyle and age of parity. 
Perhaps we should focus on lifestyle risk as a means of further reducing burden. 
Lifestyle risk include diet, alcohol consumption, exercise, etc (Hiatt, et al., 2018). 
Understanding dietary risk factors better might present a means of reducing risk.  
 
The well documented relationship between phytoestrogen consumption and breast 
cancer risk has fuelled the widespread belief that some xenoestrogens can reduce 
breast cancer risk (Bilal, et al., 2014, Gikas, et al., 2005, Pelekanou, et al., 2011). 
Results presented in this thesis clearly support this argument and suggest a 
concentration dependent protective effect elicited by the phytoestrogens studied, 
along with the anti-microbial agent butylparaben and the endogenous estrogen, estriol. 
The possibility of the proposed two-site binding model could provide new 
opportunities in preventative therapies which aim to target AF-2 site binding, 
exploiting the intricate ER control mechanisms. The dysregulation of ERa expression 
is a hallmark of breast cancer (Lim, et al., 2016); thus, if xenoestrogens were able to 
target the ER, preventing the dysregulation of ERa and maintaining the ERa/ERb 
ratio control, they could be a prime candidate for preventative drug therapies. On the 
other hand, due to the prevalence of xenoestrogens in food and the environment 
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women could simply employ lifestyle changes that might reduce their breast cancer 
risk. For example, increasing their vegetable consumption (many vegetables contain 
estrogenic flavonoids, e.g. isoflavones) and reducing the use of plastic (many 
plasticisers are estrogenic, e.g. BPA from polycarbonates) in their households. 
However, as simple as this might sound, there are many complicating factors because 
of the uniqueness of individuals exposure scenarios. This would mean that a risk 
factor-based prevention strategy would have to be personalised.  
 
8.8. A Role for Regulation? 
One of the most difficult problems related to xenoestrogens is establishing risk 
assessment strategies for potential adverse effects on human health. Toxicological 
assessments take into considerations both the biologic potency (in a negative sense, 
e.g. NOAEL) of a chemical as well as possible or known exposure scenarios. For 
xenoestrogens, there are many complicating factors with respect to differential 
toxicity in relation to gender, age and period of development - this is further 
complicated by differences in ER isoform expressions in developmental stages 
(Singleton, et al., 2003). In addition, recently described non-genomic effects of E2 
could provide mechanisms for xenoestrogen action at concentrations several orders of 
magnitude lower than those required for its genomic modes of action. However, cause 
affect relationships between xenoestrogens and breast cancer have not been 
established. Furthermore, it must be realised that the estrogenicity of a chemical does 
not necessarily equate to breast cancer development (Xu, et al., 2008), which is 
reflected by the significant dietary consumption of phytoestrogens and their apparent 
beneficial effects. This poses a conundrum for regulators where classically regulation 
of chemicals is limited by the maximum exposure effect (i.e. NOAEL); however, in 
the case of phytoestrogens the inverse is true. Phytoestrogens clearly have a minimum 
exposure concentration which leads to the anti-proliferative effects; therefore, 
regulators would need to consider the minimum exposure concentration in order to 
determine the beneficial effects. Nevertheless, because of the presence of some 
xenoestrogens in food and the environment, the high potential for human exposure, 
and their accumulation in biological matrices, it is crucial to understand their modes 
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Appendix 1: Results of Individual and 2 Component 
Combinations of Xenoestrogens in the ERa CALUXâ Assay 
not Included in Chapter 5. Results are Presented using Non-
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BPA + EE2 ERα
BPA    
EE2
BPA + EE2  
BPA + EE2 predicted 















BPA + Butylparaben ERα
BPA    
Butylparaben
BPA + Butylparaben 



















Methylparaben + EE2 ERα
Methylparaben
EE2
Methylparaben + EE2  
Methylparaben + EE2 
predicted 



















Butylparaben   
Methylparaben + 
Butylparaben predicted


















BPA    
Methylparaben + BPA  
Methylparaben + BPA 
predicted
















Butylparaben + EE2 ERα
Butylparaben
EE2
Butylparaben + EE2  



































Butylparaben + BPA ERα
Butylparaben
BPA    
Butylparaben + BPA  
Butylparaben + BPA 
predicted














Butylparaben + Methylparaben ERα
Butylparaben





























Appendix 2: Results of Individual and 2 Component 
Combinations of Xenoestrogens in the ERb CALUXâ Assay not 
Included in Chapter 5. Results are Presented using Non-linear 













































E2 + EE2 predicted



















E2 + Butylparaben 
predicted 




















E2 + Methylparaben 
predicted














EE2 + BPA ERβ
EE2
BPA    
EE2 + BPA


















EE2 + Methylparaben ERβ
EE2
Methylparaben    
EE2 + Methylparaben
EE2 + Methylparaben 
predicted 














Genistein + EE2 ERβ
Genistein    
EE2
Genistein + EE2  
Genistein + EE2 predicted 



















EE2 + Butylparaben 
predicted














Genistein + Methylparaben ERβ
Genistein    
Methylparaben
Genistein + Methylparaben 



















Genistein + Butylparaben ERβ
Genistein    
Butylparaben
Genistein + Butylparaben
Genistein + Butylparaben 
predicted 
















BPA + Methylparaben ERβ
BPA    
Methylparaben
BPA + Methylparaben 
BPA + Methylparaben 
predicted















BPA + EE2 ERβ
BPA    
EE2
BPA + EE2  
BPA + EE2 predicted 















BPA + Butylparaben ERβ
BPA    
Butylparaben
BPA + Butylparaben 




















Methylparaben + EE2 ERβ
Methylparaben
EE2
Methylparaben + EE2  
Methylparaben + EE2 
predicted 



















Butylparaben   
Methylparaben + 
Butylparaben predicted
















Methylparaben + BPA ERβ
Methylparaben


















Butylparaben + EE2 ERβ
Butylparaben   
EE2
Butylparaben + EE2  


































Butylparaben + BPA ERβ
Butylparaben   
BPA
Butylparaben + BPA  
Butylparaben + BPA 
predicted














Butylparaben + Methylparaben ERβ






























Appendix 3: Results of 3 Component Combinations of 
Xenoestrogens in the ERa and ERb CALUXâ Assay not 
Included in Chapter 5. Results are Presented using Non-linear 











































EE2 + Combination 1 ERα
EE2
Genistein    


















BPA + Combination 1 ERα
BPA    


















Genistein + Combination 1 ERα
Genistein    


















Methylparaben + Combination 1 ERα
Methylparaben
Genistein    












































BPA + Combination 2 ERα




















Genistein + Combination 2 ERα












































EE2 + Combination ERβ
EE2
BPA    


















BPA + Combination 1 ERβ
BPA    


















Genistein + Combination 1 ERβ
Genistein    


















Methylparaben + Combination 1 ERβ
Methylparaben













































BPA + Combination 2 ERβ




















Genistein + Combination 2 ERβ



















































Appendix 4: List of References for Experimental Binding 






























(Lambrinidis, et al., 2006) 
(Lemini, et al., 2003) 
(Okubo, et al., 2001) 
(Muthyala, et al., 2004) 
(Rich, et al., 2002) 
(Kuiper, et al., 1997) 
(Kuiper, et al., 1998) 
(Waller, et al., 1996) 
(Mueller, et al., 2004) 
(Mueller, et al., 2003) 
(Blair, et al., 2000) 
(Morohoshi, et al., 2005) 
(Zhu, et al., 2006) 
(Wolohan, et al., 2004) 

























































Appendix 5: List of References for Xenoestrogen Concentration 


































(Fukutake, et al., 1996) 
(Guo, et al., 2014) 
(Guo, et al., 2014) 
(Malekinejad, et al., 2015) 
(Kuhnle, et al., 2009) 
(Handa, et al., 2009) 
(Le, et al., 2008) 
(Kubwabo, et al., 2009) 
(Nerin, et al., 2003) 
(Prabhakaran, et al., 2005) 
(Aslam, et al., 2013) 
(GolKhoo, et al., 2008) 
(Carmichael, et al., 2011) 

























































Appendix 6: Information Sheets, Consent Forms, Food and 
Lifestyle Questionnaire and Daughter’s Food and Lifestyle 
Questionnaire for Women Participating in the Questionnaire and 

























Department of Chemistry 
Telephone: +64 3 369 3100 





The Role of Xenoestrogen Combinations as Breast Cancer Risk 
Factors 
Information Sheet for Questionnaire Participants 
 
You are invited to participate in a research project studying daily exposure to 
compounds called environmental estrogens (xenoestrogens). Your participation is 
entirely voluntary (your choice). You do not have to take part in this study.  
 
Motivation for the Study 
 
There are many compounds in our food and the environment that mimic the natural 
female hormone estrogen. These mimicking compounds are sometimes known as 
xenoestrogens and people are exposed to them in their day-to-day lives. It is thought 
that humans could be exposed to many different combinations of these compounds, 
where the total exposure may be much higher than anticipated by regulatory 
authorities. If this is the case, then these compounds may be important in 
understanding diseases such as breast cancer. Therefore, in this preliminary study we 
are trying to determine the different combinations of xenoestrogens you may be 
exposed to in your day-to-day life and whether this is linked to the levels found in 





If you consent, your participation will be asked in the following:  
 
1. Filling out the questionnaire* about your food and lifestyle habits. The 
questionnaire will take no longer than 15 minutes to complete.  
2. Filling out the questionnaire about your daughters’ food and lifestyle habits on 
her behalf. We ask that you only fill out this questionnaire* if you have a 
daughter and if she has NOT had her first period. If you have more than one 
daughter, please only fill out the questionnaire for your oldest daughter that has 
NOT had her first period. This questionnaire will take no longer than 15 minutes 
to complete.  
3. Please enclose the signed consent form when you return the questionnaire/s. 
 
 
We would appreciate it if you would complete the consent form attached to this 
information sheet if you are willing to participate in the study. You may keep this 
information sheet for future reference.  
 
*We have included an online option for the questionnaire. Please type the following 
links into your search engine and complete the questionnaire on there. Your food and 
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lifestyle habits questionnaire: http://bit.ly/2n2iSmo and your daughter’s food and 
lifestyle habits questionnaire: http://bit.ly/2nxGKuj. 
 
 
If you at any time wish to withdraw yourself or your daughter from the study you can 
contact the researcher Samantha Dudley, Department of Chemistry, University of 
Canterbury (email: samantha.dudley@pg.canterbury.ac.nz; phone: +64 3 364 6872). 
Once you have requested to withdraw, all the relevant information pertaining to your, 
and if applicable your daughter’s, involvement will be destroyed within 24 hours. If 
you decide to to withdraw from the study after your information has been collected, I 
will remove all information relating to you from my files. However, once your 
information has been combined with data from other study participants, the 
information cannot be removed because it is not identifiable.  
 
The Study 
This study is being conducted by the University of Canterbury, Department of 
Chemistry with the co-operation of the University of Canterbury Health Centre and 
ESR.  
 
The project is being carried out as a requirement of the degree of Doctor of 
Philosophy in Biochemistry by Samantha Dudley under the supervision of Prof. Ian 
Shaw and Prof. Ann Richardson who can be contacted at ian.shaw@canterbury.ac.nz 
& ann.richardson@canterbury.ac.nz. They will be pleased to discuss any concerns 
you may have about participation in the project. 
 
The results of this project may be published in scientific literature, but you may be 
assured of complete confidentiality of information gathered in the study. No 
individual will be identified in any report or publication arising from this research.   
Only the researcher and named supervisors will have access to the data. Completed 
questionnaires will be stored securely in a cabinet with a lock and all electronic data 
will be stored in a password protected computer. The data will be destroyed after 10 
years following the completion of my PhD. A thesis is a public document and will be 
available through the University of Canterbury Library. Alternatively, you may 
receive a copy of the project results by contacting the researcher at the conclusion of 
the project.  
 
This project has been reviewed and approved by the University of Canterbury Human 
Ethics Committee. Participants should address any complaints to The Chair, Human 












Department of Chemistry 
Telephone: +64 3 364 6872 





The Role of Xenoestrogen Combinations as Breast Cancer Risk 
Factors 
Information Sheet for Questionnaire and Blood Analysis Participants 
 
You are invited to participate in a research project studying daily exposure to 
compounds called environmental estrogens (xenoestrogens). Your participation is 
entirely voluntary (your choice). You do not have to take part in this study.  
 
Motivation for the Study 
 
There are many compounds in our food and the environment that mimic the natural 
female hormone estrogen. These mimicking compounds are sometimes known as 
xenoestrogens and people are exposed to them in their day-to-day lives. It is thought 
that humans could be exposed to many different combinations of these compounds, 
where the total exposure may be much higher than anticipated by regulatory 
authorities. If this is the case, then these compounds may be important in 
understanding diseases such as breast cancer. Therefore, in this preliminary study we 
are trying to determine the different combinations of xenoestrogens you may be 
exposed to in your day-to-day life and whether this is linked to the levels found in 





If you consent, your participation will be asked in the following:  
 
4. Filling out the questionnaire about your food and lifestyle habits. The 
questionnaire will take no longer than 15 minutes to complete.  
5. To donate a 20 mL sample. This will be used for the purposes of identifying the 
levels of xenoestrogens in your blood. In the performance of the venipuncture, 
there are risks of fainting or feeling light-headed and multiple punctures to 
locate the veins. A standard blood test is a well-established procedure and these 
risks are extremely rare.  
6. Filling out the questionnaire about your daughters’ food and lifestyle habits on 
her behalf. We ask that you only fill out this questionnaire if you have a daughter 
and if she has NOT had her first period. If you have more than one daughter, 
please only fill out the questionnaire for your oldest daughter that has NOT had 





We would appreciate it if you would complete the consent form attached to this 
information sheet if you are willing to participate in the study. You may keep this 
information sheet for future reference.  
If you would like any left-over blood to either be returned to you after the study or 
disposed of with a karakia, please tick the appropriate box on the consent form.  
 
If you at any time wish to withdraw yourself or your daughter from the study you can 
contact the researcher Samantha Dudley, Department of Chemistry, University of 
Canterbury (email: samantha.dudley@pg.canterbury.ac.nz; phone: +64 3 364 6872). 
Once you have requested to withdraw, all the relevant information pertaining to your, 
and if applicable your daughter’s, involvement will be destroyed within 24 hours. If 
you decide to to withdraw from the study after your information has been collected, I 
will remove all information relating to you from my files. However, once your 
information has been combined with data from other study participants, the 




This study is being conducted by the University of Canterbury, Department of 
Chemistry with the co-operation of the University of Canterbury Health Center and 
ESR.  
 
The project is being carried out as a requirement of the degree of Doctor of 
Philosophy in Biochemistry by Samantha Dudley under the supervision of Prof. Ian 
Shaw and Prof. Ann Richardson who can be contacted at ian.shaw@canterbury.ac.nz 
& ann.richardson@canterbury.ac.nz. They will be pleased to discuss any concerns 
you may have about participation in the project. 
 
The results of this project may be published in scientific literature, but you may be 
assured of complete confidentiality of information gathered in the study. No 
individual will be identified in any report or publication arising from this research.   
Only the researcher and named supervisors will have access to the data. Completed 
questionnaires will be stored securely in a cabinet with a lock and all electronic data 
will be stored in a password protected computer. The data will be destroyed after 10 
years following the completion of my PhD. A thesis is a public document and will be 
available through the University of Canterbury Library. Alternatively, you may 
receive a copy of the project results by contacting the researcher at the conclusion of 
the project.  
 
This project has been reviewed and approved by the University of Canterbury Human 
Ethics Committee. Participants should address any complaints to The Chair, Human 











Department of Chemistry 
Telephone: +64 3 369 3100 




The Role of Xenoestrogen Combinations as Breast Cancer Risk 
Factors 
Consent Form for Questionnaire  
 
I……………………………………….. consent to the information provided by me 
about myself, and if applicable my daughter, to be used in this study. I understand 
what is required of me and that my participation is voluntary.  
 
I understand that if I choose to complete the questionnaire online, pressing the submit 
button is equivalent to signing this consent form. I am consenting to the data provided 
by me to be used in the study for the purposes outlined in the information sheet. 
 
I understand that the data obtained from the studies of my questionnaire will be 
confidential and all reports written utilizing the data will not include my name or any 
other information that would identify my daughter or myself.  
 
All personal information relating to the information provided will be kept confidential 
and not disclosed to anyone outside the researcher and nominated supervisors. All 
data will be stored for 10-years in a locked facility.  
 
I understand that at any time if I wish to withdraw myself or my daughter from the 
study I can contact the researcher Samantha Dudley, Department of Chemistry, 
University of Canterbury (email: samantha.dudley@pg.canterbury.ac.nz; phone: +64 
3 369 3100). Once you have requested to withdraw, all the relevant information 
pertaining to your, and if applicable your daughter’s, involvement will be destroyed 
within 24 hours. If you decide to withdraw from the study after your information has 
been collected, your information will be removed from the files. However, once your 
information has been combined with data from other study participants, the 
information cannot be removed because it is not identifiable. 
 
If you would like a copy of the final report of the findings, please tick this box  
 
I understand that I can contact the researcher Samantha Dudley, Department of 
Chemistry, University of Canterbury (email: samantha.dudley@pg.canterbury.ac.nz; 
phone: +64 3 369 3100) or supervisors Prof. Ian Shaw and Prof. Ann Richardson 
(email: ian.shaw@canterbury.ac.nz & ann.richardson@canterbury.ac.nz; phone: +64 
3 369 4302 & +64 3 369 3520) for further information. If I have any complaints, I can 
contact the Chair of the University of Canterbury Human Ethics Committee, Private 








Department of Chemistry 
Telephone: +64 3 364 6872 




The Role of Xenoestrogen Combinations as Breast Cancer Risk 
Factors 
Consent Form for Questionnaire and Blood Analysis 
 
I……………………………………………consent to a 20 mL blood sample being 
taken from a vein in my arm and that the blood can be used to measure estrogens and 
estrogen mimicking compounds. I also consent to the information provided by me 
either about myself and if applicable my daughter to be used in this study.  
 
The risks associated with the taking a blood sample are very low, but I accept these as 
part of my involvement in the study. 
 
I understand that the data obtained from the studies of my questionnaire and blood 
will be confidential and all reports written utilizing the data will not include my name 
or any other information that would identify myself.  
 
All personal information relating linked to the information provided and sample I give 
will be kept confidential and not disclosed to anyone outside the researcher and 
nominated supervisors. All data will be stored for 10-years in a locked facility.  
 
I understand that at any time if I wish to withdraw myself or my daughter from the 
study I can contact the researcher Samantha Dudley, Department of Chemistry, 
University of Canterbury (email: samantha.dudley@pg.canterbury.ac.nz; phone: +64 
3 364 6872). Once you have requested to withdraw, all the relevant information 
pertaining to your, and if applicable your daughter’s, involvement will be destroyed 
within 24 hours. If you decide to withdraw from the study after your information has 
been collected, your information will be removed from the files. However, once your 
information has been combined with data from other study participants, the 
information cannot be removed because it is not identifiable.  
 
If you would like a copy of the final report of the findings please tick this box          
If you would like any left-over blood disposed with a karakia please tick this box    
If you would like any left-over blood returned after the study please tick this box   
 
I understand that I can contact the researcher Samantha Dudley, Department of 
Chemistry, University of Canterbury (email: samantha.dudley@pg.canterbury.ac.nz; 
phone: +64 3 364 6872) or supervisors Prof. Ian Shaw and Prof. Ann Richardson 
(email: ian.shaw@canterbury.ac.nz & ann.richardson@canterbury.ac.nz; phone: +64 
3 364 3105 & +64 3 369 3520) for further information. If I have any complaints, I can 
contact the Chair of the University of Canterbury Human Ethics Committee, Private 






Questionnaire about your Food and Lifestyle Habits 
 
Xenoestrogens can be found in food (e.g. bread), plastics (e.g. wine bottle caps, 
plastic containers), personal care products (e.g. make-up) and some medicines. The 
combinations of these compounds that humans are exposed to on a daily basis could 
have some long term health effects. The information you provide in this questionnaire 
will be used to understand the different combinations of xenoestrogens and to 
calculate the total estrogenic load people are being exposed on a daily basis.  
 
Name:  ______________________________________ 
 
Date of Birth: ____________ 
 
 




1. How many slices of bread do you usually eat per day? 
 
  less than 1 per day 
  1 slice per day 
  2 slices per day 
  3 slices per day 
  4 slices per day 
  5 slices per day 
  6 or more slices per day (please specify) ________ 
  I don’t know or I’d prefer not to answer 
 
2. What sort of bread do you most frequently eat? If you eat speciality bread (e.g. 
ciabatta) please include it in the other section. 
 
  I don’t eat bread 
  white bread 
  wholemeal bread 
  multigrain bread 
  soy and linseed-containing bread (e.g. Vogel’s soy and linseed) 
  other (please specify) _________________________________ 
  I don’t know or I’d prefer not to answer 
 
3. How often do you eat soy based products (e.g. tofu, soy yogurt, etc.)? 
 
  I don’t eat soy based products 
  less than once a week 
  1-2 times a week 
  3-4 times a week 
  5-6 times a week 
  once a day  
  2 or more times a day 





4. How often do you eat fresh eggs (e.g. eggs in a carton)? 
 
  I don’t eat eggs 
  less than once a week 
  1-2 times a week 
  3-4 times a week 
  5-6 times a week 
  once a day  
  2 or more times a day 
  I don’t know or I’d prefer not to answer 
 
5. How often do you eat alternative egg products (e.g. powdered eggs, packaged egg 
whites, etc.)? 
 
  I don’t eat alternative egg products 
  less than once a week 
  1-2 times a week 
  3-4 times a week 
  5-6 times a week 
  once a day  
  2 or more times a day 
  I don’t know or I’d prefer not to answer 
 
 
6. How often do you eat any of the following vegetables? 
 
 





































































8. What type of milk do you most frequently usually drink? 
 
  I don’t drink milk 
  cows milk 
  goats milk 
  almond milk 
  rice milk 
  soy milk 
  other (please specify) ________________________ 
  I don’t know or I’d prefer not to answer 
 
 
9. How much milk do you usually drink on average per day? Note 1 glass = 250 mL 
 
  none 
  less than 1 glass  
  1-2 glasses  
  3-4 glasses  
  5 or more glasses (please specify) ____________  
  I don’t know or I’d prefer not to answer 
 
 
10. How often do you eat the following dairy products? Please DO NOT include non-
dairy based products e.g. coconut ice cream. 
 
 





































































12. How many glasses of water from the tap do you drink on average per day (1 glass 
= 250mL)? 
 
  I don’t drink water from the tap 
  less than 1 glass 
  1 glass  
  2 glasses 
  3 glasses 
  4 glasses 
  5 glasses 
  6 glasses 
  7 glasses 
  8 glasses 
  more than 8 glasses (please specify) ____________________ 
  I don’t know or I’d prefer not to answer 
 
13. How many canned drinks do you on average drink per day (e.g. Sprite, Red Bull, 
etc.)? 
 
  I don’t drink canned drinks 
  less than 1 can 
  1-2 cans 
  3-4 cans 
  5-6 cans 
  7 or more cans (please specify) ______________________ 
  I don’t know or I’d prefer not to answer 
 
14. Do you drink alcohol out of a screw top bottle (e.g. a bottle of wine)? 
 
  yes 
  no 




15. How many glasses of alcohol would you drink on average per day? Note 1 glass = 
250 mL 
 
  none 
  less than 1 glass  
  1-2 glasses  
  3-4 glasses  
  5 or more glasses (please specify) ____________  




16. How often do you microwave food in a plastic container? 
 
  Never 
  less than once a week 
  1-2 times a week 
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  3-4 times a week 
  5-6 times a week 
  once a day 
  2 or more times a day 
  I don’t know or I’d prefer not to answer 
 
17. How much drink on average do you usually consume out of a plastic bottle per 
day (e.g. sprite, orange juice, water etc.)? Note: 1 cup = 250 mL. 
 
  none 
  less than 1 cup  
  1-2 cups  
  3-4 cups  
  5-6 cups  
  7 or more cups  
  I don’t know or I’d prefer not to answer 
 
 
18. Do you ever leave plastic bottles filled with drink in the sun (e.g. a water bottle in 
your car)? 
 
   yes - please specify how often you would do this 
_______________________ 
  no 
  I don’t know or I’d prefer not to answer 
 
19. How often do you drink out of a can? 
 
  never 
  less than once a week 
  1-2 times a week 
  3-4 times a week 
  5-6 times a week 
  once a day 
  2 or more times a day 
  I don’t know or I’d prefer not to answer 
  
 
20. How often do you wrap your food in cling wrap? 
 
  never 
  less than once a week 
  1-2 times a week 
  3-4 times a week 
  5-6 times a week 
  once a day 
  2 or more times a day (please specify) ______________ 






21. How often do you eat food that has been packaged in a plastic wrapper (e.g. a 
muesli bar, meat etc.)? 
 
  never 
  less than once a week 
  1-2 times a week 
  3-4 times a week 
  5-6 times a week 
  once a day 
  2 or more times a day (please specify) ______________ 
  I don’t know or I’d prefer not to answer 
 
22. How often do you eat food out of a tin can (e.g. baked beans, tomatoes etc.)? 
 
  never 
  less than once a week 
  1-2 times a week 
  3-4 times a week 
  5-6 times a week 
  once a day 
  2 or more times a day (please specify) ______________ 
  I don’t know or I’d prefer not to answer 
 
 
23. How often do you put your plastic containers through a wash cycle in a dish 
washer? Plastic containers include lunch boxes, storage containers etc. We do 
NOT want you to include plastic trays or food packaging etc. 
 
  never 
  less than once a week 
  1-2 times a week 
  3-4 times a week 
  5-6 times a week 
  once a day 




24. Have arrived back from overseas in the last week? 
 
  yes 
  no 
  I don’t know or I’d prefer not to answer 
 
If your answer is yes, could you tell us the country you most recently visited in the 
space provided below. 
 







Tablets and Pills 
 
25. Do you currently take any form of contraceptive pill?  
 
  yes  
  no 
  I don’t know or I’d prefer not to answer 
 
If your answer is yes, can you please provide the name of the pill you are taking in 
the space provided below. 
 
 





26. Are you currently on any other form of hormone contraceptive (e.g. progesterone 
implant, Depo Provera injection or IUD)?  
 
  yes 
  no 
  I don’t know or I’d prefer not to answer 
 
If your answer is yes, please can you provide the name of the hormone 
contraceptive you are on in the space provided below. 
 





27. Are you currently on any form of hormone replacement therapy?  
 
  yes  
  no 
  I don’t know or I’d prefer not to answer 
 
If your answer is yes, please can you proved the name of hormone replacement 
therapy you are on in the space provided below. 
 
 












28. Are you currently on any form of fertility treatment?  
 
  yes  
  no 
  I don’t know or I’d prefer not to answer 
 
If your answer is yes, please can you provide the name of fertility treatment you 
are on in the space provided below. 
 






29. Do you take any dietary supplements?  
 
  yes 
  no 
  I don’t know or I’d prefer not to answer 
 
 
If your answer is yes, could you please provide the name and brand of the 
supplement in the space provided below. Dietary supplements can include 
products such as multivitamins purchased from the supermarket. 
 





Personal Care Products 
 
30. How often do you use any of the following personal care products? Please note 
that using once a day does not include re-application (e.g. if you put lipstick on in 
the morning and re-apply it twice throughout the day, then your daily use is 3 











































31. Have you taken any medication in the past week?  
 
  yes 
  no 
  I don’t know or I’d prefer not to answer 
 
If your answer is yes, could you please specify the name of the medication and 
whether you are on it long term (longer than 2 weeks) or short term (e.g. less than 
two weeks) in the space provided below. Medications can include anything from 
regular medication (e.g. warfarin) to Panadol or Nurofen. 
  





32. Have you had a tooth filling in the last week? 
 
  yes 
  no 





33. Have you had or do you have breast cancer?  
 
  yes 
  no 
  I don’t know or I’d prefer not to answer 
 
If your answer is yes, please can you tell us whether it is estrogen receptor 
positive or estrogen receptor negative in the space provided below. 
 
 





34. Before participating in this survey had you thought about estrogen mimicking 
compounds being a risk factor for breast cancer? 
 
  I had not heard of estrogen mimicking compounds before this survey 
  yes 
  no 




35. If you were previously aware of some of these estrogen mimicking compounds, 
did you take any measures to eliminate them from your daily routine (e.g. 
purchase paraben free make-up or BPA free containers)?  
 
  yes 
  no 
  I had not heard of estrogen mimicking compounds before this survey 
  I don’t know or I’d prefer not to answer 
 
If your answer is yes, could you please explain to us what measures you have 
taken to eliminate estrogen mimics from your daily routine in the space provided 
below. 
 





Preferred contact details  
Please note you do not have to provide any details you are not comfortable with. 
 






























Questionnaire about your Daughters Food and Lifestyle Habits  
 
Xenoestrogens can be found in food (e.g. bread), plastics (e.g. wine bottle caps, 
plastic containers), personal care products (e.g. make-up) and some medicines. The 
combinations of these compounds that humans are exposed to on a daily basis could 
have some long term health effects. The information you provide in this questionnaire 
will be used to understand the different combinations of xenoestrogens and to 
calculate the total estrogenic load your daughters are being exposed on a daily basis. 
It is important to consider pre-puberty exposure in females because they are more 
susceptible to the influences of estrogen mimicking compounds due to their own low 
natural estrogen levels. It is also thought that exposure to the compounds pre-puberty 
may increase their risk of developing breast cancer later in life. We ask that you fill 
out this survey if your daughter has NOT had her first period. If you have more than 
one daughter, please fill out the questionnaire for your oldest daughter that has NOT 
had her first period.  
 
Date of Birth: ____________ 
 
 




1. How many slices of bread does your daughter usually eat per day? 
 
  less than 1 per day 
  1 slice per day 
  2 slices per day 
  3 slices per day 
  4 slices per day 
  5 slices per day 
  6 or more slices per day (please specify) ________ 
  I don’t know or I’d prefer not to answer 
 
2. What sort of bread does your daughter most frequently eat? If she eats speciality 
bread (e.g. ciabatta) please include it in the OTHER section. 
 
  She doesn’t eat bread 
  white bread 
  wholemeal bread 
  multigrain bread 
  soy and linseed-containing bread (e.g. Vogel’s soy and linseed) 
  other (please specify) _________________________________ 











3. How often does your daughter eat soy based products (e.g. tofu, soy yogurt, etc.)? 
 
  She doesn’t eat soy based products 
  less than once a week 
  1-2 times a week 
  3-4 times a week 
  5-6 times a week 
  once a day  
  2 or more times a day 
  I don’t know or I’d prefer not to answer 
 
4. How often does your daughter eat fresh eggs (e.g. eggs in a carton)? 
 
  She doesn’t eat eggs 
  less than once a week 
  1-2 times a week 
  3-4 times a week 
  5-6 times a week 
  once a day  
  2 or more times a day 
  I don’t know or I’d prefer not to answer 
 
5. How often does your daughter eat alternative egg products (e.g. powdered eggs, 
packaged egg whites, etc.)? 
 
  She doesn’t eat alternative egg products 
  less than once a week 
  1-2 times a week 
  3-4 times a week 
  5-6 times a week 
  once a day  
  2 or more times a day 
  I don’t know or I’d prefer not to answer 
 
 


































7. How often does your daughter eat the following fruits? 
 
 
8. What type of milk does your daughter most frequently drink? 
 
  She doesn’t drink milk 
  cows milk 
  goats milk 
  almond milk 
  rice milk 
  soy milk 
  other (please specify) ________________________ 




9. How much milk does your daughter usually drink on average per day? Note 1 
glass = 250 mL 
 
  none 
  less than 1 glass  
  1-2 glasses  
  3-4 glasses  
  5 or more glasses (please specify) ____________  
  I don’t know or I’d prefer not to answer 
 
 
10. How often does your daughter eat the following dairy products? Please DO NOT 
























































11. How often does your daughter eat the following meat? 
 
 
12. How many glasses of water from the tap does your daughter drink on average per 
day (1 glass = 250mL)? 
 
  She doesn’t drink water from the tap 
  less than 1 glass 
  1 glass  
  2 glasses 
  3 glasses 
  4 glasses 
  5 glasses 
  6 glasses 
  7 glasses 
  8 glasses 
  more than 8 glasses (please specify) ____________________ 
  I don’t know or I’d prefer not to answer 
 
13. How many canned drinks does your daughter on average drink per day (e.g. 
Sprite, Red Bull, etc.)? 
 
  She doesn’t drink canned drinks 
  less than 1 can 
  1-2 cans 
  3-4 cans 
  5-6 cans 
  7 or more cans (please specify) ______________________ 












































14. How often does your daughter eat food microwaved in a plastic container? 
 
  Never 
  less than once a week 
  1-2 times a week 
  3-4 times a week 
  5-6 times a week 
  once a day 
  2 or more times a day 
  I don’t know or I’d prefer not to answer 
 
15. How much drink on average does your daughter usually consume out of a plastic 
bottle per day (e.g. sprite, orange juice, water etc.)? Note: 1 cup = 250 mL. 
 
  none 
  less than 1 cup  
  1-2 cups  
  3-4 cups  
  5-6 cups  
  7 or more cups  
  I don’t know or I’d prefer not to answer 
  
 
16. How often does your daughter eat food wrapped in cling wrap? 
 
  never 
  less than once a week 
  1-2 times a week 
  3-4 times a week 
  5-6 times a week 
  once a day 
  2 or more times a day (please specify) ______________ 
  I don’t know or I’d prefer not to answer 
 
17. How often does your daughter eat food that has been packaged in a plastic 
wrapper (e.g. a muesli bar, meat etc.)? 
 
  never 
  less than once a week 
  1-2 times a week 
  3-4 times a week 
  5-6 times a week 
  once a day 
  2 or more times a day (please specify) ______________ 







18. How often does your daughter eat food out of a tin can (e.g. baked beans, 
tomatoes etc.)? 
 
  never 
  less than once a week 
  1-2 times a week 
  3-4 times a week 
  5-6 times a week 
  once a day 
  2 or more times a day (please specify) ______________ 
  I don’t know or I’d prefer not to answer 
 






20. Has your daughter arrived back from overseas in the last week? 
 
  yes 
  no 
  I don’t know or I’d prefer not to answer 
 
If your answer is yes, could you tell us the country she most recently visited in the 
space provided below. 
 











































Tablets and Pills 
 
21. Does your daughter take any dietary supplements?  
 
  yes 
  no 
  I don’t know or I’d prefer not to answer 
 
 
If your answer is yes, could you please provide the name and brand of the 
supplement in the space provided below. Dietary supplements can include 
products such as multivitamins purchased from the supermarket. 
 





Personal Care Products 
 
22. How often does your daughter use any of the following personal care products? 
Please note that using once a day does not include re-application  
 
























































23. Has your daughter taken any medication in the past week?  
 
  yes 
  no 
  I don’t know or I’d prefer not to answer 
 
If your answer is yes, could you please specify the name of the medication and 
whether your daughter is on it long term (longer than 2 weeks) or short term (e.g. 
less than two weeks) in the space provided below. Medications can include 
anything from regular medication (e.g. warfarin) to Panadol or Nurofen. 
  





24. Has your daughter had a tooth filling in the last week? 
 
  yes 
  no 




25. Before participating in this survey had you thought about estrogen mimicking 
compounds being a risk factor for breast cancer for your daughter? 
 
  I had not heard of estrogen mimicking compounds before this survey 
  yes 
  no 




















26. If you were previously aware of some of these estrogen mimicking compounds, 
did you take any measures to eliminate them from your daughter’s daily routine 
(e.g. purchase BPA free containers)?  
 
  yes 
  no 
  I had not heard of estrogen mimicking compounds before this survey 
  I don’t know or I’d prefer not to answer 
 
If your answer is yes, could you please explain to us what measures you have 
taken to eliminate estrogen mimics from your daily routine in the space provided 
below. 
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Compound/s Mean (cells/mL) SEM 
Control 9.5 x 105 2.7 x 104 
E2 1.2 x 106 1.8 x 104 
EE2 1.4 x 106 1.3 x 104 
BPA 1.1 x 106 2.4 x 104 
Genistein 1.1 x 106 1.8 x 104 
Butylparaben 1.5 x 106 1.8 x 104 
Tetrahydrocurcumin 1.2 x 106 1.2 x 104 
Kaempferol 1.1 x 106 1.4 x 104 
Estriol 1.2 x 106 3.1 x 104 
EE2 + E2 1.2 x 106 1.9 x 104 
BPA + E2 1.1 x 106 1.0 x 104 
Genistein + E2 6.5 x 105 8.7 x 103 
Butylparaben + E2 8.8 x 105 2.4 x 104 
Tetrahydrocurcumin + E2 6.6 x 105 6.9 x 103 
Kaempferol + E2 5.9 x 105 2.5 x 104 
Estriol + E2 6.3 x 105 2.2 x 104 
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